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Abstract 
Chemokines are a family of low-molecular weight proteins that mediate their effects 
through binding with chemokine receptors (a group of seven trans-membrane spanning G-
protein coupled receptors).  Chemokines are well known for their role in leukocyte 
trafficking, although they also mediate a range of other physiological functions including 
cell proliferation, growth and differentiation. Chemokines are integral to the development 
and functioning of the immune system and are implicated in the pathogenesis of a wide 
range of diseases including autoimmune disorders, HIV infection and malignancies. 
 
Non-Hodgkin’s lymphoma (NHL) is a malignancy of the lymphoid system, which can 
affect any tissues in the body but has a predilection for the secondary lymphoid organs and 
the bone marrow. NHL represents a heterogeneous group of disorders with variations in 
presentation and prognosis. Whilst there have been improvements in overall survival in the 
last few decades following developments in treatment there is still a significant mortality 
associated with NHL as well as significant morbidity associated with the treatments 
required to control the disease or affect a cure.  
 
There is increasing evidence that chemokines and their receptors play a role in the 
pathogenesis of NHL with increased chemokine receptor expression seen in certain 
subtypes. Chemokines have also been shown to influence prognosis in particular NHL 
subtypes. This thesis describes studies to examine the relationship between constitutive 
chemokine receptor expression and NHL subtype with subsequent correlation between 
chemokine receptor expression and outcome. Results from studies on clinical samples 
obtained from patients with a range of B-cell NHL subtypes revealed significant 
differences in chemokine receptor expression between subtypes. Predominantly these 
differences were noted with the receptors CCR4 and CCR7. CCR4 has previously been 
examined in relation to T-cell lymphomas and high CCR4 expression has been associated 
with an adverse prognosis in adult T-cell leukaemia/lymphoma. However, systematic 
examination of CCR4 in B-cell NHL has not been done before. In this study CCR4 
expression was seen in samples of diffuse large B-cell lymphoma (DLBCL), mantle cell 
lymphoma (MCL), MALT lymphoma and Burkitt’s lymphoma. Furthermore high CCR4 
expression was associated with a significantly improved survival in patients with DLBCL. 
CCR7 expression was significantly higher in cases of MCL and chronic lymphocytic 
lymphoma/small lymphocytic lymphoma (CLL/SLL), this however did not equate to 
   
 iii 
differences in outcome. The high expression of CCR7 in MCL and CLL/SLL does 
however make this receptor an ideal target for the development of targeted therapies. 
 
Further studies in this thesis describe strategies used to target the chemokine system with 
cytotoxic agents. CCR7 was chosen for targeting experiments due to its restricted 
expression (naïve T-cells, memory T-cells, dendritic cells and subsets of B-cells) in normal 
tissues, the fact that it controls homing of leukocytes to lymph nodes, and that is the second 
most commonly reported chemokine receptor detected in cancers. The first approach for 
targeting the chemokine system used radio-labelled chemokines to induce cytotoxicity in 
cells expressing the cognate receptor. Unfortunately, the results from this were not 
conclusive and further studies are required to explore this approach. 
 
The second approach described in this thesis entailed the potential use of oncolytic 
adenoviral gene therapy. This approach requires the redirection of adenoviral tropism from 
the coxsackie and adenovirus receptor (CAR) and through CCR7. This was successfully 
achieved in cell lines engineered to express and those endogenously expressing CCR7 by 
‘shrouding’ the virus in CCL19. However, background infection was high and this led to 
the engineering of an adenoviral vector incorporating a peptide within the viral knob 
protein to allow for more efficient ‘shrouding’ of the virus and thus more efficient 
redirection of the virus. However, final experiments with this vector were not performed 
due to time constraints.  
 
The final part of this thesis relates to the characterisation of EL4 cells (a murine T-cell 
lymphoma cell line) for use as a potential in-vivo mouse model for targeting experiments. 
Following injection into the flank of C57/BL6 with these cells, measurable tumours 
develop. It was demonstrated that this cell line expressed CCR7, and finally after a number 
of modifications, it was shown that adenoviral tropism could be redirected through 
chemokine receptors on the surface of these cells.  
 
In summary the results in this thesis shows for the first time that CCR4 is expressed across 
a number of B-cell NHL subtypes and that this is associated with outcome in DLBCL.  
Results also demonstrate that therapeutic targeting of CCR7 is a reasonable therapeutic 
approach in NHL. In addition, redirection of oncolytic adenoviral vectors through 
chemokine receptors provides a potential strategy for obtaining this targeted therapy. 
Finally, EL4 cells have the potential to be used as an in-vivo mouse model for CCR7 
targeted therapies. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Overview of the Immune System  
During our life we encounter a diverse range of infectious organisms.  These vary in size 
and composition from the barely detectable prion to large intestinal parasites.  The effects 
of these pathogens are also highly variable; from those that can kill within hours such as 
the Ebola virus, to those with which we can coexist in an uneasy symbiosis for numerous 
years.  In response to this constant bombardment we have developed a highly complex and 
sophisticated defence system, the immune system. The immune system can be broadly 
divided into the innate and adaptive systems.  The innate system is generally non-specific 
and is not affected by prior contact with infectious agents.  In contrast acquired immunity 
occurs in response to specific microorganisms.  However, the immune system is complex 
and the division between the innate and adaptive systems are not always clear.   
1.1.1 Haematopoiesis 
This process results in the production of the cells, which form a large component of the 
immune system. Definitive haematopoiesis originates from aortic endothelial cells arising 
from the aorta-gonado-mesonephros region of the embryo; this is followed by migration of 
cells to initiate haematopoiesis within the foetal liver [1]. Shortly after birth, 
haematopoietic stem cells (HSCs) from the liver migrate to the bone marrow that becomes 
the primary site of haematopoiesis throughout life, except under pathological states when 
the spleen and even the liver can become sites for haematopoiesis [2]. As haematopoietic 
cells are relatively short lived and have no capacity for self-renewal, it falls upon the HSCs 
which do have self-renewing capacity to continuously provide the pool needed for a 
functioning immune system. HSC are able to differentiate into all lineages of the 
haematopoietic system of which ‘white cells’ provide a functioning immune system [3]. In 
response to a variety of cytokines produced by stromal cells within the microenvironment 
(see figure 1.1), HSCs undergo a system of continuous differentiation [4]. Once the cell is 
partially differentiated its ability to proliferate becomes restricted and it is destined to 
follow a distinct differentiation pathway.  
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Figure 1.1: Overview of haematopoiesis demonstrating the different cytokine profiles 
required for cellular differentiation. Adapted from Delves et. al, 2006 [4] 
 
1.1.2 Innate Immunity 
The innate immune system is able to act without any prior exposure to the pathogen 
attempting to evade it. What follows is a limited overview of this system, with a later 
emphasis on the adaptive immune system.  
1.1.2.1 External Barriers to Infection 
The skin is the first major line of defence preventing, microorganisms from gaining initial 
access. Intact skin is impermeable to most major infectious agents, and also provides a 
hostile environment for bacteria via excretion of low pH lactic and fatty acids in the sweat 
and sebum. Secretions from mucous membranes also prevent invasion, including gastric 
acid, lysozymes, nasal secretions and saliva, blocking adherence of inhaled or ingested 
organisms. Physical mechanisms have developed including, cilia within the respiratory 
tract that push foreign material back out into the environment. Furthermore, commensal 
bacteria colonise our mucous membranes and assist in our defence by suppressing the 
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growth of potentially pathogenic bacteria by competing for essential nutrients or by 
producing inhibitory substances [4]. 
1.1.2.2 Cellular Components of the Innate Immune System 
If a microorganism does bypass the external barriers then it has to face the humoral and 
cellular defence mechanisms in place. Perhaps the most important amongst the cellular 
components are the phagocytes, literally meaning, “eating cells”, these engulf 
microorganisms via a process termed phagocytosis.  
 
Neutrophils are a key initial line of defence against microorganisms, which they destroy by 
phagocytosis and digestion. These are short-lived polymorphonuclear cells, normally 
found in the circulation [5]. Neutrophil recruitment to inflamed tissues is a key feature of 
the innate immune system, allowing localised eradication of invading pathogens. In 
contrast the longer-lived tissue macrophages form the mononuclear phagocyte system. 
They are found in connective tissues and basement membranes of small blood vessels. 
Macrophages are especially numerous within the liver (Kupffer cells), lung (alveolar 
macrophages), kidney, splenic sinusoids and medullary sinuses of lymph nodes. In these 
locations they are ideally placed to filter foreign antigens. These cells are also major 
players in humoral mechanisms of immunity [6]. Macrophages have the additional 
advantage of being able to combat intracellular as well as extracellular pathogens. 
 
Other cells of the immune system include mast cells, basophils, eosinophils and natural 
killer cells. The first three cell types have roles in allergies, hypersensitivity reactions and 
parasite eradication. Eosinophils are of particular interest with the release of eosinophilic 
granules in the absence of parasitic infection being the hallmark of allergic reactions [7]. 
Natural killer (NK) cells are large granular lymphocytes, which, account for 10-15% of 
circulating lymphocytes [8]. These cells are predominantly involved in the eradication of 
infected or abnormal host cells by either inducing humoral responses or via antibody 
dependant cell mediated cytotoxicity (ADCC). [9, 10]. 
1.1.3 Chemical Components of the Immune System 
Cells do not function in isolation and cellular recruitment to sites of inflammation is 
essential for the efficient destruction of pathogens. This is achieved through cellular 
responses to, or interaction with, peptides including cytokines, adhesion molecules, 
interferons and chemokines.  
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Cell adhesion molecules (CAMs) are transmembrane receptors, which mediate cellular 
adhesion and signalling. They are predominantly expressed on haematopoietic and 
endothelial cells; integrins interact with the extracellular matrix (ECM), and selectins, 
cadherins and the immunoglobulin super family CAMs mediate adhesion to adjacent cells 
[11]. These molecules can be expressed constitutively, or become up or down regulated in 
response to a number of stimuli including a variety of pro-inflammatory cytokines. CAMs 
can regulate numerous cellular functions including development, apoptosis, haemostasis, 
homing and activation [12]. Addressins are tissue specific adhesion molecules that act 
along with chemokines in the targeting of lymphocytes to lymphoid tissue at particular 
anatomical sites including the gut, lung, skin and peripheral lymph nodes.   
 
Cytokines form a complex system of over 250 proteins and glycoproteins [13] secreted by 
both haematopoietic and non-haematopoietic cells, which have a diverse range of effects 
on a variety of cell types. These effects result from intracellular signalling following 
interaction with specific cell surface receptors. Cytokines can be categorised by function 
such as those stimulating haematopoietic cell growth and differentiation including 
granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony 
stimulating factor (G-CSF) and erythropoietin. Cytokines produced by, and exerting, their 
effect on leucocytes are termed interleukins [14].  Tissue necrosis factors (TNF), produced 
primarily by monocytes and macrophages [15], were initially named for their ability to kill 
tumour cells in-vitro [16]; more importantly they mediate inflammatory and metabolic 
responses during disease states [13]. Chemokines are discussed in more detail later. 
Cytokines have a central role in cell-to-cell communication and have a major role in the 
control and development of the innate and adaptive immune systems. 
 
Interferons form a major class of cytokines first described in 1957 due their inhibitory 
effect on viral replication [17]. Whilst initially described in relation to their role in antiviral 
defence mechanisms they do have other biological effects including cell growth, 
differentiation and apoptosis [18]. Interferons (IFNs) are divided into, type 1 (viral IFNs) 
including the IFNs α, β and ω and their subclasses, and type 2 (immune IFN) encompasses 
only IFN γ [19]. Type I IFNs are induced in response to viral infections, whilst mitogenic 
or antigenic stimuli induce IFN γ [18]. Additionally, type 1 IFNs have, two other protective 
effects. Firstly, they induce up regulation of MHC class I molecules, thereby enhancing 
pathogen antigen presentation and increasing susceptibility to attack by cytotoxic T cells. 
Secondly, they promote up regulation of inhibitors of viral RNA and DNA production. NK 
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cells and CD4+ Th1 cells only produce IFN γ whilst CD8+ cytotoxic cells produce the 
remaining interferons [18]. IFN γ helps immune responses by increasing MHC class II 
expression, regulating cytokine expression and promoting activation of immune effector 
cells. IFNs are in widespread clinical use for conditions as varied as hepatitis C infection, 
myeloproliferative disorders, multiple sclerosis and carcinoid tumours. 
1.1.4 Adaptive Immunity 
The innate immune system is non-specific and certain microorganisms have developed 
strategies to evade it. Additionally it can cause substantial collateral damage to the host. 
The hallmark of the adaptive immune system is its ability to target specific 
microorganisms and reduce host tissue damage. Central to adaptive immunity are B and T-
lymphocytes and the application of their receptors with specificity towards particular 
microbes. Following microbe recognition a series of events occur leading to targeted 
effector responses. What follows is a general overview of this system. 
 
1.1.4.1 Organisation of the Immune System 
Lymphoctes emerging from the thymus or bone marrow (primary lymphoid organs) are 
antigen naïve, relocating to secondary lymphoid tissues from the peripheral circulation, 
which include lymph nodes; spleen, tonsils and mucosa associated lymphoid tissue (see 
figure 1.2). Only a few naïve T and B-cell are able to react with specific foreign particles 
and systems are in place enabling them to encounter their specific antigens.  Lymphoid 
tissues provide the microenvironment for this process, containing antigen presenting cells 
and a variety of stromal cells able to produce the cytokines necessary to maintain T and B-
lymphocytes.  Adhesion molecules are expressed by lymphoid tissues, in an ordered array, 
allowing cells to move through tissue, thereby increasing the chance of contact with 
antigen.  
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Figure 1.2: Location of primary and secondary lymphoid organs in man.    
 
 
Figure 1.3: Anatomical organisation of lymph nodes showing the route taken by naïve B-
cells through the structure. 
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1.1.4.2 Generation of Antigen Specific Receptors in Lymphocytes 
T and B-cell clones are continually created throughout life, although production falls after 
the second decade in adults [14]. Lymphocyte antigen receptors are the means by which 
foreign antigens can be recognised, and they are key in the initiation of effector responses. 
Antigen receptors on B-cells are immunoglobulins (Ig), and those on T-cells are T-cell 
receptors (TCR). Each receptor has unique antigen specificity. Each individual has billions 
of lymphocytes, each with a particular receptor providing an incredibly diverse range of 
antigen recognition, achieved through somatic DNA recombination [20].  
 
1.1.5 B Lymphocytes 
B-cells are characterised by expression of cell surface immunoglobulins [21] and antibody 
production following activation. This is the humoral immune response. Early B-cell 
development occurs in the bone marrow and involves IgH and IgL rearrangement, these Ig 
proteins also play a role in the regulation of B-cell development [22]. The development of 
the B-cells can be followed by cell surface expression of certain molecules and the stage of 
IgH and IgL rearrangement [23] and as shown in table 1.1 and figure 1.4. Early in B-cell 
development the membrane-bound molecule Ig acts as the B-cell receptor (BCR) [24].  
During this time the BCR internalises antigen and processes it to act as antigen presenting 
cells for T-cell responses.  B-cells are then negatively selected within the bone marrow. 
Exposure of surface immunoglobulin positive (sIg+) B-cells to autoantigen leads to 
maturation arrest and apoptosis of those with high affinity [25], whilst those with no 
avidity are released into the circulation where they migrate to the spleen or lymph nodes 
and complete maturation. The final result is a B- cell producing one Ig and subsequently 
one specific antibody (Ab).     
 
Different antibody classes have differing anatomical localisations. IgM is found 
predominantly in the intravascular space and IgG is the predominant class found in blood 
and tissues [14]. IgA is secreted by B-cells in mucosa associated lymphoid tissues 
(MALT); found in the gut, bronchus, urogenital and oro-pharangeal areas [26].  
Antibodies function in one of three ways. Firstly, they can neutralise antigen by directly 
binding to it. Secondly, coating antigen facilitates recognition by other cells through, the 
Ab Fc portion and thus induces phagocytosis. Finally, it can activate complement, 
enhancing opsonisation or directly kill the pathogen [27]. Therefore antibody production 
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not only forms part of the adaptive immune system but forms a role within the innate 
system too.     
 
1.1.5.1 B Lymphocyte Receptor (Immunoglobulin) Rearrangement 
Immunoglobulin rearrangement occurs in B-cells within the bone marrow environment, 
prior to antigen exposure [28]. Each immunoglobulin (Ig) molecule consists of heavy and 
light chains within which are found variable (V) and constant (C) domains. Both heavy and 
light chain gene sequences contain more than one gene segment each of which has 
numerous potential genes [29] that can be utilised giving rise to a huge number of 
combinations. Rearrangement of the V domains in heavy and light chain genes is followed 
by RNA splicing into the C region genes [30]. These rearrangements are guided by a 
number of non-coding flanking DNA sequences [30], DNA modifying enzymes and 
recombination activation genes (RAG-1 and RAG-2) [31]. Additional variability is 
introduced by the fact that splicing is an inaccurate process and frame shift errors occur, 
deoxyribonucleotidyltransferase is able to insert nucleotides into the gene sequence and 
finally following antigen exposure; somatic hypermutation of the Ig heavy chain occurs 
[32]. As B-cells develop, the Ig receptor is present as an IgM molecule that can also 
internalise antigen and present it to T-cells acting as APCs. Subsequently the B-cells co-
express IgD. The final stage of B-cell maturation, follows activation.  
 
 
Stage Heavy Chain Light Chain Ig CD19 CD20 
Progenitor B 
cell 
germline germline - - - 
Early Pro-B cell D-J rearrangement germline - - - 
Late Pro-B cell V-DJ rearrangement germline - - - 
Large Pre-B cell VDJ rearranged germline m ? - 
Small Pre-B cell VDJ rearranged VJ rearranged m ? - 
Immature B cell VDJ rearranged VJ rearranged IgM + - 
Mature B cell VDJ rearranged VJ rearranged IgM, IgD + + 
Table 1.1: Expression pattern and stage of immunoglobulin rearrangement according to 
maturational stage of B cell development along with expression of cell surface markers CD19 
and CD20. 
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Figure 1.4: Localisation and antigen expression during B-lymphocyte maturation. (Taken 
from Edwards and Cambridge, 2006 [33]). 
 
1.1.5.2 B-cell Activation 
B-cell activation occurs following interaction of antigen with the BCR. This can occur in 
one of two ways. Firstly, binding of the BCR to antigen directly initiates a number of 
intracellular signals. Secondly, the BCR can deliver the antigen to intracellular sites where 
it is processed and then presented along with MHC class II molecules on the cell surface. 
Th cells then recognise the antigens and further B cell proliferation and differentiation to 
antibody secreting cells ensues. The resulting plasma cells can produce and secrete one of 
the Ig subclasses (IgA, IgG, IgM, IgE and IgD). Antibodies are able to recognise the 
conformational structure of antigens in turn leading to further B-cell activation [34]. The 
result is an enormous number of B-lymphocytes each producing only one type of heavy 
chain and one type of light chain, with potential to recognise the variety of microbes 
encountered throughout life. Two broad mechanisms of B-cell activation have been 
described; T cell dependent and independent activation.  
1.1.5.3 T-cell Dependent Activation, Isotype Switching and Somatic 
Hypermutation 
Primary B-cell activation occurs within the T-cell rich areas of secondary lymphoid 
organs. Class II molecules presented with antigenic peptides are recognised by antigen 
primed Th cells, which then release a number of activating signals to the B-cell, 
stimulating proliferation and maturation. To achieve this Th cells forms contact with B-
cells by a number of mechanisms, central to which is the CD40L on the Th cell and CD40 
on the B- cell surface [35]. Other molecules include CD30L and CD30, IL-4, and BLys 
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and TACI [27]. However, this initial response is short lived and can only form IgM 
molecules which, have limited effector functions, therefore a further process is required. 
 
Primary follicles are then formed at the B cell-T cell border (marginal zone), during which 
clonal expansion of both the B and T-cells occur over several days, with migration of 
germinal centre cells to this area. A proportion of the activated B-cells undergo intense B-
cell proliferation here to form the germinal centre [36]. A rim of resting B-cells and a 
meshwork of follicular dendritic cells (FDCs) surround the germinal centre, forming the 
mantle zone. Initially, B-cells have reduced sIg expression, the centroblasts, forming the 
densely packed dark zone, where somatic hypermutation occurs. Somatic hypermutation 
consists of a series of predominantly single point mutations within the IgV gene leading to 
subtle alterations in the specificity and affinity of the resulting protein [37]. A small 
number of B-cells result which have higher affinity and specificity for the foreign antigen, 
these cells are then provided with further survival signals such as increased BCL-XL 
expression, mediated by CD40/CD40L and BLys/TACI, whilst B-cells (the majority) with 
poor antigen affinity apoptose [38, 39].  
 
Subsequently, sIg is up regulated, and the cells become less densely packed and 
interconnect with FDCs, becoming centrocytes, at which point isotype switching occurs. 
Isotype switching entails the replacement of the IgM CH region with that of IgG, IgA or 
IgE through the up regulation of mRNA production and splicing. The type of 
immunoglobulin molecule produced is influenced by the cytokine release from the Th 
cells, with IL-4 driving IgG1 and IgE, TGFβ driving IgG2b and IgA, IL-5 driving IgA and 
IFNγdriving IgG2a and IgG3 production? [27]. B cells are then induced to become either, 
memory B-cells or plasma cells yet; the exact mechanism by which differentiation to either 
of these cells types occurs is unclear.  
1.1.5.4 T-cell Independent Responses 
Thymus independent (TI) antigens include bacterial polysaccharides, lipopolysaccharides 
(LPS) and proteins. These TI antigens fall into two categories. TI-1 antigens include LPS, 
which can directly induce proliferation and differentiation of most B-cells regardless of 
their antigen specificity. This is termed polyclonal activation [40]. This response is more 
rapid than the Th dependant responses, and does not induce isotype switching, maturation 
or the formation of memory B-cells, and is therefore short lived. TI-2 antigens can induce 
the production of IgG and IgM antibodies, but only in mature B-cells [41]. The B-cells 
react to the bacterial capsular antigen and thus this response of importance for our defence 
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against encapsulated bacteria such as Haemophilus influenzae, as these bacteria are able to 
avoid T cell priming.  
1.1.6 T-lymphocytes 
1.1.6.1 Maturation in the Thymus 
T-cell maturation and TCR (T-cell receptor) rearrangement occurs in the thymus, with T-
cell precursors (also known as thymus-settling progenitors (TSPs)).  TSPs populate the 
thymus via entry through the cortical-medullary junction (CMJ) after which they migrate 
to the sub-cortical-zone [42]. Maturation then ensues with both negative and positive 
selection steps [43] along with TCR rearrangement. Furthermore expression of particular 
CD antigens characterise particular stages of T-cell maturation (see figure 1.5) 
 
T cell receptor (TCR) rearrangement occurs in a fashion analogous to that of 
immunoglobulin rearrangement [44]. The same enzyme systems are used to produce two 
types of T-cell receptor. TCRs have two forms; TCRαβ and TCRγδ [45]. TCRαβ is 
predominantly expressed on CD4+CD8- or CD4-CD8+ lymphocytes, whilst TCRγδ is 
expressed on CD4-CD8- T cells? [46]. As with B-cells, the TCRs incorporate different V, 
D and J genes to develop a diverse receptor repertoire [45]. TCRαβs form approximately 
90% of the TCR repertoire with TCRγδ making up the final 10%. TCRs are associated 
with particular anatomical localisations with TCRαβ located predominantly in the 
secondary lymphoid organs, and TCRγδs in epithelial tissues, enabling earlier and more 
general responses to foreign antigens [47]. In contrast to B-cells, these receptors recognise 
short antigen peptide sequences expressed by antigen presenting cells in combination with 
class I or II MHC molecules [34].  
 
Positive selection occurs within the cortex, where cells bearing TCRs able to bind MHC 
class I or II molecules have a survival advantage over the others which die ‘by neglect’ 
[48]. MHC class I binding cells develop into CD8+ T cells whilst MHC class II binding 
cells become CD4+ T-cells. Negative selection steps follow in the medulla where T-cells 
having high affinity for self-antigens are induced to undergo apoptosis, reducing the risk of 
autoimmunity. The antigen naïve T cells then egress into the peripheral circulation (see 
figure 1.5).  
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Figure 1.5: Steps of T-cell maturation within the thymus. (Taken from Zúñiga-Pflücker, 2004 
[49]) 
 
1.1.6.2 Innocence to experience: Meeting of the Naïve T-cell and 
Antigen 
T-cell activation and subsequent initiation of immune response requires interaction 
between the T-cell and its antigen via presentation on antigen presenting cells (APCs) such 
as dendritic cells or macrophages. The probability of these low frequency cell types 
meeting is increased by firstly, continuous migration of naïve T-cells between and within 
lymph nodes ‘searching’ for foreign antigens [50]. Lymphocytes traffic between the lymph 
nodes via blood and lymphatic vessels finally entering the lymph nodes via the high 
endothelial venules (HEV) mediated by L-selectin [51] in combination with chemokines 
and their receptors. During intra-lymph node migration T- cells transiently bind to 
numerous APCs postulated to be guided by chemokine gradients. Secondly, dendritic cells 
that have taken up antigen from infected tissue are stimulated to migrate to draining lymph 
nodes [52] via up regulation of lymphoid homing chemokine receptors such as CCR7 [53].  
Once a T-cell has had contact with an APC bearing its antigen, activation takes place over 
48-72 hours.   
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1.1.6.3 Antigen Processing and the MHC Molecules 
Antigenic peptides are processed and presented with major histocompatibility complex 
(MHC) molecules and is a prerequisite for T-cell activation. MHC molecules fall into 2 
classes. Intracellular antigens cut into short peptides within the cytosol of APCs are 
subsequently bound and presented with MHC class I molecules [54], which can then be 
recognised for targeting by cytotoxic T-cells. Extracellular antigens taken in via endocytic 
pathways are processed by APCs including dendritic cells, B-cells and macrophages, and 
subsequently this antigen is processed and re-expressed with MHC class II molecules [55]. 
Under normal circumstances MHC class II expression is restricted to APCs. 
1.1.6.4 Antigen Recognition by T-cells 
CD4+ and CD8+ have differing functions, and so the MHC molecule used to present an 
antigen determines the effector response generated [56]. MHC class I molecules are 
expressed on all nucleated cells highlighting the fact that many cells can be infected with 
viruses or express abnormal tumour peptides [34]. MHC class I-antigen complexes are 
open to highly targeted attack by CD8+ cytotoxic T-cells [57].  In contrast CD4 activation 
is regulated by limited expression of MHC class II molecules expressed by APCs [34] 
helping to limit CD4 effector responses which entails the release of cytokines leading to 
subsequent activation of surrounding cells. Inappropriate antigen presentation or effector 
cell attack is limited as TCR binding to the antigen-MHC complex alone is insufficient to 
induce cellular activation; stimulation with co-receptors is also required. 
1.1.6.5 T-cell Receptor Signalling 
TCRs are complexed with CD3 molecules [58]. Following antigen binding, receptor 
aggregation occurs, resulting in signal transduction and ultimately gene activation and T-
cell proliferation [14]. Additional co-receptors participate in signal activation following 
TCR engagement. CD28 is a major stimulatory molecule [59] which, binds to CD80. Other 
major co-stimulatory molecules include CD86 which binds CTLA-4 [60] and CD40 which 
binds CD40L [48]. These molecules are found in large numbers on dendritic cells, with 
expression up regulation after stimulation [60], so dendritic cells are the most potent 
stimulators of naïve T-cells. Following activation; division and clonal expansion occurs 
[14]; the majority of these are effector cells, although memory T-cells are also produced.  
Up regulation of organ specific homing receptors in diseased tissues aids homing of 
activated T-cells, via responses to molecules released from these sites. Long-lived memory 
cells can then reside in these tissues, thereby eliciting a rapid immune response if the same 
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foreign antigen/MHC combination is encountered again. These cells can reside in tissues 
for as long as ten years. 
1.1.6.6 T cell Sub-sets 
T helper (Th) cells characteristically express CD4 and include Th1, Th2, Th-17 and T 
follicular helper cells (TFH). Th1 cells mediate cell dependant immune responses through 
the release of cytokines such as IL-2 and IFNγ? [61], leading to T-cell proliferation, 
cytotoxic T-cell activation, and stimulation of macrophages and NK-cells. Therefore Th1 
cells are critical for responses against intracellular pathogens. These cytokines also provide 
a positive feedback loop by stimulating differentiation of Th0 cells to Th1, whilst 
simultaneously blocking Th2 differentiation [62]. In contrast Th2 cells mediate antibody 
responses and are a central defence against extracellular pathogens, particularly parasites 
[62]. Th2 cells release a variety of cytokines including IL4, IL5, IL6 and IL10 which, 
favour antibody production. IL-4 directly induces IgE production [63], whilst IL-5 
promotes eosinophil development. As with Th1 cells a positive feedback loop occurs with 
IL-4 stimulating differentiation to Th2 cells whilst simultaneously suppressing Th1 
development.  
 
Th-17 cells are characterised by secretion of IL-17, and their development is suppressed by 
cytokines produced by Th1 and Th2 cells, demonstrating that they are a separate Th subset 
They appear to have a role in both inflammatory and antibody mediated responses [64]. 
 
TFH cells provide assistance for immunoglobulin production by B-cells within the germinal 
centre. These cells are characterised by CXCR5 expression, and facilitate migration to 
CXCL13 rich germinal centres, and thus interaction with germinal centre B-cells [65, 66]. 
Additionally, high expression of co-stimulatory molecules such as CD40L on TFH cells 
highlights their role in providing cognate assistance to B-cells within the germinal centres 
[67]. 
 
Cytotoxic, CD8+, T cells (Tc) are directly cytotoxic to specific antigen bearing cells. As 
they recognises MHC class I associated peptides, they have a major role in the control of 
intracellular pathogens [57]. Following antigen binding these cells kill in one of three 
ways. Firstly, by releasing cytokines such as IFNγ and TNFα?? IFNγ causes up regulation 
of antigen and Fas expression on cell surfaces thereby enhancing targeted cell lysis. 
TNFαengages with target cell receptors and induces apoptosis directly? [68]. The other 
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mechanisms involve direct cell-cell contact, including mediation by FasL on the Tc cell 
surface binding to Fas receptor (CD95) on the target cells triggering apoptosis [69]. The 
second cell-cell mediated mechanism involves the release of highly toxic, pre-synthesised, 
secretory lysosomes containing perforin and granzymes which, interact with the target cell 
and cause cell death [70, 71]. As with Th cells, Tc are subdivided according to the cytokine 
profile they release with Tc1 cells releasing IFNγ, TNFα and IL-2 and Tc2 cells releasing 
IL-4, IL-5 and IL-10 [72]. However, the exact role for these two subsets is not as clear as 
with Th cells. CD8+ cytotoxic cells are predominantly involved in antiviral and probably 
anti-tumour activity.  
 
T regulatory (Treg) cells play a role in the control of the immune system by silencing self-
reactive T-cells [73], thereby reducing autoimmunity. Differing subsets of Tregs have been 
described based upon their cell surface expression, cytokine production profiles and 
postulated mechanisms of action, these include CD4+CD25+FOXP3+ and CD4+CD25-
FOXP3+ cells producing either IL-10 or TGFβ (tissue growth factor β) and mediating 
cytokine or cell-cell contact mediated effects [73]. The mechanisms of suppression by 
these cells have not been fully elucidated. However binding of Treg and T effector cells 
with CTLA-4 has been shown to mediate ligation of CD80/CD86 inducing suppressive 
signals [74], and  reduce both proliferation and IFNγ production [75]. Another possible 
mechanism is that of simple competition between Treg and T effector cells for APCs and 
survival signals [76]. The role of these cells in immunosurveillance and the pathogenesis of 
autoimmune disease and malignancies are becoming clearer. 
1.1.7 Regulation of Autoimmune Responses 
As has been described, lymphocytes with affinity for self-antigens do arise through the 
mechanisms required for formation B and T-cell receptors formation. Yet, a number of 
mechanisms are in place to reduce the proliferation of these lymphocytes and the 
subsequent autoimmunity that would result. These include positive and negative selection 
in the thymus, the positive selection of B-cells in the bone marrow environment, and the 
anergy and apoptosis of lymphocytes in the periphery due to the lack of co-stimulatory 
molecule activation. Yet, of course some of these cells do escape these quality control 
processes leading to the development of autoimmune diseases.  
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1.1.8 Interactions Within and Outside of the Immune System 
Understandably, research into immune based therapies for a wide range of disorders has 
been a major focus of research groups and pharmaceutical companies. This has led to the 
development of many products in clinical use today. Examples include the use of cytokines 
and their antagonists, monoclonal antibodies, cellular therapies and therapeutic 
vaccinations.  It should be noted though that immune reactions are complex and changes in 
one part of the system can lead to unforeseen changes in others.  This has been highlighted 
with the use of CD28 agonists in early clinical trials and the unforeseen consequence of 
multi-organ failure occurring in study participants [77].  Despite this, it is clear that there is 
a huge therapeutic potential to be gained from further understanding of the immune 
system. 
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1.2 Chemokines and their Receptors  
 
In the previous section gave a basic overview of the immune system. Chemokines form 
and integral part of the immune system, and are studied in this thesis. In this section an 
overview of the chemokine system will be discussed, along with a more detailed discussion 
of the role of chemokines in the adaptive immune system. 
1.2.1 Historical Perspective   
Chemokines are a group of small (~8-14kDa) structurally related peptides [78]. These 
peptides primarily perform as chemoattractants, thereby explaining the derivation of their 
name; CHEMOattractant cytoKINES. To date over 40 chemokines have been discovered 
since the first one; CXCL4/PF4 was described in 1977 [79]. Initially, the chemokines were 
shown to be clearly associated with inflammatory conditions, leading to the conclusion 
that, they played an integral role in the recruitment of leucocytes to sites of inflammation. 
Subsequently, it was shown that chemokines also displayed a distinct and conserved 
structural homology as well as having potent chemotactic effects on leucocytes. However, 
chemokines are also able to influence various other aspects of cell function, such as 
adhesion, proliferation, maturation, differentiation, apoptosis, replication, and malignant 
transformation. Therefore since 1977 research into chemokines and their receptors have 
implicated them in the pathophysiology of many disease processes including infection, 
autoimmune disease and cancer. Of most interest, perhaps, is the discovery that 2 
chemokine receptors, CXCR4 [80] and CCR5 [81] act as co-receptors for HIV entry into 
cells. Soon after a population of individuals that carry a mutation in CCR5 (CCR5Δ32) 
were indentified, which in the homozygous state renders the individual resistant to HIV 
infection and in the heterozygous state less likely to develop AIDS [82, 83]. Consequently, 
an antagonist to CCR5, Maraviroc has been developed and shows efficacy in reducing HIV 
viral loads in infected individuals [84]. Other agents targeting the chemokine system are 
now in clinical use or in clinical trials and will be discussed in more detail later. 
1.2.2 Nomenclature and Structural Classification of Chemokines 
Initially the names of chemokines highlighted the function for which they were first 
discovered, e.g. MIP1α or monocyte inflammatory protein 1α. However it has become 
clear that individual chemokines have a number of functions and so, to avoid confusion an 
international system of nomenclature has been introduced based upon their structural 
classification. Chemokines can be divided into four families according to the arrangement 
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of the first two cysteine residues at the N-terminus of the molecule. The two major families 
are CXC (or alpha) and CC (or beta) depending upon the presence or absence of an 
intervening amino acid between these first two cysteine residues (Figure 1.4). Two other 
groups include the C (lymphotactin and SCM-1) and CX3C (fractalkine) chemokines, the 
first lacks two of the first three cysteine residues and the second has three amino acids 
between the first two cysteine residues.  
 
Chemokines are named according to the order in which their gene was characterised and 
by their cysteine motif. So, MIP-1α becomes CCL3 and IL-8 becomes CXCL8 and so on. 
At present this nomenclature accounts for 43 human chemokines [78]. In this thesis the 
international nomenclature will be used. Chemokine cell signalling is mediated through 
seven-transmembrane G protein-coupled receptors (GPCRs). These receptors are 
expressed on a number of different cell types, but are predominantly expressed on cells of 
the haematopoietic system. The international system of nomenclature is also used for the 
chemokine receptors where L is replaced by R, e.g. CXCR4, CCR5 etc. Table 1.2 and 1.3 
demonstrates the chemokines and their receptors known at the present time (it excludes the 
atypical chemokine receptors which will be briefly discussed later). 
 
However, the chemokine system is not straightforward with different chemokines being 
able to bind to more than one receptor and with most receptors having more than one 
ligand. This apparent ‘redundancy’ in the system reflects subtlety and intricacy, which we 
are only just beginning to understand.   
 
Characteristic chemokine conformation results from interactions between the cysteine 
residues, via disulphide bonds [85]. The bonds forms between the 1st and 3rd and the 2nd 
and 4th residues, numbered according to their position in the peptide sequence. The first 2 
cysteine residues are located together (with or without intervening amino acids) at the N-
terminus, the 3rd is found central to the molecule and the fourth close to the C-terminus. An 
understating of the structure of chemokines is essential in the understanding of their 
function and ultimately in the development of agents to act either as agonists or 
antagonists. 
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SYSTEMATIC 
NAME 
COMMON 
NAME 
RECEPTORS 
CCL1 I-309 CCR8 
CCL2 MCP-1 CCR1, 2 
CCL3 MIP-1α CCR1, 5 
CCL4 MIP-1β CCR1, 5, 8 
CCL5 RANTES CCR1, 3, 5 
CCL7 MCP-3 CCR1, 2, 3, 5 
CCL8 MCP-2 CCR1, 2, 3, 5 
CCL11 Eotaxin CCR2, 3, 5 
CCL13 MCP-4 CCR1, 2, 3, 5 
CCL14 HCC-1 CCR1, 5 
CCL15 MIP-1δ CCR1, 3 
CCL16 HCC-4 CCR1, 2, 5 
CCL17 TARC CCR4, 8 
CCL18 PARC CCR3 
CCL19 MIP-3β/ELC CCR7 
CCL20 MIP-3α CCR6 
CCL21 6Ckine/SLC CCR7 
CCL22 MDC CCR4 
CCL23 MPIF-1 CCR1 
CCL24 Eotaxin-2 CCR3 
CCL25 TECK CCR9 
CCL26 Eotaxin-3 CCR2, 3 
CCL27 CTACK CCR10 
CCL28  CCR3, 10 
Table 1.2: Overview of the CC chemokines and their cognate receptors. 
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SYSTEMATIC 
NAME 
COMMON    
NAME 
RECEPTORS 
CXCL1 GROα CXCR2 
CXCL2 GROβ CXCR2 
CXCL3 GROγ CXCR2 
CXCL4 PF4 CXCR3 
CXCL5 ENA-78 CXCR1, 2 
CXCL6 GCP-2 CXCR1, 2 
CXCL7 NAP-2 CXCR2 
CXCL8 IL-8 CXCR1, 2 
CXCL9 MIG CXCR3 
CXCL10 1P-10 CXCR3 
CXCL11 I-TAC CXCR3, CXCR7 
CXCL12 SDF-1 CXCR4, CXCR7 
CXCL13 BCA-1 CXCR5 
CXCL14 BRAK  
CXCL16 
 
XC Chemokines 
 CXCR6 
XCL1 Lymphotactin XCR1 
XCL2 SCM-1β XCR1 
CX3CL1 Fractalkine CX3CR1 
Table 1.3: Overview of the CXC, XC and CX3C chemokines and their cognate receptors. 
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Figure 1.6: Positioning of the cysteine residues in the different structural classes of 
chemokines. 
 
1.2.3 Functional Classification of Chemokines 
Chemokines can be broadly classified, according to their function, into inflammatory 
(inducible) and constitutive (homeostatic) chemokines. This classification of chemokines 
highlights the integral role they play in the organisation of the immune response. 
Chemokines control the directed migration of leukocytes. Under homeostatic conditions 
this is controlled by the constitutive chemokines through interaction with specific receptors 
on the cell surfaces. Furthermore, a number of constitutive chemokine receptors display 
compartmentalisation in their expression. For example CCR7 expression is limited to T- 
lymphocytes, subsets of B-cells and mature dendritic cells. In contrast CXCR4 is widely 
expressed and found on haematopoietic stem cells, thymocytes, B and T-cells, dendritic 
cells, some endothelial cells and neutrophils [86].  
 
In contrast, inflammatory chemokine receptors such as CCR1, CCR2, CCR3, CCR5 and 
CXCR2 are up-regulated and responding to the corresponding up regulation of ligands 
expressed within damaged tissues.  These receptors and their ligands are also up-regulated 
in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease 
and multiple sclerosis [87]. 
 
Under homeostatic conditions chemokines have an integral role in the organisation of the 
immune system. However it is worth reflecting on the differences between these two 
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groups of chemokines in terms of the overall impact on the immune system. Constitutive 
chemokines are expressed at much lower levels than the inflammatory chemokines (when 
induced), yet, disruption of these chemokines have more profound affects. This is 
demonstrated in knock-out mice, for example deletion of CCR7 leads to a severe 
disruption of the secondary lymphoid organs both structurally and functionally [88]. In 
contrast mice with deletions of the inflammatory receptors such as CCR3 have a 
surprisingly normal phenotype under normal circumstances, and only display a phenotype 
under certain inflammatory conditions [89]. 
 
Not surprisingly, chemokines have been shown to play a significant role in the 
pathogenesis of a number of diseases including asthma, HIV infection, autoimmune 
conditions and malignancy.  
1.2.4 N-terminal Domain of Chemokines 
The N-terminal domain of chemokines is required for receptor mediated signalling as 
initially established by using CCL2 analogues with differing N-terminal amino acids [90]. 
N-terminus truncated forms of CCL2, demonstrate binding affinity with its receptor but 
does not result in chemotaxis [91]. Additionally, variations in the N-terminal domain can 
lead to varying biological affects, for example the presence of the glutamic acid-leucine-
arginine (ELR) motif on CXC chemokines (CXCL8, CXCL5 and CXCL1-3) is associated 
with angiogenesis, whereas those lacking the ELR motif  (CXCL9-11, CXCL4 and 
CXCL13) are angiostatic [92]. One notable exception to this rule is CXCL12, which, while 
lacking the ELR, motif appears to angiogenic [93]. Additional receptor binding sites are 
present on chemokines including the N-loop between the first 2 cysteines and the 310 helix 
[85]. 
1.2.5 Chemokine Regulation  
Chemokine secretion and function is regulated in a number of ways including 
oligomerisation, heterodimerisation, interaction with glycosaminoglycans (GAGs) and 
post-translation control. The latter two mechanisms will be discussed briefly. 
1.2.5.1 Regulation by Glycosaminoglycans 
GAGs are carbohydrate structures presented on the surface of most cells [85].  Chemokine 
gradients facilitate directed migration of leukocytes. In vivo this is dependent on binding of 
chemokines to GAGs on endothelial cell surfaces [94].  Interaction between endothelial 
cells (ECs) and GAGs enables chemokines to be presented to circulating blood cells 
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without being removed by blood flow; thus facilitating leukocyte adhesion to vessel walls.  
GAGs are classified in a number of families including the heparans, based upon length and 
disaccharide units, and it appears that these families display differing chemokine affinities 
and vice versa.  For example the affinity of CXCL8 for a particular sub-fraction of heparin 
is not demonstrated by either CXCL4 or CXCL7 [95]. Cellular bound and soluble 
GAG/chemokine complexes act differently, with the former enabling concentration of 
chemokines at a particular location thereby triggering the cognate chemokine receptor 
whilst, soluble GAG/chemokine complexes have an inhibitory effect [96].  
1.2.5.2 Post-translational Control 
Alterations in the N-terminal sequence of chemokines can affect its biological function. 
This occurs naturally in vivo via proteases such as CD26 and matrix metolloproteinases 
(MMPs), which truncate the N-terminal domain of post- translational secretory 
chemokines [85]. Truncated chemokines differ functionally from their full-length 
counterparts in signalling ability, receptor specificity and receptor affinity. For example 
CD26 cleavage of full length CCL4 leads to a truncated product which, retains the ability 
to down-regulate cell surface expression of CCR5 and block HIV-1 entry into cells, whilst 
gaining the ability to bind to CCR1 and CCR2b [97, 98]. In a situation analogous to GAG 
affinity, chemokine affinity as substrates for different MMPs has also been noted. Thus 
post-terminal truncation of the N-terminal domain adds another level to the increasingly 
complex in vivo regulation of chemokines.  
1.2.6 Chemokine Receptors  
To date more than 20 chemokine receptors have been described with all but 4 (DARC, D6, 
CXCR7 and CCX-CKR) initiating intracellular signalling events following binding with 
their ligands. Chemokine receptors form a group within the 7 transmembrane spanning G-
protein coupled receptor family. Helical transmembrane regions are linked by 3 
extracellular loops and 3 intracellular loops, with the N-terminal end positioned 
extracellulary and the C-terminal end intracellularly. Signalling through chemokine 
receptors is largely due to a DRYLAIVHA (or variation thereof) motif, located on the 
second intracellular loop. The role of this motif is highlighted by the fact that it is lacking 
in atypical, non-signalling, receptors [85]. Yet, it should be noted that, to date, the structure 
of chemokines is speculative, based upon presumed chemokine receptor binding sites on 
chemokines and on elucidated crystal structures of other GPCRs such as rhodopsin [99]. 
Mutagenesis studies have helped to determine receptor ligand binding sites. It has been 
demonstrated that binding sites in the N-terminal domain of chemokines enables correct 
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orientation of ligand within its receptor allowing for interaction with residues within the 
transmembranous helices [100]. Further binding sites are present on other extracellular 
loops (ECLs), offering further assistance in correct orientation of the ligand [100, 101]. 
Additionally, some receptors are glycoslylated or tyrosine sulphated and show greater 
affinity for their cognate ligands [85].  
 
1.2.6.1 Receptor Activation and Guanine Nucleotide Binding Proteins 
Following ligand binding, conformational changes in the receptor occur enabling tyrosine 
phosphorylation within the DRYLAIVHA motif (figure 1.7). This leads to activation of the 
guanine nucleotide-binding (G protein) pathway via interaction of G-protein subunits with 
components of the DRYLAIVHA motif [102]. Usually, this involves activation of the Gαi 
protein, indicated by interruption of downstream signalling following exposure to, the Gαi 
inhibitor, pertussis toxin, in numerous chemokine/receptor interactions including 
CXCL8/CXCR1 [103]. The Gαi subunit contains inactive GDP and forms a heterotrimeric 
structure with Gβ and Gγ subunits. Following activation, GDP is replaced by GTP, leading 
to, dissociation of the Gαi subunit from the Gβγ subunit, the latter then activates a number 
of downstream signalling pathways [104].  However, whilst this is the classical paradigm 
of G protein chemokine mediated signalling, other G proteins have also been implicated, 
for example Gαq proteins have been identified to induce signalling in granulocytes [105].  
Gαi acts as a GTPase leading to gradual hydrolysis of GTP to GDP, which, in turn leads to 
re-association of the G protein subunits and quenching of signalling responses. This is 
facilitated by a family of GTPase activating proteins (GAP) known as regulators of G 
protein signalling (RGS) that inhibit G protein signalling by increasing the rate of GTP 
hydrolysis [106, 107], thus having a regulatory role in G protein mediated activities.  
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Figure 1.7: Outline of the 7 transmembrane structure of the chemokine receptor, 
demonstrating the N-terminus binding with the chemokine and the C-terminus activation following 
binding of the DRY motif (red arrow) with the G-protein complex.  
 
1.2.6.2 Signalling Pathways and Intracellular Control of Migration 
Chemokine induced signal transduction is implicated in numerous cellular functions such 
as growth, proliferation, adhesion and apoptosis (Figure 1.6). However, a complete 
exploration of these pathways is beyond the scope of this discussion, and will be limited to 
those involved in the control of chemotaxis.  
 
Numerous signalling pathways have been shown to be required for chemotaxis foremost 
amongst these are those transduced by the phosphoinositide-3 kinases (PI3K), however, 
pathways will vary depending upon the cellular context and receptor ligand interaction. In 
brief, following ligand binding, PI3Ks are rapidly activated leading to generation of 
phosphatidylinositol-3,4,5-triphosphate (PIP3), these molecules translocate to the leading 
edge of the cells, where Rac (part of the Rho family of GTPases), induces polymerization 
of actin within the leading edge. This pathway is the predominant mechanism for 
chemotaxis within neutrophils, but is not essential for lymphocyte migration. In 
lymphocytes a protein DOCK2 instead of PI3Ks is essential for lymphocyte migration. 
DOCK2 is a haematopoietic-specific protein which has been shown to be important for 
chemokine induced activation of Rac and actin polymerisation, with DOCK2-/- mice 
displaying impaired chemokine induced B and T-lymphocyte migration and atrophied 
lymphoid follicles [108].  
 
The trailing edge of the cell undergoes independent morphological changes. It is unclear 
how this occurs in lymphocytes, but in other leucocytes, this is mediated through Rho 
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activation via an alternative G protein subunit; Gα12/13 [109]. Rho localises to the trailing 
edge, inducing retraction of this through formation of actin/myosin complexes.  
 
 
Figure 1.8: Outline of major signalling pathways activated following receptor activation and 
their outcome on cellular function. 
 
1.2.6.3 Desensitisation, Internalisation and Recycling of Receptors 
Following ligand binding and receptor activation, mechanisms are in place to prevent 
further unwarranted downstream signalling. Once activated GPCRs, undergo 
phosphorylation of serine and threonine residues on the C terminus  [110]. This leads to 
steric hindrance to G protein binding and increased affinity for a group of cytosolic 
proteins, the β-arrestins. Binding of GPCRs to β-arrestin leads to further inhibition of 
steric binding. These actions effectively block further G protein mediated signalling, 
leading to receptor desensitisation.  
 
Clathrin mediated endocytosis is the most frequently observed mechanism for chemokine 
receptor internalisation. Other mechanisms have been observed, but, in this thesis, 
discussion will be restricted to clathrin-mediated mechanisms as these have significance 
for adenoviral uptake, discussed later in section 1.5.  
 
β-arrestins mediate receptor internalisation, by providing a link between the desensitised 
receptor complex and internalisation (endocytic) machinery. β-arrestin binds directly to 
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clathrin via a Leu-Xaa-Glu/Asp binding motif  [111] whilst also, interacting with the β2-
adaptin subunit of a clathrin adaptor protein (AP2) [112]. The clathrin terminal domain 
orientated towards the plasma membrane, thought to act as an anchor for arrestins and 
AP2, facilitates recruitment of the receptor complex into clathrin-coated pits [111]. Coated 
pits form a bud via pinching of the plasma membrane with assistance of dynamin [113]. 
The buds are then released into the cytoplasm as clathrin-coated vesicles.  
 
Once internalised, the receptor is distributed to various intracellular sites guided by one of 
the Rab GTPases. Rab GTPases cycle between active and inactive forms [114, 115]. 
Different members of the Rab family appear to have specific functions within the cell. 
Rab5 promotes fusion with early endosomes assisting in regulating internalisation. Rab5 
dominant-negative mutants have been shown to inhibit or reduce CXCR2, CCR5 and 
CXCR4 internalisation [116, 117]. Rab4 and Rab11a are involved in rapid and slow 
receptor recycling respectively [117]. Re-sensitisation occurs during recycling, enabling 
re-establishment of functioning cell surface chemokine receptors.  
 
Finally, receptor degradation occurs with some chemokine receptors following prolonged 
exposure to ligands, by localisation to lysosomes, mediated by Rab7 and Rab9. 
Degradation of both CXCR2 and CXCR4 in association with Rab7 has been observed, 
although not all chemokine receptors are degraded including CCR7, which undergoes 
recycling [118]. 
 
The fate of the chemokine itself varies and is not always clear, in most studies, degradation 
following uncoupling with the receptor occurs within lysosomes. Yet, this is not always the 
case as seen with CCL21 where binding does not appear to elicit CCR7 internalisation 
[119]. In other instances modified chemokines such as AOP-CCL5 have been shown to 
recycle back to the plasma membrane following CCR5 associated internalisation [120]. 
The mechanisms described above are complex, and the fate of the receptor depends not 
only on the ligand bound but also on the cellular context, with a number of other 
controlling factors yet to be determined.  
1.2.6.4 Decoy Receptors 
To date four decoy receptors; the Duffy antigen receptor for chemokines (DARC), D6, 
CXCR7and CXC-CKR have been discovered. These receptors bind chemokines with high 
affinity, but differ from  ‘typical’ chemokine receptors in a number of aspects. Firstly, 
neither G-protein coupled signal transduction nor Ca2+ fluxes have been noted following 
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ligand binding to these receptors [121, 122]. This relates to an absence of the DRY motif 
on the second intracellular loop that is required for signal transduction [123]. Decoy 
receptors are proposed to function by modulating immune inflammatory responses through 
scavenging chemokines from the microenvironment in inflamed tissues. This leads to 
dampening of inflammation as shown in D6 knock out mice, which demonstrate an 
exaggerated cutaneous inflammatory response compared to wild type mice [124]. The 
ability of the decoy receptor to reduce inflammatory responses may have other impacts 
such as reduced metastatic spread in carcinomas [125]. Additionally, membrane surface 
expression of these decoy receptors is not down-regulated following prolonged exposure to 
ligands. Instead, as has been shown with D6 (inflammatory CC chemokines) and CXC-
CKR (CCL19, 21 and 25), these receptors constitutively bind, internalise and then deliver 
the chemokine to lysosomes for degradation, prior to recycling to the surface [126, 127]. 
There is also wider expression of these receptors on non-leukocyte cells than with ‘typical’ 
chemokine receptors. These various aspects support the role of decoy receptors as control 
mechanisms for inflammatory responses and the potential role of these in the pathogenesis 
of cancer and other conditions.  
1.2.7 Chemokines and Organisation of the Immune System 
Chemokines have a central role in effective functioning of both the innate and adaptive 
immune systems. Post capillary venules express different chemokine and integrin 
combinations depending on their tissue location. Whilst they control the trafficking of all 
leukocytes, this discussion will focus predominantly on lymphocyte development and 
trafficking, as an understanding of this is central to later discussions regarding lymphoma 
biology.  
1.2.7.1 Chemokine Control of Lymphocyte Trafficking 
In the adult, primary lymphoid organs consist of the bone marrow and thymus. These are 
the sites of lymphocyte production and chemokine receptor expression of the lymphocyte 
precursors and particular chemokine expression profiles lead to clearly defined 
microenvironments within these organs.  
 
The multi-step paradigm is thought to explain the process of adhesion and activation of 
leucocytes to tissues across high endothelial venules (HEV)[128]. Initially tethering and 
rolling of cells across endothelial surface occurs via transient interactions between 
selectins on cell surfaces and carbohydrate ligands or integrins. This enables the leukocyte 
to sample the endothelial surface for signals, such as chemokines, which trigger endothelial 
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adhesion and leukocyte arrest via integrin activation. Chemokines then direct the adherent 
cell to migrate trans-endothelially into extra-vascular tissues. The exact mechanism by 
which cells transmigrate through the endothelial lining is not entirely clear, but it has been 
shown continuous shear forces promote transmigration without the need for chemokine 
gradients [129]. From here the cell can migrate further through a series of chemokine 
gradients to target tissues. This process is diagrammatically represented in figure 1.7. 
 
 
Figure 1.9: Multistep paradigm of leukocyte adhesion and activation. Cells are initially 
transiently tethered by selectins on endothelial surfaces. This enables leukocytes to sample the 
endothelial surface for signals such as chemokines, which if encountered leads to adhesion on the 
endothelial surface via activation of integrins. Trans-endothelial migration of the adherent cell into 
extra-vascular tissues is then directed by chemokines.  
 
1.2.8 T Lymphocyte Development in the Thymus  
Pre-thymocytes enter the thymus via the cortico-medullary junction (CMJ). The first step 
in maturation requires CCR7 induction of migration of CD4-CD8-CD117+ or double 
negative 1/2 (DN1/2) thymocytes to the sub-cortical zone (SCZ). Disruption of the 
CCR/CCL19/CCL21 axis results in failure of this process with accumulation of DN1/2 
cells at the CMJ and a reduction in more mature, CD4-CD8-CD117- (DN3/4) cells [130]. 
During positive selection CCR7 expression is up regulated, enabling the CD4+CD8+ 
(double positive (DP)) cells to undergo guided migration into the medulla, where final 
maturation to single positive (SP) cells occurs [131].  
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Thymocyte migration of thymocytes to the cortex depends upon CXCR4 expression. 
CXCR4-/- precursors do not develop beyond the DN1 stage and tend to accumulate within 
the CMJ rather than migrating to the SCZ [132]. Failure to develop is probably due to lack 
of pro-survival signals in the CMJ compared to those the SCZ such as IL-7 [133]. Whilst, 
immature CCR9+ thymocytes usually accumulate within the SCZ, CCR9 directed homing 
might not be essential for thymocyte development. CCR9-/- thymocytes appear randomly 
distributed throughout the thymic cortex, but despite this abnormal localisation, maturation 
to SP cells appears to be intact [134]. CCR4 also assists in migration of T-cells following 
positive selection. CCL17 and CCL22 are produced by CD30L+ medullary cells, and thus 
guide “transitional” thymocytes into the medulla as CCR4 expression is increased [135]. 
However, CCR4 appears to be complementary rather than essential for thymic 
development with grossly normal thymus development in CCR4-/- mice [136]. 
 
Once development is complete, the positively/negatively selected SP cells up-regulate 
CCR7. CCR7 and CCL19, together with sphinosine-1-phospahte1 (S1P1), then enable 
migration of these naïve T-cells in to the circulation [137]. A summary of the position, site 
and receptor expression of thymocytes and different developmental stages, is shown in 
figure 1.8. 
                   
 
Figure 1.10: Positioning of thymocytes within the thymus and chemokine receptor 
expression at different developmental stages. [adapted from Stein, 2005 (138)] 
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1.2.9 Chemokines during B cell Development 
In adults B-cells are produced by and develop within the bone marrow under normal 
conditions.  B-cell precursors express a variety of receptors at different stages, the most 
important of which besides the chemokine receptors are shown in table 1.1. Chemokines 
and their receptors are essential for the development of the B-cell compartment. CXCR4 
plays the most central role in B-cell maturation with lack of CXCR4 or CXCL12 resulting 
in severely impaired B-cell development and has been shown to be essential at the earliest 
stages of B-cell development within the foetal liver [139]. Retention of B- cell precursors 
within the bone marrow microenvironment relies on CXCR4 mediated signals, preventing 
premature release of these cells into the circulation.  Interruption of the CXCR4/CXCR12 
axis leads to the mobilisation of myeloid and B-cell precursors into the circulation [140]. 
However, immature and naïve B-cells are subsequently released appropriately into the 
circulation despite continuing to express high levels of CXCR12. So, how are the retention 
signals bypassed with maturation? This appears to be related to integrin expression. Early 
precursors respond to CXCR4 signals by activating adhesion molecules such as VLA-4, 
allowing for retention, however as B-cells undergo maturation, activation of adhesion 
molecules diminishes until eventually adhesion mediated retention is lost [141]. Pro-pre B-
cells have also been shown to respond to CCL25, however, unlike CXCR4, CCR9 does not 
appear to be essential for B- cell maturation. CCR9-/- mice demonstrate reduced numbers 
of pro-pre B-cells, yet overall B-cell development is only minimally impaired, with a 
seemingly normal mature B-cell population [142]. 
 
As B-cells develop their ability to respond to chemokines predominantly associated with 
secondary lymphoid organs (CCL19, CCL21 and CXCL13) increases, with initial 
responsiveness to CCL21 and CCL19. Once the B-cells have egressed into the circulation 
they home predominantly to the spleen at the T-B cell border. Initially, CXCR5 expression 
is relatively low, but later increases in response to pro-survival signals from B-cell 
follicles, promoting migration in to these areas [143]. 
1.2.10 Homing of Naïve Lymphocytes to Lymph Nodes 
Naïve lymphocytes home to secondary lymphoid organs from the circulation. Migration of 
T-cells into secondary lymphoid organs is predominantly mediated by CCR7. Ligands for 
CCR7 are presented via endothelial cells on HEVs (CCL21) or on the luminal surface of 
HEVs following release from stromal cells in the lymph node T-cell areas (CCL19). The 
importance of CCR7 and its ligands are demonstrated with plt/plt (plt –paucity of lymph 
node T-cells) mice in which T-cell migration into and development of secondary lymphoid 
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organs is severely impaired. plt/plt mice have a deletion on chromosome 4 leading to the 
loss of expression of CCL19 and CCL21 [144] [145]. TFH cells also express CXCR5 
enabling their migration into the B- cell rich follicles, providing B-cell help. If the naïve T-
lymphocyte does not encounter its cognate antigen in 12 hours, it will re-enter the 
circulation to restart the process in another lymphoid organ.  
 
B-cell migration into secondary lymphoid organs shows slight differences, in part 
dependent upon the lymphoid tissue. In peripheral lymph nodes, both CXCR4 and CCR7 
are required for integrin activation on B-lymphocytes. Whilst CXCL13 is found in 
peripheral lymph nodes its role is uncertain, yet homing to Peyer’s patches does require 
CXCL13. The CXCR5/CXCL13 axis is also implicated in homing of B-cells to mesenteric 
lymph nodes [146]. B-cells also arrest on HEVs associated with B-cell follicles aided by 
CXCL13 production by follicular dendritic cells. There also appears to be a role for 
CXCR4 in maintaining B-cells within this area, highlighted by the observation that 
CXCR4-/- B-cells are not maintained solely within the follicles but can also be detected 
within the lamina propria [147]. Specialised cells are found within the B-cell follicle. 
Follicular dendritic cells are able to capture and display antigen on their surface. Again in 
the event that the B-lymphocyte does not meet its cognate antigen, after 24 hours it is re-
released into the circulation.   
1.2.11 Migration within and out of Secondary Lymphoid Organs 
Intra-vital microscopy has shown that T and B-cells move constantly within their 
microenvironment thus increasing the chances of them coming into contact with APCs or 
foreign antigens [148, 149]. These movements appear to be random rather than directed, 
however in the absence of CCL19/21 and CXCL13 chemokine gradients chemokinesis 
occurs, indicating that they are likely to be important in the positioning of cells [149]. In 
the event that the lymphocyte does not encounter its antigen it will leave the lymph node 
via efferent lymphatic vessels to re-enter the bloodstream. This egress appears to be 
regulated by shingosine-1-phosphate 1 (S1P1) receptors rather than chemokine receptors 
[150].  
1.2.12 Tissue Specific Homing of Leukocytes 
Specific combinations of adhesion molecules and chemokines provide a system whereby 
leucocytes are guided to where they are required. Furthermore, the presence of chemokine 
gradients within tissues provides further specificity to the final stages of leukocyte 
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migration. These combinations can be easily detected and consequently the specificity for 
homing to particular tissues can be elucidated.  
 
To clarify this concept further a well described, lymphocyte sub-set will be discussed. Gut-
homing lymphocytes express integrin α4β7, that mediates rolling and adhesion to intestinal 
venules through MAdCAM-1. Furthermore, it has been shown that α4β7hi cells have 
memory for intestinal pathogens [136]. Chemokines play an essential role in further 
specifying the tissue tropism of these lymphocytes. Out with the thymus, CCL25 is almost 
exclusively produced by epithelial cells, which are found in crypts of the small intestine. 
Moreover examination of intestinal lymphocytes reveals that almost all of the T-cells and a 
majority of B-cells co-express CCR9 and α4β7 [151]. Additionally, CCL25 appears to 
attract IgA producing plasma cells rather than those producing other immunoglobulin 
classes. These features therefore strongly suggest that these lymphocytes play a central role 
in the mucosal humoral immune response of the small intestine. Furthermore, inhibition of 
CCL25 inhibits migration of antigen-specific CD8+ T-cells to the small intestine, 
strengthening the case for a central role of CCR9/CCL25 interaction in lymphocyte 
localisation to the small intestine [152]. 
 
It should however be noted that not all chemokine receptor pairs have defined tissue-
tropism. Many others are broadly expressed in normal and inflamed non-lymphoid tissues, 
for example CXCR3 and CCR5 are expressed by nearly all tissue infiltrating T cells. These 
two receptors bind to many different ligands, which are predominantly expressed during 
inflammation. However, there is a high degree of redundancy in the system as highlighted 
by the effects of CCR5 deficiency in humans (discussed previously). It should also be 
noted that these chemokines receptors can not compensate for the loss of any of the tissue 
specific chemokines receptors. Figure 1.9 provides a summary of the chemokines and their 
receptors involved in the homing of lymphocytes to specific areas. 
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Figure 1.11: Known and proposed functions for constitutive chemokines and their receptors 
in lymphocyte development, trafficking and function. Taken from, Campbell et al 2003. 
 
How do tissue specific effector and memory cells arise? Lymphocyte precursors isolated 
from the intestinal or cutaneous lymphatic systems later localise to these areas, suggesting 
that the site at which the lymphocyte is activated determines its tissue tropism. There is 
emerging evidence that vitamins have a role in determining tissue tropism. Vitamin D3 
produced by sun-exposed DCs has been shown to induce T-cells to up-regulate CCR10 and 
thus induce skin-tropism, whilst simultaneously down-regulating the gut homing receptors 
α4β7 and CCR9 [153]. In contrast, retinoic acid produced by mucosal cells in the gut 
generates gut-homing tropism in T-cells, including Th-17 cells, up-regulating α4β7 and 
CCR9 [154, 155]. 
1.2.13 Chemokines and T cell Subsets  
1.2.13.1 Memory T cells 
Memory T-cells are distinguished by a CD4+CD45RO+ phenotype [156].  Currently they 
are classified as either central memory (TCM) or effector memory (TEM) lymphocytes. TCM 
cells are characterised by high CCR7 and L-selectin expression, thus retaining their ability 
to home to secondary lymphoid organs. TCM cells provide B-cell help and assist with 
immunoglobulin class switching [157]. In contrast, TEM cells have low CCR7 and L-
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selectin expression and after stimulation produce a range of cytokines and up-regulate the 
chemokine receptor expression required for migration to the inflamed tissues [157].  
 
However, this division may be over simplistic. CCR7 expression can often be detected on 
effector cells within inflamed tissues, although as the TEM cells migrate to more peripheral 
tissues, CCR7 expression tends to become down-regulated [158]. Yet, CCL19 and CCL21 
are often presented on the post capillary venules under certain inflammatory conditions 
[159], and the presence of CCR7+ TEMcells may reflect their homing capacity under these 
circumstances. Additionally, TCM cells have been detected out with secondary lymphoid 
organs [160]. 
 
These findings demonstrate a number of points. Firstly, CCL19 and CCL21 can act as both 
inflammatory and homeostatic chemokines. Secondly, it reiterates the point that chemokine 
expression alone is not sufficient to determine the migratory paths taken by cells. Finally, 
the distinction between TEM and TCM cells is not as transparent as initially described once 
in vivo studies are carried out. 
1.2.13.2 Helper T-cells 
Th1 and Th2 cells express particular chemokine receptors patterns with Th1 cells 
expressing CXCR3 and CCR5 and Th2 cells expressing CCR4, CCR3 and CCR7, whilst 
both subsets express CXCR4, CCR1 and CCR2 [161, 162]. The expression of chemokine 
receptors and response to specific chemokines fits with their proposed roles in immunity. 
For example allergic reactions require the presence of Th2 cells, the ligand for CCR3 and 
CCR11, is up regulated in sites where such reactions take place [162]. However, as is often 
the case, the picture becomes less clear with in vivo studies. Examination of T-cell subsets 
in human blood revealed more heterogeneous populations, with populations of Th1 cells 
co-expressing chemokine receptors, thought to reflect a Th2 phenotype and vice versa, for 
example CXCR3+CCR4+ positive cells could be detected in both subsets [163]. This 
highlights that the system is far more complex and rigid categorisation of these cells and 
their migratory capacities is not helpful.  
 
As described previously, these cells are characterised by low CCR7 expression and high 
CXCR5 expression, thereby facilitating their positioning within the CXCL13, producing 
germinal centres to provide germinal centre B-cell help. 
Th17 cells have been implicated in the development of inflammation. Th17 cells are able 
to recognise signals released from inflamed tissues, and have been shown to express 
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CCR2, CCR5, CCR7, CXCR3 and CCR4, and CCR6 [164, 165]. There is an overlap with 
those chemokine receptors expressed by both Th1 and Th2 cells, likely to reflect the fact 
that these subsets all migrate to inflamed tissue. Th17 cells also share chemokine receptor 
profiles with T-regulatory cells (namely CCR4, CCR5, CCR6, CXCR3 and CXCR6) and 
these cells are often co-located [165]. This would be beneficial, in that the T-regulatory 
cells can act as a dampener to profound inflammatory responses produced by Th17 cells.  
1.2.13.3 Regulatory T cells 
Regulatory T-cells (Tregs) have a homeostatic function by suppressing T-cell activation 
and promoting self-tolerance. Tregs are currently divided into subsets dependant upon the 
expression of αEβ7 integrin [166]. αEβ7+ Tregs (both CD25+ and CD25-) display a TEM cell 
phenotype reflected in mRNA expression of CCR4, CXCR3 and CCR6 and migrate in 
response to the inflammatory chemokines CCL17, CXCL9 and CCL20,  [167]. Thus 
reflecting their ability to migrate to inflamed tissues and mitigate inflammatory responses 
there. The αEβ7- Tregs are all CD25+, and re-circulate through lymphoid tissues, express 
CCR7 and respond readily to CCL19 thus homing efficiently to secondary lymphoid 
organs [167]. Re-circulating of these Tregs provides immunosurveillance by increasing the 
chance of encountering inflamed tissues.  
1.2.14 Germinal Centre Organisation and B cell Immune Responses 
At the time of an immune response the correct positioning of B and T-cells is vital. T-cell 
activation leads to up-regulation of CXCR5 and down-regulation of CCR7, whilst the 
converse occurs in B-cells allowing for interaction at the T-B cell border. A number of 
activated B-cells then form the germinal centre, becoming organised into dark and light 
zones. In the former centroblasts are attracted and retained via CXCL12 released by the 
stoma interacting with CXCR4 on the B-cell surface [168]. CXCR5 bearing cells, both B-
cells and follicular T-helper cells, home to form the light zone in response to CXCL13 
released by follicular dendritic cells [168, 169], where affinity maturation and class 
switching with assistance from TFH cells occurs. The resulting B-cell populations then 
home according to their initial site of induction.  
1.2.15 Initiation of Immune Responses by Constitutive Chemokines 
The role of chemokines in the initiation of immune responses does not appear to be 
essential. In CCR7 deficient mice, there is a disturbed lymph node micro-architecture due 
to defective homing of dendritic cells and T-cells, however, immune reactions as measured 
by immunoglobulin production do occur, although at lower levels and with different 
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isotypes [88]. Additionally, plt/plt mice lacking expression of both CCL19 and serCCL21 
(a murine variant of CLL21), display disturbed lymphoid architecture despite this, 
pronounced T-cell responses could be elicited following antigen exposure, albeit delayed 
and with altered dendritic and T-cell localisation within lymph nodes [145]. Further work 
on plt/plt mice demonstrated a delayed/absent resolution of the inflammatory responses 
when compared to wild type mice [145], implicating the lack of constitutive chemokines 
and subsequent lymphoid organ organisation in the defective immunosurveillance and Treg 
function. Therefore whilst initiation is not completely impaired by the absence of certain 
constitutive chemokines, it is possible that resolution may well be. 
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1.3 Non-Hodgkin’s Lymphoma 
In section 1.1 the immune system and in section 1.2 the chemokine system was outlined 
with a particular emphasis on the adaptive immune system. Central to the adaptive immune 
system are lymphocytes and this section discusses the clinical and pathological aspects of 
one of the diseases involving the lymphoid system, and the disease under study in this 
project - non-Hodgkin’s lymphoma. 
1.3.1 Historical Perspective 
Lymphoma is a malignancy of the lymphoid system. Whilst its main sites of involvement 
are the primary or secondary lymphoid organs, it can affect any site in the body, due to 
infiltration by malignant lymphocytes. The pathological appearance of the disease was first 
described by Thomas Hodgkin (figure 1.10a) in 1832 in his paper titled "On Some Morbid 
Appearances of the Absorbent Glands and Spleen" [Reviewed in 170]. It was later when 
Samuel Wilkes revisited the disease that it was given the eponymous name of Hodgkin's 
disease [171]. Some 60 years later lymphoma was further classified into Hodgkin's disease 
and non-Hodgkin's lymphoma (NHL). Dorothy Reed and Carl Sternberg described the 
presence of the cell now termed the Reed-Sternberg cell [172, 173] shown in figure 1.10d. 
This cell, currently thought to be a germinal B-cell, distinguishes the two broad categories 
of lymphoma from each other, with Hodgkin's disease having the Reed-Sternberg cell.  
 
In the 1940’s NHL was the first malignancy for which chemotherapy was used, with 
mustine producing a dramatic, but short-lived reduction in tumour bulk [174]. Since that 
time a number of advances in treatment have led to improved outcomes for those affected 
by NHL. First attempts at NHL classification were based on histological appearances and 
included three subtypes [175]; this has been replaced by numerous classification systems 
over the decades with increased understanding of the biology and clinical outcomes of 
NHL. The WHO classification, containing over 60 NHL subtypes (see appendix 8.1), is 
based on histological, immunophenotypical, cytogenetic and molecular characteristics and 
is now the current standard [176]. Lymphomas were also the first diseases in which clinical 
tumour staging systems were proposed. The original Rye staging was described in 1966 
[177], subsequently this was revised and the Cotswold Revised Ann Arbor staging 
classification is now in use [178].  
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So, from the initial descriptions by physician and philanthropist Thomas Hodgkin in 1832 
to molecularly targeted therapies in 2010, our understanding and treatment of lymphomas 
has come a long way. 
 
     
a)                                                             b) 
    
c)                                                                       d)  
Figure 1.12: Illustrations and images of Hodgkin’s Disease: a) Portrait of Thomas Hodgkin b) 
Hodgkin's disease watercolour drawing by Robert Carswell in 1828 of case number 7 in Hodgkin’s 
paper, c) Photograph of abdominal lymph nodes from Thomas Hodgkin’s 2nd case now kept in the 
Gordon Museum, GKT, King's College London, d) An image of Dorothy Reed’s original illustration 
of Reed-Sternberg cells, demonstrating the characteristic large binucleated cells. 
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1.3.2 Epidemiology of Lymphoma 
NHL is approximately six times more common than Hodgkin’s lymphoma and is currently, 
the fifth most common malignancy in men and the seventh in women in the UK. It is more 
common in men, and Caucasians have a higher incidence than other races. Whilst 
Hodgkin’s lymphoma incidence has remained stable over time, the incidence of NHL is 
increasing by 3-5% per year (Figure 1.11B); this appears to be a genuine worldwide trend. 
Whilst there is increasing incidence with advancing age (Figure 1.11A), an aging 
population cannot entirely account for this, as shown in figure 1.11B where the incidence 
is adjusted for age. There have been many theories as to why this is occurring but as yet, 
the actual cause is unknown. There are also differences in incidence and predominant NHL 
subtypes worldwide, with T-cell lymphomas being more common in the Far East and 
Burkitt’s Lymphoma predominating in certain areas of Africa.  
 
Over the last 30 years there has been an improvement in treatment outcomes with 
Hodgkin’s lymphoma patients, with a five-year survival of 80% or more. However, 
improvements in overall survival for those with NHL has only gradually improved, with 
falling mortality rates only observed within the last 5 years or so. This latter aspect is 
interesting, as the mortality rates have fallen despite increasing incidence (Figure 1.11D). 
In the last decade an anti-CD20 monoclonal antibody, rituximab, has been used widely in 
the treatment of the more common B-cell lymphomas, leading to significantly improved 
outcomes, which may in part have contributed to the reduced mortality rates. The latest 
available data shows that in the UK, there were 10,569 new cases of NHL in 2006, whilst 
in 2008 there were 4,533 deaths relating to NHL. A major factor in overall survival is age, 
with older patients faring less well than younger patients with current five year survival 
figures for the 65-74 male group being 53% compared to 73% in the 15-44 male age group 
[ISD, National Services Scotland 179]. It is also interesting to note that there does not 
appear to be a significant impact of social deprivation or ethnicity on the incidence of NHL 
within the UK.  
 
Except where specified, the statistics quoted in this section and the data used to formulate 
the graphs have been obtained from the Cancer Research UK, Cancer statistics pages 
[180]. 
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Figure 1.13: Graphical representation of the incidence of NHL and the mortality rates 
associated with NHL in the UK. A) Differences in NHL incidence rates according to age and sex, 
B) Demonstration of increasing age adjusted incidence of NHL over time, C) Differences in NHL 
mortality rates according to age and sex, D) Age standardised mortality rates over time Data and 
graphs from Cancer Research UK (2009). 
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1.3.3 Aetiology of NHL 
In the majority of cases the aetiology of NHL is unknown. With the increasing incidence of 
NHL, a wide range of potential risk factors have been explored. Smoking, hair dye use and 
exposure to ionizing or non-ionizing radiation do not appear to increase the risk of NHL 
[181, 182]. Other factors show weak associations such as benzene, herbicide 
nitrites/nitrates exposure or working in agricultural, farming or manufacturing occupations, 
although of course these factors are linked [183, 184] and, there is emerging data 
indicating that there may be a link between silicone breast implants and primary breast 
ALK1-negative anaplastic large cell lymphoma [185]. Finally, other studies have shown a 
trend towards a lower risk of NHL with exposure to sunlight and alcohol consumption 
[186, 187].   
 
In a minority of cases the causative agent can be established, including particular 
microorganisms, immunosuppressive agents, autoimmune disorders including rheumatoid 
arthritis and inherited immunodeficiency states. The most established microorganism 
associated with lymphoma is the Epstein-Barr virus (EBV). EBV was first discovered in 
samples given to Epstein by Burkitt of cases now known as Burkitt’s lymphoma [188, 
189]. Since that time EBV has been implicated in the pathogenesis of a number of other 
lymphomas including NK cell lymphomas, post-transplant lymphoproliferative disease and 
a proportion of Hodgkin’s lymphoma cases [190].  
 
Human immunodeficiency virus (HIV) is associated with an approximately 100 fold 
increased incidence of lymphoma, with a higher than normal incidence of more aggressive 
subtypes such as Burkitt’s lymphoma and primary CNS lymphoma [176, 191]. Human T-
lymphocyte virus (HTLV) is associated with adult T-cell lymphoblastic 
leukaemia/lymphoma, which is more common in Japan and the Caribbean reflecting 
increased rates of HTLV infection in these populations [192]. Hepatitis C virus (HCV) is 
associated with low and high grade lymphomas [193], whilst Human herpes virus 8 
(HHV8) is associated with primary effusion lymphomas [194].  
 
Chronic infection with bacteria has also been associated with the development of NHL. 
Helicobacter pylori is associated with gastric lymphomas, especially gastric MALT 
lymphomas [195] and eradication of this organism leads to resolution of the lymphoma in a 
significant proportion of those affected [196]. Chlamydia psittaci infection has been 
associated with MALTomas of the lacrimal glands [197] and Borrelia Bergdorfi has been 
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associated with NHL [198].  It is likely that further associations between viral and bacterial 
infections and particular NHL subtypes will become apparent over time.  
 
Finally, there is a strong association with disorders or drugs that cause immune 
dysfunction. A number of immunodeficiency states, whether inherited, acquired or 
iatrogenic have a strong association with the development of lymphoma as well as 
conversely chronic inflammatory conditions such as rheumatoid arthritis [199]. EBV-
driven post-transplant lymphoproliferative disorders occur on the background of 
immunosuppression following solid organ or bone marrow transplantation, in some 
instances withdrawal of immunosuppressive agents leads to regression of the lymphoma 
[Reviewed by 200]. 
 
1.3.4 Clinical Features 
NHL presents in a variety of ways and it can, at times, be difficult to establish the 
diagnosis. The median age at diagnosis typically lies in the 6th or 7th decade of life. In the 
majority of patients painless lymphadenopathy is a presenting feature ranging from, a 
single node to widespread lymphadenopathy. Patients may also have splenomegaly or 
hepatomegaly at presentation. The presence of “B” symptoms is significant; these include 
unexplained fevers of greater than 38oC, drenching night sweats and unexplained weight 
loss of more than 10% of their body mass over 3 months, conferring an unfavourable 
outcome. However, lymphomas can develop in any anatomical site, and extra-nodal 
disease causing a range of symptoms and clinical signs depending on its location. For 
example, common extra-nodal sites include the skin presenting as nodules or generalised 
skin rashes, gut lymphomas can present with indigestion, diarrhoea or even bowel 
obstruction, and mediastinal involvement with features ranging from mild shortness of 
breath, chest pain through to potentially life threatening superior vena-cava obstruction. 
Less common sites include the bones presenting with fractures, spinal cord compression 
and/or bone pain, the central nervous system presentation including but not limited to 
hemiparesis, cranial nerve palsies, cognitive impairment and even cerebellar signs; more 
rarely, ovarian, kidney and pancreatic involvement has been described. Therefore, knowing 
that lymphoma can present in such a myriad of ways, it is no surprise that it can be 
frequently difficult to diagnose.  Most of the information above can be found in standard 
medical or general haematology textbooks such as Postgraduate Haematology, [214].  
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1.3.5 Diagnosis of NHL 
 A number of investigations are required to confirm a diagnosis of NHL.  These range from 
simple haematological and biochemical tests to more complex molecular testing.  A full 
blood count is often normal, however if patients have heavy bone marrow infiltration, 
anaemia thrombocytopenia and/or leucopoenia may result. Lymphopenia when seen often 
negatively impacts on the prognosis. In certain lymphoma subtypes anaemia or 
thrombocytopenia may occur due to autoimmune phenomena this is particularly true of 
chronic lymphocytic leukaemia/ small lymphocytic lymphoma (CLL/SLL). Testing for 
lactate dehydrogenase (LDH), albumin, and beta-2-microglobulin impact on prognostic 
scores. Some lymphomas may be associated with monoclonal gammopathies or 
hypogammaglobulinaemia, and so testing for these can be useful.  
 
Investigating the possibility of an aetiological agent is always advisable with serology for 
EBV, HIV, and Hepatitis C forming part of the lymphoma work up. Hepatitis B and CMV 
status are also checked and have implications for treatment, the presence of the former 
being a relative contra-indication for rituximab and the latter guides the type of blood 
products used in supportive care.  Other microbial testing is guided by the NHL sub-type, 
e.g. HTLV-1 testing in those with T-cell leukaemia/lymphoma. 
 
A tissue biopsy is essential to establish the diagnosis and treatment should not be 
commenced on suspicion alone. Definitive histology is obtained by biopsy of the affected 
gland or tissue.  Sides are examined with haematoxylin and eosin (H & E) staining initially 
before deciding upon immunohistochemistry panels. Various antibody panels have been 
developed to aid in the diagnosis of NHL subtypes and guidance on appropriate panels can 
be found in guidelines published by the British Committee for Standards in Haematology 
(www.bcshguidelines.com). An outline of the immunophenotypes for the more common 
B-cell lymphomas is shown in table 1.4. Demonstration of clonality is an integral aspect of 
lymphoma diagnosis. For B-cell lymphomas this is relatively easy, B cells express either 
kappa or lambda light chains on the surface, with a normal κ: λ ratio of 2-4:1, if there is a 
clonal B-cell population then this ratio is disturbed with either kappa or lambda restriction. 
However, T-cell clonal populations are less easy to detect and PCR is required to 
demonstrate a monoclonal TCR αβ or γδ population. 
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Further tests including cytogenetic analysis, fluorescent in-situ hybridisation, and 
molecular studies are also indicated in certain lymphomas, some of which will be explored 
later. 
 
 
 
 
 
 CD20 CD79a CD10 Bcl-6 CD5 CD23 Cyclin 
D1 
Bcl-2 Others 
Follicular lymphoma + + +/- + - -/+ - +/- MUM1- 
CLL/SLL* + + - - + + - +  
Lymphoplasmacytic  
Lymphoma 
+ + - - - - - + CD25-/+ 
CD11c- 
B-cell PLL# + + -/+ -/+ -/+ - - +  
Nodal marginal zone 
lymphoma 
+ + - - - - - + CD11c +/- 
Extranodal marginal 
zone lymphoma 
+ + - - - - - + CD11c 
+/- 
Splenic marginal zone 
lymphoma 
+ + - - - - - + DBA44 
-/+ 
CD25-/+ 
Mantle cell lymphoma + + - - + - + + MUMI- 
CD11c- 
Myeloma/ 
plasmacytoma 
-/+ +/- - - - - -/+ - MUM1+ 
CD138+ 
CD38+ 
DLCBL^ germinal 
centre type 
+ + + + -/+ -/+ - +/- MUM1- 
DLBCL activated B-cell 
type 
+ + - -/+ -/+ -/+ - +/- MUM1+ 
Mediastinal large B-
cell lymphoma 
+ + -/+ + - +/- - +  
Burkitt’s lymphoma + + + + - - - - MUM1 
Table 1.4: Immunophenotypic profile of B-cell non-Hodgkin’s lymphomas. CLL/SLL – chronic 
lymphocytic leukaemia/small lymphocytic lymphoma, #PLL-prolymphocytic leukaemia, ^DLBCL – 
diffuse large B-cell lymphoma. [Taken from 215]. 
 
Once the diagnosis of NHL has been confirmed testing is required to stage the disease. 
Computed Tomography (CT) scanning (figure 1.12b) is employed to determine how 
extensive lymphoma is enabling clinicians to determine how many lymph node groups are 
involved and if there is any extra-nodal organ involvement. A bone marrow biopsy is 
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performed on every patient requiring treatment with the presence of lymphoma in the bone 
marrow automatically classifying the patient with advanced disease.  On occasion, the 
diagnosis is made on the bone marrow leading to a search for lymphoma elsewhere. Other 
investigations such as examination of cerebro-spinal fluid (CSF), magnetic resonance 
imaging (MRI) (figure 1.12d) or bone scans may also be required, depending upon the 
setting. Once information from CT and bone marrow studies have been collated, the 
patient is then staged using the Cotswold revision of the Ann Arbor staging classification 
[216], outlined in table 1.5.   
 
In recent years fluorodeoxyglucose-positron emission tomography (FDG-PET) has been 
utilised in staging and response assessments of patients with higher grade NHLs and 
Hodgkin’s lymphoma. Increased PET avidity reflects an increased metabolic rate and thus 
highly metabolic lymphomas can be distinguished from physiological activity (figure 
1.12c). Its role in management of lymphomas is becoming clearer, certainly, if a patient is 
PET-negative at the end of treatment, they have an improved outcome and may escape 
consolidative treatment such as radiotherapy [178]. 
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a)                                                               b) 
 
 
c)                                                                 d)   
Figure 1.14: Radiological images from patients with lymphoma. a) Plain chest x-ray 
demonstrating a widened mediastinum due to lymphadenopathy, b) CT-scan of the same patient 
highlighting the mediastinal mass, c) FDG-PET scan, showing abnormal, increased avidity in the 
mediastinum and left axilla (red and yellow), the brain and bladder are PET avid due to the high 
metabolism in the brain, and excretion of the FDG through the bladder, d) MRI scan of brain, 
demonstrating lesion in the left cerebellum. (These images were obtained from patients seen at the 
Gold Coast Hospital, QLD, Australia). 
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Stage Definition 
I Involvement of a single lymph node region or lymphoid structure (e.g. spleen, thymus, Waldeyer 
ring) 
II Involvement of two or more lymph node regions on the same side of the diaphragm (the 
mediastinum is a single site; hilar nodes are lateralized); the number of anatomic sites should be 
indicated by suffix (e.g.II3) 
III Involvement of lymph node regions or structures on both sides of the diaphragm. 
 
III1 With or without splenic, hilar, coeliac or portal nodes 
III2 With para-aortic, iliac or mesenteric nodes 
IV Involvement of extranodal site(s) beyond those designated E, including bone marrow 
E, involvement of a single extranodal site, or contiguous or proximal to known nodal site of disease 
Stage followed by A or B where: 
A – absence of symptoms 
B- presence of B symptoms; ≥ 10% loss of body mass in preceding 6 months, drenching night sweats, 
unexplained fevers of ≥ 380C for 3 or more days. 
Table 1.5: Cotswolds revision of the Ann Arbour Staging Classification [217]. 
 
1.3.6 Classification of NHL 
Non-Hodgkin’s lymphoma consists of a diverse range of tumour types, which are currently 
classified according to the World Health Organisation system [178]. These are based on 
the histology, immunocytochemistry and molecular biology (Appendix 8.4). The subtypes 
of lymphoma behave very differently with regards to their clinical presentation, course and 
distribution of disease.  
1.3.7 General Principles of Treatment 
Very occasionally treatment modalities such as triple therapy (proton pump inhibitor, 
metronidazole and amoxicillin) in the case of H.pylori related MALTomas, or surgery for 
localized gastric lymphomas may be employed. However, at present the mainstay for the 
treatment of NHL involves the use of immunotherapy, chemotherapy, radiotherapy or a 
combination of the three. The problem with the latter two treatment modalities is the 
degree of toxicity to non-malignant tissue. Chemotherapy is given systemically and has 
numerous potential short-term and long-term side effects including immunosuppression, 
cytopenias, emesis, alopecia, renal and hepatic toxicity, neuropathies, mucositis, 
cardiomyopathies, pulmonary fibrosis, haemorrhagic cystitis, infertility and unfortunately 
an increased risk of secondary tumours, particularly leukaemia. The development of side 
effects depends upon the type of chemotherapeutic agent used, its quantity and duration. 
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Additional modalities such as autologous or allogeneic stem cell transplantation may also 
be utilised in lymphoma management with similar toxicity profiles with the additional 
complication of graft versus host disease in the latter. 
 
Whilst the side effects of radiotherapy are more likely to be localised, the side effects are 
again numerous including localised burns and mucositis, marrow suppression (pelvic 
irradiation), adhesions, skin malignancies, cardiac failure, pulmonary fibrosis and an 
increased risk of second malignancies, especially skin or breast cancer within radiotherapy 
fields. 
 
Although these treatments are undoubtedly efficacious in a proportion of patients, toxicity 
limits the amount of treatment given and so alternate treatment modalities have been 
sought. Rituximab is a monoclonal human anti-CD20 antibody. CD20 is found on the 
surface of mature B-cells, and thus on mature B-cell tumours. Rituximab has been shown 
to increase response rates and 5year survival in elderly patients who receive this as an 
adjunct to standard chemotherapy for DLBCL [176]. It is has also been shown to improve 
outcomes in other B-cell lymphomas and is now a standard addition to treatment for these. 
However there are still a significant number of patients for whom this additional treatment 
is ineffective, and exploration of alternative immunotherapies are ongoing, including 
idiotype anti-lymphoma vaccinations and the use of cytotoxic T-lymphocytes (CTLs). The 
use of EBV specific CTLs in EBV driven post transplant lymphoproliferative disease 
(PTLD), has had some success [218].  
 
In addition to immunotherapy, molecularly targeted treatments are being trialed. The 
proteosome inhibitor, bortezomib, has been shown to have some activity in mantle cell 
lymphoma [219]. Other agents target epigenetic phenomena, and the histone deacetylase 
inhibitor, vorinostat, has shown efficacy in T-cell lymphomas [220]. Finally, the 
immunomodulatory drugs (IMiDs) thalidomide and lenalidomide have also given some 
promising results in those with mantle cell lymphoma [221].  
 
It can be seen, that there is still the need to develop more specific and less toxic therapies 
in lymphoma and one potential avenue for such therapy development is the exploitation of 
the chemokine system.  
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1.3.8 Pathophysiology of NHL 
Distinct NHL subtypes have different pathological mechanisms, but this discussion will be 
limited to those driving the B-cell lymphomas, reflecting the clinical sub-types examined 
in this thesis. 
1.3.8.1 Genetic and Molecular Aspects of B-cell Neoplasms 
Morphological and immunophenotypical studies of malignant B-cells have demonstrated 
that different subtypes appear to be “stuck” at particular stages of differentiation. Recent 
developments in molecular profiling have shown how malignant B-cells ‘hijack’ the 
regulatory mechanisms of normal B-cells to their own nefarious ends. During 
differentiation, modification of DNA occurs at a number of points, which can result in 
disruption of genes and lead to oncogenic processes.  
 
The point at which this may occur is during V(J)D gene rearrangement. In lymphomas 
RAG mediated recombination may be aberrant leading to chromosomal translocations in 
which regulatory gene sequences drive inappropriate genes, this occurs with the t(14;18) 
translocation detected in follicular lymphomas and a proportion of diffuse large B-cell 
lymphomas (DLBCL). With t(14;18) the gene for IgH drives BCL-2, leading to over 
expression of the latter [201]. Aberrant over expression of BCL-2 results in inhibition of 
programmed cell death, providing NHL cells with a survival advantage over their normal 
counterparts [202]. In mantle cell lymphoma, t(11;14), is also a consequent of RAG 
complex dysfunction, here the IgH gene drives CCND1, encoding cyclin D1, leading to 
over expression and subsequent dysregulation of the cell cycle and bypassing of tumour 
suppressor genes such as p21 [203]. Whilst these translocations are necessary in the 
pathogenesis of lymphomas, they are not sufficient, and other poorly understood 
mechanisms are required for disease development.  
 
Deregulation of a mutator enzyme, activation-induced cytidine deaminase (AID), may also 
have a role in the development of aberrant translocations mediated by the RAG complex 
[204]. DNA breakages also occur within the germinal centre, during somatic 
hypermutation and class-switch recombination. Both of these mechanisms rely on AID 
[205]. It perhaps no surprise then that, many lymphomas arise from the germinal centre, 
where AID appears to be central to these processes and thus implicated in the pathogenesis 
of many lymphomas.  Mouse models have demonstrated that over expression of AID is 
associated with development of DLBCL [206]. In DLBCL, errors during somatic 
hypermutation dependant upon AID, lead to the accumulation of mutations in proto-
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oncogenes such as PIM1 and MYC, the latter of which is involved in control of cell 
growth, proliferation and apoptosis [207]. Class switch recombination is also mediated by 
AID, with the risk of aberrant breaks in the IgH, this occurs with translocations involving 
the MYC locus, leading to over-expression and dysregulation of a variety of intra-cellular 
homeostatic mechanisms, and the eventual development of Burkitt’s lymphoma [208].  
 
Whilst these mechanisms explain the aberrant expression of proto-oncogenes and 
regulatory genes, how do they explain the maturation arrest observed in B-cell neoplasms? 
One way, in which this occurs, is demonstrated by the role of BCL-6 in DLBCL. BCL-6 is 
a repressor of transcription found in cells originating from the germinal centre, when this is 
involved in translocations, over expression leads to suppression of genes such as Blimp-1 
which is a master regulator of plasma cell differentiation [209]. Alternatively, neoplastic 
cells may lose their response to microenvironmental triggers of differentiation such as 
antigens, cytokines and other immune cells. Under normal circumstances, antigenic 
stimulation is required for triggering of the BCR leading to phosphorylation of IκBα and 
its subsequent degradation, which usually sequesters NF-κB within the cytoplasm. This 
enables NF-κB to relocate to the nucleus where target genes involved in the prevention of 
apoptosis and the stimulation of autocrine signals are then activated. In malignant B-cells 
such as the ABC-subtype of DLBCL, constitutive activation of NF-κB negates the need for 
antigenic stimulation, thus rendering the cells non-responsive to environmental 
components [Reviewed in 207]. 
1.3.8.2 Antigenic Stimulation 
The role of chronic antigenic stimulation is highlighted by chronic infections with bacteria 
such as Helicobacter pylori and Chlamydia psittaci, and viruses such as Epstein Barr virus 
and Hepatitis C and their strong association with lymphoma. Eradication of these 
microorganisms can lead to disease regression. Gastric MALT lymphomas have a strong 
association with Helicobacter pylori infection, therapy to eradicate the bacteria leads to 
resolution of the lymphoma in up to 70% of cases [207], a similar picture is seen with 
splenic marginal zone lymphomas when hepatitis C is treated with interferon alpha therapy 
[210]. 
1.3.8.3 Role of the microenvironment 
Whilst it is clear that the microenvironment has a huge role to play in the pathogenesis of 
Hodgkin’s lymphoma, where less than 1% of the tumour bulk is comprised of the 
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malignant cells, our understanding of the role the microenvironment in the pathogenesis of 
NHL is only just beginning. Over the last decade gene expression profiling (GEP) has been 
utilised to better characterise both malignant and non-malignant cells within tumours, these 
studies have revealed that the non-malignant cells in the microenvironment also have an 
influence on the outcome and response to treatments. 
 
GEP profiling applied to malignant (CD19+) and non-malignant (CD19-) cell populations 
from follicular lymphoma tissue reveal that two non-malignant gene-expression signatures, 
immune response-1 and immune response-2, are more predictive for outcome than 
differences in malignant cell profiles [211]. Further studies have confirmed the role of the 
tumour-infiltrating cells on prognosis in follicular lymphoma with poorer outcomes 
associated with profiles similar to those found in normal activated lymphoid tissue, with 
mediators of activated T-cells, macrophages and follicular dendritic cells being over-
expressed, particularly CCL19, CCL20 and CCR1, along with a tendency for the T-cell 
population to be that of T helper 1 type. In contrast those with a more favourable outcome 
demonstrate non-activated T-cell signatures [212]. 
 
Examination of the cellular milieu and extra-cellular matrix in DLBCL has also 
demonstrated differences. Two stromal signatures are identified, the first conferring a more 
favourable outcome compared to the second. In stromal signature 1, there are changes 
consistent with a more fibrotic picture, with extra-cellular matrix deposition and infiltration 
by histiocytes; this is associated with a better outcome. In contrast stromal signature 2 
reveals an increase in endothelial cells and pro-angiogenic cytokines such as VEGF and 
CXCR4, and an adverse outcome [213].  
 
It is thought that the cellular milieu and the cytokines they release influence the behaviour 
of these malignancies by ensuring the most advantageous positioning within the bone 
marrow or lymph nodes thus enhancing their exposure to various survival signals. 
Additionally, understanding the nature of these microenvironments, adds to the list of 
potential therapeutic agents, for example a monoclonal antibody to VEGF, bevacizumab, is 
being investigated in phase 2 and phase 3 trials in those with DLBCL [214]. 
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1.3.9 B-cell Neoplasms Studied in this Thesis 
Below is a more detailed discussion of the six NHL sub-types studied in this project. 
1.3.9.1 Diffuse large B-cell lymphoma 
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma Worldwide, 
accounting for 30-40% of new cases. No obvious aetiological agent has been detected for 
the majority of cases of DLBCL, however, a small proportion arise on a background of 
HIV or EBV infection. DLBCL is a high-grade lymphoma and is potentially curable. It can 
arise de-novo or on the background of more indolent lymphomas such as follicular 
lymphoma or CLL/SLL.  Diagnosis depends upon finding a clonal B-cell population and 
the pattern of cell markers seen in DLBCL is shown in table 1.4. The most common 
translocation detected in DLBCL involves 3q27 and the coding region for BCL-6 [222]. 
The typical t(14;18) translocation of follicular lymphoma is found in 20-30% of cases of 
DLBCL and may reflect transformation from follicular lymphoma [223]. The translocation 
associated with Burkitt’s lymphoma, t(8;14), and the associated oncoprotein, c-myc, is 
present in up to 15%. Distinguishing DLBCL from Burkitt’s lymphoma may therefore be 
difficult [224].  
 
DLBCL encompasses a fairly heterogeneous group of lymphomas, with gene expression 
profiling, revealing 4 distinct sub types; germinal centre (GC) cell type, activated B-cell 
(ABC) type, primary mediastinal B-cell lymphoma and type 3. Markers can be used to 
distinguish between these types, with MUM1 being positive in ABC type but negative in 
GC type [225]. However, at present this distinction does not alter therapeutic choices. 
The revised international prognostic index (R-IPI) for DLBCL takes in to account the 
impact of rituximab on outcomes in DLBCL. It is based on a number of clinical features 
each scoring 1 and include age greater than 60 years, Ann Arbor stage III/IV, ECOG 
performance status > 2 (appendix 8.5), elevated LDH, and more than 1 involved extra-
nodal site. The patient are then categorised as very good, good or poor risk with an 
estimated 4-year overall survival of 94%, 79% and 55% respectively. (see table 1.6). The 
prognostic score doesn’t alter initial management, but will guide patient counseling, and 
may assist decisions on entry into available clinical trials or consolidative treatment [226].  
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 No. of IPI 
factors 
% of patients 4-year EFS*, 
% 
4-year OS#, % 
Very good 0 10 94 94 
Good 1,2 45 80 79 
Poor 3,4,5 45 53 55 
Table 1.6: Revised-International Prognostic Index and observed outcomes at 4 years [227]. * 
EFS – event free survival, #OS- overall survival. 
 
CHOP (cyclophosphamide, hydroxydoxorubicin, vincristine (Oncovin) and prednisolone) 
has formed the backbone of DLBCL therapy since the 1970’s. CHOP has traditionally 
been given every 21 days for 6-8 courses. For those with early, stage I-IIA disease, the 
addition of rituximab to CHOP (R-CHOP) has lead to survival exceeding 90% in those 
receiving six courses of R-CHOP or undergoing dual modality (with radiotherapy) 
treatment [227, 228]. R-CHOP also forms the mainstay of treatment for those with 
advanced disease. The GELA study compared CHOP with R-CHOP in elderly patients, 
revealing a significantly increased survival, response rate and failure free survival in the R-
CHOP arm [229]. Similar results were obtained in the MInT study with younger patients 
[218].  
 
Following treatment, CT and PET scan +/- bone marrow examination depending on 
marrow findings at diagnosis are performed to assess response. Complete response (CR) is 
defined as there being no detectable disease. In a sub-group of patients, i.e. those starting 
with bulky disease (>10cm diameter) consolidative radiotherapy to the site of initial bulk is 
often employed, especially if there is still avidity by PET or a residual mass of  >1.5cm in 
diameter.  
 
In sub-groups of patients with DLBCL additional or alternative treatment modalities may 
be required. CNS prophylaxis is used in patients identified as being at high risk including 
those with testicular, sinus or epidural involvement, circulating lymphoma cells, more than 
2 extra-nodal sites and with an elevated LDH. Those with primary CNS B-cell lymphomas 
have regimens incorporating high dose methotrexate; this drug is one of the few 
chemotherapy agents that have been shown to be effective in this subgroup [229].  
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Finally, patients who relapse or have suboptimal responses to treatment, require 
alternative, more intensive treatments. The time from CR to relapse has prognostic 
significance, with those relapsing within 12 months having a poorer prognosis. Repeat 
biopsy is essential, as other pathologies do occur including second malignancies and 
chronic infections such as tuberculosis. Chemotherapy is re-instituted with ‘salvage’ 
regimens such as R-DHAP (rituximab, dexamethasone, cytosine and cisplatin) or R-ICE 
(rituximab, ifosfamide, cytosine and etoposide). If chemosensitivity is demonstrated, 
eligible patients (biologically fit and younger than 70 years) proceed onto an autologous 
stem cell transplant (ASCT). The CORAL study has demonstrated no differences in 
outcome with either of the ‘salvage’ regimens described above with overall survival at 5 
years being ~50%[230]. 
1.3.9.2 Follicular Lymphoma 
Follicular lymphoma accounts for about 20% cases of NHL. The highest incidence is 
found in the USA and Western Europe, where it can account for up to 40% of cases. It is 
rare in those under the age of 20 years and the median age of presentation is somewhere in 
the sixth decade [231]. Follicular lymphoma is a low grade lymphomas and not currently 
curable. The current median survival is estimated at 12-14 years following diagnosis [176].  
Follicular lymphoma cells are derived from follicle centre (germinal centre) B-cells. These 
cells demonstrate clonal restriction usually expressing surface immunoglobulin (sIg) along 
with the B-cell antigens (CD20, CD79a, CD22), BCL-2, BCL-6 and CD10. The 
translocation t(14;18) is detected in up to 90% of cases. This translocation involves the 
BCL-2 locus leading to interruption of the normal apoptotic pathways. Other cytogenetic 
abnormalities have been described and often involve BCL-6, making distinction from 
DLBCL difficult [232].  Primary cutaneous follicular lymphoma is usually negative for 
BCL-2 and t(14;18) [176]. 
 
Many patients present with advanced stage disease, with 40-70% having marrow 
involvement at diagnosis [176]. Despite widespread disease, the majority, are 
asymptomatic at diagnosis. It predominantly affects nodal sites, but extra-nodal 
involvement may occur, and occasionally, may only involve extra-nodal tissue. A clinical 
prognostic staging system has been developed, the follicular lymphoma international 
prognostic index or FLIPI. This is based on 5 prognostic factors; age > 60 years, 
haemoglobin concentration (Hb) <120g/L, elevated LDH, more than 4 nodal areas 
involved and Ann Arbor stage III/IV, resulting in 3 prognostic groups; low, intermediate 
and high risk [233]. These are outlined in table 1.7 along with the expected overall survival 
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figures. In 2009 a revised FLIPI score was devised based on patient data following the 
routine use of rituximab, this revealed differences in predictive prognostic information and 
the adverse risk factors were noted as age > 60 years, Hb <120g/L, bone marrow 
involvement, elevated serum β-2-microglobulin and the largest involved lymph node 
exceeding 6cm in diameter. Again the patients were assigned to a low, intermediate or high 
risk group [234]. However, as data in those receiving rituximab is not yet mature, only 3 
year overall survival figures were given, as such it remains to be seen if this prognostic 
scoring system will hold true at 10 years.  
 
In the minority of patients presenting with stage I disease, involved field radiotherapy is 
potentially curable. However, in the majority follicular lymphoma is not curable. The 
decision therefore, is not what treatment to give, but when to give it. Not all patients 
require immediate treatment and studies comparing a watch and wait approach with 
chemotherapy up front, demonstrate no improvement in overall survival between the two 
arms. A study by the BNLI (British National Lymphoma Investigation) group, also defined 
a population for whom treatment was not immediately required; absence of B symptoms, 
no rapid disease progression, absence of marrow compromise, no life threatening organ 
involvement, absence of renal infiltration or macroscopic liver involvement, no bone 
lesions and no masses >7cm [235]. Such guidelines are reasonable to follow in deciding 
when to initiate treatment, and some patients can go for a number of years without it. 
Currently unclear is whether or not rituximab alone is preferable than a watch and wait 
approach in asymptomatic patients, the results of a recently closed study addressing this 
question are awaited. 
 
Risk Group No. Of risk 
factors 
Proportion of 
patients (%) 
5 year overall 
survival (%) 
10 year overall 
survival (%) 
Low 0-1 36 91 70 
Intermediate 2 37 78 51 
High ≥ 3 27 53 36 
Table 1.7: Overall survival and progression free survival (PFS) in patients with follicular 
lymphoma based upon FLIPI score [236]. See text for details about the risk factors. 
 
Once treatment is required, a number of regimens are available. Follicular lymphoma was 
the first of the NHLs to demonstrate an advantage with adding rituximab up front to CHOP 
or CVP (cyclophosphamide, vincristine and prednisolone) [234, 237]. Following either R-
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CHOP or R-CVP, maintenance with 2 years of rituximab maintenance therapy has proven 
successful in maintaining responses; the PRIMA study demonstrated a significant 
improvement in 2 year progression free survival in those receiving rituximab maintenance 
compared to those who did not (PFS: 82% vs. 66%) [238]. This has now become standard 
treatment.  
 
Patients invariably relapse, with a pattern of progressively shorter periods of remission 
between treatments, frequently ending in transformation to DLBCL or the development of 
refractory disease. Decisions regarding treatment at first relapse depend upon age and 
performance status and as at presentation, a period of observation is often employed. 
Eligible patients are offered ASCT if they respond following immunochemotherapy, and 
this has been shown to improve OS and PFS [239]. In a very select young and fit group, 
allogeneic transplantation may be considered and long term survival has been seen in those 
with refractory disease [240]. 
 
For those in whom ASCT is not viable, immunochemotherapy can be used varying from 
intensive regimens such as R-ICE, to a single agent palliative approach with drugs such as 
chlorambucil or fludarabine with or without rituximab. Rituximab maintenance given 
every 2-3 months has been shown to be efficacious following treatment for relapsed and 
refractory disease, with median survival following rituximab maintenance versus 
observation only being 51.5 versus 14.9 months [241].  
1.3.9.3 Mantle Cell Lymphoma 
Mantle cell lymphoma accounts for 3-10% of cases of NHL. The median age at diagnosis 
is 60-65 years, with a male predominance of >2:1. Mantle cell lymphoma (MCL) is not 
curable in the majority and has the worst outcome of all B-cell lymphomas with a median 
survival of 3-5 years [242]. MCL cells are derived from the mantle zone with a variety of 
histological types seen. More aggressive variants consist of blastoid and pleomorphic types 
corresponding to the most unfavourable outcomes, contrasting with small cell and 
marginal-zone like variants. All MCL cells display the same immunophenotype, with 
sIgM/IgD, CD20, CD5, FMC-7 and CD43 positivity and negative or only weak positivity 
for CD23 (distinguishing them from CLL/SLL). Cyclin D1 in positive in the majority of 
cases [176]. The hallmark of MCL is t(11;14), resulting in deregulated over expression of 
cyclin D1 [176]. This abnormality has potential utility as a marker of minimal residual 
disease (MRD). 
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Presentation with early stage I/II disease is unusual and the majority present with 
widespread disease. MCL cells are frequently detected in the circulation, bone marrow and 
extranodal involvement is common, especially the gastrointestinal tract in which 
involvement is detected over 80% cases [243]. It is argued that endoscopic examination of 
the gut is required in all MCL, however, a more pragmatic approach is to reserve this 
investigation for those who present with early stage, and therefore potentially curable, 
disease prior to localised treatment, as it will not affect the management of the majority 
presenting with advanced disease.  
 
A prognostic scoring system has been proposed for MCL the mantel cell lymphoma 
international prognostic index (MIPI), based upon age, LDH, ECOG performance status 
and white cell count. This prognostic index is a little more complex with a scoring system 
for each prognostic factor. For the low risk group median survival there is an estimated 5 
year OS of 60%, the median survival for the intermediate and high risk groups are 51 
months and 29 months respectively [244]. However, the MIPI was developed on the basis 
of 455 patients compared to the thousands in both the FLIPI and R-IPI scores, and on 
patients entered into clinical trials (an independent good prognostic indicator), so 
correlation with widespread clinical practice is yet to be verified.  
 
For those few with genuinely limited stage disease, involved field radiotherapy following 
3-4 courses of chemotherapy have been reported to induce long-term remissions of over 8 
years [245]. Unfortunately, the majority present with advanced disease with most requiring 
treatment with immunochemotherapy with or without ASCT consolidation as first line. 
Rituximab has been used in MCL, initially the results were rather disappointing, but in 
2008 the Nordic Lymphoma Group published their study, which for the first time did not 
show any relapses beyond five years post-treatment. R-CHOP alternating with R-high dose 
cytosine, followed by a R-BEAM (BCNU, etoposide, ara-c, melphalan) conditioned ASCT 
in 160 consecutive patients, recorded an overall response rate of 96%, 6 year overall 
survival of 70% and EFS of 56%. In contrast to the MIPI only Ki-67 was demonstrated to 
have prognostic significance [246]. This has now become the preferred treatment for 
transplant eligible patients at our centre. 
 
For those who are not transplant eligible, treatment depends upon their performance status, 
those that are fitter may tolerate intense regimens, however, as these do not significantly 
impact on overall survival, less intense regimens may preferable, as these will debulk the 
disease and lead to symptomatic improvement, but without the toxicity profile inevitably 
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associated with more intense regimens. Other useful regimens include those based on 
fludarabine and in recent years bendamustine has shown some promise [247]. In the very 
elderly and unfit, a palliative approach with chlorambucil with or without rituximab is 
often useful for symptomatic relief. 
 
At relapse, the aim of treatment is palliative in the majority, and regimens with lower 
toxicity profiles are preferred, as quality of life becomes the aim. Novel agents such as 
bortezomib, lenalidomide and temsorilimus have shown some efficacy, and bendamustine 
has been particularly successful. Trials using these agents along with more conventional 
agents first line, either as induction (bendamustine) or as maintenance (lenalidomide) are 
underway [248].  
1.3.9.4 Chronic Lymphocytic Leukaemia/ Small Lymphocytic 
Lymphoma 
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia occurring in adults 
in the West, with an annual incidence of 2-6 cases/100,000 persons. Interestingly, it is rare 
in the Far East, and a similarly low incidence is seen in migrants from these regions, 
suggesting a genetic predisposition. It has an increasing incidence with age, and the 
median age at diagnosis is 65, although it is being increasingly diagnosed in younger 
patients. There is a slight female predominance. Diagnosis is usually made on blood 
samples, but when diagnosed following lymph node or tissue biopsy it accounts for ~7% of 
NHL cases [248].  
 
Although CLL/Small lymphocytic lymphoma (SLL) are classified as the same condition, 
clinically a division is made; those with circulating cells are classified as CLL, whilst those 
with no abnormal circulating cells have SLL. In the majority, diagnosis is made on the 
presence of circulating CLL cells. The diagnosis is made in those with a persistent 
lymphocytosis of, ≥ 5 x 109/L with a typical immunophenotype; CD20, CD5, CD19, 
CD79a, CD23 (negative in MCL) positivity, weak sIgM/IgD and CD11c expression and 
negative for FMC7. A scoring system has been devised based on a composite of the above 
markers to help in distinguishing CLL/SLL from other B cell neoplasms [176]. No single 
B-cell lineage has been identified in CLL with two broad groups noted, IgVH – unmutated 
and IgVH-mutated. Unmutated status is associated with a poorer outcome, and can be 
identified by a surrogate marker, ZAP-70 [249]. Additionally, expression of CD38 is 
associated with a poorer outcome [250].  
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Genetic abnormalities are detectable in ~80% of cases. There is a strong association 
between the cytogenetic abnormality and the clinical picture. For example the presence 
deletion 13q confers a favourable prognosis with a median survival of 133 months, where 
as deletion of 17p (and thus p53) has the poorest median survival of 32 months [251].  
CLL/SLL is not curable with survival from diagnosis ranging from a few months to over 
20 years. Two different clinical staging systems are commonly used these are the Binet 
[252] and Rai [253] staging systems based upon, lymphocytosis, lymphadenopathy, 
organomegaly, haemoglobin concentration and platelet counts. These two staging systems 
are summarised in table 1.8. However, if a patient is anaemic or thrombocytopenic, 
autoimmune haemolytic anaemia (AIHA) or immune thrombocytopenia (ITP) needs to be 
excluded, these phenomena occur in approximately 5% of patients. AIHA or ITP require 
treatment, but do not always necessitate treatment of the CLL/SLL, a full description of the 
management of AIHA and ITP is out with the scope of this thesis, but a number of drugs 
used in CLL/SLL are effective whilst others are contra-indicated.  
 
Treatment is indicated for those with Binet stage B or Rai stage I/II disease in the presence 
of one or more of the following; massive splenomegaly (>6cm below costal margin), 
lymph node mass ≥ 10cm diameter, increasing lymphocytosis of >50% in 2 months or 
doubling time of <6 months, AIHA or ITP failing to response to standard treatments and 
significant constitutional symptoms. Treatment is indicated in those with Binet stage C or 
Rai stage III/IV disease [254]. 
 
Once the decision to treat has been made, the staging investigations including bone marrow 
examination, CT scanning and cytogenetic analysis are performed. The current standard 
for treatment naïve patients is rituximab, fludarabine and cyclophosphamide. Treatment 
will be guided by the patient’s age and performance status. The German CLL Study Group 
CLL8 trial group has recently shown an improvement in overall response of 95% with 
rituximab, fludarabine, cyclophosphamide (FCR) compared to 85% in the FC arm, which 
has equated to prolonging PFS from 33 to 52 months [255]. However, for those who are 
older and frailer, single agent chlorambucil or fludarabine with or without rituximab can 
still achieve useful responses, disease control and symptomatic relief.  
 
CLL/SLL is not curable and the disease inevitably relapses in a pattern analogous to that 
seen with follicular lymphoma. A proportion of patients undergo high grade transformation 
to DLBCL (Richter’s transformation). Treatment at relapse depends upon time since first 
treatment, depth of response to the initial treatment, age, performance status and the 
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presence of abnormalities such as deletion of 17p. The latter is recognised as having some 
resistance to fludarabine, and some advocate using agents such as alemtuzumab (anti-
CD52 monoclonal antibody) to overcome this [256]. For those who are younger and have a 
donor, allogeneic transplantation is a consideration, and has been reported to induce 
durable remission [257]. For the others, re-induction of remission can often be achieved 
using the original regimen. Richter’s transformation is treated as for de-novo DLBCL. 
Whilst for those who are elderly or have a poor performance status, palliative approaches 
with agents such as chlorambucil, corticosteroids or cyclophosphamide are reasonable. 
 
System Clinical Features Median Survival 
(years) 
   
Rai Stage (simplified 3 stage)   
0 (Low risk) Lymphocytosis in blood and 
marrow only 
>10 
I & II (Intermediate risk) Lymphadenopathy, 
splenomegaly +/- 
hepatomegaly 
7 
III & IV (High risk) Anaemia, thrombocytopenia* 0.75-4 
   
Binet Group   
A Less than 3 areas of 
lymphadenopathy, no anaemia 
or thrombocytopenia 
12 
B More than 3 involved lymph 
node areas, no anaemia or 
thrombocytopenia  
7 
C Haemoglobin < 100g/L* 
Platelets <100 x 109/L* 
2-4 
Table 1:8: Outline of the two clinical staging systems for CLL/SLL, along with median survival 
for each stage. * as long as autoimmune causes of cytopenias have been excluded  [Taken from 
257]. 
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1.3.9.5 Burkitt’s Lymphoma 
Burkitt’s lymphoma is a highly aggressive lymphoma, which often presents with 
extranodal disease or as acute leukaemia, yet has one of the highest cure rates. Clinically 
there are three distinct groups. Endemic Burkitt’s lymphoma has an incidence of 5-10 per 
100,000 in Equatorial Africa, and Papua New Guinea (PNG), with a geographical 
association with endemic malaria. Endemic Burkitt’s lymphoma is a disease of childhood 
with a peak incidence occurring in the 4-7 age group and male predominance, it has a 
predilection for the jaw and facial bones. HIV-associated Burkitt’s lymphoma has a more 
nodal presentation and a high risk of CNS involvement, occurring in approximately 6 of 
every 100 AIDS cases. Finally, the group that will be discussed here is sporadic Burkitt’s 
lymphoma. This is rare occurring in 2-3 per million per year. It is predominantly a disease 
of childhood and early adulthood with a median age at diagnosis of 30 years, there is a 
male predominance, and abdominal disease is the most common presentation [257].  
The histology in Burkitt’s lymphoma is characteristic with intermediate sized cells, with 
round or oval nuclei. There is a high degree of proliferation leading to a number of 
apoptotic cells, taken up by clearer histiocytes giving the characteristic ‘starry night’ 
microscopic appearance at low power [258]. However patients can present with a 
predominantly leukaemic picture. Other tests are required to confirm the diagnosis, 
including examination for EBV, FISH for typical translocations including t(8;14), 
detection of c-myc or other translocations involving myc. Burkitt’s lymphoma cells are 
typically CD20, CD19, CD10, BCL-6, CD38 positive [176]. 
 
Treatment for Burkitt’s lymphoma depends upon the age at presentation, with many 
paediatric centres using the complex regimens for acute lymphoblastic leukaemia such as 
the BFM 90 protocol which achieved an event free survival (EFS) of 89% at 6 years, the 
median age of this cohort was 9 years [176]. In adults toxicity profiles of such regimens 
has led to the development of alternative regimens including the CODOX-M/IVAC 
protocol. The British LY06 study, achieved a 2 year overall survival of 73% and 2 year 
EFS of 65% using this [259]. Since that time rituximab has been incorporated into 
regimens, with the best results reported with dose-adjusted EPOCH and an overall survival 
reported of 100% and EFS of 95% at 27 months [260], however this study is still ongoing 
and these results whilst promising are only based on an interim analysis.  
 
Compared to other lymphomas, Burkitt’s lymphoma has a high cure rate, however a 
proportion of patients will relapse or develop refractory disease, for these patients, 
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outcomes are very poor with the disease rarely responding to chemotherapy or 
radiotherapy. For those with relapse, who are fit and who can demonstrate 
chemosensitivity, ASCT has been shown to provide a 37% 3 year overall survival 
compared to 7% in chemoresistant cases [261]. Therefore, in many cases it is appropriate 
to adopt a palliative approach. 
1.3.9.6 Marginal Zone Lymphoma  
Marginal zone lymphomas (MZL) account for 7-8% of all B-cell NHLs [258] but for up to 
50% of primary gastric lymphomas [233]. The median age at diagnosis is 61 with a slight 
female preponderance. The marginal zone lymphomas fall into three broad clinical types, 
extranodal, splenic and nodal MZLs. MZL cells represent mature B-cells. It appears that 
this results from chronic antigenic stimulation as, evidenced by the observation that genes 
involved in autoantibody formation, VH4, VH3 and VH1, are used by these cells [262]. 
MZL cells are positive for mature B-cell markers (CD20 and CD79a), and marginal zone 
antigens CD21 and CD35, they also have sIgM or sIgD [263].  
 
Staging procedures are similar to other lymphomas with CT scanning and bone marrow 
examination, the staging systems themselves are however quite complex due to the variety 
of potential sites. Extranodal MALT lymphomas form the bulk of MZL cases, of which 
about a third are primary gastric MALT lymphomas. A geographical variation has been 
seen with higher incidence recorded in North East Italy, where a higher rate of H.pylori 
infection was also noted [176]. Other common extranodal sites include the salivary glands 
(16%), ocular adenxa (10-12%), skin (8-10%), lung (6-10%), intestine (3-9%) and upper 
airways (5-10%), in up to 11% of cases multiple sites are involved with or without bone 
marrow or nodal involvement. MALT lymphomas are indolent with 5 year overall survival 
rates ranging from 46% in those with upper airway involvement to 100% in those with 
intestinal, skin, lung, breast or thyroid involvement [262]. A number of cytogenetic 
abnormalities have been associated with MALT lymphomas including t(11;18), t(1;14), 
t(14;18) and t(3;14). The first of these is unique to MALT lymphomas, the presence of this 
translocation is of value in that it usually occurs in H.pylori negative cases, or if co-
existing predicts for a lack of response to eradication therapy [263].  
 
In gastric MALT lymphomas eradication of H.pylori, when present, leads to regression of 
the lymphoma in a significant proportion of cases [263]. The same principle applies to 
MALT lymphomas associated with other organisms such as Campylobacter, Chlamydia or 
Borrelia. If no infective aetiology is noted, treatment depends upon symptoms and the 
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extent of disease. Localised disease is potentially curable with localised radiotherapy. In 
those with more advanced disease, cure is not achievable and treatment depends upon the 
extent of the disease and symptoms. In the majority a watch and wait approach is 
appropriate with many not requiring treatment. Reasonable responses can be gained from 
single agents such as chlorambucil or fludarabine, with or without rituximab. In rare cases 
with extensive disease, combination chemotherapy regimens such as those used for 
follicular lymphoma or CLL/SLL are favoured [210].  
 
Splenic marginal zone lymphoma accounts for approximately 1% of lymphoma cases. The 
usual presentation is that of isolated splenomegaly. Splenic hilar nodes are often involved 
but disseminated lymph node involvement is unusual. Bone marrow involvement occurs in 
95% of cases, and circulating villous lymphocytes can be detected in up to 15% of cases 
[264]. There is an association with autoimmune haemolytic anaemia. Additionally, some 
cases are associated with hepatitis C infection. Management usually involves a watch and 
wait approach, many may not require treatment for up to 10 years. The mainstay of 
treatment is splenectomy, performed in the presence of massive splenomegaly or 
cytopenias associated with either hypersplenism or marrow involvement. The disease, if 
not caught early is not curable, but prolonged survival is seen with > 50% still alive at 5 
years. Interestingly, splenectomy leads to an improvement not only in peripheral 
cytopenias, but also to a reduction in marrow infiltration [211]. If treatment beyond 
splenectomy is required, a similar approach is taken as with MALT lymphomas, including 
treating hepatic C infection if present [265].  
 
Nodal marginal zone lymphomas account for less than 1% of NHL cases. Patients present 
with disseminated nodal involvement and less than half have marrow involvement at 
diagnosis. A paraprotein is detectable in about 8% of cases. The estimated 5 year survival 
is reported to be somewhere between 50% and 70%, with relapses continuing to occur 
beyond this time, suggesting that it is not curable. At present the number of cases are 
small, but similar treatments to those for advanced MALT lymphomas, are recommended 
with a period of observation being appropriate in some [264].  
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1.3.10 Summary 
Non-Hodgkin’s lymphoma is a heterogeneous group of malignancies affrecting. It has a 
significant impact with an increasing incidence. Depsite recent advances in therapy, a 
significant number of patients fail to response or relapse and ultimately succumb to their 
illness. Therefore new ways of targeting this disease are needed. One system, which could 
be utilised, is the chemokine system, owing to its central role in the organisation of the 
adaptive immune system through homing of haematolpoietic cells. The next section 
explores the role of the chemokine system in NHL.
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1.4 Chemokines and Lymphoma 
Having previously discussed the role that chemokines have in the organisation of the 
immune system, and the fact that lymphoma is a malignancy of the same, it is logical to 
examine the role that chemokines and their receptors may have in lymphomas. In fact there 
is increasing evidence for a significant role for chemokines and their receptors in the 
pathogenesis of lymphoma, as well as evidence that expression of these can influence 
outcomes and assist in determining the sub-type of lymphoma. Finally, there is increasing 
research and interest in looking at ways by which this system can be targeted 
therapeutically.  
1.4.1 Chemokines and Malignancy  
Chemokines and their receptors have been studied in a wide range of malignancies. Studies 
to date show that CXCR4 is the most widely expressed chemokine receptor across a range 
of tumour types and it is implicated in a number of malignant processes including 
metastasis, neo-angiogenesis, repression of apoptosis and invasion [264]. It is clear that 
there are a number of different mechanisms by which chemokines influence, or are 
influenced by, tumour biology and consequently can have effects on outcomes. A fully 
detailed discussion is not possible here, but a broad overview of some of these mechanisms 
will be presented. 
 
Firstly, chemokine and receptor expression may be directly influenced by oncogenes or the 
consequent dysregulation of transcription factors. One example is the role of β-catenin in 
breast cancer.  It has been shown that abnormal translocation of this protein leads to the 
activation of a number of transcription factors and leads to the transactivation of CCL2, 
which has been implicated in the development of metastasis and invasion [86]. 
Alternatively, dysregulated transcription factors such as is seen in melanoma with NF-κB 
leads to up regulation of chemokines such as CXCL1 [266]. 
 
Many malignant cells actively recruit leucocytes to the tumour site. These can include any 
of the cells from the innate or adaptive systems. Foremost amongst these are the tumour-
associated macrophages (TAMs) and CCL2 and CCL5 are major attractants for monocyte 
precursors into tumour sites [267]. TAMs are associated with tumour progression, and are 
recruited in large numbers in response to chemokines. They are implicated in 
neoangiogenesis and are thought to have suppressive effects on anti-tumour T cells, thus 
TAMs are associated with more aggressive disease and poorer outcomes in a wide range of 
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tumours including breast cancer, melanoma, colon cancer and pancreatic cancer. The 
production of CCL2 and CCL5 has frequently been detected by both stromal and 
malignant cells in these tumours [Reviewed in 268]. Chemokines also play a role in the 
recruitment of neutrophils, dendritic cells, NK cells and tumour infiltrating lymphocytes 
into tumour sites.  
 
Tumour angiogenesis is central to tumour progression and survival, and chemokines have 
been shown to have a central role here. Pro-angiogenic chemokines including CXCL5 and 
CXCL8 act upon the CXCR1 and CXCR2 expressing endothelial cells to promote 
proliferation and down regulate apoptosis, thereby promoting angiogenesis. The presence 
of these chemokines has been detected in a number of tumours including, prostate and 
renal carcinoma, and are associated with tumour angiogenesis and subsequent disease 
progression [269, 270]. The CXCR4/CXCL12 axis also has a significant role in 
angiogenesis. CXCR4 is expressed on endothelial cells, and proliferation and cellular 
migration is induced by CXCL12.  However angiogenesis has also been seen to be 
stimulated via a synergistic action between CXCR4 and VEGF in ovarian tumours [271]. 
In addition, the CXCR4/CXCL12 axis assists in the migration of endothelial cells, and thus 
subsequent angiogenesis, to tumour sites and the bone marrow.  
 
As previously described, the CXCR4/CXCL12 axis is integral to the maintenance of stem 
cells within their bone marrow niche, as well as their involvement in endothelial cell 
migration, thus explaining the fact that the bone marrow is one of the favoured sites of 
CXCR4-dependent metastasis in a number of tumours. In contrast, CCR7 is involved in the 
homing of lymphocytes to the secondary lymphoid organs in response to CCL19 and 
CCL21. CCR7 expression has been shown to be unregulated in those tumours with lymph 
node metastases, and is likely to be predictive of the development of lymph node 
metastases when detected in tumours [Reviewed in 272].  
 
Finally, the atypical chemokine receptors have also been implicated in tumour biology. D6 
plays an anti-inflammatory role by sequestering inflammatory chemokines. Two recent 
papers have suggested that D6 also has a tumour suppressor affect. In both cases murine 
models were used to induce either skin or colitis associated cancers, with the observation 
that a greater susceptibility to tumour development and progression was noted in D6-/- 
mice [269, 273]. In contrast, the atypical receptor CXCR7 seems to act in a tumour 
promoting fashion. CXCR7 is expressed on transformed but not normal cells and binds to 
CXCL12 and CXCL11 with great avidity. Its role as a tumour promoter is demonstrated by 
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the fact that inhibition leads to poorly vascularised and smaller tumours, whilst its 
expression in malignancies such as prostate and lung cancer is associated with more 
aggressive disease and a higher risk of recurrence following resection [274]. 
Thus, chemokines and their receptors have diverse roles in the development and 
progression of a range of malignancies, and represent viable therapeutic targets. 
1.4.2 Chemokines and Lymphoma Development  
In contrast to solid tumours, there is evidence to suggest that the chemokine expression 
found on malignant lymphocytes reflects the physiological expression of the stage of 
differentiation at which they are ‘trapped” [Pals et al. 269] see figure 1.13. However, this is 
not the whole story and chemokines have been directly implicated in the development of 
lymphomas under chronic inflammatory conditions [275]. As previously discussed 
chemokines CXCL13 and CCL21 play a central role in the organisation of secondary 
lymphoid tissues. Studies have shown that inducing ectopic expression of CXCL13 and 
CCL21 in areas such as the pancreas result in the development of ectopic lymphoid tissue 
[276, 277]. Can demonstration that, ectopic lymphoid tissue can be induced under 
experimental conditions, provide an insight into the role of chemokines in the pathogenesis 
of lymphomas? In the case of those lymphomas associated with chronic antigenic 
stimulation, such as MALT lymphomas and other B-cell lymphomas, it provides some 
explanation. For example, lymphoma of the thyroid is uncommon, but when diagnosed the 
majority of patients have a history of autoimmune thyroid disease [278]. Histological 
examination of specimens from those with autoimmune thyroid diseases such Hashimoto’s 
thyroiditis or Grave’s disease reveal the presence of ectopic lymphoid tissue, furthermore it 
has been demonstrated that CXCR5 and CXCL13 have a major role in the maintenance of 
this tissue [279]. Whilst, the final trigger for lymphomatous transformation is unclear, what 
is clear is that chemokines have a role in the pathogenesis of thyroid lymphomas with a 
greater than 60 fold increase in incidence noted in patients with autoimmune thyroid 
diseases [280]. Similar patterns are seen in other autoimmune disorders such as Sjörgren’s 
Syndrome and chronic infections including Helicobacter pylori. 
 
However, in primarily nodal lymphomas (the majority), the role of chemokines in 
pathogenesis is less clear. Certainly, chemokine expression has been examined in a number 
of differing lymphoma subtypes, with particular interest on the microenvironments, 
although whether the malignant cell creates the microenvironment or vice versa is not all 
together clear. The lymphoma subtype in which the microenvironment has been best 
studied is actually Hodgkin’s lymphoma, where <1% of the cells are malignant. The Reed-
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Sternberg cells have been shown to release CCL17, a ligand for CCR4, which goes some 
way into explaining the high numbers of T-cells in the surrounding cellular milieu in 
Hodgkin’s lymphoma.  
 
Some discussion of the microenvironment in the pathogenesis of lymphoma, including the 
role of chemokines, was discussed earlier during the discussion of lymphoma 
pathogenesis, yet further points are worth discussing. It is increasingly clear that the 
microenvironment has a role in the pathogenesis of lymphomas. Such examples include 
CLL and mantle cell lymphomas (MCL). Mesenchymal stem cells (MSC) are found in the 
bone marrow and release CXCL12 amongst other cytokines, which has been shown 
experimentally to lead to the migration of CLL and MCL to these areas.  Following 
migration adhesion molecules such as VLA-4 lead to retention and provide pro-survival 
signals, including adhesion-dependant drug resistance [281, 282]. 
 
 
Figure 1.15: Demonstration of chemokine receptor expression at different stages of B-cell 
differentiation and the corresponding lymphoma sub-types. Taken from Pals, 2007 [283]. PP – 
Peyer’s patches, PLN – peripheral lymph node, BM – bone marrow, MCL – mantle cell lymphoma, 
MLP – malignant lymphomatous polyposis, MALT-L – mucosa associated lymphoid tissue 
lymphoma, FL-follicular lymphoma, DLBCL – diffuse large B-cell lymphoma, MM – multiple 
myeloma. 
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1.4.3 Lymphoma Subtype and Chemokine Expression 
A full discussion of all of the various lymphoma subtypes and the chemokines studies 
performed with them is out with the scope of this discussion, and only a selection of them 
will be discussed. A number of the initial studies were performed using lymphoma cell 
lines, however what follows will primarily relate to studies on primary tissue. 
 
In general CXCR4 and CXCR5 are expressed on the majority of B-cell lymphoma 
subtypes, and therefore expression alone does not provide a clear differentiation between 
subtypes [Pals et al 275]. However, CXCR5 and its ligand CXCL13 have been shown to be 
of value in distinguishing angio-immunoblastic T-cell lymphoma (AITL) from other types 
of T-cell lymphoma and Hodgkin’s lymphoma.  AITLs are composed of follicular T helper 
cells, which secrete CXCL13 [275] and up-regulate CXCR5.  This is thought to occur in 
response to the presentation of EBV viral proteins, leading to T helper cell activation, 
thereby leading to a positive feedback loop involving B- cells and the malignant follicular 
T helper cells [284]. The expression of CXCL13 in AITL has now been recognised as part 
of the distinct immunophenotypic profile and is of diagnostic value [Swerdlow et al 285]. 
Whilst chemokine receptor expression in most B-cell lymphomas cannot help distinguish 
between subtypes, or even their normal B-cell counterparts, with heterogeneity 
demonstrated in studies, some research has shown that there are differences between the 
responses of malignant and normal B-cells to chemokines. One example is mantle cell 
lymphoma (MCL), chemokine receptor expression in MCL B-cells and normal CD5+ cells 
are similar, both expressing CXCR4 and CCR7 amongst other receptors.  However, the 
MCL B-cells demonstrate migration in response to CCL19 whilst their normal counterparts 
do not [176]. Moreover, chemotaxis in response to CCL19 is enhanced by exposure of the 
cells to CXCL12 [286]. Whilst these differences may simply reflect differences in the 
numbers of cell surface receptors, it does suggest that disrupting the CCR7/CCL19 axis 
will have a detrimental affect on MCL B-cells.  
 
Of course, one group of lymphomas in which chemokine expression is specific is in the 
cutaneous lymphomas. In cutaneous T-cell lymphomas (CTCL) and Sézary Syndrome (the 
rare leukaemic form of CTCL) the malignant T-cells co-express the skin homing receptors 
CCR4 and CCR10 [286].  
 
Finally, expression and the response to ligands of receptors are not the only way in which 
differences between lymphoma subtypes can be demonstrated. The pattern of chemokine 
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receptor expression within the cell may also reveal differences. For example, CXCR4, 
CXCR5 and CCR7 can be detected in the malignant B-cells of primary central nervous 
system lymphomas. However in contrast to lymphomas with peripheral involvement, these 
receptors are present in the cytoplasm rather than on the cell surface [287], indicating that 
they may not respond to their corresponding ligands in the same way. 
 
 
 
Receptor Expression on 
Lymphocytes 
Expression on  
Lymphomas 
Ligands Predominant 
sites of 
homing 
 
Adhesion Molecules 
L-selectin Naïve T & B cells, central 
memory T cells 
B-CLL, MCL, 
MZBCL, nodal PTCL 
PNAd 
(MAdCAM-1) 
PLN 
CLA 
 
Skin homing T-cells CTCL E-selectin Skin 
α4β7 Naïve B & T cells, gut-homing 
T-cells, IgA plasma cells 
GI-tract MCL, GI-
tract MZBCL, GI-
tract FL, EATL 
MAdCAM-1 
(VCAM-1) 
 
Gut 
αEβ7 Intraepithelial cells GI-tract PTCL, GI-
tract MZBCL 
E-cadherin Epithelium 
αLβ2 (LFA-1) Broad expression on B & T 
cells 
Broad expression on 
B & T cell 
lymphomas, MM 
ICAM-1, 
ICAM-2 
Multiple sites 
α4β1 (VLA-4) Broad expression on B & T 
cells 
Broad expression on 
B & T cell 
lymphomas, MM 
VCAM-1 Inflammatory sites 
& bone marrow 
 
Chemokine Receptors 
CCR4 
 
Skin-homing T-cells CTCL, A-TLL CCL17, CCL22 Skin  
CCR7 Naïve T-cells, central memory 
T cells 
CTCL, CLL, MCL CCL19, CCL21 PLN 
CCR9 Gut homing T cells, 
intraepithelial T cells, IgA 
plasma cells 
Unknown CCL25 Intestinal mucosa 
& crypt epithelium 
CCR10 Skin homing T cells, IgA 
plasma cells 
CTCL CCL27, CCL28 Skin, intestine 
CXCR4 Pre-B cells, B cells, plasma 
cells 
Broad expression on 
B & T cell 
lymphomas, MM 
CXCL12 Secondary 
lymphoid tissues & 
BM, migration to 
germinal centres 
CXCR5 Mature B cells Broad expression on 
B & T cell 
lymphomas, MM 
CXCL13 Migration to GCs 
in PLN and Peyer 
patches 
Table 1.9: Adhesion molecule and chemokine receptor expression on lymphoma subtypes 
and the normal lymphocyte populations along with the anatomical distribution where applicable 
[Adapted from 288].  
 
© Michelle Bryson, 2010 CHAPTER ONE INTRODUCTION  72 
 72 
1.4.4 Expression and Clinical Stage 
There is limited information with regards to the stage of disease and chemokine expression 
in lymphomas. However one lymphoma in which chemokine receptor expression 
correlates with disease stages is in CTCL. An intriguing observation has been the reduction 
in CCR4 expression in those with CTCL as the lymphoma progresses to more advanced 
stages whilst a corresponding increase in CCR7 expression is noted [275], suggesting that 
there is a gain in the lymph node homing ability of the cells whilst skin-homing 
capabilities are diminished. 
 
Of interest, in an associated disease B-cell acute lymphoblastic leukaemia, higher CXCR4 
expression has been correlated with the presence of extramedullary disease demonstrating 
a more advanced disease presentation [289]. This also has implications for prognosis with 
extramedullary disease being associated with an adverse outcome. 
1.4.5    Expression and Prognosis 
Again there is limited information on the role of chemokines in the prognosis of non-
Hodgkin’s lymphoma. As described previously, stromal signatures and chemokines in the 
microenvironment impact on the prognosis of follicular lymphomas and diffuse large B-
cell lymphomas. 
 
However, one of most detailed associations described is the impact of CCR4 expression in 
Adult T-cell leukaemia lymphoma (ATLL), in which ~88% of cases demonstrate CCR4 
expression on the malignant cells [290]. Further analysis has shown that the CCR4+ cases 
have a significantly poorer prognosis than CCR4- cases [291]. 
 
Whilst the study did not specifically address prognosis, the role of CXCR3 in the 
responsiveness to therapy in Helicobacter pylori positive cases of gastric MALT 
lymphomas has been investigated. Yamamoto et al demonstrated that expression of 
CXCR3 by the malignant cells was associated with an increased risk of non-responsiveness 
to Helicobacter pylori eradication [291]. Therefore it is reasonable to postulate that such 
cases will require chemotherapy or localized radiotherapy to obtain effective treatment, 
and testing for CXCR3 expression may be of value in guiding treatment.  
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1.4.6 Using the Chemokine System as Targeted Therapy 
1.4.6.1 General Principles 
There is no doubt that the chemokine system is an attractive target for a wide range of 
diseases including lymphoma. There are a number of ways in which the system could be 
targeted and two of these have now progressed beyond phase 3 clinical trials into daily 
clinical use. The most obvious ways include the development of monoclonal antibodies or 
small molecule anatagonists. However, another approach is that of forming a chemokine-
cytotoxic ligand. This latter approach could involve conjugation with a radioisotope, 
cytoxic agent or even a viral vector. Work has been done in all of these areas, some of 
which will be explored below.  
1.4.6.2 Small Molecule Antagonists of Chemokine Receptors 
Currently this is where most of the work has been concentrated.  Two chemokine receptor 
antagonists, plerixafor and maraviroc, are now in clinical use. The first, plerixafor, is a 
CXCR4 antagonist and was initially developed as an anti-HIV agent. However, it was 
noted that it lead to the release of haematopoietic stem cells into the circulation, and has 
since been developed and marketed as a new agent to mobilise stem cells prior to 
harvesting and haematopoietic stem cell transplantation in those who respond poorly to G-
CSF.  It has been shown to be effective in previously treated patients with myeloma and 
non-Hodgkin’s lymphoma [292]. In addition, stem cells collected following mobilisation 
with plerixafor have been shown to be as efficient in engrafting as those obtained with G-
CSF alone [293]. Furthermore, it has been postulated that plerixafor could be utilised in an 
attempt to mobilise malignant cells out of protective bone marrow niches and into the 
circulation where they would be susceptible to cytotoxic agents.  However there are 
concerns that this approach may affect self-renewing stem cells and therefore any agents 
used should be targeted to the malignant population. Consequently, early clinical studies 
are underway, using this approach in CLL combined with the administration of rituximab 
to improve the depth of response.  
 
Maraviroc is an antagonist of CCR5. CCR5 along with CXCR4, acts as a co-receptor with 
CD4 to allow entry of HIV into cells.  A mutation in the receptor, CCR5 Δ32, is associated 
with resistance to HIV infection [294] and therefore provided a natural proof-of-principle 
that inhibiting CCR5 would provide benefit in infected individuals. The MOTIVATE 1 
and MOTIVATE 2 trials investigated the use of maraviroc in addition to standard anti-
retroviral therapy in those infected with the R5 HIV-1 virus (which predominates in the 
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earlier stages of infection). The addition of maraviroc demonstrated greater efficacy when 
compared to placebo in reducing HIV-1 loads and increasing CD4 counts [82] and thus has 
been added to the armature for the treatment of HIV. Further CCR5 antagonists are in trial 
or development. 
1.4.6.3 Antibody Therapy Targeting the Chemokine System 
With the success of monoclonal antibody therapies such as rituximab, there has been much 
pharmaceutical interest in the development of antibodies for use in a wide range of 
disorders. The discussion that follows explores the current picture with regards to anti-
chemokine receptor therapies in lymphoma. 
 
One of the first reports of the effects of inhibiting chemokine receptors in lymphoma was 
by Bertolini et al. In their work CXCR4 neutralising antibodies were incubated with 
Namalwa cells (a human Burkitt lymphoma cell line), prior to injection into NOD/SCID 
mice and compared with non-incubated cells. In the CXCR4 antibody incubated group, 
83% of the mice were alive and disease free >150 days post injection compared to the 
control group in which all mice died from disease by day 36. Moreover circulating 
malignant cells were detectable at higher levels in the CXCR4 antibody group at 24 hours 
[84] in keeping with disruption of the CXCR4/CXCL12 axis required for entry of cells into 
protective microenvironments. 
 
Monoclonal antibodies against chemokine receptors for the treatment of 
lymphoproliferative disorders are also in development, one of which has reached clinical 
trial stage. The first of these is an anti-CCR7 antibody that was developed with the 
treatment of CLL in mind. CLL cells have high surface expression of CCR7 therefore this 
is a good and specific target for treatment. Murine in-vivo studies have demonstrated 
complement-mediated toxicity against CLL cells treated with anti-CCR7, with relative 
sparing of normal T-lymphocytes; however antibody dependent cell-mediated cytotoxicity 
was low [295].  These results show promise in using monoclonal anti-CCR7 antibodies for 
this disease, but are yet to enter clinical trials. 
 
Finally, a monoclonal anti-CCR4 antibody therapy has reached the  human clinical trials 
stage. KW-0761 a humanized anti-CCR4 antibody has been used in phase I clinical trials 
in patients with relapsed ATLL and peripheral T cell lymphomas.  This has demonstrated 
that the treatment is generally well tolerated, with a third of patients demonstrating a 
response [296]. Phase II trials are awaited. 
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1.4.6.4 Chemotoxins and Gene Therapy 
There has been an increasing amount of work on the conjugation of monoclonal antibodies 
with cytotoxic agents such as radioisotopes or cytotoxic drugs, in order to deliver targeted 
treatments. This approach can be taken with chemokines with the development of 
chemotoxins; chemokines that have been fused with toxic moieties. In-vivo studies with a 
chemotoxin containing CCL17 and a fragment of the Pseudomonas exotoxin 38, 
demonstrated that cutaneous T-cell lymphomas developing in NOD/SCID mice were 
significantly reduced in size following intra-tumoural injection of this agent [297]. 
However, the tumours eventually relapsed at which point resistance to further treatment 
had developed due to reduced surface expression of CCR4 on the tumour cells [298], 
perhaps indicating that whilst effective, further consolidative therapy would be required to 
affect a cure. 
 
Finally, a recent case report has indicated that gene therapy may offer a therapeutic tool for 
those with HIV infection. An HIV-1 positive patient underwent an allogeneic stem cell 
transplant for acute myeloid leukaemia. His donor had been screened for the presence of 
the homozygous CCR5 Δ32 mutation, and the recipient’s anti-retroviral therapy was 
discontinued at the time of the transplant. 20 months following the transplant the patient 
had no viral rebound, remained off anti-retroviral therapy and was still in remission [298]. 
Whilst this may initially appear to be a cellular based therapy, it highlights that stem cells 
could potentially be manipulated to contain the CCR5 Δ32 mutation, or as in this case, that 
donors could be genetically screened for the presence of it, prior to use in transplantation. 
In Summary there are a number of potential ways in which the chemokine system can be 
targeted to therapeutic effect, some of which have already made it into regular clinical use.  
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1.5 Adenoviral Vectors 
In the previous section, gene therapy was briefly discussed as a potential modality for 
targeting the chemokine system. Stem cell transplantation is not feasible in the majority of 
patients, however there are other ways in which gene therapy can be provided, and the use 
of viral vectors such as adenoviruses and retroviruses have been the focus of research in 
many institutions. Adenoviral vectors are widely used in gene therapy studies due to their 
high capacity to transfer genetic material without integrating viral DNA into the host 
genome. They are also stable in-vivo, have a low risk of mutagenesis, and benefit from an 
understanding gained from decades of study [299]. What follows is an overview of 
adenoviruses, which were chosen as a potential vector for targeting the chemokine system 
with gene therapy in this project. 
1.5.1 Overview 
The adenovirus was first isolated from adenoid tissue in 1953. Since that time over 50 
serotypes have been identified and these are divided into six subgroups A-F depending on 
features such as genetic organization, agglutination, nucleic acid homology and cross-
immunoreactivity [300]. Adenoviral vectors (Ad vectors) generally have a low 
pathogenicity in immunocompetent people, although they are associated with enteric, 
urological, ocular and respiratory diseases including the common cold. Some subgroups, 
including A and B, have also been observed to have oncogenic potential in cell culture and 
animal studies, however, it remains to clarified whether, these lead to malignancy in 
humans. Adenoviruses are of great interest as they are able to efficiently transfer genes into 
a wide variety of cells in-vivo and because of these qualities; Ad vectors have been widely 
employed as gene-delivery vehicles in a variety of applications including gene therapy. 
Some of these aspects are discussed below. 
1.5.2 Structure of the Adenovirus 
The adenovirus (figure 1.14) is a non-enveloped, double stranded virus, with a total 
molecular weight of approximately 150MDa. All of the subtypes have the same caspid 
structure into which up to 36kbp of DNA can be packed, aided by packaging proteins. The 
caspid is about 100Å in diameter with a 25-x icosahedral structure. This is composed of 
three polypeptides, the first, hexon (polypeptide II), forms the major viral antigen and is 
composed of 12 copies of a trimeric hexon protein. The penton base (polypeptide III) is 
formed by a complex of 2 proteins creating, the pentameric base. Finally, the fibre 
(polypeptide IV) is composed of a trimeric protein, which protrudes from the penton base 
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ending in the C-terminal knob domain. The latter two polypeptides are integral to 
adenoviral entry into the cell and are discussed below [Reviewed in 301].  
 
Figure 1.16: Diagrammatic representation of the adenoviral particle, with the major structural 
components labelled. 
 
1.5.3 Components of Adenoviral DNA and Viral Replication  
Within the wild type virus can be found 36kbp of DNA encoding a number of proteins 
responsible for the transformation of host cells, (i.e. incorporation of viral DNA into host 
DNA), evasion of host immune defenses and viral replication. The early DNA regions 
include E1A, E1B, E2, E3 and E4. E1A contains 3 regions leading to the transcriptional 
activation of the other early viral promotors and also drives transcription of the major late 
promotors leading to transcription of the structural late viral products forming the caspid 
[301]. E1A products also act as transcriptional repressors, preventing inhibition of cell-
cycle arrest [302]. E1B has a role in infection and transformation, producing 2 proteins one 
of which has similarities to the anti-apoptotic BCL-2 protein. The second, along with the 
E4 open reading frame (ORF), forms complexes with the tumor suppressor p53 leading to 
abrogation of its transcription or even its degradation. These therefore serve to block 
apoptosis allowing for transformation of the cell [302]. 
 
E2 encodes proteins essential for viral DNA replication. Finally, E3 encodes at least 7 
proteins that prevent the destruction of the infected cell by evading the host immune 
system such as preventing TNF induced apoptosis and the killing of cells by cytotoxic 
lymphocytes through blockade of MHC class I expression on the cell surface [302].  
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Once within the nucleus, replication occurs dependent upon the initiation primer or 
terminal protein along with “inverted terminal repeats” (ITRs) at either end of the origin of 
replication. A common late promoter then guides transcription of the structural elements 
after splicing of precursor transcripts [303]. The initial events occur 5-6 hours following 
infection with assembly of virions within the nucleus occurring at approximately 8 hours. 
30-40 hours later proteolytic cell lysis results in the release of between 104 and 105 viral 
particles [304]. 
1.5.4 The Coxsackie and Adenovirus Receptor 
Adenoviruses primarily gain entry into cells through attachment to the coxsackie-and 
adenovirus-receptor (CAR) via the knob domain of the virus (see figure 1.15). The mature 
human CAR is a type-1 transmembrane protein of 365 amino acids, which forms part of 
the conserved subfamily of the Ig superfamily [304]. The receptor is composed of an 
extracellular domain consisting of two Ig loops (Ig domain D1 and D2), the 
transmembrane domain and a variable cytoplasmic tail. The extracellular domain is 
involved in interaction and binding with the adenovirus as demonstrated by the continued 
ability of the CAR receptor to function with truncation of its transmembrane or 
cytoplasmic components. Mutational studies have demonstrated that the CAR receptor 
binds with residues on the AB, DE loops and β sheet of the adenovirus fiber knob, with the 
latter able to bind to three molecules of the former [305].   
 
However, although the CAR receptor was initially described due to its association with 
adenovirus and coxsackie virus B, its physiological role is only just being understood, with 
a proposed role as an adhesion molecule. It is widely expressed in human tissues with 
hCAR mRNA being detectable in the liver, kidney, lung, brain, heart, colon, small 
intestine, testis, prostate and pancreas, with no expression in skeletal muscle (beyond the 
neonatal period), ovaries, thymus or placenta [306].  Furthermore, it has been difficult to 
infect haematopoietic cells, particularly lymphocytes, with adenovirus of the C subgroup 
(the most widely used vehicles in gene therapy), although CAR expression can be detected 
in 10-15% of CD34+ cells [307]. Expression in tumour cells is variable, probably 
reflecting their cell of origin.  
 
What regulates CAR expression is unclear. However, CLL cells and peripheral blood 
lymphocytes can be rendered susceptible to adenoviral infection by activation with 
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cytokines such as IL-4, IL-2 and CD40L [307].  Whether this relates to up regulation of 
CAR on the cell surface or is due to other mechanisms, discussed later, remains to be seen.  
Finally, as mentioned, the physiological role of the CAR receptor is only just being 
elucidated. It has a clear role in development with maximal CAR expression detected in 
neonates in a wide range of tissues, including skeletal muscle, and a rapid fall in 
expression following birth [308]. Murine CAR knock out models have demonstrated a 
lethal phenotype at approximately day 11 due to multiple cardiac defects [309]. 
Interestingly, the potential role of CAR in neuronal development has recently been 
published where the interaction of the CAR Ig domain D2 with a fibronectin fragment 
including the heparin-binding domain-2 promoted neurite extension, whilst extension did 
not occur in its absence [309]. 
 
Therefore, whilst the precise physiological role of CAR is yet unknown, it is clear that it 
has a central role in the infectivity of adenoviruses. 
1.5.5 Entry of Adenovirus into Cells 
As described previously the extra-cellular membrane contains glycosaminoglycans 
(GAGs), which can bind chemokines and other molecules.  However GAGs can also store 
viral particles such as herpes viruses, human immunodeficiency virus and adenoviruses. 
Whilst the trapping of adenoviruses in this milieu may reduce infectivity, it also provides a 
mechanism by which adenoviruses can enter cells [310]. Adenoviruses can enter cells by 
more than one mechanism, the most efficient of which involves the CAR receptor in all 
subgroups except B [311].  
 
The first step occurs when the C-terminal knob domain of the fibre protein binds to the 
amino-terminal V-like Ig domain (D1) of the CAR receptor [312] via residues on loops 
AB, DE and the β sheet of the fibre protein [305, 306]. The group B adenoviruses have 
been shown to enter cells via CD46 [311]. Following initial binding, αvβ3 or αvβ5 
integrins (other integrins may also be involved) in the cell membrane act as co-receptors 
through interaction with the highly conserved RGD motif present in the penton base, with 
as many as 5 integrins binding at once to form a ring-like structure.  This stage is essential 
for receptor internalization [301]. The clustering of integrins leads to their conformational 
change resulting in stimulation of the intracellular pathways responsible for the induction 
of internalization via clathrin-coated pits to endosomes [313]; a system that has been 
described previously with chemokine/receptor internalization. During this process the 
caspid is partially disassembled via fiber shedding [314]. As the pH falls, the remaining 
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caspid is released from the endosomes and transported along microtubules to the peri-
nuclear envelope where further caspid degeneration occurs before the viral DNA is 
imported into the nucleus [315].  
 
 
Figure 1.17: An overview adenoviral internalization following attachment to CAR and subsequent 
integrin mediated endocytosis. The first step entails binding of the fibre knob protein with CAR. 
Following this a-integrins interact with the RGD motif on the penton base thereby facilitating 
internalisation by endocytosis and subsequent incorporation into endosomes. The virion is 
subsequently disassembled allowing incorporation of viral DNA into the nucleus of the host cell. 
[Taken from 301]. 
 
Yet, ablation of the CAR receptor does not prevent adenoviral entry into cells altogether. 
This has been shown in experiments in which ablation of CAR receptor binding via 
alterations in the Y477 residue within the CAR binding region of the fibre protein has been 
engineered. In these studies, adenoviral infection was not abrogated with biodistribution of 
the virus remaining unchanged including infection of hepatocytes.  However, the 
infectivity of the virus was greatly reduced [316, 317]. It is likely that CAR independent 
entry of adenovirus into cells is mediated by integrins in most instances. This has recently 
been demonstrated in a study of adenoviral infection in low CAR expressing cell lines, in 
which adenoviral infectivity could still be detected and blockade of the CAR receptors by 
incubation with soluble fiber proteins did not affect this. However antibody blockade of the 
penton base RGD motif blocked infection, suggesting that it was the interaction with 
integrins guiding adenoviral entry into the cell. Additional, analysis confirmed that it was 
indeed αvβ5 integrins that were responsible for the attachment and internalization of viral 
particles [318]. This contradicts earlier studies, which suggested that integrins were only 
able to promote internalization [319]. Other integrins have also been implicated including 
αMβ2 integrins, which have been shown to mediate adenovirus entry, and thus gene 
delivery, into haematopoietic cells [313].    
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Furthermore, other mechanisms have been observed. Amongst these is the ability of the 
viral fibre knob domain of (adenovirus 5) Ad5 to bind directly to certain vitamin K 
dependent coagulation zymogens, namely factors; FX, FVII, FIX and protein C, to 
promote viral entry into hepatocytes and Kupffer cells, in conjunction with complement 
factor C4BP. This is achieved through the interaction of heparan sulphate on the cell 
surface and low-density receptor-related protein. Furthermore inhibition of these zymogens 
with warfarin led to a significant reduction in the infectivity of the virus. Further tests 
showed that CAR-independent mechanisms were responsible in Kupffer cells [308, 320]. 
Therefore, it is clear that adenoviral entry into cells is complex with a number of potential 
mechanisms at play depending upon the adenoviral subtype, cell type and 
microenvironment with other mechanisms not discussed here also discovered. But what is 
clear is that entry via attachment with the CAR receptor is the most efficient means of 
getting the virus into cells. 
1.5.6 Adenovirus and Gene Therapy 
Adenoviruses have been used in hundreds of clinical trials, including attempts to introduce 
a functioning transgene for monogenetic disorders and in the treatment of certain 
malignancies often involving induction of cell death in cancers. To date the majority of 
clinical trials have been for cancer and although only a minority have reached phase III 
studies, the treatments in these patients appear to have a low level of toxicity, with 1000’s 
of patients having undergone such treatments [321].  
 
The first generation of adenoviral viral vectors, were developed with the replicative E1 
viral DNA being deleted (and sometimes E3) and replaced with the transgene of interest 
[304](see figure 1.16). In order to replicate the adenovirus, helper cell lines were 
developed with the necessary replicative elements, the first amongst these being the human 
embryonic kidney 293 (HEK293) cells [304]. However, these vectors were not efficient 
enough, proved toxic and were cleared from the circulation quickly due to cytotoxic T-cell 
mediated immunogenicity. The second generation of vectors had further viral encoding 
elements removed, namely E2 and E4. However more complex helper-cell lines were 
required, and whilst transgene expression was improved, there were debates regarding the 
true reduction in toxicity and immunogenicity. This was highlighted in the only mortality 
to date directly associated with adenoviral vector therapy, in which a patient receiving 
therapy for partial ornithine transcarbamylase (OTC) deficiency, died following the 
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administration of a high titer of a second-generation vector engineered to transfect the gene 
for OTC into hepatic cells [322]. 
 
High-capacity (HC) or “gutless” Ad vectors have since been developed which are devoid 
of all of the virus coding genes except the internal terminal repeats and packaging signal 
(ψ), on which replication depends. As a result these HC Ad vectors are able to 
accommodate up to 36kb of non-viral DNA, leading to a considerable reduction in toxicity 
and immunogenicity in-vivo. Non-coding ‘stuffer’ DNA is incorporated into constructs 
where necessary to allow for a package-able size of between 28 and 36Kbp [323]. 
However, without the viral elements required for replication a variety of systems involving 
plasmids, strains of E.coli and helper-cell lines are employed to assist in replication and 
assembly of these vectors.  Further details can be found in chapter 5. 
 
Once the virus has gained entry into the cellular target, transgene expression or 
cytotoxicity can be elicited in a variety of ways. To drive expression of the transgene, 
widely expressed promoters can be employed, most commonly the CMV promoter, 
followed by the gene of interest. If cytotoxicity of malignant cells is the aim, the transgene 
expressed can encode ‘suicide’ genes causing apoptosis directly or indirectly.  These are 
termed oncolytic viruses. In the latter case, genes such as thymidine kinase or bacterial 
nitroreductase are inserted. These enzymes then enable the conversion of pro-drugs such as 
ganciclovir in the case of the former and CB1954, in the case of the latter, into the active 
metabolites which will then elicit death in these cells, therefore providing a level of 
specificity [304, 324].  
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Figure 1.18: Diagram demonstrating the various components of adenoviral genome in the 
different vector generations. E=early promoters, L=late promoters. [Taken from 325]. 
 
1.5.7 Targeting Specific Cells with Adenoviral Vectors 
1.5.7.1 Conditionally-Replicating Adenovirus and Tissue-Specific 
Promoters 
Further specificity can be gained by replacing ubiquitous promoters such as the CMV 
promoters with those that are specific for the target cell in question, i.e. tissue specific 
promoters, or by the production of conditionally replicating viruses. In the latter case 
mutations are engineered in the E1B region encoding for those proteins that disable tumour 
suppressors such as p53. This adds a degree of specificity in that viruses will only be able 
to replicate in those cells in which p53 is deficient, i.e. tumour cells rather than normal 
cells.  Following replication, cell lysis then occurs with release of the viral particles 
locally, and potentially systemically, to infect other p53 deficient cells [304]. 
 
Tissue specific promoters provide a further level of specificity with a wide range having 
been used in clinical studies including prostate-specific and bladder urothelial-specific 
promoters [326]. Another reported promoter is telomerase. This has the advantage of being 
switched off in most adult somatic cells; although expression remains in germ cells, stem 
cells, certain long-lived lymphocytes and the majority of tumor cell lines, and it can 
therefore be argued that it has a wider range of applications in cancer gene therapy. 
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Telomerase prevents the attrition of telomeres caused by cell divisions and therefore 
contributes to the immortalisation of malignant cells [327]. This has been shown to be an 
effective strategy when combined with a ‘suicide’ gene such as bacterial nitroreductase in 
pre-clinical studies and clinical trial data are now awaited [328]. Another strategy in cancer 
gene therapy uses the adenovirus vector as a vaccine to enable an immune response to be 
mounted against telomerase proteins with some promising early clinical trial results [325].  
1.5.7.2 Redirection of adenoviral tropism 
One problem with adenoviral gene therapy has been the lack of specificity in the 
biodistribution of the virus. One of the reasons for this is the wide expression of CAR, 
which consequently limits the application of adenoviral gene therapy due to its wide 
anatomical expression or due to lack of expression on the cellular target. As such, an   
approach to this problem is to block endogenous viral tropism whilst simultaneously re-
directing it through a receptor on the cell of interest.  
 
There have been a variety of strategies employed to achieve this including chemical 
modification of the caspid, the use of cross-linked neutralizing antibodies, genetic 
incorporation of a fibre protein from a different serotype and the genetic incorporation of a 
peptide ligand into elements of the fibre proteins or penton base. These ways of redirecting 
the virus essential coat the virus with a different antigens and proteins, thus ‘shrouding’ the 
virus thereby blocking entry through its natural receptor and redirecting it through the 
receptor of interest. The term ‘shrouding’ is used later in this thesis to describe this 
approach, which is used in this project. 
 
The first reports of successful adenoviral tropism redirection were published in 1996. In 
the first, an adenovirus was constructed with heparin-binding domains incorporated into 
the C-terminus of the fibre knob, thereby redirecting tropism to heparan-containing 
receptors on the cell surface [329]. Further experiments have demonstrated that peptides 
exceeding 50% of the size of the knob domain (>100 amino acid residues) can be 
incorporated into the fibre without significantly affecting its functional properties [330]. 
Douglas et al described the use of neutralizing anti-fibre antibodies conjugated with folate 
to redirect through folate receptors [331].  
 
Chemical modification of the caspid has been described using biotinylation and binding 
with bifunctional polyethylene glycol (PEG) and polymer coating the virus [332].  This 
enables the virus to be ‘shrouded’ in a peptide of choice to allow redirection.  For example 
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biotinylation followed by incubation with avidin and then antibodies against c-kit, CD34, 
IL-2 or CD44 allowed for entry of these vectors into haematopoietic stem cells (c-kit, 
CD34) or resting and activated T-cells (CD44) or activated T-cells (IL-2), thereby 
overcoming the issue of gaining entry into these low CAR expressing cells [304]. 
 
Finally, modifying the adenovirus by ‘fibre switching’ is another approach. By replacing 
the fibre of Ad5 with that of Ad35 (Ad5F35), the tropism of the virus is redirected through 
CD46, which is present on many haematopoietic cells. This approach has been taken to 
transfect leukaemia and lymphoid cells. In the former case a conditionally replicating 
Ad5F35 chimera was engineered to express tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), thus inducing apoptosis in the targeted leukaemia cells [333]. 
Ad5F35 vectors have demonstrated an improved transfection rate in lymphocytes, 
however, different lymphoid cell lines demonstrated differing levels of transduction, which 
was more dependant on the intracellular pathways utilized by the virus than on the receptor 
of entry, indicating a further level of complexity required for the development of gene 
therapies in lymphoid disorders [334]. 
 
Whilst, it has now been clearly demonstrated that adenoviral tropism can be redirected, it 
should not be forgotten that adenoviruses can enter cells by more than one mechanism, and 
independently of CAR expression, therefore these approaches may not entirely abrogate 
the natural tropism of these viruses.  
 
So, despite these advances in adenoviral gene therapy, approval from European and United 
States authorities for therapeutic administration has yet to be obtained. There are a variety 
of reasons for this including continued safety concerns, and the lack of results from Phase 
III clinical trials. Furthermore, as the last study demonstrates the effect of intracellular 
events on transduction may be unpredictable and require further study. Work is continuing 
to overcome the many issues with adenoviral gene therapy described above as well as 
those relating to low efficiencies in transgene expression, the reduction of immunogenicity 
(in those therapies aimed at continued transgene expression such as in haemophilia A), 
difficulties in anatomical targeting of the vectors and improving long-term expression of 
transgenes where needed. Yet, gene therapy remains a promising prospect especially in the 
field of cancer therapies.  
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1.6 Aims of Study 
There were a number of aims in this project: 
  
• Investigation of the relationship between chemokine receptor expression and 
lymphoma sub-type. Although there is emerging evidence to suggest that there 
might be such a relationship this was to be investigated further. To do this a system 
to assess clinical samples from patients with a range of B-cell NHL subtypes for 
constitutive chemokine receptor expression was required.  
• Correlation between chemokine receptor expression and clinical outcome. 
There is limited evidence to support a correlation between chemokine receptor 
expression in B-cell NHL subtypes and outcome. Therefore following assessment 
for chemokine receptor expression in B-cell NHL subtypes correlation with clinical 
outcomes was to be performed.  
• Identification of potential chemokine receptor targets in non-Hodgkin’s 
lymphoma. It was also hoped that a study of clinical samples would provide 
information about potential therapeutic targets in NHL.  
• Targeting the chemokine system. Utilising the chemokine system for targeted 
therapy was to be explored and experiments attempting to target the chemokine 
system with cytotoxic agents were performed. CCR7 was identified as a suitable 
target for these experiments. Initial targeting experiments used radiolabelled 
CCL19 to assess whether or not cell kill would only be elicited in CCR7+ cells.  
• Using gene therapy to target the chemokine system. The potential to use gene 
therapy with adenoviral vectors to deliver a ‘suicide’ gene to targeted cells was 
explored. However, before using adenoviral vectors containing ‘suicide’ genes a 
system to redirect adenoviral tropism through chemokine receptors had to be 
developed and this was explored in this thesis.  
• Development of a lymphoma mouse model for in-vivo targeting experiments. A 
lymphoma mouse model was required for in-vivo targeting experiments. The aim 
therefore was to characterise a cell line, which could potentially be used for this 
purpose. 
 
In summary, it was hoped that this project would provide novel data regarding chemokine 
receptor expression and its impact on outcomes in NHL, whilst also providing information 
on potential therapeutic targets. Additionally, it was hoped that approaches to successfully 
target the chemokine system with cytotoxic agents could be developed.   
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Antibodies 
Antibodies Source 
Primary Antibodies  
Mouse anti-hCCR4 R&D systems 
Mouse anti-hCCR4 - allophycocyanin R&D systems 
Mouse anti- hCCR6 Abcam 
Mouse anti-hCCR7 R&D systems 
Rat anti-mCCR7-FITC Abcam 
Mouse anti-hCCR9 R&D systems 
Mouse anti-hCCR9-allophycocyanin R&D systems 
RatAnti-hCCR10 Abcam 
Mouse anti-hCXCR4 R&D systems 
Mouse anti-hCXCR4-allophycocyanin R&D systems 
Mouse anti-CD20-phycoerythrin Becton Dickson 
Mouse anti-hexon Becton Dickson 
Mouse anti-hexon Chemicon 
Secondary Antibodies and Detection 
Reagents 
 
Viaprobe Becton Dickson 
IgG2A-allophycocyanin (isotope control) R & D Systems 
IgG2B-allophycocyanin (isotype control) R & D Systems 
IgG2B-phycoerythrin (isotype control) Becton Dickson 
Goat anti-mouse IgG-allophycocyanin R & D Systems 
Goat anti-mouse IgG -phycoerythrin Sigma 
Goat anti-rat IgG-phycoerythrin R&D Systems 
Streptavidin-phycoerythrin Invitrogen 
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2.1.2 Bacteriology 
Item Supplier 
Ampicillin           Sigma-Aldrich 
90mm bacteriological Petri dishes Sterilin 
0.1mm Electroporation Cuvettes Invitrogen 
0.2mm Electroporation cuvettes Invitrogen 
Escheria coli BJ5187 cells Stratagene 
Escheria coli Ad-1 BJ5187 cells  Stratagene 
Escheria coli DH5a Invitrogen 
ER2925 dam- cells NEB 
Kanamycin Invitrogen 
LB (Luria Burteni) Agar (sterile) GBRC Central Services 
LB broth (sterile) GBRC Central Services 
NZY broth GBRC Central Services 
SOC medium Invitrogen 
Tetracycline Sigma-Aldrich 
XL Blue Supercompetent cells Stratagene 
XL Gold Supercompetent cells Stratagene 
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2.1.3 Cell Culture 
Item/Reagent Supplier 
Bijoux/ Universal containers Bibby Sterilin 
Blasticidin Invitrogen 
4 well Chamber slide Nunc 
Cryotubes Nunc 
Distilled water (sterile) GBRC Central Services 
DMEM cell culture medium Invitrogen 
Effectene Transfection Kit Qiagen 
Fibronectin Sigma 
Foetal calf serum Invitrogen 
Geneticin Invitrogen 
L-Glutamine 200mM Invitrogen 
HEPES 1M solution Invitrogen 
Penicillin/streptomycin Invitrogen 
Phosphate buffered solution (sterile) GBRC Central Services 
1ml, 5ml, 10ml, 25ml plastic pipettes Costar 
Polyfect Transfection Kit Qiagen 
Puromycin Sigma-Aldrich 
RPMI 1640 cell culture medium Invitrogen 
60mm, 90mm TC dishes Sterilin 
T25, T75, T175 TC flasks Corning 
6 well, 12 well, 24 well TC plates Corning 
96 well TC plates Corning 
TE buffer Ambion 
250ul, 1000ul Tips Ranin 
0.5% Trypsin Invitrogen 
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2.1.4 Cell Lines 
 Cell Origin Source  
CHO Chinese hamster ovary  CRG cell bank 
Daudi Human Burkitt lymphoma, EBV positive Prof. Ruth Jarrett 
EL4  Murine Thymic lymphoma ATCC 
HEK.293 Human embryonic kidney CRG cell bank 
Jurkatt Human T-lymphoblastic lymphoma CRG cell bank 
MOLT-4 Human T-lymphoblastic 
lymphoma/leukaemia 
CRG cell bank 
Raji Human Burkitt lymphoma, EBV positive Prof.Ruth Jarrett 
 
2.1.5 Chemicals 
Chemical Supplier 
Acetic Acid Sigma 
Acetone Sigma 
Agarose (electrophoresis grade) Invitrogen 
Bovine Serum Albumin Sigma 
Bromophenol Blue Sigma 
Chloroform Fisons Scientific Equipment 
Dimethyl sulfoxide (DMSO) Fisons Scientific Equipment 
Ethanol James Burrough Ltd 
Ethidium bromide Invitrogen 
Ethylene diamine tetra acetate disodium salt (EDTA) Fisons Scientific Equipment 
Glycerol GBRC central services 
Hydrochloric acid Fisons Scientific Equipment 
Methanol Fisons Scientific Equipment 
Paraformaldehyde Sigma 
Propan-2-ol Fisons Scientific Equipment 
Sodium acetate Sigma 
Sodium azide Sigma 
Tris-base Fisons Scientific Equipment 
TRIZOL reagent Invitrogen 
© Michelle Bryson, 2010                     CHAPTER TWO                  MATERIALS AND METHODS 
 
 91 
2.1.6 Miscellaneous 
Item Supplier 
0.2ml Microcentrifuge tubes Ambion 
1KB DNA ladder Invitrogen 
1.5ml Microcentifuge tubes Eppendorf 
15ml centrifuge tubes Corning 
24 well chemotaxis plate (3mm pore) Corning 
50ml centrifuge tubes Corning 
DEPC treated water Ambion 
Electron Microscopy Cribs Professor Lawrence Tetley 
Glass coverslips Fisher Scientific Ltd 
Glass slides Fisher Scientific Ltd 
Haemocytometer Fisher Scientific Ltd 
Nanovan Nanoprobes 
Poly-L-lysine Sigma 
Polypropylene FACS tubes Becton Dickson 
Sterile 0.2mm acrodisc filters Gelman Sciences Ltd 
Trigene Medichem International 
Vectashield with DAPI Vector labs 
Whatman 3mm filter paper Whatman International Ltd 
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2.1.7 Molecular Biology 
2.1.7.1 Plasmids 
Item Supplier 
pAdEasy-1 Stratagene 
pBlueScript KSII(-) Stratagene 
pShuttle-CMV Stratagene 
pShuttle-IRES-hrGFP-1 Stratagene 
pShuttle-CMV-LacZ Stratagene 
pCR2.1 TOPO®TA Invitrogen 
pcDNA3.1/V5 His©TOPO®TA Invitrogen 
pEF6/V5-His TOPO®TA Invitrogen 
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2.1.7.2 Oligonucleotides 
Oligonucleotide Name Oligonucleotide Sequence  
ScreeningOligos  
Forward - tccatcatgaagtgtgacgt Actin (human and murine) 
Reverse - tactcctgcttgctgatccac 
Forward - gtggggcgccccaggcacca Actin (hamster) 
Reverse - ctccttaatgtcacgcacgatttc 
Forward - gttgggagattagacagagga Alpha Integrin (human) 
Reverse - caaaacagccagtagcaacaa 
Forward - agtggtttggagcctctgtgag Alpha Integrin (murine) 
Reverse - cagaaaatccaaaatacgcagcc 
Forward - agctcctggtgttgcaaataagaag hCAR 
Reverse - taagaccaatgagcgctagagcaag 
Forward - aatgtgaccaacctgcagct mCAR 
Reverse - agcacaagggccagcagcgt 
Forward - gatatagcagacaccaccctcgatg hCCR4 
Reverse - tatgccactgtaaaagcccaccaag 
Forward - aggtcaggcagttctccaggctat hCCR6 
Reverse - tgctgcgcggtagtgttctggatc 
Forward - gtgctggtggtggctctccttgt hCCR7 
Reverse - gtaggagcatgccactgaagaagc 
Forward - gctcaacctggccgtggcagacatcc mCCR7 
Reverse - ccacttggatggtgatcaaggcctcc 
Forward - atggctgatgactatggctctgaat hCCR9 
Reverse - aatgtacctgtccacgctgatgca 
Forward - ggtttcctggggccattactctg hCCR10 
Reverse - gacggagaccaagtgtgcgcgg 
Forward - aggaaatgggctcaggggactatg hCXCR4 
Reverse - gatgaaggccaggatgaggacact 
Forward - tacccgctaacgctggaaatggac hCXCR5 
Reverse - gtaggcatggacggcgtggacaat 
AdV Flanking  Forward caaggcaaaatgtagcaggaggac 
AdV Flanking Reverse cacgtggtgccaacattgatatca 
Primers for sequencing  
Forward - atggacctggggaaacctatgaaa CDS.hCCR7  
Reverse - ctatggggagaaggtggtggtgg 
Forward - atggacccagggaaaccgaggaaa CDS.mCCR7 
Reverse - ctacggggagaaggttgtggtggt 
Acceptor Peptide Insertion Forward ttcgaggcccagaagatcgagtggcacgagtgatctagata 
aagaatcgtttgtgtt 
 Reverse - ccactcgatcttctgggcctcgaagatgtcgttcaggccttctt 
gggcaatgtatga 
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2.1.7.3 Restriction Enzymes 
Enzyme 
 
Recommended Buffer Supplier  
AflII 
 
NEBuffer 2 NEB 
ApaI 
 
NEBuffer 4 NEB 
BamHI 
 
REact 3 Invitrogen 
DpnI 
 
REact 4 Stratagene 
EcoRI 
 
REact 3 Invitrogen 
EcoRV 
 
REact 2 Invitrogen 
HindIII 
 
REact 2 Invitrogen 
KpnI 
 
NEBuffer 1 NEB 
MluI 
 
NEBuffer NEB 
NaeI 
 
NEBuffer NEB 
NotI 
 
NEBuffer 3 NEB 
NruI 
 
NEBuffer 3 NEB 
PacI 
 
NEBuffer 1 NEB 
PmeI 
 
NEBuffer 4 NEB 
PvuI 
 
NEBuffer NEB 
SalI 
 
NEBuffer 3 NEB 
SbfI 
 
NEBuffer 4 NEB 
SpeI 
 
NEBuffer 2 NEB 
XbaI 
 
NEBuffer 2 Invitrogen 
XhoI 
 
NEBuffer 2 NEB 
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2.2 Methods 
2.2.1 Obtaining Ethical Committee Approval for use of Patient Samples 
In order to comply with the Scottish Human Tissue Authority Act (2006) Ethical approval 
was required before using clinical samples composed of lymphocyte preparations from 
affected lymph nodes. An online form was completed via the Central Office for Research 
Ethics Committees (COREC), via their website www.corecform.org.uk and was submitted 
to the Regional Ethics Committee. Ethical approval was granted on 17th April 2007. 
2.2.2 Tissue Culture 
All tissue culture was performed under sterile conditions within a class II biological safety 
cabinet with laminar flow. The adherent cell lines HEK.293 and CHO were grown in 
complete medium (1x DMEM with 10% foetal calf serum, 20mM L-Glutamine, penicillin 
(100IU/ml) and streptomycin (50µg/ml)). Before splitting, the cells were trypsinised using 
between 1 and 3ml of 0.05% trypsin-EDTA. The cells were then incubated at 370C for two 
minutes. After this the cells were examined microscopically to ensure that they had 
disassociated from the plastic, the trypsin was then neutralised with 5x volume of complete 
media, and then the cells were transferred to a 25ml universal container. Cells were spun at 
660g for 5 minutes, the supernatant was removed and the cells re-suspended in fresh 
medium and split according to need, e.g. 1 in 10. 
 
Non-adherent cells lines were split to a concentration of 2 x 105 cells/ml once or twice each 
week. EL4 cells were grown in 1xDMEM as outlined above. The cell lines; Daudi, Raji, 
MOLT-4, and Jurkat were grown in RPMI 1640 with 10% FCS, 20mM L-Glutamine, 
penicillin (100IU/ml) and streptomycin (50µg/ml). 
2.2.2.1 Freezing Cells 
2 x106 cells were suspended in 900µl of the appropriate medium for the cell type. 100µl 
DMSO was then added to the cells (giving a 10% solution of DMSO). The cells were then 
transferred to cryotubes, before being placed in a "Mr Frosty" containing 250ml of 
isopranol. This allows gradual cooling of the samples when the "Mr Frosty" is placed in 
the -70oC freezer for 12-16hrs prior to transfer to liquid N2 tanks for long-term storage 
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2.2.2.2 Defrosting cells 
Cells were taken from liquid N2 storage and placed into a waterbath at 37oC to thaw.  The 
cells were then placed in a universal container to which 20ml of sterile PBS was added. 
The cells were then spun down at 660g for 5 minutes and the supernatant discarded. The 
cell pellet was then re-suspended in 10ml of the appropriate growth medium and 
transferred to a T25 flask 
2.2.2.3 Counting Cells 
To count the cells, a Neubauer haemocytometer was used. The cover slip was placed over 
the grid. 5ml of 0.4% (w/v) trypan blue was then added to 20µl of the cell suspension and 
the mixture was placed under the cover slip. The cells were then counted, with the number 
of blue cells noted. The blue cells stained with the trypan blue indicate those cells that are 
not viable as viable cells do not take up the dye due to intact membranes. Ideally at least 
100 cells should be counted within the grid. The cell concentration is then calculated as 
follows:  
 
Number of cells in central grid      x 104 = cells/ml 
Number of squares in central grid  
 
This figure was then multiplied by 1.2 to take into account dilution with the trypan blue 
solution. 
 
Cell viability was then calculated as follows: 
% viable cells = number of viable cells  x 100 
                           Total number of cells 
 
2.2.2.4 Transfection of Cells 
2.2.2.4.1 Stable Transfection of HEK.293 and CHO Cells Using 
Effectene® 
The day before transfection 60mm tissue culture plates were set up to contain 2.5x105 cells 
and 4mls of complete DMEM for each vector to be transfected. An additional plate was set 
up to act as a control. The plates were examined the following day to ensure that the cells 
were between 40-80% confluent, prior to proceeding. The transfection was then carried out 
according to the manufacturers instructions using the Qiagen Effectene® transfection kit. 
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24 -48 hours following transfection the cells were assessed for protein expression. If stable 
transfectants were required then the complete medium was replaced with selective medium 
containing the appropriate antibiotic. 
2.2.2.4.2 Transient Transfection of CHO Cells using Polyfect® 
Cells were prepared and assessed for transfection as in 2.2.2.4.1 above. Once prepared, the 
cells were transfected using the Qiagen Polyfect® reagent, according to the manufacturers 
instructions. After 24-48hours the cells were assessed for protein expression and used as 
required. 
2.2.2.4.3 Transfection of EL4 Cells by Nucleoporation 
For each nucleoporation 1x106 cells were used per well of a 6 well tissue culture plate. The 
EL4 cells were nucleoporated using the Amaxa Nucleoporation Kit L, according to the 
manufacturers instructions. 24 hours after nucleoporation the cells were spun down and re-
suspended in selective medium. At this point they were assessed for protein expression if 
required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Michelle Bryson, 2010                     CHAPTER TWO                  MATERIALS AND METHODS 
 
 98 
 
2.2.3 Analysis of Cell Fluorescence by FACS 
a) HEK-293, CHO, and Lymphoma Cell Lines for Single Colour Detection 
Cells from the experiments were collected into a 5ml polypropylene FACS tube, spun 
down and then re-suspended in 400µl of ice-cold FACS buffer (PBS with 2% FBS). Data 
acquisition was performed using CellQuestTM software on a Becton Dickson FACSscan. 
Cells were gated using forward and side scatter (see figure 2.1).  Negative controls were 
used such that >95% of the cells fell between 100 and 101 on the FL2-H (for 
phycoerythrin) or the FL1-H (for GFP) channels (see figure 2.1). Test results were 
analysed using 10,000 gated events, whenever possible, per sample. The data collected was 
analysed using either the CellQuestTM or FlowJo software programmes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Gating for single-colour flow cytometry. Data acquisition of cells was performed 
using CellQuestTM software on a Becton Dickson FACSscan. Cells to be analysed were gated 
using forward and side scatter as shown in a) demonstrating gating of Raji cells using a dot plot. b) 
Histogram plot of the same Raji cells used as a negative control, demonstrating that more than 
95% of the cells are between 100 and 101 on the FL2-H gate. 
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b) Lymphoma cell lines and clinical samples for Two-colour Flow Analysis 
After incubation of the cells with the antibodies, 10µl of Viaprobe (Becton Dickson) was 
added to each cell pellet, and incubated for 10 minutes at 40C before being re-suspended in 
400µl of ice-cold FACS buffer. Cells stained with Viaprobe are apoptotic or necrotic and 
detected on the FL3-H setting (figure 2.2), these were excluded from the final analysis. 
Forward and side scatter gating of the cells was then performed as before. Two-colour flow 
using FL2-H (phycoerythrin) and FL4-H (allophycocyanin) gates were then set up using 
double negative, FL2-H positive, FL4-H positive and double positive controls, with Raji 
cells as the control cell line. This ensured that any overlap in the light frequencies used was 
compensated for. Data was acquired using the Becton Dickson FACSscan and analysed 
using either CellQuestTM or FlowJo software (Figure 2.3). 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure 2.19: Determination of cell viability using ViaProbe. Cells were incubated with 5µl of 
ViaProbe for 5 minutes prior to analysis using flow cytometry. Cells of the correct size and 
granularity as determined by forward and side scatter were then gated as shown in a) 
demonstrating a dot plot with gating of the lymphocyte population to be analysed. Using a 
histogram plot, cells stained with ViaProbe produced a shift along the FL3-H gate, the peak shifted 
to the right represented non-viable cells and were excluded from further analysis as shown in b) 
this demonstrates the viable (FL3-H negative) population accounts for 69.7% of the cells gated in 
a).   
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Figure 2.3: Setting up the flow cytometer for 2 colour analysis of lymphocytes. The figure in 
the top-left shows the negative control, and settings were adjusted to ensure that the cells 
incubated with isotype controls fell in the bottom left quartile. The figure in the bottom-right 
demonstrates how the settings were adjusted for compensation ensuring that the cells bound to 
antibodies conjugated with APC fell to the left of the line. The figure in the top-right demonstrates 
how the settings were adjusted for compensation ensuring that the cells bound to antibodies 
conjugated with PE fell below the line. The figure in the bottom right shows how analysis can 
proceed for double stained cells following compensation. 
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2.2.4 Molecular Biology 
2.2.4.1 Oligonucleotide Synthesis 
All oligonucleotides were designed using complete coding sequences obtained through the 
NCBI nucleotide search engine. Once appropriate sequences for oligonucleotides were 
identified they were sent to VHBio for synthesis. The oligonucleotides were received as 
pellets, which were then re-suspended in sterile distilled water and used at the working 
concentration of 10nM. 
2.2.4.2 Nucleic Acid Preparation 
2.2.4.2.1 Genomic DNA Extraction  
The cells were pelleted by centrifugation at 660g for 5 minutes. The supernatant was 
discarded and the cells re-suspended in 1ml of PBS and transferred to a 1.5ml micro-
centrifuge tube. The cells were then centrifuged for 1 minute at 3000rpm using an 
Eppendorf 5415C microcentrifuge, the supernatant was carefully removed and then 500µl 
of cell lysis buffer and 5µl of proteinase K were added to the cell pellet. This mixture was 
then incubated overnight at 55oC. 500µl of isopropanol was added to the mixture and then 
rotated for 5-10 minutes until the viscosity had disappeared and strands of DNA were 
visible. This was then spun at 5000rpm in an Eppendorf 5415C microcentrifuge for 5 
minutes. The supernatant was removed. 500µl of 70% ethanol was added, being careful not 
to disturb the pellet (if this occurred the sample was re-spun and the supernatant again 
disgarded), and then carefully removed. 100ml of 1xTE buffer was then added and the 
sample was incubated at 60oC for 30 minutes to evaporate off any remaining ethanol. The 
DNA was then stored at 4oC. 
2.2.4.2.2 RNA Extraction using Trizol ® 
Cells were harvested and centrifuged for 10 minutes at 170g. The cells were then re-
suspended in 1ml of Trizol® and transferred to a microcentrifuge tube. These were left to 
incubate at room temperature for 5-10 minutes. 200µl of chloroform was then added to the 
cells and the mixture shaken by hand for 15 seconds. The mixture was then centrifuged at 
13200rpm for 10 minutes at 4oC in a Fisher Scientific Accuspin Micro 17R refrigerated 
microcentirfuge. The aqueous phase was carefully removed and transferred to a fresh 
microcentrifuge tube. RNA was precipitated by adding 500µl of isopropanol to the 
aqueous phase and incubating at room temperature for 10 minutes. It was then centrifuged 
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at 13200rpm for 10 minutes at 40C as above. The supernatant was discarded and the pellet 
allowed to air dry before being re-suspended in RNAase free water.    
2.2.4.2.3 DNAase Treatment of RNA 
To remove genomic DNA contamination from the prepared RNA it was treated with 
DNAase prior to further experiments. To do this a kit from Ambion was used. Briefly, 
10µl buffer and 1µl of DNAase was added to the RNA and incubated at 37oC for 30 
minutes. 10µl of DNAase inactivator was then added and incubated at room temperature 
for 5 minutes. The micro-centrifuge tube was flicked intermittently during this time. The 
RNA mixture was then centrifuged for 1 pulse at 13200rpm in an Eppendorf 5415C 
microcentrifuge. The supernatant containing the RNA was then removed and placed into a 
fresh micro-centrifuge tube. The RNA was then stored at -80oC prior to use. 
2.2.4.2.4 cDNA Synthesis from RNA 
cDNA was obtained by reverse transcription from RNA using the Invitrogen SuperscriptTM 
First-Strand Synthesis System for RT-PCR.  The manufacturer’s instructions were 
followed, but briefly, 2 microcentrifuge tubes were prepared with the following 
components: 5µg of the sample RNA, 10µg/ml Oligo (dT) 12-18, 200nM dNTP mix, the 
volume was then adjusted to 10µl using diethylpyrocarbonate (DEPC) treated water. This 
was incubated at 650C for 5 minutes, and then placed on ice for 1 minute. A 9µl mixture of 
the following components was added at these concentrations: 1 x RT-buffer, 5mM MgCl2, 
10nM DTT and 1ml of RNaseOutTM Recombinant RNase Inhibitor. The samples were then 
incubated at 42oC for 2 minutes. To one tube (+RT) 1µl (50 units) SuperscriptTM III 
Reverse Transcriptase was added with 1µl of DEPC treated water added to the other (-RT 
control). The samples were then incubated at 42oC for 50 minutes followed by incubation 
at 70oC for 15 minutes. Following this the samples were stored at -20OC until used for 
PCR amplification. 
2.2.4.3 Polymerase Chain Reaction (PCR) 
2.2.4.3.1 Reverse Transcriptase PCR (RT-PCR) 
ReddymixTM PCR Master Mix tubes were used in all applications unless otherwise stated. 
2-4µl of an oligonucleotide primer mixture (forward and reverse primers) was added to 
each tube giving a final primer concentration of 10-20µM. When the concentration of the 
template cDNA was known, 50-100ng of the DNA was added to the appropriate tubes, and 
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the final volume adjusted to 50µl with ddH2O if required. When the template DNA 
concentration was unknown (as after cDNA amplification) then 3µl of DNA was added to 
each tube. The tubes were then placed in a thermo-cycler and incubated according to the 
application as follows: 
 
Screening of cDNA from Lymphoid Cell Lines for Chemokine Receptor Expression: 
Step  Temperature Time No of Cycles 
1 92oC 2 minutes 1 
2 92oC 30 seconds 
3 54oC 30 seconds 
4 70oC 3 minutes } 35 
5 70oC 10 minutes 1 
6 4oC To end 1 
 
 
Screening of AdEasy Constructs: 
Step Temperature Time No of Cycles 
1 920C 2 minutes 1 
2 92oC 30 seconds 
3 52oC 30 seconds 
4 68oC 3 minutes 
} 10 
5 92oC 30 seconds 
6 55oC 30 seconds 
7 68oC 3minutes 
} 20 
8 68oC 10 minutes 1 
9 4oC To end 1 
 
2.2.4.3.2 Overlap-extension PCR 
Higuchi et al first described this method in 1988. It enables the introduction of a mutation 
or short peptide sequence at a specific site in the DNA. In this case a short peptide 
sequence was to be introduced at a specific point. To do this 4 primers were designed. The 
first 2 primers (flanking primers) were designed to be homologous to regions 1kb 5' and 3' 
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from the site of interest. The second 2 primers (peptide primers) had the first 24bpb 
homologous to the 3' and 5' regions beyond to the site of insertion and then the rest of the 
primer consisted of the sequence required for the peptide to be introduced.  
Three PCR reactions were set up using 3µl of cDNA and 1µl of each of the following 
primer pairs in a ReddyMixTM PCR tube: 
5' and 3' flanking primers 
5' flanking and 3' peptide primers 
3' flanking primer and 5' peptide primer 
 
The PCR programme used for this was the same as that detailed on the previous page for 
screening of AdEasy constructs. 
 
This produced 3 PCR products. The two 1kb PCR products were then used as template 
cDNA with the two flanking primers and the PCR reaction was repeated with the above 
programme. This resulted in a 2kb PCR product. To confirm that the PCR had worked the 
PCR product was initially digested with the restriction enzyme for the site that had been 
introduced and then sent for sequencing. 
2.2.4.4 Agarose Gel Electrophoresis 
A 0.9% gel was used throughout unless otherwise specified. Electrophoresis grade agarose 
was dissolved in 1 x TAE by heating. The solution was then allowed to cool to 60oC before 
ethidium bromide was added at a concentration of 0.5mg/ml. This was then poured into gel 
casts and left to set at room temperature. 
 
DNA loading buffer (40% sucrose, 100mM Tris pH7.5, 1mM EDTA and 0.5mg/ml BγPB) 
was added to each sample before loading onto the gel. For PCR reactions using Reddy mix 
tubes the addition of a loading buffer was not required. The samples were then added to the 
appropriate well of the gel and 5µl of 1kb DNA ladder was added alongside. Unless 
otherwise indicated the gels were run from the power pack at 100V in TAE buffer until the 
DNA bands were clearly separated. The gel was then placed on a UV trans-illuminator for 
visualisation and photography. 
2.2.4.5 Restriction Enzyme Digests 
A reaction volume of between 20-50µl was used for each digest. Between 5-10 units of the 
restriction enzyme was used along with the appropriate reaction buffer at 1x concentration. 
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The mixture was then incubated for 1-2 hours at 37oC. The reaction mixture was then run 
on a 0.9% agarose gel and the appropriate DNA fragment was cut and gel purified. If the 
DNA was to be used for a ligation reaction and had undergone digestion with a single 
restriction enzyme, then dephosphorylation was required to prevent re-ligation. To do this 
1 unit of shrimp alkaline phosphatase was added to the DNA and the mixture incubated for 
30 minutes at 37oC. 
2.2.4.6 Partial Digests 
This was performed if two restriction enzyme sites were present in the target DNA and 
cleavage at only one site was desirable. Four reaction mixtures were set up with 5µl of 
DNA. A reaction buffer with 50% activity for the appropriate restriction enzyme was 
chosen and added to the reaction mixture. 5 units of the restriction enzyme was then added 
to each tube and incubated at room temperature for the following times; 5 minutes, 7.5 
minutes, 10 minutes and 12.5 minutes. DNA loading buffer was added to each of the tubes 
at the appropriate time to inactivate the restriction enzyme. The reaction mixtures were 
then run on agarose gel until the bands had separated sufficiently to locate the desired 
DNA fragment. 
2.2.4.7 Gel Purification of DNA Fragments and PCR Products 
The DNA fragments were cut from agarose gels using a clean scalpel and purified using a 
Qiagen Qiaquick Gel Extraction Kit according to the manufacturers instructions. The DNA 
was then eluted from the columns using 20-40µl of distilled water or 1 x TE buffer (pH 
8.0). The DNA concentration was then determined by either spectrophotometry and/or by 
running a 5µl aliquot of DNA alongside a DNA ladder of known concentration. 
2.2.4.8 Cloning of PCR Products into TOPO® Vectors 
3µl of the PCR product was added to 1µl of vector and 1µl of the salt solution from the 
TOPO® Vector kit. This mixture was then left to incubate at room temperature for 5-30 
minutes. After this time, 3µl of the reaction mixture was used in a transformation reaction 
(see 2.2.4.1.4).  Following this, colonies were picked and overnight cultures set up. Mini-
preps were then carried out and the resulting pDNA was assessed to see if the PCR product 
had been successfully inserted using restriction enzyme digests.  
2.2.4.9 Annealing of Oligonucleotides 
One pair of oligonucleotides were designed to act as a linker containing specific restriction 
enzymes sites which enabled the introduction of a new restriction enzyme site into a 
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vector. 10µM (1µl) each of the forward and reverse oligonucleotides were placed into a 
PCR tube. To this 10µl of ligation buffer 1 and 2µl ligation buffer 2 (from the Roche Rapid 
Ligation Kit) were added along with 6µl of ddH2O and 1µl (10 units) of PNKinase. The 
reaction mixture was then incubated at 37oC for 20 minutes. The oligonucleotides were 
then denatured and the kinase deactivated by placing the tube in a water bath at 95oC, the 
water bath was then switched off and the mixture allowed to cool gradually to room 
temperature. The annealed oligonucleotide was then ready to be used for ligation into a 
vector.  
2.2.4.10 DNA Ligation using the Roche Rapid Ligation Kit 
This was used to insert oligonucleotides or fragments of DNA into vectors. 
Oligonucleotides were prepared as above. Vectors and DNA fragments were prepared by 
restriction enzyme digestion to obtain fragments with complimentary ends. If a single 
enzyme was used to prepare the DNA fragments and plasmids, then the DNA was 
dephosphorylated as described in 2.2.4.5. The Roche Rapid Ligation Kit was used  
according to the manufacturer's instructions. The amount of vector and insert used was 
calculated to give a molar ratio of between 1:1 and 1:3, e.g. 50ng vector and 150ng insert. 
The ligation product was then used in a transformation reaction as in 2.2.4.14. 
2.2.4.11 Site Directed Mutagenesis  
The QuickChange® Site-Directed Mutagenesis Kit from Stratagene was used for this 
according to the manufacturer’s instructions. Briefly a control and sample reaction was 
prepared. The control reaction contained 5µl of 10 x reaction buffer, 2µl (10ng) 
pWhitescript control plasmid, 1.25µl (125ng) primers #1 and #2, 1µl dNTP mix 38.5µl 
ddH2O giving a total reaction volume of 50µl. The sample reaction contained the above 
reagents with pShuttle.CMV.LacZ instead of the control plasmid and primers designed for 
site directed mutagenesis instead of primers #1 and #2. To each reaction mixtue 1µl of Pfu 
ultra HF DNA polymerase was added and the following PCR programme was then used; 
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Step Temperature Time No of 
Cycles 
1 95oC 30 seconds 1 
2 95oC 30 seconds 
3 55oC 1 minute 
4 68oC 1 minute/kb of plasmid 
length 
 
} 12-18 
 
After the PCR reaction was completed 1µl of the restriction enzyme Dpn1 was added to 
each mixture. These were then incubated for 1 hour at 370C. The mixtures were then 
transformed using XL-Blue supercompetent cells, using NZY medium as described in 
2.2.4.13 below.  
2.2.4.12 Preparation of Chemically Competent Cells 
Certain strains of E.coli used were not chemically competent when obtained. Following 
calcium chloride treatment the resulting chemically competent cells facilitate the 
attachment of plasmid DNA to the cell membrane thus allowing for efficient 
transformation of the E.coli. To prepare the cells, they were initially spread onto a LB agar 
plate. The next day a single colony was picked and placed into 5ml of LB broth for 
overnight culture. 1ml of the overnight culture was placed into a 100ml of LB broth and 
incubated at 37oC on an orbital shaker.  The optical density (OD) was monitored at 260nm 
and 280nm, using a Beckman DU 650 spectrophotometer, and when it reached 0.2-0.3 the 
cells were placed on ice for 10 minutes. The cells were then harvested in 50ml centrifuge 
tubes at maximum speed at 4oC for 10 minutes in an Eppendorf Centrifuge 5810R. The 
supernatant was then discarded and the cell pellet re-suspended in 40ml of ice-cold 
100mM CaCl2 and placed on ice for 30 minutes. The cells were then re-pelleted by 
centrifugation as above. The cell pellet was then re-suspended in 1ml of ice-cold 100mM 
CaCl2. They could then be used for transformation or prepared for storage by adding 
250ml of sterile 50% glycerol in 100mM Cacl2. 
2.2.4.13 Transformation using Chemically Competent Cells 
This method was used to expand stocks of plasmid DNA. Initially 50µl of the appropriate 
chemically competent E.coli strain was placed into a 15ml polyproplylene tube. To this 3-
5µl of plasmid DNA was added. This mixture was then incubated on ice for 30 minutes. 
The contents were then ‘heat shocked’ at 42oC for 40 seconds and placed immediately on 
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ice again. 250µl of SOC or NZY medium was then added and the tube placed in an orbital 
shaker and incubated at 37oC for 1 hour. After this between 50 and 250µl of the mixture 
was spread onto an agar plate containing antibiotics (depending upon which antibiotic 
resistance gene the plasmid contained). The plates were then incubated overnight. The 
following day colonies were picked and placed in 5ml of LB broth containing antibiotics 
for overnight culture before proceeding to minipreps or maxipreps 
2.2.4.14 Transformation Using Electrically Competent Cells 
This was used for homologous recombination according to the Stratagene AdEasyTM XL 
Adenoviral Vector System.  The E.coli strain BJ5183 contains efficient homologous 
recombination machinery and was used. First the electroporation cuvettes (with a 0.2cm 
gap) were placed on ice. For each reaction 40µl of BJ5183 cells, 1µg linearised plasmid 
containing the gene to be inserted and 1µl (100ng) pAdEasy were added to a 
microcentrifuge tube.  These were then transferred to the cuvette and placed into the 
electroporator set at 200Ω, 2.5kV and 25µF and given one pulse. The cells were then 
immediately added to 1ml of SOC medium and incubated at 37oC for 1 hour before being 
spread onto an LB agar plate containing the appropriate antibiotic for selection. The plates 
were then incubated overnight and the colonies picked for proceeding to minipreps. 
2.2.4.15 Plasmid DNA Preparation (Mini/Maxipreps) 
Single bacterial colonies were selected and placed in 5ml of LB-medium containing either 
50ug/ml ampicillin or 50ug/ml kanamycin. These were incubated overnight at 37oC in a 
shaker at 225rpm. For minipreps, 1.5ml of the overnight bacterial culture was pelleted by 
centrifugation at 13200rpm for 10 minutes using an Eppendorf 5415C microcentrifuge. 
The plasmid DNA was then purified using the QIAprep Spin Miniprep Kit according to the 
manufacturer's instructions. For larger DNA quantities, 1ml of an overnight culture 
obtained as described above was placed into 100ml of LB-broth and incubated overnight. 
This was then purified using the QIAGEN Maxi kit as per the manufacturer’s instructions. 
2.2.4.16 DNA Sequencing 
All DNA preparations were sequenced using the service at AGOWA. The DNA 
preparations were at initially quantified and if of a concentration of 100ng/ml or more were 
suitable for sequencing. The appropriate primers for sequencing were also sent with the 
preparations.  
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2.2.5 In-vitro assays 
2.2.5.1 Antibody Staining for Surface Receptor Expression 
a) Chemokine receptor antibody staining of HEK-293, CHO and Lymphoma Cells. 
Cells were counted and 2.5 x105 cells obtained for each sample. These were then washed 
twice in ice-cold FACS buffer re-suspended in 100µl of ice-cold FACS buffer and 
transferred to a clean 1.5ml micro-centrifuge tube. The primary antibody (with or without 
fluorochrome conjugation) was then added at the appropriate concentration (see table 
2.2.1) and incubated at 40C for 30 minutes. 1ml of ice-cold FACS buffer was then added to 
each sample, which was then spun at 2000rpm for 5 minutes at 40C using a Fisher 
Scientific Accuspin Micro 17R refrigerated microcentrifuge. The supernatant was 
discarded and then the pellet re-suspended in 400µl of ice-cold FACS buffer if the 
antibody was conjugated to a fluorochrome. If the antibody was not conjugated then the 
cell pellets were re-suspended in 50µl of FACS buffer and a secondary detection antibody 
conjugated to a fluorochrome was added at the appropriate concentration.  These samples 
were then incubated at 40C for 30 minutes before being washed with 1ml of FACS buffer 
and centrifuged at 2000rpm for 5 minutes at 4oC as above. These were then re-suspended 
in 400µl of FACS buffer. All samples were then analysed as in 2.2.3. 
 
b) Chemokine receptor and CD20 antibody staining of Human Lymphoid Cell Lines 
and Lymphoma Samples. 
Cells were incubated with the primary and secondary detection antibodies as above using 
anti mouse or rat IgG conjugated to APC as the secondary antibody. Before proceeding to 
FACS analysis the cells were incubated for a third time with anti-CD20-PE. Following the 
final wash with FACS buffer 5µl of Viaprobe was added to the cell pellet and the cells 
were incubated at 4oC for 10 minutes. The cells were then re-suspended in 400µl of FACS 
buffer and analysed as in 2.2.3. Viaprobe enabled the detection of apoptotic or necrotic 
cells using FL3-H. FL3-H positive cells were then excluded from the final FACS analysis. 
In addition lymphoma cell lines were used as negative controls by incubating with isotype 
antibodies conjugated with fluorochromes. 
2.2.5.2 CCL19-Biotin Uptake  
Initially a mixture was prepared containing 0.5µl biotinylated CCL19 from Almac 
(formerly Albachem) (at a concentration of 500µg/ml), 3µl streptavidin-PE and 7.5µl PBS 
per sample. A separate mixture without the CCL19 was also prepared to act as a negative 
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control. This mixture was incubated in the dark at room temperature for 45 minutes. In the 
meantime cells were harvested and washed in PBS to ensure that the growth medium had 
been removed. 2x105 cells per sample were then re-suspended in 40µl DMEM (with 
20mM HEPES at pH 7.3). 10µl of the biotin-CCL19 mixture was then added to each 
sample and the cells incubated in the dark at 37oC for 1 hour. The cells were then moved to 
ice and washed with 1ml of ice cold FACS buffer, and spun at 2200rpm for 5 minutes in an 
Eppendorf 5415C microcentrifuge. The supernatant was removed and the cell pellet re-
suspended in 400µl of FACS buffer and analysed by flow cytometry as in 2.2.3.  
2.2.5.3 Radiolabelled Ligand Uptake 
All appropriate measures were taken during this experiment to limit exposure to the 
radiolabelled ligands. Uptake assays were performed using 96-well plates. The 
radiolabelled ligands 125I-CCL19 and 125I-PM2 (a structural variant of CCL3) were used. 
These radiolabelled ligands were obtained from Almac. Cells were harvested and washed 
once with PBS. For each control sample 1x104 cells were re-suspended in 100µl of 
standard growth medium and transferred to the wells. Medium containing 1µl of 
925kBq/ml (specific activity 2200Ci/mmol) of the radio-ligand was prepared. For each 
sample 1x104 cells were re-suspended in 100µl of the prepared medium. As additional 
controls, un-conjugated CCL19 and PM2 were added to cells re-suspended in 100µl 
medium at 1µl CCL19 (500µg/ml) and 5µl PM2 (100µg/ml) giving the same concentration 
of chemokine in all wells. The 96 well plate was then incubated at 37oC for 2, 4, 8 or 12 
days and cell proliferation was analysed using the MTT cell proliferation assay outlined 
below.  
2.2.5.4 MTT Proliferation Assay 
The Chemicon MTT cell proliferation assay kit was used according to the manufacturer’s 
instructions.  Reagent A (50mg MTT) and Reagent B (15ml PBS at pH 7.4) were 
combined and 10µl of this solution was then added to each well of the 96 well plate and 
mixed well. The plate was then incubated at 37oC for 4 hours, to allow cleavage of the 
MTT. Wells containing live cells developed black crystals of MTT formazan. 100µl 
reagent C (isopropanol with 0.04M HCl) was then added to each well to develop the 
colour, dissolving the MTT formazan to give a blue solution. The plate was then read 
within the hour, using an ELI SA plate reader at a test wavelength of 570nm and a 
reference wavelength of 630nm and the absorbance recorded. A calibration curve was also 
developed.  
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2.2.5.5 Chemotaxis Assays 
2.2.5.5.1 Chemotaxis using 24 well HTS Transwell ® Plates 
Chemotaxis buffer was prepared with either DMEM or RPMI medium containing 20mM 
HEPES and 1% BSA. The Transwell® plates were prepared by removing the inserts and 
adding 600µl of chemotaxis buffer to each well with 0, 0.1nM, 1nM, 10nM or 100nM of 
chemokine. The inserts were then replaced. Then 5 x 105 cells were re-suspended in 100µl 
of the chemotaxis buffer without chemokine and placed carefully into each of the inserts. 
The plates were incubated for 3 hours at 37oC. Following incubation, the inserts were 
removed from the wells and the cells in the medium were counted using a 
haemocytometer.  
 
2.2.5.5.2 QCMTM Chemotaxis 3µm 96-Well Cell Migration Assay 
The assay was performed according to the manufacturer’s instructions. In brief, cells were 
starved, by incubating them in either RPMI, or DMEM without serum for 24 hours. 
Following this the cells were re-suspended in chemotaxis buffer as outlined above at a 
concentration of 1 x 105 cells/100µl. Chemotaxis buffer was then prepared with the 
following concentration of chemokine; 0, 0.1nM, 1nM, 10nM and 100nM, and 150µl of 
these solutions were added to each well of the feeder tray. The migration chamber was then 
added and 100µl of the cell suspension added to each well. The cells were then incubated 
for 3 hours at 37oC. After incubation the migration chamber is removed and the cells from 
the top side are gently discarded by flipping out the remaining cell suspension. The 
migration chamber is then placed into a fresh feeder tray containing 150µl of detachment 
buffer in each well. This is then incubated for at 37oC for 30 minutes. Meanwhile, 75µl 
from each well of the chemotaxis buffer from the original feeder tray is transferred into a 
fresh 96 well and after incubation add 75µl of medium from the second feeder tray is 
added to the same 96 well plate, the second feeder tray is then discarded. The lysis 
buffer/dye solution is then prepared as per instructions and 50µl of this is added to each of 
the wells in the remaining 96 well plate. The plate was then incubated for 15 minutes at 
room temperature in the dark. Following this, 150µl of the solution in each well was 
transferred to a fresh 96 well plate suitable for luminometry. The plate was then read using 
a 480/520nm filter set.  
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2.2.6 Adenovirus Preparation, Modification and Infections 
All adenovirus work was performed under sterile conditions within a class II biological 
safety cabinet with laminar flow. All disposable equipment was soaked in Trigene® for 24 
hours to inactivate any live virus before disposal. Approval from the University of 
Glasgow Genetically Modified Organisms Committee was attained before any work 
described here was carried out. 
2.2.6.1 Expanding Adenoviral Stocks 
Initially, 11 x T150 flasks of HEK.293 cells were set up using 25ml of DMEM with 10% 
FCS and incubated at 37oC. When the cells were approximately 80% confluent the cells in 
1 flask were trypsinized and the total number of the cells in the flask calculated. It was then 
assumed that for the remaining flasks the cell numbers were similar. An adenoviral stock 
solution of known PFU value was then used to make up a 10ml solution in PBS equating to 
1 PFU per cell. The growth medium was removed from the 10 flasks and the cells gently 
washed with 3mls of PBS. 1ml of the adenovirus solution was then added to each flask and 
left to incubate at room temperature for 1 hour rocking the flasks occasionally to ensure 
even coverage. 25mls of DMEM with 2% FCS was then added to each of the flasks, and 
left to incubate at 37oC for 7-14 days, allowing the adenovirus to form plaques. Once the 
cells had lifted off the bottom of the flasks and were no longer clumped, the adenovirus 
was ready to harvest and purify. 
 
2.2.6.2 Purification of Adenovirus using the BD Adeno-XTM Virus 
Purification Kit 
The kit was used as per the manufacturer’s instructions. In short, the cells from all 10 
flasks were transferred to 2 sterile conical centrifuge tubes. These were then centrifuged 
for 10 minutes at 1600rpm in a Sorval RC-5B refrigerated superspeed centrifuge. The 
supernatant was transferred to a fresh T175 flask and kept on ice. The remaining cell 
pellets were then re-suspended in 5mls of the supernatant and the cells lysed by freeze-
thawing 3 times in dry-ice and methanol. The cells were centrifuged again as above and the 
supernatant added to the T175 flask. The supernatant was then filtered using a bottle-top 
filter unit and 0.45micron filter, and placed into a fresh T175 flask. Benzonase was then 
added at 10units/ml to remove any cellular DNA and incubated at 37oC for 30 minutes. 
The benzonase treated filtrate was then added to an equal volume of 1 x dilution buffer, 
and using the filter assembly kit provided, passed through the filter at a rate of 
20ml/minute. Once all of the filtrate had been passed the entire volume of 1 x wash buffer 
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(provided in the kit) was passed through the filter (which now held the virus). To elute the 
adenovirus, 3mls of elution buffer was drawn up in a 5ml syringe. First 1ml of the elution 
buffer was pushed into the filter with the filtrate collected in a sterile micro-centrifuge 
tube. The filter was then left to incubate at room temperature for 5 minutes, before flushing 
through the remaining buffer, and collecting the filtrate in micro-centrifuge tubes. To 
obtain any remaining adenovirus, 5mls of air was then pushed through the filter. The eluted 
adenovirus was then centrifuged at 14000rpm for 10 minutes in the Fisher Scientific 
Accuspin 17R refrigerated microcentrifuge, the supernatant was removed and the 
remaining adenoviral pellet re-suspended in 50-100µl of formulation buffer. The 
adenovirus was left at room temperature for 30 minutes before being stored at -70oC in a 
second container for safety. 
 
2.2.6.2 Adenoviral Titre Assay using the BD Adeno-XTM Rapid Titre Kit 
This assay enabled a quicker calculation of the adenoviral concentration than the 
traditional plaque assays giving a titre in IFUs (infection forming units), which is 
equivalent to PFUs. It was used to calculate the amount of adenovirus obtained following 
the purification outlined above. The kit was used according to the manufacturer’s 
instructions. In brief, 5 x 105 HEK.293 cells in 1ml of growth medium (DMEM with 10% 
FCS) were placed in each well of two 12 well plates. Serial dilutions of the stock 
adenovirus and a control adenovirus of known concentration were then prepared as 
follows: 
Volume of PBS (µl) Volume (µl) & Concentration  
of adenovirus solution 
Final adenovirus Concentration 
1000 - Nil 
990 10 of x 1 10-2 
900 100 of x 10-2 10-3 
900 100 of x 10-3 10-4 
900 100 of x 10-4 10-5 
900 100 of x 10-5 10-6 
900 100 of x 10-6 10-7 
 
100µl of the adenoviral solutions were then added to each well of the HEK.293 cells with 
the lower concentrations being duplicated. The cells were then incubated for 48 hours at 
37oC.  
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The medium from each well was aspirated and the cells were left to air dry for 5 minutes. 
The cells were then fixed by adding 1ml of ice-cold methanol to each well and incubating 
at -200C for 10 minutes. The cells were then washed 3 x with 1ml of PBS + 1% BSA 
buffer, trying not to disturb the cell layer. 500µl of mouse anti-hexon antibody (diluted 
1:1000 in PBS + 1%BSA) was then added to each well and incubated at 37oC for 1 hour. 
The cells were washed three times with the buffer, and 500µl of rat anti-mouse –HRP 
conjugated antibody (diluted 1:500 with PBS + 1% BSA) was added to each cell. Again 
the plates were incubated for 1 hour at 37oC. The cells were again washed with the buffer. 
Following this 500µl of the DAB working solution was added to each well and the plates 
were left to incubate at room temperature for 10 minutes. The DAB solution was then 
removed and 1ml of PBS added to each well. The number of brown cells per field were 
then counted at x20 objective, a minimum of 3 fields per well were counted. 
The adenovirus concentration was then calculated as follows: 
 
IFU/ml =       (infected cells/field) x (fields/well)* 
Volume virus (ml) x dilution factor 
 
For example: 
Infected cells/field =13.2 
*Fields/well at x20 objective = 573 (for a 12 well plate) 
Volume of adenovirus= 0.1ml 
Dilution factor = 10-6 = 0.000001 
 
Therefore the IFU/ml =   13.2 x 573   = 7.56 x 1010 IFU/ml 
                                      0.1 x 0.000001 
 
 
2.2.6.3 Shrouding of Adenovirus with Chemokine 
This was performed in two parts. Firstly, a NeutrAvidinTM-virus conjugate was prepared by 
adding 100µl of NeutrAvidinTM (5mg/ml) to a known quantity of adenovirus in 100µl PBS. 
This was incubated at room temperature for 4 hours. The adenovirus-NeutrAvidinTM 
mixture was then added to a DispoDialyzer with a 100kDa pore size (from Spectrum), and 
left to dialyse for 1 hour, to remove any un-conjugated NeutrAvidinTM. The adenovirus-
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NeutrAvidinTM conjugate was then placed in a fresh micro-centrifuge tube and centrifuged 
at 14000rpm for 20 minutes in a Fisher Scientific Accuspin Micro 17R refrigerated 
microcentrifuge. The supernatant was discarded and the pellet re-suspended in 100µl of 
PBS. The adenovirus-NeutrAvidinTM-chemokine conjugate was then prepared by adding 
2µl of chemokine (500µg/ml) to the adenovirus and the solution was incubated at room 
temperature for 2 hours. The solution was then transferred to a fresh DispoDialyzer and 
dialysed for 1 hour to remove unbound chemokine. The solution was then transferred to a 
micro-centrifuge tube and centrifuged at 14000rpm for 20 minutes as above. The 
supernatant was discarded and the adenovirus-NeutrAvidinTM-chemokine conjugate 
(shrouded adenovirus) was re-suspended in formulation buffer (as used in the adenovirus 
purification protocol in 2.2.6.2) and stored at -70oC. 
 
2.2.6.4 Infection of Mammalian Cells 
The method described in 2.2.6.3.1 was used up to the point of incubation for 48 hours.  
5 x105cells/well were used for all cell lines, and the majority of cases were incubated for 
48 hours at 37oC before analysis by one of the method described below. This method was 
used for infecting cells with the chemokine-shrouded adenovirus. 
2.2.6.5 Assessment of Mammalian Cell Infection by Staining for Beta-
galactosidase 
The Invitrogen β-galactosidase staining kit was used according to the manufacturer’s 
instructions. After incubation with the virus, the cells were washed with PBS. For adherent 
cells each well was washed with 500µl of PBS. For suspension cells, the cells were 
transferred to micro-centrifuge tubes, centrifuged for 5 minutes at 2000rpm in the 
Eppendorf 5415C microcentrifuge, the supernatant removed and the cells re-suspended in 
100µl of PBS. The suspension cells were then placed on a poly-L-lysine coated slide and 
left at room temperature for 45 minutes to enabled adherence to the slide. After washing, 
the cells were fixed with 500µl (per well or slide) of 1 x fixative solution and left to 
incubate at room temperature for 10 minutes. The cells were then washed once with PBS. 
The staining solution was then made up according to manufacturer’s instructions. To each 
sample 500µl of the staining solution was added, and the samples were incubated for up to 
2 hours until a blue colour developed. The staining solution was then removed. If 12 well 
plates had been used for the infections, 1ml of 70% glycerol was added to each well before 
examination under the microscope. For the slides obtained using slide chambers, the 
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samples were allowed to air dry and then covered with a cover slip before microscopy. The 
number of blue cells in each field was then counted. The IFU could then be calculated, if 
required as in 2.2.6.3 above. 
2.2.6.6 Assessment of Mammalian Cell Infection using the Promega 
Luciferase assay 
Cells were incubated with adenoviral vectors containing a luciferase reporter gene in a 96 
well plate. Following incubation 1 x lysis buffer was made up as per manufacturer’s 
instructions and 20µl was added to each well and the cells were left for a few minutes to 
lyse. 100µl of luciferase assay reagent was added to each well. The 96 well plate was then 
immediately transferred to a luminometer and the plate was read using a 570/630nm filter 
set. 
2.2.6.7 Assessment of Mammalian Cell Infection by FACS 
Cells that had been incubated with the virus were collected, transferred to micro-centrifuge 
tubes and washed in FACS buffer followed by centrifugation at 2000rpm in an Eppendorf 
5415C microcentrifuge. The supernatant was discarded and the cells were re-suspended in 
100µl of FACS buffer. Mouse-anti-hexon antibody was then added to the cells and they 
were left to incubate at 40C for 45 minutes. The cells were washed once in 1ml PBS and 
centrifuged as above. Again the supernatant was discarded and the cells were re-suspended 
in 50µl FACS buffer. This was followed by the addition of anti-mouse-PE antibody (1:50) 
and incubation at 4oC for 45 minutes. The cells were again washed with 1ml of FACS 
buffer as above, and the cell pellet was re-suspended in 400µl of FACS buffer and 
analysed as in 2.2.5.2.3. 
2.2.6.8 Preparation of Adenovirus for Visualisation by Electron 
Microscope 
Initially, carbon cribs were prepared by coating in poly-L-lysine. This was done by, 
placing 1 drop of 0.01% poly-L-lysine solution onto each crib, and incubating them at 
room temperature for 30 minutes. The cribs were then rinsed by placing them on drops of 
distilled water three times for 5 minutes. They were then left to air dry. 20µl drops of a 
solution containing the adenovirus to be examined were placed onto parafilm. The carbon 
cribs were then placed onto these drops ‘shiny’ face up, and left to adhere to the 
adenovirus for 15-20 minutes. The cribs were then rinsed with PBS as outlined above with 
the distilled water. Excess fluid was removed by blotting with filter paper after the third 
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rinse. The cribs were then placed on a 20µl drop of 2.5% glutaraldehyde for 10-15 
minutes. The cribs were then rinsed with drops of distilled water as above. The cribs were 
then transferred to drops of Nano-van for 30 seconds. The cribs were then held in forceps 
to dry. Once dry, they could be placed in a crib holder before examination under the 
electron microscope. 
 
If the virus was to be labelled with gold, the cribs were first placed on drops of 0.1M 
glycine, to quench the glutaraldehyde, for 20 minutes. They were then placed on drops of 
biotin-gold and left for 15-20 minutes. This was then followed by 3 rinses with distilled 
water before being stained with the Nano-van. 
 
2.2.7 In-vivo Assays 
2.2.7.1 Maintenance of Mice 
Mice were housed in a pathogen free environment within the animal facility at the 
University of Glasgow. They were fed and watered ad libitum. The procedures outlined 
below were in accordance with United Kingdom Home Office guidelines, with the 
appropriate personal and project licences. An approved schedule one technique was used to 
kill the mice.  
2.2.7.2 Infection of Mice with Adenovirus 
Enough “Shrouded” and non-“shrouded” virus was prepared in sterile PBS at the 
concentration of 1 x 108 IFU/200µl for 12 mice. 6 mice were injected via the tail vein with 
the shrouded virus and 6 mice with the non-shrouded virus. This was performed by, staff 
members of the University of Glasgow, animal facility. Three mice from each group were 
then sacrificed at 48 hours and 96 hours. The inguinal lymph nodes, spleen, gut, lungs, 
kidneys and heart were then collected from each mouse. Sacrificing of the mice, and 
subsequent dissection of the mouse tissues, was performed by Prof. Gerard Graham. 
2.2.7.3 Assessment of Virus Infection in Mouse Tissues 
2.2.7.3.1 Cryopreservation of Mouse Tissues and Preparation of Slides 
Each of the collected tissues were embedded in a tissue freezing medium then stored at   
-70oC. Once the tissues had been frozen, slides were prepared using a cryostat. The slides 
were then stored at -70oC. 
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2.2.7.3.2 β−galactosidase Staining of Mouse Tissues 
The slides containing the mouse tissues were allowed to thaw on ice. They were then fixed 
by incubation in a solution of 0.5% glutaraldehyde and 4% formalin for 10 minutes. This 
was followed by washing in PBS for 1 minute, and, if required, placed in a solution of 
haematoxylin for a few seconds followed by thorough rinsing. The slides were then stained 
for β−galactosidase expression as outlined in 2.2.6.6 above and the slides examined under 
light microscopy. 
2.2.8 Statistical Analysis 
All statistical analysis was performed using the Microsoft Excel or Graph Pad Prism 4 
software package.
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CHAPTER THREE 
 
ANALYSIS OF CHEMOKINE RECEPTOR 
EXPRESSION IN NON-HODGKIN’S LYMPHOMA 
3.1 Introduction 
As described in the introduction there is some evidence to suggest that there is a 
relationship between the subtype of non-Hodgkin’s lymphoma and chemokine receptor 
expression [335]. One of the primary aims of this project was to examine this hypothesis 
further, thus potentially aiding in the diagnosis and classification of lymphomas. 
Constitutive chemokine receptors, rather than inflammatory chemokine receptors, were 
studied because expression is more restricted to particular cell types and they have a more 
predictable anatomical distribution [275]. Any co-existent inflammatory processes, and 
consequent up regulation of inflammatory chemokines, in the affected lymph node tissues 
such as infection or tissue injury from preliminary investigations such as fine needle 
aspiration, were also less likely to confound any results obtained. Such studies may also 
provide more specific targets for certain subtypes or enable more accurate prognostic 
information to be obtained. In order to examine whether or not there are any differences in 
chemokine receptor expression between subtypes of NHL primary tissues from patients 
with a variety of NHL subtypes were obtained. The primary tissues consisted of 
lymphocyte preparations from the affected lymph nodes of the patients with NHL. 
 
However, before testing patient samples, an accurate method for determining chemokine 
receptor expression on the surface of lymphocytes was needed to ensure that the patient 
samples were utilised to their full potential. This method was developed and optimised 
using selected lymphoma cell lines, in which chemokine receptor expression was initially 
verified by a variety of methods, before being used as controls in the set up of testing of 
clinical samples.  
This chapter describes the system and results pertaining to chemokine receptor expression 
obtained initially with lymphoma cell lines, and subsequently on testing of patient samples. 
Finally, chemokine receptor expression on clinical samples was correlated with clinical 
presentation and outcomes and the results from this are presented. 
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3.2 Use of Cell Lines to Verify Oligonucleotides for the Detection of 
Chemokine Receptors 
3.2.1 Identifying Cell Lines to be used 
Before commencing antibody testing, cells lines expressing the receptors of interest were 
needed and the presence or absence of RNA for these receptors was examined first. 
Oligonucleotides were designed to identify the presence of RNA for the human 
constitutive chemokine receptors: CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4 and 
CXCR5. In the case of CXCR5 two splice variants, termed CXCR5a and CXCR5b in this 
thesis, were identified and thus two primer pairs were designed for this receptor.  
To identify cell lines expressing the constitutive chemokine receptors CCR4, CCR6, 
CCR7, CCR9, CCR10, CXCR4 and CXCR5 a literature search was performed. Raji 
(human B-cell Burkitt lymphoma) cells were identified as expressing CCR7 and CCR10 
with Daudi (human B-cell Burkitt lymphoma) cells identified as also expressing CCR10 
along with CCR6 [136]; both cell lines express CXCR4 and CXCR5 [336]. MOLT-4  
(human T-cell leukaemia/lymphoma) cells express CCR9 [336]. Finally, KU-812 (human 
basophilic) cells were identified as endogenously expressing CCR4 [337].  
3.2.2 RT-PCR Results on Cell Lines  
Using the primers for the constitutive chemokine receptors shown in section 2.1.7.2, RT- 
PCR was performed on the cell lines described above with the exception of the KU-812 
cells.  This showed that CCR4 was expressed in Daudi and MOLT-4 cells despite a lack of 
literature at the time to support CCR4 expression in these cells. In the case of the Daudi 
cells, the levels of CCR4 RNA were low, and so not clearly evident in figure 3.1. 
However, cloning of the PCR product subsequently confirmed its presence in Daudi cells, 
and interestingly, Daudi cells are now recommended by manufacturers such as Thermo 
Fisher Scientific and Imgenex, as positive controls for their anti-CCR4 antibodies. As 
expected, CCR6 was expressed in the Daudi cells but was also apparent at a low level in 
both the MOLT-4 and Raji cells.  CCR7 was expressed in Raji cells and Daudi cells, but 
only very weakly in MOLT-4 cells. CCR9 was demonstrated in MOLT-4 as expected but 
was also seen in Raji and Daudi cells.  CXCR4 and CXCR5 were expressed in all three 
cell lines described above, with both splice variants of CXCR5 being detected in Raji and 
Daudi cells (CXCRb not shown) and only CXCR5b detected in MOLT-4 cells.   
 
However, CCR10 expression was not seen in any of the cell lines despite reports in the 
literature to the contrary [338]. Therefore a cell line, which had previously been developed 
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within the laboratory to express human CCR10, L1.2.hCCR10 cells, were used as the 
positive control to demonstrate that the CCR10 primers were functional. Of note, although 
it appears in the gels that CCR10 is expressed in all three cell lines, this PCR product was 
the incorrect size and when sent for sequencing did not correspond to CCR10. The results 
of RT-PCR are shown in figures 3.1 and 3.2 and summarised in table 3.1.  
 
a)   b)  
 
  c) d)  
Figure 3.1: Expression of constitutive chemokine receptor expression in human lymphoma 
cell lines. a) Raji cells b) Daudi Cells, c) MOLT-4 cells, d) minus RT control. RNA was prepared 
from the cell lines using Trizol®, DNAase treated and cDNA was synthesised ± reverse 
transcriptase. Primers for actin and the chemokine receptors CCR4, CCR6, CCR7, CCR9, CCR10, 
CXCR4, CXCR5a and CXCR5b were then used for amplification of cDNA using the PCR 
programme in 2.2.4.3. The PCR products were then run on a 1% agarose gel containing ethidium 
bromide. The arrows on figure a) indicate the size of the PCR product obtained with actin and 
demonstrate the 2kbp mark on the DNA ladder. 
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Figure 3.2: Confirmation of hCCR10 RNA expression in L1.2.hCCR10 cells. RNA was 
prepared from L1.2.hCCR10 cells using Trizol®, DNAase treated and cDNA was prepared using ± 
reverse transcriptase. Primers for actin and CCR10 were used for amplification of cDNA using the 
PCR programme in 2.2.4.3. The PCR products were then run on a 1% agarose gel containing 
ethidium bromide. The arrows indicate the size of the PCR product obtained with actin (400bp) and 
demonstrate the 2kbp mark on the DNA ladder. 
 
 
 
 
  
 DAUDI MOLT-4 RAJI 
CCR4 +/- + - 
CCR6 + + - 
CCR7 + - + 
CCR9 + + + 
CCR10 - - - 
CXCR4 + + + 
CXCR5a 
CXCR5b 
+ 
+ 
- 
+ 
+ 
+ 
Table 3.1: Expression of constitutive chemokine receptor RNA in Raji, Daudi and MOLT-4 
cells. RNA was prepared from the cell lines using Trizol®, DNAase treated and cDNA was 
prepared with or without reverse transcriptase. Primers for chemokine receptors CCR4, CCR6, 
CCR7, CCR9, CCR10, CXCR4, CXCR5a and CXCR5b were used to amplify cDNA using the PCR 
programme in 2.2.4.3. PCR products were run on a 1% agarose gel containing ethidium bromide 
and the expression chemokine receptor RNA was recorded for each cell line. + positive, - negative, 
+/- weak positive. 
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3.2.3 Topocloning and Sequencing to Verify the Chemokine Receptor 
Primers 
All of the RT-PCR products obtained in 3.2.2 above were cloned into the pCR2.1TOPO® 
TA vector and subsequently sent for sequencing.  For each primer pair, sequencing 
confirmed that the RT-PCR product obtained corresponded with the appropriate 
chemokine receptor.   
3.3 Testing of Chemokine Receptor Antibodies Using Cell Lines 
Having characterised chemokine receptor expression at the transcript level in MOLT-4, 
Raji and Daudi cells, testing of chemokine receptor antibodies on the cell lines using single 
colour flow cytometry was performed.  Once the antibodies had been verified in this way, 
they could then be used for further optimisation of a system to analyse the clinical samples.  
 
Antibodies to CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4 and CXCR5 (known to bind 
both splice variants) were obtained and used at concentrations recommended by the 
manufacturer. Following incubation with the primary chemokine receptor antibody the 
cells were incubated with a secondary antibody, (anti-IgG- phycoerythrin (PE) or anti-IgG- 
allophycocyanin (APC)) and were then subsequently analysed by single colour flow 
cytometry as detailed in section 2.2.3a. This analysis confirmed that Raji cells have surface 
expression of CCR7, CCR9, CXCR4 and CXCR5, Daudi cells have surface expression of 
all of the chemokine receptors studied except CCR10 and that MOLT-4 cells have surface 
expression of CCR4, CCR6, CCR9, CXCR4 and CXCR5. Finally, the CCR10 antibodies 
were verified using L1.2.hCCR10 cells and this confirmed surface expression of this 
receptor. Figure 3.3 shows a selection of the results obtained, indicating that a positive 
control for each of the chemokine receptors had been identified prior to the testing of 
clinical samples.  
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a)      b)  
c)      d)  
e)        f)   
g)  
Figure 3.3: Results of single colour flow cytometry on Raji, Daudi or L1.2hCCR10 cells with 
chemokine receptor antibodies. a) Daudi cells and CCR4 antibody, b) Daudi cells and CCR6 
antibody, c) Raji cells and CCR7 antibody, d) Raji cells and CCR9 antibody, e) L1.2.hCCR10 and 
CCR10 antibody, f) Raji cells and CXCR4 antibodies and g) Raji cells and CXCR5 antibodies. The 
cells were incubated with the appropriate primary chemokine receptor antibody or FACS buffer 
alone, followed by incubation with a secondary antibody conjugated with PE or APC or an isotype 
control conjugated with PE or APC. The cells were then analysed using flow cytometry. In each 
case the blue line represents the isotype (negative) control and the red line expression of the 
chemokine receptor analysed. 
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Once the primary antibodies had been verified in this manner, two- colour flow cytometry 
was optimised prior to the testing of clinical samples.  The mature B-cell marker, CD20, 
was chosen to identify the B-cells (and therefore malignant cells) in the clinical samples 
obtained from patients with B-cell NHL. Incubating the clinical samples with CD20 and 
the chemokine receptor antibodies would then allow analysis of the degree of chemokine 
receptor expression on B-cells from the patient samples. In order to set up two-colour flow 
Raji cells were used.  The same first steps used for single flow cytometry where used 
however in this instance the secondary antibody was conjugated with APC, and was 
followed by incubation of the Raji cells with an anti-CD20 antibody directly conjugated 
with PE. Following incubation with the anti-CD20 antibody and the chemokine receptor 
antibody the Raji cells were incubated with ViaProbe to ensure that only viable cells were 
analysed. ViaProbe binds to necrotic or apoptosing cells and so in analysing the data, cells 
demonstrating binding with this probe were excluded. Figures 2.1 and 2.2 and in the 
methods section demonstrate the process of gating on viable cells and setting up 2-colour 
flow cytometry.  
3.4 Testing of Patient Samples 
Once the antibodies had been successfully verified as being suitable for use in this study, 
the next step was to proceed with the testing of patient samples for chemokine receptor 
expression.  This would enable the collection of data to determine firstly, if there was a 
variation in receptor expression with differing subtypes, and subsequently enable 
correlation with clinical data such as mortality and disease stage at presentation. Patient 
samples were obtained from frozen stocks maintained by Prof. Ruth Jarrett’s research 
group at the Leukaemia Research Laboratory within the Glasgow Veterinary School. The 
non-Hodgkin’s lymphoma subtype samples obtained were as follows; diffuse large B-cell 
lymphoma (DLBCL) - 17 cases; follicular lymphoma - 16 cases; mantle cell lymphoma 
(MCL) - 17 cases; chronic lymphocytic leukaemia/small lymphocytic lymphoma 
(CLL/SLL) - 24 cases; MALT lymphoma -10 cases and Burkitt's lymphoma - 9 cases.  
Each sample was thawed and then washed once with PBS prior to dividing into 8 aliquots 
of equal size.  Each aliquot contained at least 2 x 105 cells, and 7 of these underwent the 
incubation steps as described in 2.2.3b of the methods section, whilst the 8th sample was 
used as a negative control and incubated with an isotype control.  Each sample was then 
analysed for viability and only viable cells were gated for further analysis.  The mean 
overall viability for the clinical samples was 69.89% (95% CI: 62.63-77.16%). For each 
sample analysed, the total number of CD20 positive (or in the case of CLL/SLL CD19 
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positive as, this subtype has a lower level of expression of CD20 [336]) cells were 
recorded, along with the number of cells demonstrating dual expression for both CD20 and 
the chemokine receptor, these figures were then used to calculate the percentage of B-cells 
expressing the chemokine receptor of interest. 
3.4.1 Comparison of Chemokine Receptor Expression within Each NHL 
Subtype. 
Within each lymphoma subtype there were notable differences in constitutive chemokine 
receptor expression. The median percentage of B-cells expressing the receptor of interest 
with the 95% confidence intervals in brackets will be used to outline the results outlined 
for the 6 NHL sub-types which follow.  
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i) Follicular lymphoma cases had a median age at presentation of 55 (37-72) years 
with a male: female ratio of 1:1.75, representative of demographic data in the literature for 
follicular lymphoma [176]. Follicular lymphoma represented the NHL sub-type with the 
lowest expression of chemokine receptors. In the follicular lymphoma cases the mean 
percentage of B-cells expressing each of the chemokine receptors were as follows (with 
95% confidence intervals in brackets; CCR4 11.84% (10.0-27.0), CCR6 10.35% (3.2-
17.4), CCR7 25.54% (14.5-36.6), CCR9 13.04% (6.5-19.6), CCR10 0.18% (0.04-0.3), 
CXCR4 52.17% (39.9-64.4) and CXCR5 84.5% (67.3-101.7). Having lower levels of 
CCR6 and CCR9 when compared to the other NHL sub-types can be explained by the 
anatomical distribution of this lymphoma with predominantly nodal and bone marrow 
disease being typical [176] and CCR6 and CCR9 expression is predominantly associated 
with gut and mucosal tissues [176]. However, what is surprising is the lower expression of 
CXCR4 than that demonstrated by other NHL subtypes, which cannot be readily 
explained, especially with its predilection for bone marrow. The results above are shown in 
figure 3.4. 
 
 
Figure 3.4: Distribution of chemokine receptor expression in 16 follicular lymphoma cases. 
The horizontal lines indicate the mean expression of the chemokine receptor studied. Lymphocyte 
suspensions from lymph node tissues were obtained from patients diagnosed with follicular 
lymphoma. These were then divided into 8 aliquots. Each aliquot was incubated with a primary 
antibody for one of CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4, CXCR5 or FACS buffer only. 
The cells were then incubated with a secondary antibody (or isotype control if only incubated with 
FACS buffer) conjugated with APC. Following this, all cells (except the isotype control) were 
incubated with anti-CD20-PE, following which the cells were analysed by 2-colour flow cytometry. 
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ii) Diffuse large B cell lymphoma cases also had a representative demographic with the 
median age at presentation being 64 (21-80) years and a male: female ratio of 1:1.(75) 
[339]. The DLBCL cases had a more varied expression of receptors (see figure 3.5), with 
CCR10 detected at the lowest levels and CXCR5 at the highest. The results for the mean 
percentage of B-cells with detectable receptor expression were as follows; CCR4 61.59% 
(47.7-75.5), CCR6 27.34% (17.2-37.5), CCR7 60.89% (47.2-74.6), CCR9 38.87% (28.0-
49.8), CCR10 1.57% (-1.0-4.1), CXCR4 78.26% (68.2-88.3) and CXCR5 96.01% (93.9-
98.1). The most surprising result was a high % of CCR4 expression, a receptor, which is 
usually expressed on Th2 and Treg cells along with skin homing T-cells [176].  Certainly, 
CCR4 expression has not previously been widely reported in B-cell lymphomas other than 
in a single case report [340], and reports have been restricted to CCR4 expression in T-cell 
lymphomas and Hodgkin’s disease [341].  
 
 
Figure 3.5:Distribution of chemokine receptor expression in 17 diffuse large B-cell 
lymphoma cases. The horizontal lines indicate the mean expression of the chemokine receptor 
studied. Lymphocyte suspensions from lymph node tissues were obtained from patients diagnosed 
with diffuse large B-cell lymphoma. These were then divided into 8 aliquots. Each aliquot was 
incubated with a primary antibody for one of CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4, 
CXCR5 or FACS buffer only. The cells were then incubated with a secondary antibody (or isotype 
control if only exposed to FACS buffer) conjugated with APC. Following this, all cells (except the 
isotype control) were incubated with anti-CD20-PE, following which the cells were analysed by 2- 
colour flow cytometry. 
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iii) Mantle cell lymphoma cases demonstrated some interesting findings. Again the 
demographic were representative with male predominance (male: female ratio 2:1) and a 
median age at presentation of 63 (46-86) years [291]. As with DLBCL, there was variety 
between the mean expressions of the different receptors (see figure 3.6) these were as 
follows; CCR4 56.67% (42.0-71.3), CCR6 24.09% (9.2-38.9), CCR7 91.03% (80.5-101.6), 
CCR9 35.34% (19.0-51.7), CCR10 0.16% (-0.0-0.3), CXCR4 95.33% (92.1-98.5) and 
CXCR5 93.89% (85.2-102.6). As with DLBCL, there was marked expression of CCR4, 
with MCL cases demonstrating the highest mean expression of this receptor. The other 
striking feature of these cases is the high expression of CCR7. However rather than being a 
new finding, this supports findings already reported in the literature [176]. Moreover, it 
emphasises the potential role of this receptor as a therapeutic target.  
 
Figure 3.6: Distribution of chemokine receptor expression in 17 mantle cell lymphoma 
cases. The horizontal lines indicate the mean expression of the chemokine receptor studied. 
Lymphocyte suspensions from lymph node tissues were obtained from patients diagnosed with 
mantle cell lymphoma. These were then divided into 8 aliquots. Each aliquot was incubated with a 
primary antibody for one of CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4, CXCR5 or FACS buffer 
only. The cells were then incubated with a secondary antibody (or isotype control if only exposed to 
FACS buffer) conjugated with APC. Following this, all cells were incubated with anti-CD20-PE 
(except the isotype control), after which the cells were analysed by 2-colour flow cytometry. 
 
 
 
 
 
 
 
 
© Michelle Bryson, 2010                         CHAPTER THREE                                     RESULTS 
 
 130 
iv) The Burkitt’s lymphoma cases were unusual in that all the cases occurred in male 
patients with a median age of 35 (0-82) years, reflecting the higher incidence in the 
younger age groups. However, Burkitt’s lymphoma does have a higher incidence in males 
than females [286]. Again there was a variation in chemokine receptor expression within 
the B-cell population with the mean results obtained as follows; CCR4 56.89% (38.0-
75.8), CCR6 27.85% (14.9-40.8), CCR7 52.94% (27.8-75.1), CCR9 39.10% (20.5-57.7), 
CCR10 1.93% (-0.6-4.5), CXCR4 97.63% (94.0-101.3) and CXCR5 98.58% (97.3-99.8). 
These figures are shown graphically in figure 3.7. It is interesting to note that the sample 
from the oldest patient (82 years) demonstrated the lowest level of expression for all of the 
chemokine receptors an observation that was not seen with any of the other NHL subtypes. 
Again there was notable expression of CCR4 in these cases, although there were no other 
significant findings or differences from the other lymphoma subtypes. Despite the 
literature previously discussed pertaining to CCR10 expression in Burkitt’s lymphoma cell 
lines, CCR10 was not significantly expressed in any of the 9 cases studied. It is of course 
possible that there are differences in chemokine receptor expression between the endemic 
cases of Burkitt’s lymphoma (which Daudi and Raji cell lines represent) and sporadic 
cases of Burkitt’s lymphoma reported here. Although of course, CCR10 expression was 
not demonstrable at either the RNA or protein level in Daudi and Raji cells during this 
study. 
 
Figure 3.7: Distribution of chemokine receptor expression in 9 Burkitt’s lymphoma cases. 
The horizontal lines indicate the mean expression of the chemokine receptor studied. Lymphocyte 
suspensions from lymph node tissues obtained from patients diagnosed with Burkitt’s lymphoma. 
These were then divided into 8 aliquots. Each aliquot was incubated with a primary antibody for 
one of CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4, CXCR5 or FACS buffer only. The cells were 
then incubated with a secondary antibody (or isotype control if only exposed to FACS buffer) 
conjugated with APC. Following this, all cells were incubated with anti-CD20-PE (except the 
isotype control), after which the cells were analysed by 2-colour flow cytometry. 
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v) The MALT lymphoma cases were also consistent with the known demographic data 
for this subtype with a median age of 65 (44-78) years and a female predominance with a 
male:female ratio of 4:1 [176]. Again there were differences with chemokine receptor 
expression (see figure 3.8) and the mean percentage of B-cells expressing the chemokine 
receptors analysed were as follows; CCR4 51.13% (40.3-61.9), CCR6 38.84% (19.4-58.2), 
CCR7 57.37% (36.6-78.1), CCR9 50.63% (25.7-75.6), CCR10 1.62% (0.1-3.1), CXCR4 
90.66% (84.7-96.6) and CXCR5 95.72% (91.2-100.2). The MALT lymphoma cases 
represented the highest expression of both CCR6 and CCR9. This, however, would be 
expected as these lymphomas involve the mucosal tissues, most commonly the gut, with 
CCR6 and CCR9 demonstrating tropism for these anatomical sites [151, 176]. 
Interestingly, yet again, CCR4 expression was seen. Expression of the remaining 
chemokine receptors demonstrated no differences on comparison with the other NHL 
subtypes. 
 
Figure 3.8: Distribution of chemokine receptor expression in MALT lymphoma cases. The 
horizontal lines indicate the mean expression of the chemokine receptor studied. Lymphocyte 
suspensions from lymph node tissues were obtained from patients diagnosed with MALT 
lymphoma. These were then divided into 8 aliquots. Each aliquot was incubated with a primary 
antibody for one of CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4, CXCR5 or FACS buffer only. 
The cells were then incubated with a secondary antibody (or isotype control if only exposed to 
FACS buffer) conjugated with APC. Following this, all cells were incubated with anti-CD20-PE 
(except the isotype control), after which the cells were analysed by 2-colour flow cytometry. 
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vi) The median age at presentation of the chronic lymphocytic leukaemia/small 
lymphocytic lymphoma cases was 65 (15-89) years with an equal sex distribution, again 
consistent with published demographic data in CLL/SLL patients [342]. The mean 
chemokine receptor expression on the B-cells, as identified by CD19 expression, from 
these cases were as follows; CCR4 24.90% (16.1-33.7), CCR6 9.50% (0.9-18.0), CCR7 
95.83% (91.4-100.3), CCR9 32.22% (21.3-43.2), CCR10 0.12% (-0.1-0.3), CXCR4 
76.81% (68.3-85.4) and CXCR5 94.82% (91.7-97.4) (see figure 3.9). In general chemokine 
receptor expression was comparatively lower in CLL/SLL cases when compared to other 
subtypes (comparable to those levels found in follicular lymphoma). However there was 
one notable exception in that CCR7 expression in these cells was higher than with any 
other subtype [176]. This is akin to the CCR7 levels in mantle cell lymphoma cases, and 
thus demonstrating that CCR7 is an ideal target for CLL/SLL.  
 
 
Figure 3.9: Distribution of chemokine receptor expression in 24 CLL/SLL. The horizontal lines 
indicate the mean expression of the chemokine receptor studied. Lymphocyte suspensions from 
lymph node tissues from patients diagnosed with CLL/SLL were obtained. These were then divided 
into 8 aliquots. Each aliquot was incubated with a primary antibody for one of CCR4, CCR6, CCR7, 
CCR9, CCR10, CXCR4, CXCR5 or FACS buffer only. The cells were then incubated with a 
secondary antibody (or isotype control if only exposed to FACS buffer) conjugated with APC. 
Following this, all cells were incubated with anti-CD19-PE (except the isotype control), after which 
the cells were analysed by 2-colour flow cytometry.  
 
 
 
 
 
 
© Michelle Bryson, 2010                         CHAPTER THREE                                     RESULTS 
 
 133 
Whilst it would have been ideal to test against normal B-lymphocytes this was not done for 
a variety of reasons.  It is difficult to compare malignant B-cells with normal B-cells as 
different lymphoma sub-types represent different stages of B-cell differentiation and it is 
not easy to isolate these B-cell subpopulations. B-cell populations in normal lymph node 
would potentially, but not necessarily, encompass all of these stages. Peripheral blood or 
bone marrow lymphocytes would have been incomparable due to the differences in 
chemokine receptor profiles in normal lymphocytes at these sites. Finally, plenty of 
literature is available to determine expected chemokine expression on the normal B-cell 
population at the various stages of B-cell differentiation, and information on this can be 
found in the discussion in chapter 7. 
 
A summary of the results described in this section can be found in table 3.2 below. 
 
 % of B-cells Expressing the Chemokine Receptor 
 
 DLBCL 
n=16 
FL 
n=16 
MCL 
n=17 
BL 
n=9 
MALT 
n=10 
CLL/SLL 
n=25 
 
CCR4 
 
61.59 ± 
6.52 
 
11.84 ± 
3.98 
 
56.67 ± 
6.92 
 
56.89 ± 
8.20 
 
51.13 ± 
4.77 
 
24.90 ± 
4.27 
 
CCR6 
 
27.34 ± 
4.75 
 
10.35 ± 
3.11 
 
24.09 ± 
6.56 
 
27.85 ± 
6.12 
 
38.84 ± 
8.58 
 
9.50 ± 
4.13 
 
CCR7 
 
60.89 ± 
6.44 
 
25.54 ± 
5.20 
 
91.03 ± 
4.97 
 
52.94 ± 
10.89 
 
57.37 ± 
9.18 
 
95.83 ± 
2.16 
 
CCR9 
 
38.87 ± 
5.12 
 
13.04 ±  
3.07 
 
35.34 ± 
7.70 
 
39.10 ± 
8.07 
 
50.63 ± 
11.02 
 
32.22 ± 
5.30 
 
CCR10 
 
1.57 ± 
1.21 
 
0.18 ± 
0.07 
 
0.16 ± 
0.08 
 
1.93 ± 
1.09 
 
1.62 ± 
0.68 
 
0.12 ± 
0.09 
 
CXCR4 
 
78.26 ± 
4.71 
 
52.17 ± 
5.75 
 
95.33 ± 
1.49 
 
97.63 ± 
1.58 
 
90.66 ± 
2.62 
 
76.81 ± 
4.14 
 
CXCR5 
 
96.01 ± 
0.96 
 
84.5 ± 
7.72 
 
93.89 ± 
4.11 
 
98.58 ± 
0.55 
 
95.72 ± 
1.98 
 
94.52 ± 
1.37 
Table 3.2: Summary of mean chemokine receptor expression across different NHL 
subtypes. Each point shows the mean % of B-cells expressing the chemokine receptor ± standard 
error of the mean (SEM). Lymphocyte suspensions obtained from lymph node samples from 
patients with follicular lymphoma, DLBCL, MCL, Burkitt’s lymphoma, MALT lymphoma and 
CLL/SLL were incubated with chemokine receptor antibodies, followed by incubation with 
secondary antibodies conjugated with APC and finally anti-CD20-PE or anti-CD19-PE. 2-colour 
flow cytometry was then used to analysis the percentage of B-cells expressing the different 
chemokine receptors. 
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3.4.2 Comparison of Constitutive Chemokine Receptor Expression 
Between Lymphoma Subtypes 
 As well as noting the chemokine receptor expression in individual NHL subtypes, 
analyses were performed to see if there were any significant differences between the 
subtypes and chemokine receptor expression. Expression of a number of chemokine 
receptors showed significant differences across the NHL subtypes whilst with the 
remainder no significant differences were detected. These differences are discussed in this 
section. All statistical analyses between chemokine receptor expressions in the different 
NHL subtypes were performed using the un-paired student’s t-test.  
3.4.2.1 CCR4 Expression 
Expression of CCR4 varied across the different NHL subtypes with the higher grade 
lymphomas (DLBCL, Burkitt’s lymphoma and MCL), having significantly higher 
expression than the more indolent lymphomas (follicular lymphoma and CLL/SLL) (see 
figure 3.10). In all comparisons between follicular lymphoma and DLBCL, Burkitt’s 
lymphoma and MCL, the difference in CCR4 expression was significant with p<0.0001 in 
all cases. The difference in expression between CLL/SLL cases and DLBCL, Burkitt’s 
lymphoma and MCL was also highly significant with p-values of p<0.0001, p=0.0008 and 
p=0.0002 respectively. As mentioned earlier, the expression of CCR4 in B-cell lymphomas 
has not previously been reported beyond a single case report, and thus it is difficult to 
explain these differences. However, the MALT lymphoma, cases also demonstrated higher 
CCR4 expression, and was significantly higher than that seen in both follicular lymphoma 
and CLL/SLL cases (p-values; <0.0001 and 0.0012 respectively). Whilst expression of 
CCR4 in the MALT lymphoma cases was lower than with DLBCL, Burkitt’s lymphoma 
and MCL, this was not significant with p-values of p=0.2619, p=0.5418 and p=0.5788 
respectively. Of course, whilst MALT lymphomas tend to be indolent, the fact that in the 
clinical cases examined here, nodal, rather than the more typical extra-nodal disease was 
present; they may not be wholly representative of this lymphoma subtype. Yet, higher 
CCR4 in MALT lymphomas may be explained by the fact it is of mucosal origin and that 
that up regulation of CCR4 in mucosal tissues has been observed in response to 
inflammatory stimuli such as allergens [296]. Moreover CCR4 and its ligands have been 
implicated in the homing of T-cells to the gastric mucosa during Helicobacter pylori 
infection [343] (a known aetiological agent in MALT lymphomas). Whether a similar 
response is also seen in B-cells is an interesting question. Of course it is also possible that 
inflammation explains the higher CCR4 expression in the DLBCL, Burkitt’s lymphoma 
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and MCL cases, as these lymphomas often have a higher inflammatory component than the 
more indolent forms.  
 
 DLBCL MCL BL MALT CLL/SLL 
FL p<0.0001 p<0.0001 p<0.0001 p<0.0001 ns 
DLBCL - ns ns ns p<0.0001 
MCL  - ns ns p=0.0002 
BL   - ns p=0.0008 
MALT    - p=0.0012 
CLL/SLL     - 
Figure 3.10: Comparison of CCR4 expression between the lymphoma subtypes. 
Lymphocytes obtained from lymph node tissues taken from patients with follicular lymphoma (FL), 
DLBCL, MCL, Burkitt’s lymphoma (BL), MALT lymphoma and CLL/SLL. Each sample was 
incubated with anti-CCR4. This was followed by incubation with a secondary antibody conjugated 
with APC and finally incubation with anti-CD20-PE or anti-CD19-PE. 2-colour flow cytometry was 
then used to assess what proportion of B-cells expressed CCR4. The error bars represent the 
standard error of the mean. The table summarises the comparisons performed between the 
lymphoma sub-types, the analysis was performed using the unpaired t-test. 
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3.4.2.2 CCR6 Expression 
The differences in CCR6 expression between the lymphoma subtypes was less striking 
than those seen with CCR4 expression (see figure 3.11) although, again there was 
significantly lower expression in follicular lymphoma cases when compared to DLBCL 
(p=0.0071), Burkitt’s lymphoma (p=0.0217) and MALT lymphoma (p=0.0017). CLL/SLL 
cases also demonstrated lower expression of CCR6 when compared to DLBCL 
(p=0.0083), Burkitt’s lymphoma (p=0.0136) and MALT lymphoma (p=0.0015). MCL 
cases did not demonstrate any significant difference in expression of CCR6 when 
compared to the other subtypes including follicular lymphoma and CLL/SLL. 
Unsurprisingly, the highest expression of CCR6 was seen in the MALT lymphoma cases. 
However this difference in expression was not significant when compared to any of the 
subtypes other than follicular lymphoma and CLL/SLL as described above, perhaps this 
may be explained by the fact that the tissue from these cases comprised of affected lymph 
nodes, and that CCR6 had been down regulated thus enabling homing of the malignant 
lymphocytes to the nodes.   
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 DLBCL MCL BL MALT CLL/SLL 
FL p=0.0071 ns p=0.0217 p=0.0017 ns 
DLBCL - ns ns ns p=0.0083 
MCL  - ns ns p=0.0002 
BL   - ns p=0.0136 
MALT    - p=0.0015 
CLL/SLL     - 
Figure 3.11: Comparison of CCR6 expression between the lymphoma subtypes. 
Lymphocytes obtained from lymph node tissues taken from patients with FL, DLBCL, MCL, BL, 
MALT lymphoma and CLL/SLL. Each sample was incubated with anti-CCR6. This was followed by 
incubation with a secondary antibody conjugated with APC and finally incubation with anti-CD20-
PE or anti-CD19-PE. 2-colour flow cytometry was then used to assess what proportion of B-cells 
expressed CCR6. The error bars represent the standard error of the mean. The table summarises 
the comparisons performed between the lymphoma sub-types, the analysis was performed using 
the unpaired t-test. 
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3.4.2.3 CCR7 Expression 
There was a wide variation in CCR7 expression across the NHL subtypes as shown in 
figure 3.12. Yet again the lowest expression was noted in the follicular lymphoma cases 
with significantly lower expression of CCR7 in this subtype when compared to all of the 
other with the FL vs. DLBCL p=0.0002, FL vs. MCL p<0.0001, FL vs. Burkitt’s 
lymphoma p=0.0171, FL vs. MALT lymphoma p=0.0033 and FL vs. CLL/SLL p<0.0001. 
However in this instance rather than having lower expression, CLL/SLL had significantly 
higher expression of CCR7 when compared to follicular lymphoma, DLBCL, Burkitt’s 
lymphoma, and MALT lymphoma with a p-value in all of these comparisons of p<0.0001. 
A similarly high expression of CCR7 was also seen in MCL with MCL vs. FL p<0.0001, 
MCL vs. DLBCL p=0.0008, MCL vs. Burkitt’s lymphoma p=0.0012 and MCL vs. MALT 
lymphoma p=0.0016. As discussed in the previous section, high CCR7 expression in MCL 
and CLL/SLL has been demonstrated in a number of studies, although comparison of 
CCR7 with other lymphoma subtypes is not widely reported. It is possible that the very 
high CCR7 expression seen in the MCL and CLL/SLL cases reflects the fact that these 
cells are found in the mantle zone of the lymph node where the B and T cell interactions 
occur and are mediated by CCR7 [344]. However, with expression of CCR7 exceeding 
50% in all subtypes analysed (other than follicular lymphoma), exploration of targeted 
therapy against CCR7 would not be unreasonable in NHL. 
 
In contrast, the lower expression of CCR7 in follicular lymphoma may also be explained 
by the stage of differentiation of the B cells, as the normal counterpart of the follicular 
lymphoma cells are entering a stage of differentiation when CCR7 expression is down 
regulated [143]. 
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 DLBCL MCL BL MALT CLL/SLL 
FL p=0.0002 p<0.0001 p=0.0171 p=0.0033 p<0.0001 
DLBCL - P=0.0008 ns ns p<0.0001 
MCL  - p=0.0012 p=0.0016 p<0.0001 
BL   - ns p<0.0001 
MALT    - p<0.0001 
CLL/SLL     - 
Figure 3.12:Comparison of CCR7 expression between the lymphoma subtypes. Lymphocytes 
obtained from lymph node tissues taken from patients with FL, DLBCL, MCL, BL, MALT lymphoma 
and CLL/SLL. Each sample was incubated with anti-CCR7. This was followed by incubation with a 
secondary antibody conjugated with APC and finally incubation with anti-CD20-PE or anti-CD19-
PE. 2-colour flow cytometry was then used to assess what proportion of B-cells expressed CCR7. 
The error bars represent the standard error of the mean. The table summarises the comparisons 
performed between the lymphoma sub-types, the analysis was performed using the unpaired t-test. 
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3.4.2.4 CCR9 Expression 
There were differences in CCR9 expression between the different subtypes (see figure 
3.13), however in this instance the only significant difference demonstrable was between 
follicular lymphoma and the other 5 subtypes, again with lower expression seen, the results 
were as follows, FL vs. DLBCL p=0.0002, FL vs. MCL p=0.0132, FL vs. Burkitt’s 
lymphoma p=0.0015, FL vs. MALT lymphoma p=0.0006 and FL vs. CLL/SLL p=0.01. 
Although MALT lymphoma had the highest median expression of CCR9, as with CCR6, 
this was not significant, and the previous observation regarding lymph node tissue may 
apply here too. It was also a little surprising that the MCL cases had lower CCR9 
expression as this lymphoma has a high incidence of gut involvement [143], with many 
clinicians advocating colonoscopy and biopsy as part of the staging procedure. Moreover 
α4β7 integrins, which are co-expressed with CCR9 in gut homing lymphocytes, have been 
detected in those cases of MCL with gut involvement [244]. Although, of course the same 
argument regarding nodal vs. extra-nodal tissue could be used here, and widespread nodal 
involvement is far more common than with MALT lymphomas [345].   
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 DLBCL MCL BL MALT CLL/SLL 
FL p=0.0002 p=0.0132 p=0.015 p=0.0006 P=0.01 
DLBCL - ns ns ns ns 
MCL  - ns ns ns 
BL   - ns ns 
MALT    - ns 
CLL/SLL     - 
Figure 3.13: Comparison of CCR9 expression between the lymphoma subtypes. 
Lymphocytes obtained from lymph node tissues taken from patients with FL-follicular lymphoma, 
DLBCL, MCL –mantle cell lymphoma, BL-Burkitt’s lymphoma, MALT lymphoma and CLL/SLL. 
Each sample was incubated with anti-CCR9. This was followed by incubation with a secondary 
antibody conjugated with APC and finally incubation with anti-CD20-PE or anti-CD-19-PE. 2-colour 
flow cytometry was then used to assess what proportion of B-cells expressed CCR9. The error 
bars represent the standard error of the mean. The table summarises the comparisons performed 
between the lymphoma sub-types, the analysis was performed using the unpaired t-test. 
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3.4.2.5 CCR10 Expression 
CCR10 expression in all of the lymphoma subtypes was low, with less than 0.5% of cells 
expressing this receptor overall (see figure 3.14). Although CCR10 has been detected in 
the endemic Burkitt’s lymphoma cell lines in published studies (although not verified in 
this study) [176], the absence of expression is not entirely surprising considering that this 
receptor is involved predominantly in the homing of lymphocytes to the skin [336], and the 
lymphocytes analysed here were all derived from lymph nodes, furthermore lymphoma 
subtypes studied here have a low incidence of cutaneous involvement [136].  
 
 DLBCL MCL BL MALT CLL/SLL 
FL ns ns ns ns ns 
DLBCL - ns ns ns ns 
MCL  - ns ns ns 
BL   - ns ns 
MALT    - ns 
CLL/SLL     - 
Figure 3.14: Comparison of CCR10 expression between the lymphoma subtypes. 
Lymphocytes obtained from lymph node tissues taken from patients with FL, DLBCL, MCL, BL, 
MALT lymphoma and CLL/SLL. Each sample was incubated with anti-CCR10. This was followed 
by incubation with a secondary antibody conjugated with APC and finally incubation with anti-
CD20-PE or anti-CD19-PE. 2-colour flow cytometry was then used to assess what proportion of B-
cells expressed CCR10. The error bars represent the standard error of the mean. The table 
summarises the comparisons performed between the lymphoma sub-types, the analysis was 
performed using the unpaired t-test. 
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3.4.2.6 CXCR4 Expression 
Once again follicular lymphoma cases represented the group with the lowest receptor 
expression, with CXCR4 expression being significantly lower in comparisons with other 
subtypes although CXCR4 expression was generally high (see figure 3.15). The results of 
the comparative studies with follicular lymphoma were as follows; FL vs. DLBCL 
p=0.0014, FL vs. MCL p<0.0001, FL vs. Burkitt’s lymphoma p<0.0001, FL vs. MALT 
lymphoma p<0.0001, FL vs. CLL/SLL p=0.0010. There were no significant differences in 
CXCR4 expression between the other lymphoma subtypes. CXCR4 has been noted in B-
cells at all stages of differentiation, with expression occurring in the earliest stages of 
lymphocyte development and persisting to the latter stages [176], therefore the lower 
expression of this chemokine receptor on follicular lymphoma cells cannot be readily 
explained.  
 
 DLBCL MCL BL MALT CLL/SLL 
FL p=0.0014 p<0.0001 p<0.0001 p<0.0001 P=0.001 
DLBCL - ns ns ns ns 
MCL  - ns ns ns 
BL   - ns ns 
MALT    - ns 
CLL/SLL     - 
Figure 3.15: Comparison of CXCR4 expression between the lymphoma subtypes. 
Lymphocytes obtained from lymph node tissues taken from patients with FL, DLBCL, MCL, BL, 
MALT lymphoma and CLL/SLL. Each sample was incubated with anti-CXCR4. This was followed 
by incubation with a secondary antibody conjugated with APC and finally incubation with anti-
CD20-PE or anti-CD19-PE. 2-colour flow cytometry was then used to assess what proportion of B-
cells expressed CXCR4. The error bars represent the standard error of the mean. The table 
summarises the comparisons performed between the lymphoma sub-types, the analysis was 
performed using the unpaired t-test. 
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3.4.2.7 CXCR5 Expression 
As with CCR10, there were no significant differences between the lymphoma subtypes 
with regards to CXCR5 expression (see figure 3.16). However, in contrast to CCR10, 
CXCR5 expression was universally high, which corresponds to the fact that CXCR5 
expression is found on B-cells at virtually all stages of development (albeit at varying 
levels) [143] and is considered by many as a B-cell marker. Once again lower expression 
was seen in the follicular lymphoma cases, but this was not significant with more than 80% 
of cells expressing the receptor.  
 
 
 FL DLBCL MCL BL MALT CLL/SLL 
FL - ns ns ns ns ns 
DLBCL  - ns ns ns ns 
MCL   - ns ns ns 
BL    - ns ns 
MALT     - ns 
CLL/SLL      - 
Figure 3.16: Comparison of CXCR5 expression between the lymphoma subtypes. 
Lymphocytes obtained from lymph node tissues taken from patients with FL, DLBCL, MCL, BL, 
MALT lymphoma and CLL/SLL. Each sample was incubated with anti-CXCR5. This was followed 
by incubation with a secondary antibody conjugated with APC and finally incubation with anti-
CD20-PE or anti-CD19-PE. 2-colour flow cytometry was then used to assess what proportion of B-
cells expressed CXCR5. The error bars represent the standard error of the mean. The table 
summarises the comparisons performed between the lymphoma sub-types, the analysis was 
performed using the unpaired t-test. 
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3.5 Correlation of Constitutive Chemokine Receptor Expression with 
Clinical Outcome 
As discussed in the introduction there have been studies demonstrating that expression of 
certain chemokine receptors are associated with differences in prognosis and clinical 
presentation.  Following analysis of the chemokine receptor expression on the clinical 
samples, the differences in CCR4 expression were the most surprising, and subsequently of 
most interest. Expression of the other constitutive chemokine receptors in the different 
NHL subtypes could be explained by correlation with chemokine receptor expression of 
their normal B-cell counterpart or by the natural tropism of the lymphoma.  As has 
previously been discussed, CCR4 expression is associated with an adverse prognosis in T-
cell lymphomas, such as adult T-cell leukaemia/lymphoma [143].  Therefore it would be of 
interest to see if the same held true for the B-cell lymphomas studied here, and therefore 
the association between CCR4 expression and outcome was examined. In order to do this 
patient data correlating with the samples analysed previously were collected from 
established databases, the Scottish & Newcastle Lymphoma Group (SNLG) and West of 
Scotland Lymphoma Group (WOSLG). Prior to entry in these databases, consent had been 
obtained from all patients allowing their clinical information to be released to researchers 
in the field of lymphoma.  Only clinical details for diffuse large B-cell lymphoma, 
follicular lymphoma and mantle cell lymphoma were analysed.  The reasons for this were 
three fold; firstly the number of cases of Burkitt’s lymphoma was too low to be of value in 
this study and was unlikely to be representative of this lymphoma subtype as all patients in 
this group were male. Secondly, MALT lymphomas were excluded from clinical 
correlation, as by definition if there is nodal involvement, these are already an unusual 
subtype of this lymphoma, which is usually associated only with mucosal involvement. 
Finally, the majority of CLL/SLL cases were not followed up as part of either database. 
This is because although CLL/SLL is considered by current WHO guidelines to be a single 
disease entity, clinically CLL and SLL present in a very different manner with the 
leukaemic presentation being more common and therefore, these cases would not have 
been entered into either database on many occasions.  
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3.5.1 Correlation Between CCR4 Expression and Clinical Course 
3.5.1.1 Overall Survival and CCR4 Expression 
When looking at the correlation between CCR4 expression and outcome in the three, 
lymphoma subtypes, the only significant difference was in those patients with DLBCL (see 
figure 3.17a). For the purposes of this analysis CCR4 expression was considered to be high 
in an individual patient if the percentage of B-cells expressing CCR4 in their sample was 
higher than the median observed from the above studies for that lymphoma sub-type. In the 
case of DLBCL the median % of B-cells expressing CCR4 was 61.1%, with 8 patients in 
the high CCR4 expression group and 7 in the low CCR4 expression group. Analysis was 
performed using the log-rank (Mantel-Cox) test. The Kaplan-Meier charts below show the 
overall survival in the patient groups for DLBCL, mantle cell lymphoma and follicular 
lymphoma. Figure 3.17a clearly demonstrates a significant (p=0.004) survival advantage in 
those patients with a higher than median expression of CCR4, with all 4 deaths occurring 
in the low CCR4 expressing cohort. Furthermore, median survival for the high CCR4 
expressing group had not been reached. However the median survival for the low 
expressing CCR4 group was only 22 months. This is contrary to previous studies looking 
at CCR4 expression and outcome in T-cell lymphoma [291] and Hodgkin’s lymphoma 
[291] where high expression of CCR4 correlated with a poorer clinical outcome.  
 
In contrast, when assessing the outcome in mantle cell lymphoma patients where the 
median % of CCR4 expressing B-cells was 62.4%, the median survival for those 6 patients 
with high expression of CCR4 (20.4 months) was lower than for the 8 patients with low 
CCR4 expression (46 months), suggesting that higher CCR4 expression adversely affected 
outcome, but this difference was not statistically significant (p=0.2545). The Kaplan Meier 
chart for this is shown in figure 3.17b. Finally, the differences between high and low 
CCR4 expression in follicular lymphoma cases were not significant (p=0.1737) either with 
the median % of CCR4 expression being 11.8%, the median survival was not reached in 
either arm, with the high expressing group containing 6 patients and the low expressing 
group containing 7 patients (figure 3.17c). Although it is interesting to note that all deaths 
occurred in the high CCR4 expression arm. The fact that median survival was not reached 
in either arm and that differences in survival were not significant between low and high 
CCR4 expressing patients was perhaps not surprising considering that follicular cases have 
lower overall CCR4 expression and that the disease has a more indolent course with a 
median survival beyond 10 years from diagnosis [340]. 
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Figure 3.17: Kaplan-Meier charts comparing survival between NHL patients with high or low 
levels of CCR4 expression on B-cells. a) Diffuse large B-cell lymphoma cases, b) Mantle cell 
lymphoma cases, c) Follicular lymphoma cases. Survival data was obtained on those patients 
whose samples were analysed in section 3.4 from the SNLG and WOSLG; this data was then used 
to create these survival graphs. Patients were considered as having high CCR4 expression if the 
percentage of B-cell expressing CCR4 in their samples was greater than the median for that NHL 
group. Statistical analysis was performed using the log-rank (Mantel-Cox) test. 
 
3.5.1.2 Stage of Lymphoma at Presentation and CCR4 Expression 
If this is explored further, it can be shown that, with diffuse large B-cell lymphoma, 
clinically more advanced stage disease appears to be seen more frequently in those with 
low CCR4 expression. No significant differences could be detected however, due to the 
very small patient group, but the results are shown graphically in figure 3.18, which show 
higher numbers of patients with most advanced stage of disease (Stage IV) seen in the low 
CCR4 expression group compared to the high CCR4 expressing group (3 vs. 1). No 
obvious differences in stage at clinical presentation was seen in those patients with mantle 
cell lymphoma and the level of CCR4 expression, with all patients presenting in the 
advanced stages (stage III and IV). Unfortunately, too few of the follicular lymphoma 
cases had initial staging information available and no conclusions could be made about the 
relationship between CCR4 expression and clinical stage at presentation.  
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No conclusions can be made with regards to CCR4 expression and the clinical stage of 
disease in DLBCL, MCL or follicular lymphoma. However, although the numbers are 
small, there is an indication that CCR4 expression may correlate with prognosis in DLBCL 
with higher expression appearing to confer a good prognosis. In contrast there was a non-
significant trend towards to more adverse outcomes in MCL and follicular lymphoma. 
Further discussion of these observations can be found in chapter 7.  
 
 
Figure 3.18: Correlation between clinical stage and CCR4 expression in patients with 
DLBCL, MCL or follicular lymphoma. Clinical data relating to the stage of disease at 
presentation was obtained on those patients whose samples were analysed in section 3.4 from the 
SNLG and WOSLG, this data was then used to analyse whether or not there was a relationship 
with stage at presentation and the level of CCR4 expression. Patients were considered as having 
high CCR4 expression if the percentage of B-cell expressing CCR4 in their samples was greater 
than the median for that NHL group. No obvious relationship was demonstrated, however, data on 
the clinical stage at presentation was not recorded for all patients. 
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3.6 Summary 
Further discussion of the results outlined in this chapter can be found in chapter 7.  
However the following summary points can be made with regards to the studies described. 
 
1. Constitutive chemokine receptor expression has been characterised in MOLT-4, 
Daudi and Raji cells by using RT-PCR and flow cytometry studies. 
 
2. A relationship between constitutive chemokine receptor expression and non-
Hodgkin’s lymphoma subtype has been shown. 
 
3. CCR4 expression is significantly higher in higher grade lymphoma sub-types when 
compared to more indolent lymphoma sub-types, with the exception of MALT 
lymphomas. 
 
4. There appears to be a correlation between high CCR4 expression and a favourable 
outcome in patients with DLBCL. This is not seen in cases of MCL or follicular 
lymphoma with a non-significant trend to poorer outcomes. 
 
5. A trend towards more advanced disease is seen in those patients with low CCR4 
expression and DLBCL. However, the number of cases was too low to draw any 
firm conclusions.  
 
6. No obvious relationship was noted between disease stage and CCR4 expression in 
MCL or follicular lymphoma. 
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CHAPTER FOUR 
IN-VITRO STUDIES OF CCR7 
4.1 Introduction 
Having characterised chemokine receptor expression on a selection of non-Hodgkin’s 
lymphoma (NHL) subtypes, the second aspect of this project was to examine how the 
chemokine system could be targeted to provide a therapeutic strategy in NHL. However, 
before doing this a suitable chemokine receptor and in-vitro model was required in order to 
provide a proof-of-principle for subsequent targeting strategies that may be employed.  
In this case CCR7 was the chemokine receptor chosen. CCR7 was chosen for a number of 
reasons; firstly, it is the second most commonly expressed receptor in cancers following 
CXCR4 [176]. However unlike CXCR4 is has a more restrictive pattern of expression in 
normal tissues, namely naïve T cells, central memory T-cells, [86], dendritic cells, 
thymocytes and naïve B-cells [346].  Another reason for choosing CCR7 as a target is its 
integral role in the homing of lymphocytes to secondary lymphoid organs (the most 
common sites of dissemination in lymphomas). This is highlighted by studies in CCR7-/- 
mice in which gross abnormalities in the structural organisation of secondary lymphoid 
organs are observed. Furthermore, these abnormalities correlate with dysfunctional 
immune responses including delayed antibody responses [347] Additionally, CCR7 has 
clearly been demonstrated to be involved in the development nodal metastases in other 
malignancies, demonstrating that this target could have therapeutic potential across a range 
of tumour types [88].  
 
In order to test CCR7, cell lines expressing this receptor were required for study. Cell lines 
were engineered to express hCCR7 so that cells with high expression of the receptor could 
be studied. In addition, Raji cells were chosen as a cell line known to endogenously 
express hCCR7. Results from experiments using Raji cells would be more likely to 
resemble those expected from studies on primary lymphoma tissue samples or from in-vivo 
lymphoma studies, than engineered cell lines. Finally, although CCR7 responds to two 
ligands, CCL19 and CCL21, the experiments that follow used CCL19. This was a 
deliberate choice as although CCR7 responses to CCL21 are up to 100 fold more potent, 
only CCL19 is internalised following receptor binding [348]. This is important as many of 
the methods explored for targeting and killing CCR7 positive cells require internalisation 
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of the ligand bound to a cytotoxic agent such as 125I (described in this chapter), adenovirus 
(described in chapter 5) or chemotoxins. This chapter outlines the development of an 
hCCR7 expressing cell line, along with functional assays on these and Raji cells, and 
finally the results obtained from one approach to target CCR7 cells and induce 
cytotoxicity.  
4.2 Constructs and Cell Lines 
The PCR-based strategy outlined in sections 2.2.4.3.1 and 2.2.4.8 was used to develop the 
pcDNA3.1-hCCR7 vector (Figure 4.1). This was used to develop a human CCR7 (hCCR7) 
expressing cell line. Human embryonic kidney cells (HEK 293) cells were used to engineer 
a cell line with high levels of hCCR7. In brief, primers were developed to obtain a PCR 
product encompassing the complete coding sequence of hCCR7. cDNA from Raji cells 
was synthesised using reverse transcriptase, this was subsequently used for RT-PCR using 
the primers detailed above. Following verification by sequencing, the PCR product 
obtained after RT-PCR was inserted into the pcDNA3.1/V5 His©TOPO®TA vector using 
Hind III and EcoR V restriction enzyme sites, now termed pcDNA3.1.hCCR7 (figure 4.1. 
This plasmid was then transfected into HEK-293 cells using Effectene® (2.2.2.4.1). Stable 
transfectants were obtained by selection with G418 (neomycin) (0.8mg/ml) added to the 
culture medium. The resulting pool of transfectants was then sub-cloned in order to obtain 
a pool of high hCCR7 expressing cells. These cells were analysed for hCCR7 expression in 
the two ways as described below. 
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Figure 4.1: pcDNA3.1.hCCR7 used to engineer hCCR7 expressing cell lines. Primers were 
developed to enable amplification of the complete coding sequence for hCCR7 by PCR. This was 
then cloned into the pcDNA3.1/V5 His©TOPO®TA using HindIII and EcoRV restriction enzyme 
sites. The resulting construct is outlined above. 
 
4.2.1 Assessment of hCCR7 Expression by Flow Cytometry 
Once adequate numbers of stably transfected cells were obtained through G418 selection, 
they were harvested and examined for expression of hCCR7 using an anti-hCCR7 
antibody. Single-colour flow cytometry as described in 2.2.3 was then used to analyse the 
expression of hCCR7 following incubation with anti-hCCR7 antibody and a secondary 
antibody conjugated to the fluorochrome phycoerythrin (PE). Un-transfected HEK293 
cells were used as a negative control. The results of flow cytometry on the sub-pool with 
the highest CCR7 expression (HEK.hCCR7.1) are shown in figure 4.2. This demonstrates 
successful transfection of HEK293 cells with hCCR7, as evidenced by a shift in 
fluorescence to the right along the FL2-H gate in figure 4.2b as compared to figure 4.2a, 
which represents untransfected HEK 293 cells. However, in the dot plot (figure 4.2b) and 
the overlay histogram (figure 4.2c), it can be seen that there are 2 distinct populations 
within the transfected cells expressing hCCR7 at different levels. All of these cells are 
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subsequently referred to as HEK.hCCR7 cells and the two populations were maintained as 
a pool in medium containing G418.  
 
a)          b)  
 
c)  
 
Figure 4.2: hCCR7 surface expression in HEK293.hCCR7 cells. a) Untransfected HEK293 cells 
incubated with anti-hCCR7 antibody, b) HEK.hCCR7 cells incubated with anti-hCCR7 antibody c) 
Overlay histogram confirming expression of hCCR7 by HEK.hCCR7 cells. Note 2 peaks of hCCR7+ 
indicating a pool of HEK.hCCR7 cells. HEK293 cells were transfected with pcDNA3.1.hCCR7 using 
Effectene® (section 2.2.2.4.1) and incubated in a selective media containing G418. The cells were 
then analysed for hCCR7 expression using single colour flow cytometry. This data is representative 
of the results obtained from this analysis on at least 3 occasions.  
 
 
4.2.2 Functional assessment of hCCR7 Expression by biotin-CCL19 
Uptake 
Although the HEK.hCCR7 cells demonstrated good surface expression of hCCR7, the 
functional competence of this receptor had to be formally demonstrated. In order to do this, 
analysis of the ability of the cells to take up one of the ligands for CCR7, CCL19, was 
analysed. For this, CCL19 with biotinylation at the C-terminus of the protein was used, 
enabling binding of streptavidin-PE, whilst leaving the N-terminus free to interact with its 
cognate receptor. This method is described in section 2.2.5.2, and similar experiments 
performed in the laboratory using confocal microscopy, have demonstrated that the biotin-
CCL19/streptavin-PE complex is internalised by cells expressing CCR7 (Iain Comerford, 
PhD thesis, 2005). Following incubation of the cells at 370C for one hour, in the dark, with 
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biotin-CCL19 and streptavidin-PE, up take of the complex was detected using single-
colour flow cytometry, The results of the biotin-CCL19 uptake studies are shown in 
figures 4.3 and 4.4.  Figure 4.3 is a graphical representation of the mean fluorescent 
intensity obtained following analysis of two pools of the hCCR7 transfected cells, 
HEK.hCCR7.1 and HEK.hCCR7.2, compared with HEK293 cells. This shows that with 
increasing concentrations of the biotin-CCL19, increased uptake of the chemokine is noted 
in the hCCR7+ cells, with the HEK.hCCR7.1 pool having the highest degree of uptake, 
this correlated with higher hCCR7 expression in the HEK.hCCR7 cells as determined by 
flow cytometry analysis using anti-hCCR7 antibodies. Subsequent analysis, including the 
results shown in figure 4.2 and 4.4 were performed using the HEK.hCCR7.1 pool, now 
referred to as HEK.hCCR7 cells. The dot plots also demonstrate that the hCCR7 receptors 
are functional and are able to bind to, and internalise, CCL19 (figure 4.4b) with a shift to 
the right along the FL2-H gate noted in comparison to the negative control (4.4a). Again it 
can be seen that there are two populations within these cells, corresponding with the two 
populations observed in the previous section. CCL19 is therefore a useful tool in assessing 
the ability of the receptor to internalise on binding with its cognate ligand. 
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Figure 4.3: Biotin-CCL19 uptake by pools of HEK.hCCR7 cells. Cells were incubated with 
biotin-CCL19 and streptavidin-PE for 1hr at 37oC using different concentrations of CCL19. 
Following this biotin-CCL19 binding/uptake by the cells was analysed using single-colour flow 
cytometry. Results from the negative control sample, HEK 293 cells, can just be observed at the 
0.5nM concentration point on the graph. This experiment was performed in triplicate on one 
occasion. 
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a)   b)  
 
 
                   c)  
 
Figure 4.4: Biotin-CCL19 uptake by HEK.hCCR7 cells. a) Un-transfected HEK293 cells 
incubated with biotin-CCL19 and streptavidin-PE, b) HEK.hCCR7 cells incubated with biotin-
CCL19 and streptavidin-PE c) Overlay demonstrating that the HEK293-hCCR7 (pink line) cells take 
up biotin-CCL19 with lack of uptake by HEK293 cells (purple curve). Cells were incubated with 
biotin-CCL19 and streptavidin-PE for 1hr at 37oC using different concentrations of CCL19. 
Following this biotin-CCL19 binding/uptake by the cells was analysed using single-colour flow 
cytometry. The mean fluorescent intensity was calculated from the population of cells contained 
within the upper right quadrant in figure b). This data is representative of results obtained from this 
experiment and represents single data points. 
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4.3 Functional Analysis of CCR7 in Raji Cells 
As described in the introduction to this chapter, in addition to studying hCCR7 in cells 
engineered to express it, it was also the aim to study the function of hCCR7 in cells with 
endogenous expression. In Chapter 3, it was demonstrated that Raji cells express hCCR7 at 
both the transcriptional and protein level and further assays were then undertaken to 
elucidate whether or not the expressed receptor was functional. This is important because, 
as seen in some studies on normal and malignant B cells, expression of CCR7 does not 
always equate with function [119]. This may be due to a number of reasons including the 
concentration of receptors on the cell surface, the concentration of the ligand in the 
microenvironment, the presence of stimulatory or inhibitory substances and other 
microenvironmental factors. By knowing if expression translated into function, it could be 
determined whether or not the Raji cells were suitable to be used as an in-vitro lymphoma 
model for targeted cellular toxicity. The functional aspects of hCCR7 in Raji cells were 
tested in two ways; these are outlined below. 
 
4.3.1 Biotin-CCL19 Uptake in Raji Cells 
The biotin-CCL19 uptake assay was used to assess whether or not CCR7 on Raji cells 
were capable of internalising this ligand. The same method was used for this assay as for 
the HEK.hCCR7 cells described in section 4.2.2. using a biotin-CCL19 at a concentration 
of 0.5nM. In this case, the negative control consisted of Raji cells incubated with 
streptavidin-PE and PBS only. Following incubation, again at 370C for 1 hour, the cells 
were analysed using single colour flow cytometry. The results are shown in figures 4.5a-d. 
These show that there is increased fluorescence detected in the Raji cells incubated with 
the biotin-CCL19 (figure 4.5b), with a shift to the right along the FL2-H gate as compared 
to those not exposed to biotin-CCL19, with no shift detected (figure 4.5a). Figure 4.5c 
shows the overlay histogram with blue peak shifted to the right, representing Raji cells 
incubated with biotin-CCL19, whilst the red peak representing those cells not exposed to 
the biotin-CCL19 does not show any shift. Furthermore, figure 4.5d demonstrates the mean 
fluorescent intensity (MFI) obtained during the analysis. There was a significantly higher 
MFI (p=0.0005) detected in the Raji cells, incubated with the biotin-CCL19, with a MFI of 
178.63 (95% confidence interval: 106.4-245.96) when compared to the Raji cells incubated 
with the streptavidin-PE only with a MFI of 5.67 (95% confidence interval: -3.97-19.03). 
These data therefore demonstrate that CCR7 on Raji cells is able to bind to, and internalise, 
CCL19. It could be assumed that all binding of CCL19 was due to the endogenously 
expressed hCCR7. However another explanation could be that the Raji cells also express 
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the atypical receptor CCX-CKR. CCX-CKR also binds to and internalises CCL19, 
although to date no signalling events have been detected as a consequence [286]. Therefore 
it is possible that not all of the biotin-CCL19 is being internalised by CCR7 but rather 
through this atypical receptor too. This is addressed in the next section. 
 
 
 
       a)                                                             b) 
 
          
 c)                                                                             d) 
 
Figure 4.5: Biotin-CCL19 uptake in Raji cells. Cells were incubated with biotin-CCL19 and 
streptavidin-PE or streptavidin-PE alone, for 1hr at 37oC. Following this biotin-CCL19 uptake by the 
cells was analysed using single-colour flow cytometry. a) Raji cells incubated with streptavidin-PE 
alone, b) Raji cells incubated with the biotin-CCL19-streptavidin-PE complex, c) Overlay histogram 
plot comparing Raji cells incubated with biotin-CCL19 (blue peak) or streptavidin-PE alone (red 
peak), d) Graph showing a significant difference in mean fluorescent intensity between Raji cells 
incubated with or without biotin-CCL19. The samples were set up in triplicate and the results in the 
graph experiment represent the results obtained on a single occasion. MFI for the positive cells 
was calculated from the population seen in the lower right quadrant in figure b). 
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4.3.2. Chemotaxis Assays on Raji cells 
CCX-CKR is an atypical receptor that to date has not demonstrated any intracellular 
signalling following internalisation of CCL19 [349], and thus does not support chemotaxis. 
In retrospect it would have been interesting to assess Raji cells for expression of CCX-
CKR, however this was not done. Yet, studies were performed to assess whether or not 
CCR7 expression on Raji cells was sufficient to induce chemotaxis. If chemotaxis could be 
induced in Raji cells following exposure to CCL19, it could be concluded that biotin-
CCL19 uptake was, at least in part, due to binding to CCR7. The following assays were 
performed to assess the ability of CCL19 to induce chemotaxis. 
 
4.3.2.1 Chemotaxis Assay using Transwell® Plates. 
The method described in section 2.2.5.5.1 was employed. 1 x 105cells were added to the 
insert of each well containing varying concentrations of either CCL19 or CXCL12. 
Negative controls consisted of wells containing no chemokine. CXCL12, the ligand for 
CXCR4 was used as a positive control as CXCR4 is known to be highly expressed on B-
cells and has been consistently demonstrated to induce chemotaxis in both normal and 
malignant B cells, furthermore CXCR4 expression had been confirmed on Raji cells as 
shown in section 3.4.1. Following incubation, the cells that had passed through the 
chemotaxis chamber into the medium below were counted and a migration index 
calculated as follows: 
 
Number of cells migrating to chemokine             =    Migration Index 
Number of cells migrating without chemokine 
 
The results of this are shown in figure 4.6. This demonstrates that both CCL19 and 
CXCL12 induce chemotaxis in the Raji cells, confirming that the endogenously expressed 
CCR7 and CXCR4 on these cells are functional. The highest migration index was obtained 
at a chemokine concentration of 100nM with each ligand, with a migration index of 29 ± 
7.51 following exposure to CCL19 and 33 ± 5.86 following exposure to CXCL12. It is 
possible that higher levels of chemotaxis could be achieved at higher concentrations of 
chemokine although it is just as likely that the degree of chemotaxis would fall due to 
receptor desensitisation. There was however, some concern during the experiment that not 
all of the cells passing through the wells were being counted and that chemotaxis was 
being under reported, so an alternative method for assessing chemotaxis was sought. This 
is outlined in the next experiment. 
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Figure 4.6: Chemotaxis of Raji cells using Transwell® chemotaxis plates. Chemotaxis buffer 
containing different concentrations of CCL19 or CXCL12 was added to each well of a Transwell® 
plate. The inserts were added, and into each of these Raji cells were placed. Following incubation 
at 37oC for 3 hours, the number of Raji cells passing through the chemotaxis chamber into the 
buffer below was counted.  A migration index was calculated as outlined in section 4.3.2.1, with 
migration index of greater than 1 indicating that migration has occurred. Analysis at each 
chemokine concentration was performed in triplicate and the error bars represent the standard 
error of the mean. Each sample was set up in triplicate, and the experiment was performed once. 
 
 
4.3.2.2 Chemotaxis of Raji Cells using the QCMTM Chemotaxis Assay 
This method was chosen, as it does not rely on using the haemocytometer to assess the 
number of cells that have passed through the chemotaxis chamber. Instead it uses a 
fluorescent dye that can bind to any nucleic acid that has been released following cell lysis. 
This is reported to give a more accurate measurement of chemotaxis as, cells which may 
have been attached to the base of the plates or the bottom of the chemotaxis filter are lysed 
through the process and included in the analysis; these are often missed with manual cell 
counting methods. Following cell lysis a plate reader using a 480/520nm filter set is used 
to determine the degree of fluorescence, which, in turn correlates with the number of cells 
in the lysate. The method was followed as described in section 2.2.5.5.2. Only CCL19 was 
used is this assay as it had already been established that the Raji cells migrated in response 
to this ligand. Prior to performing the experiment a calibration curve was set up, in which 
known quantities of cells were added to the bottom of the chambers followed by cell lysis 
and analysis of the degree of fluorescence. This calibration curve is shown in figure 4.7 
and demonstrates that there is a good correlation between fluorescence (RFU) and cell 
numbers as determined by linear regression analysis with a correlation co-efficient of 
r2=0.9455. This was then used to determine the number of Raji cells that had undergone 
chemotaxis following exposure to CCL19. The results of the Chemotaxis assay using the 
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QCMTM method are shown in Figure 4.8. These mirror the results obtained from the 
Transwell® Chemotaxis assay, however the migration indices obtained were lower with a 
migration index of 3.71 ± 1.86 at a CCL19 concentration of 100nM. However, further 
optimisation of this method would have been performed, if time and resources were 
available, as has the potential to be a valuable assay because more samples can be 
compared, with fewer cell numbers, which would make this assay ideal for the analysis of 
primary lymphoma samples from patients, in which only a limited amount of tissue is 
available.  
 
 
Figure 4.7: Calibration curve for QCMTM Chemotaxis Assay using Raji cells. Different 
quantities of Raji cells were added to wells of a 96 well luminometry plate. To each well lysis 
buffer/dye solution from the QCMTM kit was added and the plate incubated at room temperature for 
15minutes. The plate was then read using a 480/520nm filter set and the RFU recorded for each 
well. Each point on the calibration curve represents the mean RFU obtained from 3 wells 
containing the same number of cells, and indicates that there is a good correlation between RFU 
and cell number. 
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Figure 4.8: QCMTM Chemotaxis assay using Raji cells. Chemotaxis buffer containing a known 
concentration of CCL19 was added to each well of a 96 well feeder plate. Inserts were added, and 
Raji cells were added to each of the 96 inserts. Following the steps outlined in 2.2.5.5.2, the cells 
were incubated with lysis buffer/ dye solution for 15 minutes and transferred to a 96 well 
luminometry plate for reading using a 480/520nm filter set. A migration index of >1 indicates that 
migration has occurred. Analysis at each chemokine concentration was performed in triplicate and 
the error bars represent the standard error of the mean. This procedure was performed once.  
 
The results from both of the chemotaxis assays demonstrate that CCR7 expression on Raji 
cells was sufficient to induce chemotaxis. Furthermore, the chemotaxis assays confirm that 
at least a proportion of biotin-CCL19 uptake demonstrated in section 4.3.1 was due to 
binding with CCR7 rather than with CCX-CKR. Of course, biotin-CCL19 binding to 
CCX-CKR may still have bee occurring. However, demonstration that Raji cells are able to 
bind to, and potentially internalise, CCL19 meant that the Raji cells could be used for cell 
targeting experiments using cytotoxic agents.  
 
4.4 Cell killing by exposure to a radio-labelled chemokine 
There are a number of ways in which the chemokine system can be targeted to elicit cell 
death. One example in clinical trials is the anti-CCR4 antibody, which induces antibody 
dependant cell-mediated cytotoxicity (ADCC) [349]. Further possibilities include the use 
of chemotoxins, in which the active portion of a chemokine is fused with toxic agents such 
as Pseudomonas exotoxin 38 [297], or as described here by using a chemokine conjugated 
to a active radioisotope such as Iodine-125 (125I). The latter approach is already used in 
clinical practice with radiolabelled antibodies used in the treatment of lymphomas, such as 
Iodine-131 labelled anti-CD20 antibodies [298].  
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In this experiment chemokines labelled with 125I were used. This radio-isotope has a 
relatively long-half life of approximately 59 days, meaning that is was suitable for 
experiments requiring incubation over a period of days or weeks. 125I is a gamma emitter 
with low emission to cells out with those containing the isotope, although sufficient 
radiation may be delivered to be cytotoxic to surrounding tissues [350]. The aim here was 
to test whether a chemokine labelled with the radio-isotope 125I, would lead to enhanced 
killing of cells expressing the cognate chemokine receptor compared to the receptor-
negative cells. On day one of the experiment a calibration curve for the MTT cell assay 
was prepared using known quantities of HEK293 cells.  The MTT assay is a method by 
which viable cell numbers within a small volume of medium can be quantified whilst 
enabling maximum protection for the operator with regards to radio-isotope exposure. 
Following addition of the reagents live cells develop black crystals of MTT formazan, after 
addition of a developing reagent the crystals dissolve to form a blue coloured solution, the 
absorbance of which is measured using a 570/630nm filter set. The calibration curve is 
shown in figure 4.9 demonstrating good correlation with absorbance and cell numbers with 
a correlation co-efficient of r2=0.9931.  
 
On day 1 four 96 well plates were set up as follows: 3 wells with HEK293 cells in medium 
only, 3 wells with HEK.hCCR7 cells in 100µl medium containing 0.5µg of CCL19/100µl, 
3 wells with HEK.hD6 in 100µl medium containing 0.5µg of PM2, 3 wells with HEK293 
in 100µl medium containing 1µl of PM2-125I conjugate (925kBq/ml, specific activity 
2200Ci/mmol and 10µg/ml PM2), 3 wells with HEK.hCCR7 cells in 100µl medium 
containing 1µl of CCL19-125I conjugate (925kBq/ml, specific activity 2200Ci/mmol and 
10µg/ml CCL19) and 3 wells with HEK.hD6 in medium containing 925kBq/ml of PM2-
125I conjugate as detailed above. HEK.hD6 cells were used as a positive control as D6 is an 
atypical receptor that is capable of efficiently internalising chemokines [351] and so should 
be susceptible to killing with the PM2-125I conjugate. PM2, is a truncated form of CCL3, 
known to bind to and be internalised by D6.  The cells were then incubated for 2, 4, 8 or 12 
days at 370C with the growth medium containing the chemokine or chemokine-125I 
conjugate where appropriate, being replaced with fresh stock on day 6.  
 
The cells were then harvested on the appropriate day and the MTT cell assay performed to 
assess the number of remaining cells. The results of this are shown in figure 4.10. 
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Figure 4.9: Calibration curve for the MTT Cell assay. A known quantity of HEK293 cells was 
added to individual wells within a 96 well plate. The reagents from the MTT kit were then added to 
each well as outlined in section 2.2.5.4 and read using 570/630nm filters. Each point on the 
calibration curve represents the mean absorbance obtained from 3 wells containing the same 
number of HEK293 cells, and indicates good correlation between absorbance and cell number. 
 
 
On day 2, those cells, which had not been exposed to the radiolabelled ligands, had 
proliferated, with higher numbers of cells noted. In comparison those cells, which had been 
exposed to 125I, did not show any increase in cells numbers, with cells numbers unchanged 
when compared to day 1 suggesting that cell kill had occurred. Comparison between the 
cell numbers in those wells containing radiolabelled ligand with those that did not 
demonstrated a significant difference (p<0.0001 using student t-test). However, 
comparison between HEK293, HEK.hCCR7 and HEK.hD6 cells exposed to radiolabelled 
chemokine did not reveal any significant differences between the cell numbers suggesting 
non-specific cell killing.  
 
On day 4, the highest cells numbers were again recorded in those chambers with no 
radioisotope exposure. However, on this occasion, there were significant differences 
between HEK293, HEK.hD6 and HEK.hCCR7 cells exposed to 125I. The HEK.hCCR7 cell 
numbers were significantly lower when compared to both HEK.hD6 and HEK293 cells 
numbers with p-values of p=0.0028 and p=0.0031 respectively. This suggested an 
increased level of cell kill of CCR7+ cells by CCL19-125I, and thus potentially targeted cell 
kill had been achieved. 
 
On day 8 although there were fewer HEK.hCCR7 cells in the well exposed to CCL19.125I 
compared to the cell numbers in the HEK293 and HEK.hD6 wells exposed to PM2125I, the 
differences were no longer significant, and cell numbers in all 3 groups had started to 
increase indicating that cell killing had slowed. Of note, the cell numbers in each of the 
wells with no radioisotope exposure were lower.  The likely explanation for this relates to 
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events on day 6. When changing the medium on this day, there was such a degree of 
proliferation that the cells had lifted off the bottom of the wells and the majority of them 
were removed with the old medium, as such the results on these days reflect gross 
underestimations of cell proliferation. This also explains the findings in these chambers on 
day12. 
 
On day 12 the lowest numbers of cells were seen in the wells that did not contain 125I. No 
further increases in cell numbers were seen in the wells containing HEK293, HEK.hCCR7 
or HEK.hD6 exposed to chemokine125I indicating that cell kill had occurred. However 
although the well containing HEK.hD6 cells and PM2125I was the only one to show a fall 
in cell number, comparison with cell numbers in the wells containing HEK293 and 
HEK.hCCR7 cells and 125I did not show any significant differences suggesting that cell kill 
was again non-specific. 
 
The results of this study can be seen graphically in figures 4.10 and 4.11. 
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Figure 4.10: Comparison of cell numbers at day 2 and 4 between wells exposed or not 
exposed to radiolabelled chemokine. Cells were incubated with medium alone, or medium 
containing PM2 or CCL19 with or without radiolabelling with 125I for 2, 4, 8, or 12 days. Following 
incubation the cell numbers were determined using the MTT assay (section 2.2.5.4). These graphs 
show the cell numbers obtained using the MMT cell proliferation assay after incubation at 2 and 4, 
data from days 8 and 12 are not shown as the experiment was invalidated due to loss of the control 
cells. Each, incubation was performed in triplicate and the error bars in the graphs represent the 
standard error of the mean. 
 
 
 
© Michelle Bryson, 2010                  CHAPTER FOUR                                    RESULTS 
 
 167 
 
Figure 4.11: Cell numbers following 2, 4, 8 or 12 days incubation with radiolabelled 
chemokine. Cells were incubated with medium alone, or medium containing PM2 or CCL19 with 
or without radiolabelling with 125I for 2, 4, 8, or 12 days. Following incubation the cell numbers were 
determined using the MTT assay (section 2.2.5.4). These graphs show the cell numbers obtained 
using the MMT cell proliferation assay after incubation at 2, 4, 8, and 12 days. Each, incubation 
was performed in triplicate and the error bars in the graphs represent the standard error of the 
mean. 
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Firm conclusions about the ability to utilise the chemokine receptors to induce targeted cell 
death using radiolabelled chemokines cannot be drawn from the results of this initial 
experiment. Nonspecific killing of cells was occurring as evidenced by the fact that at 3 of 
the 4 time points, there were no significant differences in cell numbers between 125I 
exposed wells containing HEK293, HEKhCCR7 or HEK.hD6 cells. Further studies are 
required to optimise the experiment further. This would include using lower concentrations 
of the radioisotope, to see if there really was an appreciable difference between 
cytotoxicity and receptor expression as suggested with the day 4 results, by aiming to 
avoid non-specific cell kill. Additionally, HEK293 cells expressing the atypical chemokine 
receptor CCX-CKR might be a more appropriate positive control than D6 transfected HEK 
cells. The reason for this is that CCX-CKR also binds, and internalises, CCL19 [126], and 
so any differences between the level of decay of the PM2-125I and the CCL19-125I, as a 
result of the timing of the conjugation and potential differences in the degree of 
cytotoxicity would be negated.  
 
The results discussed in sections 4.2 to 4.3 of this chapter enabled progression onto further 
experiments discussed in chapters 5 and 6. 
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4.5 Summary 
In summary, this chapter had demonstrated the following: 
 
1. Stable HEK.hCCR7 cells have been successfully created that express good levels 
of hCCR7 and are capable of taking up one of its ligands, CCL19. 
 
2. Raji cells not only endogenously express hCCR7 but the receptor is also functional 
as shown by the capability of these cells to bind to CCL19. 
 
3. Functionality of hCCR7 is also demonstrated by the ability of Raji cells to migrate 
in response to CCL19. 
 
4. The results obtained with the use of radiolabelled chemokines to target the 
chemokine system were not conclusive and further optimisation of the experiments 
would be required before confirming this as an effective approach. 
 
 
 
 
 
   
 
CHAPTER FIVE 
REDIRECTION OF ADENOVIRAL TROPISM 
THROUGH CHEMOKINE RECEPTORS 
5.1 Introduction 
As detailed in the previous chapter, there are a number of ways in which the chemokine 
system can be targeted to elicit cell death. The use of radiolabelled chemokines was 
described in section 4.4, although further work is required to see if this is a suitable 
approach. In this chapter, the potential use of cytolytic gene therapy will be explored, one 
example of which includes the transduction of suicide genes such as thymidine kinase, 
which if expressed will lead to cell death following exposure of cells to ganciclovir [127]. 
The potential advantage of using gene therapy, in this case by utilising adenoviral vectors, 
is that the targeting can be more specific with additional degrees of specificity being 
included in the system, such that intracellular as well as extracellular variables can be 
taken advantage of.  
 
For example, the engineering of a vector to incorporate a telomerase promoter to regulate 
expression of the ‘suicide’ gene ensures that the gene is only expressed in those cells 
expressing telomerase, namely malignant cells as well as germ cells, stem cells and certain 
long-lived lymphocytes. This approach has been utilised to transfect cells with an 
adenoviral vector containing the ‘suicide’ gene, bacterial nitroreductase, for potential use 
in clinical cancer trials [132].  
 
However, whilst the intracellular characteristics of the target cell can be hijacked leading to 
self-destruction, more specific targeting can be achieved by trying to control the cell 
population being transfected in the first place. In the case of adenoviral vectors, this means 
redirecting the natural tropism of the vector such that it will enter through an alternate 
receptor, in this case a chemokine receptor. As described in chapter 1, adenovirus 2 (Ad2) 
and adenovirus 5 (Ad5) are the two adenoviral serotypes used most frequently in gene 
therapy due to their low pathogenicity and lack of oncogenic potential [325]. These 
serotypes enter the cell following interaction of the viral knob protein with the coxsackie-
adenovirus receptor (CAR) on the cell surface [304]. Work has been published detailing a 
number of different methods by which adenoviral tropism has been successfully redirected. 
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Such examples include ‘fibre switching” where the fibre protein from a different 
adenoviral serotype such as Ad35 replaces that of Ad2 or Ad5, which then redirects the 
virus through CD46 [306]; or the incorporation of peptides including elements of heparin 
binding domains redirecting binding to heparan sulphate, into the fibre knob protein [334]; 
or the use of anti-fibre antibodies conjugated to a ligand, such as folate, redirecting the 
virus through the folate receptor [330].  Finally, chemical conjugation of the adenovirus 
with a ligand is an alternative approach. 
 
There have been a variety of chemical ‘linkers’ used, to attach proteins to be fibre knob, 
including biotinylation. Viruses that had first been biotinylated and then incubated with 
avidin were then subsequently incubated with antibodies to elements such as IL-2 have 
also led to successful redirection into haematopoietic cells which do not normally express 
CAR [332]. This final approach was chosen for attempting redirection though chemokine 
receptors. A reason for this was that if the adenovirus could be efficiently biotinylated, and 
then conjugated with avidin, then the system could be used with a variety of different 
chemokines depending upon the cell population to be targeted. However, the difficulty 
with chemokines is that the N-terminus of the chemokine is required to interact with its 
cognate chemokine receptor, whilst the viral fibre knob protein interacts with CAR via its 
C-terminus. So, in order to re-direct adenoviral vectors through chemokine receptors, a 
system by which the N-terminus of the chemokine could remain free to interact with its 
receptor was required. It is also worth noting that, following binding with CAR, adenoviral 
particles are internalised via endocytosis into clathrin-coated pits as occurs following 
chemokine receptor-ligand binding. Thus the method of internalisation of the virus should 
not, in theory, be affected by entry through the chemokine receptor [333]. This chapter 
outlines the experiments performed attempting to re-direct viral tropism through 
chemokine receptors. 
5.2 Infection of HEK293 and HEK.hCCR7 Cells Following Chemical 
shrouding of Adenovirus with Chemokine 
In order to achieve chemical conjugation of the adenovirus with chemokine, and thus 
redirection of adenoviral tropism, the method outlined in 2.2.6.4 was used and is shown 
diagrammatically in figure 5.1. This method of chemically coating the virus is referred to 
as shrouding the virus from now onwards. EZ-Linked Maleimide Activated NeutrAvidinTM 
Protein provides a free sulfhydryl (-SH) group that allows conjugation to proteins and 
other molecules containing this group whilst still allowing for binding to biotin. The 
adenoviral fiber knob protein in Ad5 and Ad2 serotypes has been shown to contain free 
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sulfhydryl groups [311]. The viral vector used initially was a ‘high capacity, gutless’ 
adenovirus 5 containing a CMV promoter and LacZ reporter gene (Ad5.CMV.LacZ), thus 
enabling the detection of successful infection through the detection of LacZ expression. 
Following incubation of the virus with NeutrAvidinTM, the mixture was dialysed using a 
dialysis membrane with a pore size of 100kDa, in order to remove any un-bound 
NeutrAvidinTM. Following centrifugation and re-suspension of the Ad5.CMV.LacZ vector, 
shrouding of the virus was attempted using biotinylated chemokines again with a final 
dialysis stage to remove unbound chemokine. The biotinylated chemokines have the N-
terminus unaltered thereby allowing for interaction with the cognate receptor.  
 
 
Figure 5.20: Outline of strategy to redirect adenoviral tropism. Initially the Ad5.CMV.LacZ 
vector was incubated with NeutrAvidinTM in order to conjugate the fibre knob protein with this 
protein. The Ad5.CMV.LacZ-NeutrAvidinTM conjugate was then incubated with biotinylated 
chemokine to enable chemokine shrouding of the virus. The shrouded virus is therefore blocked 
from entering the cell through CAR, and redirected through the chemokine receptor. 
 
Initially 6.6 x 108 infection forming units (ifu)/ml of Ad5.CMV.LacZ were incubated for 1 
hour with 0.5mg/ml of the NeutrAvidinTM protein, before shrouding with biotin-CCL19.  
Following conjugation 12-well plates were set up for viral infection using 5 x 105 HEK293 
or HEK.hCCR7 cells in each well. 100µl of Ad5.CMV.LacZ at a concentration of 6.6 x 
104 or 6.6 x 105 ifu/ml giving final viral titres of 6.6 x 103 or 6.6 X 104 ifu per well. This 
equates to a multiplicity of infection (MOI) of 0.0132 or 0.132 ifu/cell. After 48 hours the 
cells were analysed for LacZ expression by staining for β-galactosidase, as detailed in 
2.2.6.6, with LacZ positive cells appearing blue. The degree of infection was then 
determined by microscopic examination of the plates and by counting the number of blue 
cells per field at x20 objective. The infection was then calculated as follows: 
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IFU/ml   =   (infected cells/field) x (fields/well) 
                    Volume virus (ml) x dilution factor 
 
A sample calculation can be found in section 2.2.6.3.  
 
The initial results are shown in Figures 5.2 and 5.3. The first figure shows the difference in 
the rates of infection between the CCR7+ and CCR7- cells at the two viral concentrations. 
Using a titre of 6.6 x 103 ifu/well, the rates of infection were as follows: CCR7+ cells; 2.21 
(± 0.16) x 108 ifu/ml vs. CCR7- cells; 1.38 (± 0.2) x 108 ifu/ml, these difference were 
significantly different with p=0.0023 (using an unpaired t-test). The same was seen at a the 
higher viral titre of 6.6 x 104 ifu/well with the results as follows; CCR7+ cells; 4.06 (± 
0.54) x 108 ifu/ml vs. CCR7- cells; 1.6 (± 0.27) x 108 ifu/ml and again the degree of 
infection was significantly higher in the CCR7+ cells with p=0.0002. These results are also 
shown in figure 5.3 in which it is clear that there are a higher number of LacZ positive 
(blue) cells in the CCR7+ population as compared to the CCR7- population. 
 
However, there was a high degree of background infection. There were a couple of 
potential reasons for this. Firstly, there may have been incomplete shrouding of the 
adenovirus with the chemokine allowing entry into the HEK293 and HEK.hCCR7 cells via 
the CAR receptor. Secondly, as described in section 1.5.4, adenovirus can also enter the 
cells via alpha integrins on the surface in a CAR independent fashion, albeit at a lower rate, 
via the RGD motif on the base of the viral shaft protein. This could also be responsible for, 
or at least contribute to, the degree of background infection. However it is reported that 
entry via this method is 10 fold lower and this was not the case in this instance, suggesting 
that this is not the only explanation and that the first was more likely. Yet, what was clear 
even with these preliminary results was that the adenovirus could be successfully 
redirected through the chemokine receptor by CCL19.  
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Figure 5.21: Infection of HEK293 and HEK.hCCR7 cells with Ad5.CMV.LacZ shrouded with 
biotin-CCL19.  Ad5.CMV.LacZ shrouded with CCL19 was added to HEK293 and HEK.hCCR7 
cells at two different concentrations, and then incubated for 48 hours at 37oC.  The cells were then 
assessed for LacZ expression by staining for β-galactosidase as detailed in 2.2.6.5 indicating 
successful transfection of the reporter gene. The positive cells were then counted using a 20x 
objective lens. The viral titre (ifu/ml) for each infection was then calculated as in 2.2.6.2.  Each bar 
on the graph represents 30 microscopic fields counted across nine wells containing the same cell 
type and viral concentration. These results represent data collected from experiments repeated on 
three separate occasions (3 wells counted at each time). The error bars represent the standard 
error of the mean (SEM). 
 
 
 
HEK293                                                      HEK.hCCR7 
Figure 5.22: Analysis of Ad5.CMV.LacZ infection in HEK293 and HEK.hCCR7 cells. Cells 
were incubated with Ad5.CMV.LacZ shrouded with CCL19 for 48 hours. After this staining for β-
galactosidase was performed to assess LacZ expression, and therefore successful infection by the 
adenovirus.  These images (taken at 20x objective) demonstrate a higher rate of infection in 
HEK.hCCR7 cells as indicated by a higher number of LacZ positive (blue) cells.  
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5.3 Infection of CHO and CHO.hCCR5 Cells with Adenovirus shrouded 
with CCL3. 
Whilst the initial attempts to redirect the adenovirus through hCCR7 gave results 
indicating that the approach described above was effective, the degree of background 
infection was such that further refinement of the experiments were required to 
demonstrate, with a higher degree of certainty, that adenoviral redirection was occurring. 
Chinese Hamster Ovary cells (CHO) were identified as a cell line that expresses neither 
CAR nor alpha integrins. RT-PCR was performed using primers for CAR and alpha 
integrins on RNA extracted from CHO and HEK293 cells. The RT-PCR results for CAR 
expression in HEK293 and CHO cells are shown in Figure 5.4, confirming the absence of 
CAR expression in CHO cells. Data confirming the presence of alpha-integrins in HEK293 
and their absence in CHO cells are not shown.  Therefore, in the absence of CAR and 
α−integrin, the only way in which the chemokine-shrouded adenovirus could enter the 
chemokine receptor expressing CHO cells would be through the chemokine receptor. The 
infection experiments were then repeated on CHO cells as described in section 5.2 with 
stable CHO transfectants expressing hCCR5 (CHO.hCCR5) that had previously been 
developed in Professor Graham’s laboratory. This time the Ad5.CMV.LacZ particles were 
shrouded in one of the ligands for hCCR5, CCL3. The results from this CCR5-redirected 
infection are shown in Figure 5.5. As would be expected, the background infection rate in 
the CHO cells was greatly reduced. In fact the overall rates of infection were 3 logs lower 
when compared to the HEK293 infection studies. The CHO.hCCR5 cells showed infection 
rates of 13.4 (± 1.46) x 105 ifu/ml cells which was significantly higher (p<0.0001) than 
those obtained with CHO cells with rates of 1.3 (± 0.28) x 105 ifu/ml following infection 
with CCL3 shrouded adenovirus again indicating that chemokine shrouding allowed the 
Ad5.CMV.LacZ to be successfully directed through the cognate chemokine receptor. 
 
 
 
 
 
Michelle Bryson, 2010                            CHAPTER FIVE                                         RESULTS 
 176 
                                       
 
Figure 5.23: CAR expression in CHO and HEK293 cells. RNA was prepared from the CHO and 
HEK293 cells using Trizol®, these were DNAase treated and cDNA was prepared using reverse 
transcriptase. Primers for actin (human or hamster) and CAR were then used to amplify cDNA 
using the PCR programme in 2.2.4.3. The PCR products were then run on a 1% agarose gel 
containing ethidium bromide.  
 
 
 
Figure 5.24: Infection of CHO and CHO.hCCR5 cells with Ad5.CMV.LacZ shrouded with 
biotin-CCL3.  Ad5.CMV.LacZ shrouded with CCL3 was added to CHO and CHO.hCCR5 cells at a 
concentration of 6.6 x 104 ifu/well, and incubated for 48 hours at 37oC.  The cells were assessed for 
LacZ expression and the ifu/ml titres for each sample were calculated as before. Each bar on the 
graph represents 30 microscopic fields counted across three wells containing the same cell type 
and viral concentration. This experiment was repeated twice. The error bars represent the SEM. 
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5.4 Optimisation of Infection Rates 
Now that it had been shown that adenoviral tropism could be successfully redirected 
through chemokine receptors, the next step was to try to optimise the method in order to 
obtain higher infection rates in the cell lines used. This would ensure the most efficient use 
of the vector and have implications later when proceeding to targeted cytolytic therapy.  
5.4.1 Effect of Incubation Time with NeutrAvidinTM on the Rate of 
Infection 
The first step was to determine whether or not the length of time the adenovirus was 
incubated with NeutrAvidinTM prior to chemokine conjugation, which had previously been 
1 hour, altered infection rates. Infections were performed, as before, but with virus that had 
been incubated with NeutrAvidinTM for 1, 2, or 4 hours prior to incubation with 
chemokine. In this experiment CHO.hCCR5 cells were infected with Ad5.CMV.LacZ 
shrouded in CCL3 in order to reduce the rate of background infection and make 
conclusions regarding efficiency of infection clearer. The results are shown in Figure 5.6. 
The highest infection rates were obtained with 4 hours incubation. For all experiments 
following this an incubation time of 4 hours was used. 
 
Figure 5.25: Infection rates with different durations of Ad5.CMV.LacZ incubation with 
NeutrAvidinTM.  Ad5.CMV.LacZ was incubated with NeutrAvidinTM 0.5mg/ml for 1, 2 or 4 hours. 
The resulting conjugates were then shrouded with the CCL3 prior to infection of CHO.hCCR5 cells 
with 6.6 x 104 ifu/well. Following infection and incubation for 48 hours, the cells were analysed for 
LacZ expression and the ifu/ml titre calculated for each time point. Each bar on the graph 
represents 40 microscopic fields counted across three wells containing virus incubated with 
NeutrAvidinTM for the same length of time. This analysis was performed on one occasion. The error 
bars represent the SEM.  
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5.4.2 Effect of Incubation Time with Chemokine on the Rate of Infection 
Once the optimum NeutrAvidinTM incubation time had been determined, the optimum 
incubation time with chemokine was determined in the same way, again with CHO.hCCR5 
and CCL3 and with incubation times of 1, and 4. As with NeutrAvidinTM, the optimum 
incubation time was 4 hours (see figure 5.7). An incubation time of 4 hours with the 
chemokine was used from this time onwards. 
 
Figure 5.26: Infection rates with different incubation times with CCL3. Ad5.CMV.LacZ 
conjugated with NeutrAvidinTM after 4 hours incubation was incubated with biotin-CCL3 for 1 and 4 
hours. Following this CHO.hCCR5 cells were infected with the shrouded virus from the different 
time points with a viral load of 6.6 x104 ifu/well. Subsequently infection rates were assessed using 
β-galactosidase staining as before following 48 hours incubation. Each bar on the graph represents 
40 microscopic fields counted across three wells containing virus incubated with CCL3 for the 
same length of time. This analysis was performed on one occasion. The error bars represent the 
SEM.  
 
5.4.3 Effect of NeutrAvidinTM concentration on infection rates 
The previous experiments had been performed using NeutrAvidinTM at a concentration of 
0.5mg/ml during the incubation step. The experiments were repeated, this time using 4 
hours incubation time and with NeutrAvidinTM concentrations of 0.25, 0.5, 0.75 and 
1.0mg/ml. HEK293 cells with or without hCCR7 expression were used for these 
experiments.  
 
The results demonstrated that the optimum NeutrAvidinTM concentration for infection was 
obtained at concentration of 0.75mg/ml. Again at each concentration there were significant 
differences in the rate of infection between CCR7+ and CCR7- cells with p-values of 
CCR7+ vs. CCR7- of p=0.0002, p=0.0003, p=0.0003 and p<0.0001 at 0.25 mg/ml, 0.5 
Michelle Bryson, 2010                            CHAPTER FIVE                                         RESULTS 
 179 
mg/ml, 0.75mg/ml and 1.0mg/ml NeutrAvidinTM concentrations respectively. The data for 
this is shown in Figures 5.8 and 5.9 with figure 5.9 clearly demonstrating the variations in 
infections rates as evidenced by differences in numbers of LacZ positive cells between the 
different NeutrAvidinTM concentrations. It was surprising that a lower infection rate was 
obtained with the highest NeutrAvidinTM concentration of 1.0mg/ml; one possible 
explanation for this is that the Ad5.CMV.LacZ particles start to clump together, thereby 
preventing entry into cells via either the CAR or chemokine receptor.  From this point on a 
NeutrAvidinTM concentration of 0.75mg/ml was used in chemokine shrouding 
experiments. 
 
 
Figure 5.27: Effect of NeutrAvidinTM concentration on Ad5.CMV.LacZ infection rates. 
Ad5.CMV.LacZ was incubated with NeutrAvidinTM at concentrations of 0.25mg/ml, 0.5mg/ml, 
0.75mg/ml and 1.0mg/ml for 4 hours. The Ad5.CMV.LacZ-NeutrAvidinTM conjugates were shrouded 
with CCL19 and used to infect HEK.293 and HEK.hCCR7 cells with 6.6 x104 ifu/well. Analysis of 
infection by assessment of LacZ expression was performed as before after 48 hours incubation. 
For each NeutrAvidinTM conjugate cells were counted in 30 fields across 3 wells, represented by 
the bars in the graph. This analysis was performed on one occasion. The error bars represent the 
SEM.  
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0.75mg/ml                                                      1.0mg/ml 
Figure 5.28: HEK.hCCR7 cells infected with Ad5.CMV.LacZ incubated with NeutrAvidinTM at 
different concentrations. Ad5.CMV.LacZ was incubated with NeutrAvidinTM at concentrations of 
0.25mg/ml, 0.5mg/ml, 0.75mg/ml and 1.0mg/ml for 4 hours. The Ad5.CMV.LacZ-NeutrAvidinTM 
conjugates were shrouded with CCL19 and used to infect HEK.hCCR7 cells with viral particles at 
6.6 x104 ifu/well. Analysis of infection was performed after 48 hours incubation by assessment of 
LacZ expression with positive cells staining blue.  
 
5.5 Infection of Raji Cells with Adenovirus shrouded in CCL19 
Now that it had been demonstrated that adenovirus could be successfully redirected 
through cells engineered to express CCR7 or CCR5, the next step was to demonstrate that 
it could be re-directed through CCR7 in cells that express the receptor endogenously. In 
the previous chapter it was demonstrated that Raji cells not only endogenously express 
CCR7, but that the receptor is functional in these cells. Before starting infection 
experiments in this cell line, the expression of CAR was also determined. Normally, CAR 
is expressed in all mammalian cells except stem cells, haematopoietic cells and many 
muscle cells. There is however some literature suggesting that malignant lymphoma cell 
lines do express the CAR receptor [352], albeit at a lower level than in other tissues, and 
this was certainly found to be the case with Raji cells as shown in figure 5.10.  
However, as lymphoma is the tumour type that is being explored in this thesis, infection of 
a lymphoma cell line was important thus the study progressed with Raji cells. Raji cells 
express functional CCR7 receptors and thus the infection experiments were performed 
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using CCL19 to shroud and to attempt redirection of the virus. Raji cell suspensions 
containing 5 x 105 cell in 500µl were infected with CCL19 shrouded Ad5.CMV.LacZ 
adenovirus at a MOI of 0.132 ifu/cell. Control samples were set up in parallel, with 
Ad5.CMV.LacZ that had not been shrouded with CCL19, at the same viral concentrations. 
The cells were incubated for 48 hours. Following incubation, the cells were washed once 
with PBS and then transferred to a poly-L-lysine coated microscope slide to adhere for 45 
minutes. The cells were then assessed for LacZ expression, as described previously. The 
results are shown in figure 5.11 and figure 5.12. Figure 5.11 shows images of the infected 
Raji cells, clearly demonstrating a higher degree of infection in those cells exposed to the 
CCL19 shrouded adenovirus.  
 
There was a significantly (p=0.0097), increased rate infection in Raji cells with the CCL19 
shrouded Ad5.CMV.LacZ (mean; 22.3 (± 8.4) x106 ifu/ml) compared to the non-shrouded 
virus (mean: 1.09 (± 0.18) x 106 ifu/ml), reflecting a greater than twentyfold difference. 
These results again clearly demonstrate that Ad5.CMV.LacZ can be successfully redirected 
through chemokine receptors.  
 
 
 
Figure 5.29: CAR expression in Raji Cells. RNA was prepared from Raji cells using Trizol®, 
these were DNAase treated and cDNA was prepared using reverse transcriptase (with a RT- 
control). Primers for actin and CAR were used to amplify cDNA using the PCR programme in 
2.2.4.3. The PCR products were then run on a 1% agarose gel containing ethidium bromide. For 
comparison the actin PCR product is 400bp. 
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Figure 5.30: Raji cells infected with Ad5.CMV.LacZ shrouded with CCL19. Raji cells were 
infected with Ad5.CMV.LacZ with or without shrouding with CCL19 at 6.6 x104 ifu/well. Following 
incubation for 48 hours, the cells were transferred to poly-L-lysine coated cells and left to adhere 
for 45 minutes. They were then assessed for LacZ expression by staining for β-galactosidase (blue 
cells). These figures demonstrate enhanced infection with CCL19-shrouded virus (right figure) 
compared to non-CCL19-shrouded virus.  
 
 
Figure 5.31: Infection of Raji cells with CCL19 shrouded Ad5.CMV.LacZ. 6.6 x104 ifu/well of 
Ad5.CMV.LacZ with or without CCL19-shrouding were added to Raji cells and incubated for 48 
hours. Cells were then placed on poly-L-lysine coated slides to enable adherence. Infection with 
Ad5.CMV.LacZ was then assessed as before, and the ifu/ml titres were calculated following 
counting of LacZ positive cells in 30 fields across 3 slides.  This procedure was repeated in 
triplicate three times, and the results above reflect the data obtained from each of these 
experiments. The error bars represent the SEM.  
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5.6 Increasing the Specificity of Cell Targeting using Different 
Promoters 
It has been shown that it is possible to improve the specificity of cell targeting for 
malignant cells further by using hTERT and hTR promoters, which are telomerase 
promoters predominantly expressed in germ cells and malignant cells [325, 353](Bilsland, 
2003). At a later stage, once redirection of adenovirus through chemokine receptors had 
been optimised, it was considered that using these promoters would add a valuable 
additional level of specificity when constructing the oncolytic virus for targeted therapy. 
Yet, before proceeding, it was important to determine if the telomerase promoter was 
present in HEK293 cells, as these cells would be ideal for use in initial in-vitro proof-of-
principle studies, to target the chemokine receptor positive cells.  
5.6.1 Comparison of infection rates in HEK293 and A2780 cells 
following infection with Ad5.hTERT.Luc 
Infection experiments were repeated on HEK293 and the human ovarian cancer cell line 
A2780 (which is known to express hTERT and hTR).  However, on this occasion the 
adenovirus used were Ad5.hTERT.Luc, Ad5.hTR.Luc and Ad5.SV40.Luc obtained from 
Alan Bilsland. These vectors contain hTERT, hTR or SV40 promoters, the latter promoter 
acting as a positive control, as it should promote transcription in most cell types. Luc 
encodes the reporter gene luciferase, present in each of the 3 vectors. After 48 hours 
incubation of HEK293 and A2780 cells with the virus, a luciferase assay was performed on 
the cells using the Promega Luciferase Assay kit according the manufacturer’s instructions 
outlined in section 2.2.6.6. The results of this experiment are shown in figure 5.13. There 
were higher luciferase expression levels with all three viruses in the HEK293 cells when 
compared to expression in the A2780 cells, indicating that the telomerase promoters could 
be used to efficiently initiate reporter gene expression in HEK293 cells. 
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Figure 5.32: Infection of HEK293 and A2780 cells with Ad5.hTR.Luc, Ad5.hTERT.Luc and 
Ad5.SV40.Luc. HEK293 and A2780 cells were infected with the above viral vectors, without prior 
shrouding with chemokine. Following 48 hours incubation, infection was assessed using the 
Promega luciferase assay kit (section 2.2.6.6). This experiment was repeated once only, with each 
sample set up in triplicate. There is clearly more efficient infection of HEK293 cells compared to 
A2780 cells. 
 
5.6.2 Comparison of Infection in HEK293 and HEK.hCCR7 Cells with 
Ad5.hTR.Luc shrouded with CCL19 
The above experiment was repeated, however this time HEK293 and HEK.hCCR7 cells 
were infected with Ad5.hTR.Luc with or without shrouding with CCL19 as described 
previously. Ad5.hTR.Luc was chosen as this had resulted in the highest rate of infection in 
the previous experiment. After infection, the cells were analysed for luciferase activity. 
The highest luciferase activity and hence infection rate was obtained with HEK.hCCR7 
cells incubated with CCL19 shrouded virus, although on this occasion this was not 
significantly different to the infection rate obtained in HEK293 cells incubated with the 
CCL19 shrouded virus (p=0.0597).  
 
However it was interesting to note that infection rates were higher using the CCL19 
shrouded virus than with the non-shrouded virus. Comparing HEK.hCCR7 cells incubated 
with CCL19 shrouded virus with HEK.hCCR7 cells incubated with non-shrouded virus, 
showed a significantly higher rate of infection in the former group (p<=0.001) as indicated 
by the higher rate of reporter gene activity. The difference between infection rates in 
HEK293 cells exposed to the two virus groups was not significant (p=0.1829).  One 
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explanation for this observation might be that infection through CCR7 is more efficient 
than CAR. However, the most likely explanation is that the virus is able to enter the cell by 
both CCR7 and CAR dependent mechanisms, and so the increased rates of infection 
simply reflect the fact that more receptors are available to the virus. The results are shown 
graphically in figure 5.14.  
 
 
 
Figure 5.33: Infection of HEK.hCCR7 cells with CCL19 shrouded Ad5.hTR.Luc. HEK293 and 
HEK.hCCR77 cells were incubated with Ad5.hTR.Luc with (+CCL19) or without  (-CCL19) 
shrouding with CCL19 at 6.6 x104 ifu/well. After 48 hours infection of cells was assessed using the 
Promega luciferase assay kit. Each bar represents analysis of three samples containing the same 
cells and viral vectors, with the error bars representing the SEM. This experiment was performed 
once. 
 
5.7 Assessment of NeutrAvidinTM binding to adenovirus using electron 
microscopy.  
As discussed previously, one potential reason for the degree of background infection seen 
in these experiments is incomplete binding of the NeutrAvidinTM to the viral knob proteins. 
Each adenovirus has 12 viral knobs to which one molecule of the NeutrAvidinTM can 
attach, and each molecule of NeutrAvidinTM will bind one molecule of biotin. To 
investigate the possibility of incomplete binding, electron microscopy was employed. By 
using biotin-gold, conjugation could be visualised using electron microscopy for detection 
of the gold particles. Any biotin-gold binding to NeutrAvidinTM conjugated to the viral 
knob protein would then be readily visualised and the degree of viral shrouding assessed. 
‘Cribs’ for electron microscopy were prepared as discussed in section 2.2.6.8, in which 
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adenovirus, that had undergone NeutrAvidinTM conjugation, was settled onto the ‘cribs’ 
followed by the addition of biotin-gold. Adenovirus that had not undergone conjugation 
with NeutrAvidinTM was used as a negative control. The images obtained from the negative 
controls are shown in figure 5.15.  
 
 The images in figure 5.16 represent those viral particles that had undergone incubation 
with NeutrAvidinTM. If the chemical conjugation had been 100% successful, then there 
should be 12 gold particles visible per virus, however, as can be seen, only a small 
proportion of the viral knob proteins appear to have been shrouded by the NeutrAvidinTM 
with only a few gold particles seen per virus. This strengthens the hypothesis postulated 
earlier that incomplete conjugation of the virus with NeutrAvidinTM and by extension 
incomplete shrouding with CCL19 or CCL3, was responsible, at least in part, for the high 
degree of background adenoviral infection observed in previous experiments. 
 
However, despite this, overall the experiments show a significant increase in CCR7 and 
CCR5 dependent infection rates with only this partial degree of shrouding, and so if a more 
efficient way of shrouding the virus could be found then redirection of the adenoviral 
tropism through the chemokine receptors should be even more efficient. The rest of this 
chapter describes the way in which this could potentially be achieved. 
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x 8000                                                         x 25000 
Figure 5.34: Electron micrograph of non-labelled adenovirus. Adenoviral particles were 
prepared for electron microscopy using ‘cribs’ as described in section 2.2.6.8. Images were taken 
at x8000 and x25000 magnifications. 
 
    
x 12500                                                         x12500 
Figure 5.35: Ad5.CMV.LacZ-NeutrAvidinTM conjugates incubated with biotin gold.  
Ad5.CMV.LacZ-NeutrAvidinTM conjugates were incubated with biotin-gold, following which the virus 
was prepared for electron microscopy as described in 2.2.6.8. Images were taken at x12500 
magnification. Gold particles can be seen as black dots on the image as indicated by the red 
arrows indicating that only a small proportion of the adenoviral fibre knobs have bound to 
NeutrAvidinTM. If all viral knob proteins had been conjugated with NeutrAvidinTM then 12 gold 
particles per viral particle would be observed. 
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5.8 Modification of the adenoviral knob protein 
As mentioned above more efficient shrouding of the adenovirus with the chemokine is 
required to diminish the background infection. One strategy is to increase the degree of 
NeutrAvidinTM binding by enhancing biotinylation of the adenovirus. Acceptor peptides 
(AP) are small 15 amino acid peptides that are biotinylated by the Escherichia coli enzyme 
biotin ligase [325]. Biotin ligase has previously been used to successfully biotinylate AP 
tagged proteins in-vitro [354]. This being the case it was thought that if this AP could be 
incorporated into the viral knob, then this would allow for more efficient shrouding of the 
virus via biotinylation. One potential problem with this is that incorporation of a peptide 
into the viral knob may affect its function and the ability of the adenovirus to be 
endocytosed by the cell. However, it has been shown that peptides up to 40 amino acids 
long can be incorporated into the viral knob protein without significantly affecting its 
ability to infect cells via the CAR receptor and endocytosis [354]. So it was thought that 
the above approach would be feasible. The steps taken to incorporate the AP into the viral 
knob protein are described in the following sections and the approach is showed 
diagrammatically in figure 5.17. 
 
 
 
Figure 5.36: Strategy to improve efficiency of adenovirus shrouding with chemokines. The 
acceptor peptide can be biotinylated by the enzyme biotin ligase [331]. By inserting the acceptor 
peptide into the fibre knob protein biotinylation of the virus could be achieved and thus more 
efficient conjugation with NeutrAvidinTM. This would result in improved shrouding of the virus with 
chemokine and potentially enhance adenoviral infection through the chemokine receptor. 
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5.8.1 Construction of a Vector for Homologous Recombination with the 
pAdEasy Vector 
The most effective way of incorporating genes into the adenoviral vector is through a 
system of homologous recombination. The AdEasyTM Adenoviral system from Stratagene 
was employed for this purpose. The diagram in figure 5.18, below, demonstrates how this 
system works; essentially a vector containing the gene of interest is engineered with 2 
flanking sequences homologous to the adenovirus sequence in which the gene is to be 
inserted. The vector also contains a gene to allow for selection, such as the kanamycin 
resistance gene, flanked by unique restriction enzyme sites to allow removal of this gene at 
the final stages.  
 
 
 
 
 
 
 
 
Michelle Bryson, 2010                            CHAPTER FIVE                                         RESULTS 
 190 
 
Figure 5.37: Homologous recombination using the Stratagene AdEasyTM Adenoviral System. 
In order to engineer an adenoviral vector containing the acceptor peptide a system of homologous 
recombination was attempted. However, in place of the shuttle vector detailed in the above 
diagram, a vector containing 2 arms homologous to the adenoviral fibre knob protein gene 
sequence was engineered containing the acceptor peptide and a unique Xba1 site (see figure 
5.21). Figure taken from the Stratagene AdEasyTM Adenoviral System manual. 
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The ultimate aim of this part of the project was to insert the acceptor peptide sequence onto 
the end of the viral fibre knob, and the intended vector for development is shown in figure 
5.19. The first step was to design primers to obtain two 1kbp fragments of the adenovirus 
sequence using RT-PCR described in section 2.2.4.3.1, on either side of the end of the 
sequence of the viral knob protein, the first fragment contained the last 1kbp of the fibre 
knob protein sequence, with the second fragment containing 1kbp immediately 
downstream of the fibre knob protein sequence. These fragments were used initially as a 
template to engineer the vector construct to incorporate the acceptor peptide sequence and 
subsequently, they would provide regions for homologous recombination enabling the 
insertion of the acceptor peptide into the fibre knob protein sequence. Once these 
fragments had been obtained they were used as the template for overlapping-extension 
PCR, as in section 2.2.4.3.2 and figure 5.20 to introduce both the acceptor peptide 
sequence, and a unique Xba1 restriction enzyme site, onto the end of the sequence for the 
viral knob. Xba1 was chosen as examination of the pAdEasy vector sequence did not 
demonstrate the presence of any Xba1 sites, and this could then be used as a surrogate 
restriction marker for confirmation of insertion of the acceptor peptide sequence. The 
primers used for this are outlined in 2.1.7.2 of the methods section. The sequence for the 
acceptor peptide itself is shown below. 
 
GGC CTG AAC GAC ATC TTC GAG GCC CAG AAG ATC GAG TGG CAC GAG TGA 
Gly    Leu   Asn   Asp   Ile     Phe   Glu   Ala   Gln   Lys    Ile     Glu    Trp   His    Glu    Stop 
 
The insertion of the acceptor peptide sequence and Xba1 site onto the end of the fibre knob 
protein sequence was successfully achieved as demonstrated by figure 5.21. This figure 
shows the 2kb (lane 1) product obtained by overlap-extension PCR, which was then 
digested with Xba1, showing that 1kb fragments are obtained and indicating successful 
incorporation of the acceptor peptide sequence.  
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Figure 5.38: Map of adenoviral vector containing the acceptor peptide. Note the positioning of 
the acceptor peptide at the end of the fibre knob protein sequence, followed by the unique Xba1 
site. 
 
 
 
 
 
 
 
 
Michelle Bryson, 2010                            CHAPTER FIVE                                         RESULTS 
 193 
 
Figure 5.39: Overlap extension PCR.  Step 1: 2 fragments of DNA (template DNA) are amplified 
incorporating the gene sequence into which the acceptor peptide and Xba1 sequences are to be 
inserted. Flanking primers and extension primers (containing the acceptor peptide and Xba1 
sequences as well as areas homologous to the template DNA) and PCR is set up as in section 
2.2.4.3.2. Step 2: The extension primers add the sequence to be inserted onto the ends of the 
template DNA during the early stages of PCR. Step 3: The flanking primers enable amplification of 
the entire construct consisting of the two DNA template fragments, acceptor peptide and Xba1 site. 
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Figure 5.40: Xba1 digest of overlap extension PCR product. Two 1kbp fragments consisting of 
a) last 1kbp of adenoviral fibre knob protein sequence and b) 1kpb immediately downstream of 
fibre knob protein sequence, were used in overlap extension PCR overlap with flanking primers 
and primers containing the sequence for the acceptor peptide and a Xba1 site (see figure 5.20). To 
confirm that the 2kbp product (lane 1) obtained contained the acceptor peptide sequence an Xba1 
digest was done on the PCR product and then run on a 1% agarose gel containing ethidium 
bromide. The gel image above confirms the successful incorporation of the acceptor peptide onto 
the end of the fibre knob protein sequence with 1kbp fragments (lane 2) obtained after Xba1 digest. 
 
This 2kb product was then inserted into the pCR2.1 TOPO vectors as described in 2.2.4.8, 
and the resulting vector (now termed pCR2.1.Ad5.AP shown in figure 5.22a) was sent for 
sequencing to ensure that the acceptor peptide sequence was in the correct place. In the 
meantime pBluescript vector was used to obtain the tetracycline sequence flanked by two 
Xba1 sites. The plan was to insert the tetracycline sequence into the Xba1 site at the end of 
the acceptor peptide sequence of the pCR2.1.Ad5.AP using simple ligation techniques as 
described in 2.2.4.10. However, after digesting with Xba1, no fragments were seen with 
the pCR2.1.Ad5.AP suggesting that ligation was unsuccessful or that the Xba1 digestion 
was not working.  
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a) b)  
Figure 5.41: Vectors created for homologous recombination with pAdEasy. Both vectors 
incorporate the acceptor peptide and an Xba1 site at the end of the fibre knob protein sequence a) 
pCR2.1.Ad5.AP without tetracycline selectable marker b) pCR2.1.Ad5.AP.Tet with a tetracycline 
selectable marker. 
 
Consequently, the sequence surrounding the Xba1 site was examined more carefully, and it 
was discovered that the primer developed to incorporate the acceptor peptide contained a 
methylation site encompassing the Xba1 site. DNA adenine methyltransferase (DAM) is a 
bacterial enzyme that recognises and subsequently methylates the sequence 5′GATC 3′, 
which if incorporated or partially incorporated into a restriction enzyme site, renders it 
resistant to cleavage. Therefore, as it appeared the digestion was not working because of 
methylation, a DAM negative strain of E.coli was identified and the pCR2.1.Ad5.AP 
vector was transformed using the DAM- ER2925 E.coli strain from NEB. The vectors 
produced in this way were then digested with Xba1 successfully as the Xba1 site was no 
longer methylated. Yet, before proceeding with the ligation of the tetracycline sequence, 
another problem had to be addressed. The pCR2.1 TOPO vector also contains an Xba1 site 
downstream of the Ad5.AP insertion, therefore a simple Xba1 digest would lead to the 
removal of the 2nd flanking arm of the Ad5 sequence (see figure 5.22a and b). To 
counteract this problem a partial digest was performed as in section 2.2.4.6 and the 2kb 
fragment was identified and gel purified prior to ligation with the tetracycline gene 
sequence to produce the vector termed pCR2.1.Ad5.AP.TET (figure 5.22b). The 
tetracycline gene was used as a selectable marker to ensure that colonies obtained 
following tetracycline exposure contained the construct of interest. These colonies were 
then analysed using digestion with BamH1 to identify a 4kb and a 2kb product indicating 
successful ligation. The flanking primers initially used to obtain the 2kb viral fragment 
were then used on potential colonies to detect the correct size insert of the Ad5.AP and 
tetracycline gene combined. This gave the expected 3.6kb fragment size, which also 
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demonstrated the correct band sizes with Xba1 digest (Figure 5.23) and this was then sent 
for sequencing. Sequencing confirmed the correct placement of the AP and tetracycline 
genes within the construct. This construct is termed pCR2.1.Ad5.AP.Tet shown in figure 
5.22b. The vector was then propagated by transformation into ER2925 E.coli and 
subsequent plasmid DNA preparation as described in section 2.2.4.16. The DNA 
concentration of the vector was then quantified using spectrophotometry to measure optical 
absorbance at 260 and 280nm.  
 
 
Figure 5.42: Xba1 digest on RT-PCR product from pCR2.1.Ad5.AP.Tet construct. To confirm 
that the pCR2.1.Ad5.AP.Tet construct contained the acceptor peptide gene sequence and the 
tetracycline resistance gene at the correct site, the adenovirus flanking primers were used to 
amplify the sequence of interest using the PCR programme outlined in 2.2.4.3. The resulting 
product was 3.6kb as predicted a digest with Xba1 produced 2 fragments consisting of the 1.6kb 
tetracycline resistance gene and the 1kb adenovirus gene segments. 
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5.8.2 Homologous Recombination with pAdEasy and 
pCR2.1.Ad5.AP.Tet. 
The method outlined in the Stratagene pAdEasy Adenoviral System manual was followed 
in order to engineer an adenoviral vector placing the sequence for the AP at the end of the 
fibre knob protein using the construct created in section 5.8.1. Essentially, 2µg of 
pCR2.1.Ad5.AP.Tet was linearised using Not1 and run on an agarose gel. This was gel 
purified and then dephosphorylated, and again gel purified prior to final DNA 
quantification using spectrometry. The concentration was then adjusted to 1µg/µl. 1µl each 
of the linearised plasmid and the pAdEasy vector were then added to 40µl of BJ5183 cells 
in an electroporation cuvette (0.2cm) and electroporated at 200Ω, 2.5Kv and 25µF. One ml 
of LB broth was then added and the cells transferred to a 14ml Falcon tube for 
transformation. They were plated onto tetracycline containing plates. DNA from the 
colonies obtained was then prepared using the modified DNA preparation protocol as 
described in methods section 2.2.4.16. The DNA samples were then analysed by restriction 
enzyme mapping using Asc1 and HindIII to confirm homologous recombination. However 
the expected fragment sizes were not seen despite repeated electroporation and selection of 
numerous colonies. To investigate this further, the pAdEasy vector sequence was 
examined in more detail; it unfortunately transpired that the origin of replication (ori) 
sequence of the pAdEasy vector actually contained a large portion of the tetracycline 
resistance gene.  
 
To determine whether this portion of the tetracycline resistance gene was sufficient to 
confer resistance to cells transfected with the pAdEasy vector, the vector was transformed 
into BJ5183 cells and plated onto agar plates containing tetracycline.  Colonies were able 
to grow, confirming that the pAdEasy vector provided tetracycline resistance to transfected 
cells. It was as therefore concluded that firstly, tetracycline could not be used as a 
selectable marker and that secondly one reason for the unexpected restriction enzyme maps 
was that potentially random recombination events were occurring between the ori 
sequence and the Ad5.AP.Tet construct. Therefore an alternative strategy was required. 
5.8.3 Development of pCR2.1.Ad5.AP.Kan 
Now that it was clear that tetracycline could not be used as a selectable marker an 
alternative was sought. Kanamycin was subsequently chosen as a selectable marker for 
insertion into the constructs used to incorporate the AP into the fibre knob protein as, 
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examination of the pAdEasy vector did not reveal any sequence homologous to that of the 
kanamycin resistance gene, and so random recombination events were unlikely to result.  
 
As the pCR2.1.Ad5.AP vector had already been constructed the insertion of the kanamycin 
gene was relatively straightforward. A pBlueScript vector containing the kanamycin 
resistance gene sequence flanked by Xba1 sites had been developed previously in the 
laboratory. The kanamycin gene sequence was therefore digested using Xba1 and ligated 
into the Xba1 partial digest product of pCR2.1.Ad5.AP and transformed using DAM- 
E.coli as previously described. RT-PCR using the flanking primers was then used to screen 
the colonies as before. A 4.3kb fragment was obtained indicating successful insertion of 
the kanamycin resistance sequence into pCR2.1.Ad5.AP. Analysis by restriction enzyme 
mapping was also performed using EcoR1 to give the predicted 1, 3.3 and 3.9kbp 
fragments and an Xba1 digest giving 2.3kbp and 1kbp fragments. The size of the 
kanamycin resistance sequence is 2.3kb. Analysis demonstrated the correct sizes and the 
resulting vector termed pCR2.1.Ad5.AP.Kan shown in figure 5.23, was then ready for use 
in homologous recombination. 
 
 
Figure 5.43: Vector map of pCR2.1.Ad5.AP.Kan. This replaced pCR2.1.Ad5.AP.Tet for attempts 
at homologous recombination with pAdEasy to introduce the acceptor peptide sequence onto the 
end of the adenoviral fibre knob protein sequence.  Examination of the pAdEasy sequence did not 
reveal any areas homologous to any part of the kanamycin gene sequence. 
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5.8.4 Homologous Recombination with pAdEasy and 
pCR2.1.Ad5.AP.Kan 
The method, as outlined above, was used for homologous recombination but using Sca1 to 
linearise the plasmid rather than Not1. After transformation the preparations were spread 
onto agar plates containing both ampicillin and kanamycin to select for colonies containing 
the insert and the pAdEasy vector. Analysis of the resulting colonies with restriction 
enzyme mapping using EcoR1 would have been expected to yield fragments of the 
following sizes: 
 
1238bp, 7637bp, 4546bp, 2052bp, 2623bp, 4880bp, 1011bp, 11544bp. 
 
However, this map was not obtained. The colonies obtained were also screened using the 
flanking primers as before, but no PCR products were obtained. The electroporation was 
subsequently repeated using the 4.3kb PCR product obtained when using the flanking 
primers on the pCR2.1.Ad5.AP.kan vectors. These products would consist solely of the 
construct with 2 homologous arms separated by the Acceptor peptide sequence, the Xba1 
sites and the kanamycin resistance gene. By using these products it was hoped that any 
unexpected recombination events with other areas of the pCR2.1 vector, in particular the 
other kanamycin resistance gene cassette, would not occur. However, again, no suitable 
colonies were obtained and restriction enzyme mapping revealed unexpected fragment 
sizes. It was thought that it was possible that, recombination events between the newly 
formed vectors continued, and that this explained the unexpected results. Therefore an 
alternative strategy was again required. 
 
5.8.5 Sub-cloning to obtain pAdEasy.AP 
This method involves a series of restriction enzyme digests followed by ligation to obtain 
the vector construct. The first step was to identify unique restriction enzyme sites within 
the pAdEasy vector, which would enable a fragment incorporating the entire homologous 
region used in the pCR2.1.Ad5.AP vector to be inserted. Pac1 and Spe1 sites were 
identified which after a double digest with these enzymes produced a fragment of 6.8kb in 
size incorporating the entire homologous region. The next step was to design an 
oligonucleotide incorporating the sequence for these restriction enzyme sites as a linker 
and to ligate this into a pBlueScript KSII vector as detailed in methods sections 2.2.4.9 and 
10.  The oligonucleotide used for this was as follows: 
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CGC/G/ACTAGT/CATGC/TTAATTAA/C 
 
Once the linker had been successfully incorporated into the pBlueScriptKSII vector, the 
Pac1/Spe1 fragment from the pAdEasy vector was ligated into this giving a 
pBluescript.Spe1.Pac1.Frag vector. Two unique restriction enzyme sites (Kpn1 and Apa1) 
were then identified in the Ad5 homologous regions contained within the 
pCR2.1.Ad5.AP.Kan vector (see figure 5.25). The fragment resulting from digestion with 
these two enzymes was ligated into the pBlueScript.Spe1.Pac1.Frag which had also 
undergone digestion with Kpn1 and Apa1, thereby incorporating the acceptor peptide, 
Xba1 site and kanamycin resistance gene into the 6.8kb pAdEasy fragment at the correct 
site. Once this had been achieved, the resulting vector, pBluescript.Spe1.Pac1.Frag.AP, 
was created. This vector and the pAdEasy vector were then digested with Spe1 and Pac1, 
and the new fragment containing the acceptor peptide, Xba1 site and kanamycin gene 
resistance sequence was then ligated into pAdEasy. The final step had to be repeated a 
number of times.  However eventually the final ligation resulted in colonies producing two 
constructs of the correct size, which were candidates for further analysis. The DNA 
preparation demonstrating these 2 colonies is shown in figure 5.26.  
a) b)  
Figure 5.44: Vector maps of pCR2.1.Ad5.AP.Kan and pBL.Ad5.AP.Kan. These demonstrate 
the Apa1 and Kpn1 sites in pCR2.1.Ad5.AP.Kan and the Apa1, Kpn1, Spe1 and Pac1 sites in 
pBluescript.Ad5.AP.Kan used for the subcloning strategy employed to engineer pAdEasy.AP. 
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Figure 5.45: DNA preparation of ligation with pAdEasy and pBluescript.Spe1.Pac1.Frag.AP 
fragments. The final step in the subcloning strategy was to ligate Spe1/Pac1 digests of pAdEasy 
with Spe1/Pac1 digest of pBluescript.Spe1.Pac1.Frag.AP to create pAdEasy.AP. This ligation was 
then transformed as in 2.2.4.13 following which mini-preparations of plasmid DNA (see 2.2.4.16) 
were prepared. These DNA preparations were then run on a 1% agarose gel with ethidium 
bromide. Two plasmid preparations were identified as potentially representing pAdEasy.AP these 
are highlighted in orange. 
 
These colonies were then further analysed by using the original adenovirus flanking 
primers to obtain a PCR product 4.3kb in size, consistent with the 2 homologous Ad5 
regions and the kanamycin resistance gene. This was then digested with Xba1 to confirm 
that an Xba1 site was present along with the kanamycin resistance gene in the pAdEasy 
vector. This yielded the expected fragment sizes of 2.3kb corresponding to the kanamycin 
resistance sequence and 1kb fragments corresponding to the homologous arms used 
initially. This is shown in figure 5.27. The construct, pAdEasy.AP, was then sent for 
sequencing, which confirmed the correct sequence of the acceptor peptide, Xba1 site and 
surrounding adenovirus sequence. 
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Figure 5.46: Xba1 digest on RT-PCR product from pAdEasy.AP construct. The adenovirus 
flanking primers were added to the DNA preparation obtained in figure 5.26, in order to amplify the 
construct containing the acceptor peptide sequence. A 2kbp PCR product was obtained which was 
then digested with Xba1. This resulted in a 1kbp product confirming the presence of an Xba1 and 
therefore the acceptor peptide sequence. This was later confirmed by sequencing. 
 
5.9 Incorporation of a reporter gene into pAdEasy.AP 
The pAdEasy.AP construct would be capable of producing virions following transfection 
into HEK.293 cells, however subsequent infection experiments would require the 
expression of a reporter gene to enable assessment of infection. Therefore, the 
pAdEasy.AP vector was used to develop to two additional vectors, one with LacZ and the 
other with GFP as reporter genes. This was simply achieved by using the pAdEasy 
Adenoviral system and the pShuttle vectors commercially available for use with the system 
as shown in figure 5.28. Basically, the vectors pShuttle.CMV.LacZ and 
pShuttle.CMV.IRES.GFP obtained from Stratagene were used as described in 5.8.2, to 
attempt homologous recombination with pAdEasy.AP. In both cases this was successful 
and the vectors pAdEasy.AP.GFP and pAdEasy.AP.LacZ were produced. Once these 
vectors had been produced, the plan was to transfect these into HEK.293 cells in order to 
produce  adenoviral particles containing the acceptor peptide at the end of the fibre knob 
protein. However this was not possible because of time constraints. 
 
Once produced, these vectors would be biotinylated using biotin ligase, followed by 
incubation with NeutrAvidinTM. The first step would then be to study the efficiency of 
conjugation with NeutrAvidinTM by electron microscopy study as described in section 5.7. 
If improved NeutrAvidinTM conjugation was confirmed, this would be followed by 
repeating the infection experiments outlined in this chapter with chemokine ‘shrouded’ 
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adenovirus to assess firstly, the degree of infection obtained in the chemokine receptor 
positive cells, and secondly whether or not the background level of infection had been 
reduced.  
 
Subsequently, these adenoviral vectors would be modified further to contain cytolytic 
genes such as thymidine kinase in order to study targeted oncolytic strategies. 
 
A B  
 
Figure 5.47: Vector maps of pAdEasy.AP.GFP and pAdEasy.AP.LacZ. These would be used to 
transfect HEK293 cells in order to produce adenoviral particles for, further infection experiments 
following biotinylation and shrouding with chemokine. 
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5.10 Summary 
This chapter has demonstrated the following: 
1. Adenoviral tropism can be re-directed through chemokine receptors, using simple 
biochemical shrouding of the virus with NeutrAvidinTM and biotinylated 
chemokines in CHO and HEK.293 cells that have been transfected in order to 
express CCR5 and CCR7. 
 
2. In HEK.293 cells there is a high degree of background staining. One reason for this 
is incomplete shrouding of the adenovirus using the biochemical method. This was 
demonstrated using electron microscopy. It is also possible however, that some of 
the background staining was due to entry of the adenovirus using alpha integrins on 
the cell surface. 
 
 
3. Optimisation experiments enabled a more efficient infection rate demonstrating 
optimum infection rates at an incubation time of 4 hours with the NeutrAvidinTM at 
a concentration of 0.75mg/ml. 
 
4. Infection of Raji cells, which were shown to endogenously express CCR7, resulted 
in preferential infection with the CCL19 ‘shrouded’ adenovirus, again 
demonstrating that adenoviral tropism could be re-directed through chemokine 
receptors. 
 
5. Further optimisation of this system was sought by introducing an acceptor peptide 
into the fibre knob protein sequence of the adenovirus. This should enable more 
efficient shrouding of the adenovirus by effectively biotinylating the virus using 
biotin ligase.  
 
6. Vectors consisting of pAdEasy with the acceptor peptide, and either the LacZ or 
GFP reporter gene were created, but unfortunately time constraints prevented the 
final translation of these into adenovirus particles. 
 
   
 
 
CHAPTER SIX 
EL4 CELLS AS AN IN-VIVO NON-HODGKIN’S 
LYMPHOMA MOUSE MODEL 
6.1 Introduction 
The development of an in-vivo model is an integral step in the development of targeted 
therapies for lymphoma. The next aim of this project was to develop a lymphoma mouse 
model for in-vivo studies to assess whether or not the cytotoxic therapies developed 
affected the targeted, chemokine receptor expressing, cell populations without causing 
non-specific toxicity to other tissues and cell populations. To do this a cell line was looked 
for which could establish easily measurable tumour bulk in mice, without lethality, so that 
any response to the targeted therapy could be objectively measured. EL4 cells were 
identified as potentially fulfilling this role.  
 
EL4 cells are an ascitic T-cell lymphoma cell line derived from the C57/BL6 mouse 
following inoculation with 9:10 dimethyl-1:2 benzanthracene [354]. Injection of 1 x105 
cells into the flank of a C57/BL6 mouse has been noted to lead to the development of a 
measurable tumour in 7-10 days, whilst injection of 1 x106 cells lead to measurable tumour 
development with metastasis [355]. As well as fulfilling the requirement of being able to 
induce measurable tumours, these cells had the advantage of being developed in a standard 
strain, C57/BL6 of laboratory mice. EL4 cells have been used extensively over the years in 
a variety of studies, and are therefore readily available and well characterised. For these 
reasons EL4 cells were chosen as a potential in-vivo mouse model for the adenovirus 
infection experiments and subsequent targeting of lymphoma cells.  
 
However, before proceeding with in-vivo studies further characterisation of the cell line 
was required, in particular its expression of CCR7, and this will be outlined in this chapter 
along with early in-vivo adenovirus infection experiments. 
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6.2 Assessment of mCCR7 Expression in EL4 Cells 
The first step in characterising the EL4 cells was to determine whether or not they 
expressed CCR7. This was done in two ways. 
6.2.1 Assessment of Murine CCR7 Expression by RT-PCR 
Primers were developed for the detection of murine CCR7 (mCCR7) and are shown in 
section 2.1.7.2 of the methods section. RT-PCR was performed with these primers, using 
the primers for mouse actin as a positive control. The results are shown in figure 6.1, and 
demonstrate that mCCR7 is expressed at the RNA level in EL4 cells.  
 
 
 
Figure 6.1: mCCR7 expression in EL4 cells. RNA was prepared from EL4 cells these were 
DNAase treated and cDNA was prepared using +/- reverse transcriptase. Primers for actin and 
mCCR7 were used to amplify cDNA using the PCR programme in 2.2.4.3. PCR products were then 
run on a 1% agarose gel containing ethidium bromide.  
 
 
6.2.2 Assessment of mCCR7 Expression in EL4 cells using Flow 
Cytometry  
An anti-mCCR7 antibody from AbCam with, and without, conjugation with FITC were 
used for the experiments assessing mCCR7 expression.  Initially, the unconjugated 
antibody was incubated with the EL4 cells and subsequently incubated with a secondary 
antibody conjugated with PE, as previously described. Following this, flow cytometry was 
used to assess the expression of mCCR7 on the surface of EL4 cells. In figure 6.2 it can be 
seen that the EL4 cells express mCCR7 at the protein level as demonstrated by an increase 
MFI on flow cytometry. 
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Figure 6.2: Surface mCCR7 expression in EL4 cells. EL4 cells were incubated with anti-CCR7 
antibody followed by incubation with a secondary antibody conjugated with PE. EL4 cells incubated 
with PBS or secondary antibody alone were used as negative controls. Analysis of surface mCCR7 
was performed using single colour flow cytometry. Each bar represents 3 test samples and the 
error bars show the SEM.  
 
6.3 Assessment of functional mCCR7 expression EL4 cells 
Having confirmed that EL4 cells express mCCR7, it was important to ensure that this 
expressed receptor was functional. As with the Raji cell line, this was done in 2 ways.  
6.3.1 Biotin-CCL19 Uptake by EL4 Cells 
The method described in 2.2.5.2 was used again for this cell line.  Only one negative 
control was possible as these cells had been shown to express mCCR7. This control was 
streptavidin-PE with PBS, but without the CCL19. The results are shown in figure 6.3a and 
b. In figure 6.3a, the green line representing the EL4 cells exposed to biotin-CCL19 shows 
a clear shift to the right along the FL2-H gate, when compared to the cells that were not 
exposed (purple peak), thus demonstrating that the EL4 cells had bound the biotin-CCL19. 
This is shown quantitatively in figure 6.3b, in which the uptake of biotin-CCL19 by the 
EL4 cells is shown by the high MFI of those cells incubated with biotin-CCL19 (mean 
MFI: 1125 ± 205.2) compared to those that were not (mean MFI: 7.14 ± 0.43). These 
results not only show that EL4 cells bind to, and potentially internalise, biotin-CCL19, but 
that they do so at a higher level than seen previously with the HEK.hCCR7 or the 
endogenously hCCR7 expressing Raji cells.  
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a)  
b)  
Figure 6.3: Biotin-CCL19 uptake by EL4 cells. Cells were incubated with biotin-CCL19 and 
streptavidin-PE or streptavidin-alone, for 1hr at 37oC. Following this biotin-CCL19 uptake by the 
cells was analysed using single-colour flow cytometry. a) Overlay histogram plot comparing EL4 
cells incubated with biotin-CCL19 (green peak) or streptavidin-PE alone (purple peak) b) Graph 
showing a significant difference in mean fluorescent intensity between EL4 cells incubated with or 
without biotin-CCL19, the population used to calculate the MFI for the positive cells is 
demonstrated by the arrowed marker in a). Each sample was repeated in triplicate and on three 
occasions. The error bars indicate the SEM. 
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6.3.2 Chemotaxis Assay with EL4 Cells using CCL19 
Whilst it is clear that EL4 cells are able to bind to CCL19, as previously discussed in 
chapter 4, it could not be assumed that this leads to intra-cellular signalling, as the atypical 
receptor CCX-CKR can also bind to and internalise CCL19. Therefore, the Transwell® 
chemotaxis assays (methods section 2.2.5.5.1) were performed as discussed in section 
4.4.2.1. CCL19 and CXCL12 were again used the latter acting as a positive control. The 
results of this are shown in figure 6.4. They clearly show that chemotaxis was induced in 
EL4 cells in the presence of CCL19, with a tailing off of response with the higher CCL19 
concentration of 100nM. The peak CXCL12 concentration inducing chemotaxis is not 
deducible from these results, although there is significantly more chemotaxis in response to 
CXCL12 at 100nM than with CCL19 at the same concentration (p=0.0229). However, 
although these results confirmed that the mCCR7 was functional, the degree of chemotaxis 
was less than would have been expected considering the high degree of biotin-CCL19 
binding. When comparing the migration indexes obtained with Raji and EL4 cells, the 
former had a tenfold higher rate of migration. The most likely explanation for this 
discrepancy will be discussed later in this chapter.  
 
 
Figure 6.4: Migration of EL4 cells in response to CCL19 and CXCL12. Chemotaxis buffer 
containing different concentrations of CCL19 or CXCL12 was added to each well of a Transwell® 
plate. Inserts were added, and into each of these EL4 cells were placed. Following incubation at 
37oC for 3 hours, the number of EL4 cells passing through the chemotaxis chamber. A migration 
index was calculated as outlined in section 4.3.2.1. A migration index of greater than 1 indicates 
that chemotaxis has occurred. Analysis at each chemokine concentration was performed in 
triplicate and the error bars represent the SEM. This experiment was performed once only. 
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6.4 Adenoviral Infection of EL4 Cells 
Despite the low level of chemotaxis induced in the EL4 cells, the decision was made to 
examine redirection of the adenovirus through CCR7 in EL4 cells and subsequent 
infection. However, before proceeding with this, RT-PCR was performed looking at the 
expression of the CAR receptor and alphaV-integrins in EL4 cells. This was done in order 
to assess the likelihood of significant background infection in these cells as adenovirus 
enters cells predominantly through binding with CAR although it can enter cells using αv-
integrins alone (although at a much lower rate. Figure 6.5 clearly demonstrates the absence 
of detectable RNA for these proteins both CAR and αv-integrins. The question arises, 
looking at the figure, as to whether or not the primers for CAR and αV-integrins were 
working, however repeat RT-PCR showed consistent results and, as will be demonstrated 
later in this chapter, the same primers confirmed the presence of these transcripts in a range 
of mouse tissues. The lack of CAR and αV-integrin expression provided further 
confirmation that EL4 cells were an ideal cell line to further optimise successful 
chemokine dependent redirection of adenoviral tropism through CCR7 as background 
infection rates were likley to be low. 
 
 
 
Figure 6.5: CAR and αv-integrin expression in EL4 cells.  RNA was prepared from EL4 cells 
these were DNAase treated and cDNA was prepared using +/- reverse transcriptase. Primers for 
actin, CAR and αv-integrin and were used to amplify cDNA using the PCR programme in 2.2.4.3. 
PCR products were then run on a 1% agarose gel containing ethidium bromide.  
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6.4.1 Initial Infection Experiments with Chemically shrouded 
Adenovirus. 
The EL4 cells were incubated with CCL19 shrouded adenovirus as previously described 
with Raji cells in section 5.6. The cells were incubated for 48 hours and then assessed for 
the rate of infection using β-galactosidase detection. Unfortunately, no infection was 
detected in any of the EL4 cells despite repeated attempts with longer incubation times and 
with an increased MOI of 2 ifu/cell. At this point it was thought that this could be due to 
one of three reasons. Firstly, if the adenovirus was getting into the cells, was there a 
problem with the transduced expression of LacZ? There has been some suggestion that the 
CMV promoter is less efficient in malignant cell lines and haematopoietic cells and that an 
alternative such as elongation factor 1α (EF1α) may improve the efficiency of gene 
expression [356](Teschendorf, 2002). Secondly, although mCCR7 expression had been 
detected, was the surface expression too low to enable sufficient uptake of the virus and to 
enable LacZ expression? However, it should be borne in mind that only one viral particle is 
needed to enter the cell and lead to transfection, and here a MOI of 2 ifu/cell was used in 
EL4 infection experiments. Finally, was there some other mechanism by which 
transfection was being affected? All of these issues were investigated. 
 
6.4.2 Alternate Methods of Detecting Adenoviral Infection 
6.4.2.1 Determination of the Optimum Anti-hexon Antibody 
Concentration 
To determine whether or not the cells were infected by the adenovirus, an alternative 
method of infection was sought. In this case adenoviral antibodies were employed.  An 
anti-hexon antibody was chosen that could be used in flow cytometry analysis.  However, 
before this antibody could be used it was necessary to optimise its use with a cell line 
which is readily infected by the virus.  For this purpose the HEK293 cell line was used.  
The cells were infected with adenovirus as previously described in method section 2.2.6.4 
using different quantities of adenovirus so that a variety of adenoviral infection rates could 
be assessed using this method. Following 48 hours incubation the HEK293 cells were 
counted and 2.5 x105 cells were transferred to a microcentrifuge tube. These cells were 
incubated with anti-hexon antibody at different concentrations followed by incubation with 
a secondary antibody at the same concentration for each sample (the secondary antibody 
used here was a rat anti-mouse IgG conjugated to PE at a concentration of 1:250).  
Following this, single-colour flow cytometry was performed and the results assessed.  
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These results are shown in figure 6.6 below.  They demonstrate that the optimum 
concentration of the anti-hexon antibody was 1:100 when analysed with cells incubated 
with an initial viral titre of 3.5 x 107ifu/ml, although detection of adenoviral infection at 
lower starting viral titres was less clear in discriminating between anti-hexon-body 
concentrations. From this point on an anti-hexon antibody concentration of 1:100 was used 
in experiments. 
 
 
Figure 6.6: Determination of anti-hexon antibody concentrations for use in adenoviral 
experiments. HEK293 cells were infected with different quantities of Ad5.CMV.LacZ as shown 
above and incubated for 48 hours. Each sample was repeated in triplicate. The cells were then 
washed and incubated with anti-hexon antibody at different concentrations, following which they 
were incubated with a secondary antibody conjugated with PE. The cells were then assessed by 
single colour flow cytometry to determine the optimum anti-hexon antibody concentration. In this 
case this was an antibody concentration of 1:100 was identified as giving the best results, which 
was used for subsequent infection experiments. 
 
 
6.4.4.2 Detection of Adenoviral Infection in EL4 Cells using Flow 
Cytometry 
The EL4 cells were incubated with the CCR19 shrouded adenovirus as previously 
described.  Following incubation, the cells were incubated with the anti-hexon antibody 
and secondary antibody-PE and analysed by flow cytometry.  Again, no discernible 
infection was noted and therefore further investigation as to the cause of this was initiated 
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6.5 Effect of Increasing mCCR7 Expression on the rate of Infection 
As no infection was detected using the flow cytometry method, it was felt that the problem 
was potentially due to insufficient expression of mCCR7 on the cell surface. Therefore 
next step was to attempt to increase mCCR7 expression in the EL4 cells.   
6.5.1 Development of pEF6.mCCR7and Transfection into EL4 Cells 
In order to increase mCCR7 expression vector containing the complete gene sequence for 
mCCR7 was created using the methods described in sections 2.2.4.3.1 and 2.2.4.8. The 
primers used are shown in section 2.1.7.2.  In this case a vector incorporating the EF1α 
promoter, pEF6/V5-His TOPO®TA, was employed. This was because of a previous 
suggestion that the CMV promoter was less efficient in malignant cells than this promoter.  
The vector used for transfection in the EL4 cells, pEF6.mCCR7 is shown in figure 6.7.  
 
 
Figure 6.7: Vector map of pEF6.mCCR7. This plasmid was used to transfect EL4 cells in order to 
increase surface expression of mCCR7.  
 
To transfect the EL4 cells, the Amaxa electroporation system was used as described in 
2.2.2.4.3 using pEF6.mCCR7. Following transfection, cells were selected depending on 
their resistance to blasticidin.  These cells were then subcloned and analysed for mCCR7 
expression using single colour flow cytometry following incubation with anti-mCCR7-
FITC antibody.  The results of this analysis are shown in figure 6.8.  The plots in 6.8 
compare mCCR7 surface expression on EL4 cells that have not been transfected with three 
different pools of mCCR7 transfected EL4 cells termed EL4.mCCR7.1, EL4.mCCR7.2 
and EL4.mCCR7.3.  These show that there has been a greater shift along the FL1-H gate in 
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all three pools, indicating higher expression of mCCR7 in these compared to the EL4 cells. 
It is also worth noting that in each population of cells that there were two peaks 
demonstrating low and high mCCR7 expressing subpopulations. Once it had been 
confirmed that there were populations of cells demonstrating increased mCCR7 expression 
analysis was carried out to assess CCR7 function in these cells. 
 
Figure 6.8: mCCR7 expression in pools of EL4.mCCR7 cells. a) Represents EL4 cells that have 
not been transfected and this curve is used as a comparison in graphs b), c) and d) representing 3 
pools of the mCCR7 transfected EL4 cells. EL4 cells were transfected with pEF6.mCCR7 by 
electroporation as detailed in section 2.2.2.4.3. Following selection in blasticidin, pools were 
selected for analysis of mCCR7 expression. The cells were incubated with anti-mCCR7-FITC. Cells 
were then analysed using single-colour flow cytometry. All positive cells as indicated by the marker 
in figure a) were used to calculated mean fluorescent intensity. 
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Figure 6.9: Expression of mCCR7 in pools of EL4.mCCR7 cells.  EL4 cells were transfected 
with pEF6.mCCR7 by electroporation as detailed in section 2.2.2.4.3. Following selection in 
blasticidin, pools were selected for analysis of mCCR7 expression. The cells were incubated with 
anti-mCCR7-FITC antibody. Cells were then analysed using single-colour flow cytometry. This 
experiment was repeated twice, with triplicate samples. 
 
 
6.5.2 Functional Analysis of EL4 Cells with Increased mCCR7 
Expression  
6.5.2.1 Biotinylated-CCL19 Uptake in EL4.mCCR7 Cells 
As before, in addition to confirming mCCR7 expression in the EL4.mCCR7 pools, it was 
important to establish that the CCR7 was functional. In the first instance the three clones 
were studied for biotin-CCL19 internalisation in comparison with EL4 cells. Un-
transfected EL4 cells were used as a control for this analysis in addition to cells that had 
not been exposed to biotin-CCL19. The results of this study are shown in figures 6.10 and 
6.11.  Figure 6.10 demonstrates a higher degree of biotin-CCL19 in all three EL4.mCCR7 
pools, as evidenced by a greater shift to the right along the FL2-H gate.  Again dual 
populations are seen. Furthermore, figure 6.11 clearly demonstrates the increased CCL19 
uptake in those cells with higher mCCR7 expression, with the highest mean MFI obtained 
from clone EL4.mCCR7.2 with an MFI of 2523.99 compared to that obtained in EL4 cells 
which was MFI-1480.59 and to a MFI of 6.71 in cells exposed to streptavidin-PE only.   
 
© Michelle Bryson, 2010                              CHAPTER SIX                                      RESULTS 
 
 216 
 
Figure 6.10: Biotin-CCL19 uptake in EL4.mCCR7 pools. Histogram plots demonstrating 
increased CCL19 uptake in the EL4.mCCR7 pools. The purple peaks represent EL4 cells with 
streptavidin-PE only, the green line represents untransfected EL4 cells, pink represents 
EL4.mCCR7.1 cells, orange represents EL4.mCCR7.2 cells and blue represents EL4.mCCR7.3 
cells. Cells were incubated with biotin-CCL19 and streptavidin-PE or streptavidin-alone, for 1hr at 
37oC. Following this biotin-CCL19 uptake by the cells was analysed using single-colour flow 
cytometry. All positive cells as indicated in figure a) were used to calculate the mean fluorescent 
intensity. 
 
 
Figure 6.11: Uptake of biotin-CCL19 by EL4.mCCR7 cells. Cells were incubated with biotin-
CCL19 and streptavidin-PE or streptavidin-alone, for 1hr at 37oC. Following this biotin-CCL19 
uptake by the cells was analysed using single-colour flow cytometry. The graph shows the MFI 
obtained with each cell population following biotin-CCL19 uptake. Note the highest degree of 
uptake was seen in EL4.mCCR7.2 cells. This experiment was only performed once due to loss of 
the transfected cell populations. 
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6.5.2.2    Migration of EL4 and EL4.mCCR7 cells towards CCL19   
Following analysis of the EL4.mCCR7 pools, pool EL4.mCCR7.2 was chosen for future 
experiments due to the highest level of biotin-CCL19 uptake and will now be referred to as 
EL4.mCCR7 cells. The same method using the QCMTM chemotaxis assay as described 
with the Raji cells in 4.3.2.2 was used to assess the ability of the EL4 and EL4.mCCR7 
cells to migrate in response to CCL19. This was chosen as the number of EL4.mCCR7 
cells available was too low for use in the Transwell® assay. However, before commencing 
with the assay a calibration curve was developed using known cell numbers as described 
with Raji cells in 4.3.2.2. The results of this are shown in figure 6.12, and clearly 
demonstrate a linear relationship between cell number and RFU. Once this was established, 
a chemotaxis assay was performed using EL4 and EL4.mCCR7 cells at CCL19 
concentrations of 0, 0.1, 1.0, 10 and 100nM. The RFU levels obtained on analysis were 
then used to calculate cell numbers and subsequently the migration index. The results of 
this are shown in figure 6.13. This confirms that EL4 cells do migrate in response to 
CCL19 exposure and, as would be expected, chemotaxis is more marked in the 
EL4.mCCR7 cells, although the difference in the migration indices were not significant 
between the two EL4 populations. These results again demonstrate that increased mCCR7 
expression by transfection, does correlate with enhanced function in these cells. 
 
 
Figure 6.12: QCMTM Calibration curve using EL4 cells. Known quantities of EL4 cells were 
added to wells of a 96 well luminometry plate. Lysis buffer/dye solution from the QCMTM kit was 
added to the cells and the plate incubated for 15 minutes at room temperature. The plate was then 
read using a 480/520nm filter set and RFU recorded for each well. Each point on the calibration 
curve represents the mean RFU obtained from 3 wells containing the same number of cells, 
indicating a good correlation between RFU and cell number. 
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Figure 6.13: Migration of EL4 and EL4.mCCR7 cells towards CCL19. Chemotaxis buffer 
containing different concentrations of CCL19 was added to a 96 well feeder plate. EL4 cells were 
then added to each insert.  Following incubation the cells were incubated with lysis buffer/ dye 
solution for 15 minutes before transferring to a 96 well luminometry plate for reading at 480/520nm. 
A migration index of >1 indicates that migration has occurred. This experiment was performed once 
with analysis at each chemokine concentration was performed in triplicate. The y axis figures relate 
to the mean value with the error bars representing the SEM.  
 
6.5.3 Adenoviral Infection in EL4 and EL4.mCCR7 Cells 
Adenoviral infections were again set up in EL4 cells as well as EL4.mCCR7 cells at a MOI 
of 2 ifu/cell. Following incubation with the CCL19 shrouded virus, the cells were 
incubated with the anti-hexon antibody and analysed using single colour flow cytometry. 
Whilst, the results were not significantly different, they did show infection of a small 
population of EL4.mCCR7 cells (2.41%). A smaller population of EL4 cells (0.43%) were 
positive by flow cytometry, however this was equivalent to those cells with no viral 
exposure (0.34%) and was therefore considered to be due to background artifact. The 
results are represented in the histograms in figure 6.14. 
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a) EL4 +PBS                                                                 b) EL4 + CCL19 shrouded Ad5.CMV.LacZ 
 
 
 
 
c) EL4.mCCR7 + CCL19 shrouded Ad5.CMV.LacZ. 
 
Figure 6.14: Detection of Ad5.CMV.LacZ infection in EL4 cells using anti-hexon antibody. 
EL4 cells were incubated for 48 hours with CCL19 shrouded Ad5.CMV.LacZ at a MOI of 2 ifu/cell. 
The cells were then washed and incubated with anti-hexon antibody followed by incubation with a 
secondary antibody-PE conjugate. Single-colour flow cytometry was then used to determine if any 
infection of EL4 cells had occurred. In EL4.mCCR7 cells a small population (2.41%) of cells were 
positive by flow cytometry indicated a small population of infected cells. 
 
6.6 Investigating Other Causes of Sub-optimal Infection of EL4 Cells 
One other possible reason for the sub-optimal infection of EL4 cells may relate to the 
expression of another chemokine receptor for which CCL19 is a ligand. To date, the only 
other receptor identified as binding CCL19 is the atypical chemokine receptor CCX-CKR 
[357]. Work within the chemokine research group had shown that CCX-CKR binds, and 
leads to the internalisation of, CCL19. However, it did not lead to any detectable 
downstream signalling, and it appears that the ligand is passed into lysosomes where it is 
destroyed [127]. The questions here were firstly, do EL4 cells express CCX-CKR? 
Secondly, if it is present, does the expression of CCX-CKR inhibit the ability of 
adenovirus to infect the cell in some way? The following experiments will outline the steps 
taken to investigate this possibility. 
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6.6.1 Expression of CCX-CKR in EL4 Cells 
Unfortunately there are no commercially available antibodies suitable for the detection of 
CCX-CKR either by Western blot or flow cytometry analysis. Therefore, RT-PCR was 
performed to see if CCX-CKR was expressed at the RNA level. Primers for murine CCX-
CKR had already been developed within the laboratory and were used. The results are 
shown in figure 6.15 and show that CCX-CKR is strongly expressed at the RNA level. 
Functionally, biotinylated CCL19 uptake had been previously used, however because EL4 
cells also express CCR7, it was difficult to determine which receptor contributed most to 
the CCL19 uptake at this stage.  
 
 
 
 
Figure 6.15: Expression of mCCR7 and mCCX-CKR in EL4 cells by RT-PCR. Lanes 2, 4 and 6 
represent the RT- controls.  RNA was extracted from EL4 cells, DNAase treated and cDNA 
synthesised +/- reverse transcriptase. Primers for actin, mCCR7 and mCCX-CKR were then added 
to the cDNA and the PCR programme in 2.2.4.3.1 was used. PCR products were run on a 1% 
agarose gel containing ethidium bromide. 
 
6.6.2 Development of CCX-CKR Expressing Cell Lines 
One way of determining whether or not CCX-CKR limited the ability of the adenovirus to 
infect cells was to develop cell lines expressing this receptor, but which were negative for 
CCR7. Within the laboratory, vectors for CCX-CKR as well as HEK293 cells transfected 
with CCX-CKR were available.  However, in view of the high degree of background 
infection experienced with HEK293 cells it was thought prudent to also develop a cell line 
expressing CCX-CKR which was negative for the CAR receptor.  As before, CHO cells 
were selected for this purpose. As a comparison HEK293 cells and CHO cells transfected 
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with CCR7 were used as positive controls.  CHO cells were transfected with either 
pcDNA3.1.hCCR7 (detailed in section 4.2) or pcDNA3.1.hCCX-CKR.HA (developed 
previously in the laboratory) as described in method section 2.2.2.4.2.  The transfected 
cells were then analysed for expression of CCR7 or CCX-CKR using anti-CCR7 
antibodies in the case of the former, and biotinylated CCL19 uptake studies in the case of 
the latter.  These analyses confirmed the presence of both of these receptors in the cell 
lines and can be seen in figure 6.16. Clone CHO.hCCX-CKR.1 had the highest degree of 
CCL19-binding as so was chosen for future experiments.  These cells are referred to as 
CHO.hCCX-CKR cells for the remainder of the thesis. The second graph shown in figure 
6.16 confirms successful transfection of the CHO cells with hCCR7, with the highest level 
of expression found in the first clone tested.  This clone will be referred to as CHO.hCCR7 
for the remainder of the thesis.    
 
 
 
Figure 6.16: Analysis of hCCX-CKR and hCCR7 expression in transfected CHO cells. CHO 
cells were transfected with either pcDNA3.1.hCCR7 or pcDNA3.1.hCCX-CKR.HA. Following 
incubation in selective media with G418 pools of cells were assessed for a) expression of hCCR7 
by incubation with anti-hCCR7 and a PE-conjugated secondary antibody, or b) expression of CCX-
CKR by incubation with biotin-CCL19/streptavidin-PE; followed by analysis using single-colour flow 
cytometry. The left hand graph shows increased biotin-CCL19 binding by the 4 pools of CHO cell 
lines transfected with pcDNA3.1.hCCX-CKR.HA (CHO.hCCX-CKR.1-4). The right hand graph 
demonstrates surface hCCR7 on the CHO cells transfected with pcDNA3.1.hCCR7 (CHO.hCCR7.1 
and 2). This analysis was performed once.
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6.6.3 Infection with Adenovirus shrouded with CCL19 in Cells 
Expressing CCX-CKR or CCR7 
Infection experiments with adenovirus shrouded with CCL19 were set up in HEK293 cells 
and in CHO cells expressing either CCR7 or CCX-CKR.  Following incubation, the cells 
were analysed for the presence of adenoviral infection using the anti-hexon antibody, and 
single colour flow cytometry and by staining for β-galactosidase.  The results are shown in 
figures 6.17 to 6.19.  The histograms in figure 6.18 clearly demonstrate that adenovirus 
infection is occurring at a greater rate in both the HEK.hCCR7 and HEK.hCCX-CKR cells 
with a greater shift along the FL2-H axis when compared to HEK293 cells.  This was 
confirmed by assessment of LacZ expression, which was performed to confirm the flow 
cytometry findings.  The images in figure 6.17 and the histogram in figure 6.19 
demonstrates the same results with CHO.CCX-CKR and CHO.hCCR7 cells as with HEK 
cells, albeit at a lower level of infection. Surprisingly, it appeared that the cells expressing 
CCX-CKR receptors had a higher degree of adenoviral infection when compared to cells 
expressing CCR7.  However, it is not possible to draw the conclusion that CCX-CKR 
facilitates higher rates of infection when compared to CCR7, as the number of receptors 
per cell were not analysed prior to the experiments. Yet, what is apparent is that CCX-
CKR does not appear to inhibit the ability of the adenovirus to infect cells nor does it limit 
the expression of any reporter genes. Thus further investigation into the cause of the low 
degree of adenoviral infection in the EL4 cells was required. 
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a) HEK293                                                b) HEK.hCCR7 
 
c) HEK.CCX-CKR 
         
d) CHO                                                   e) CHO.hCCR7 
 
f) CHO.CCX-CKR 
Figure 6.17: Infection of CHO and HEK293 cells expressing hCCR7 or hCCX-CKR. HEK293, 
HEK.hCCR7, HEK.hCCX-CKR, CHO, CHO.hCCR7 and CHO.hCCX-CKR cells were infected with 
CCL19 shrouded Ad5.CMV.LacZ and incubated for 48 hours. Following incubation cells were 
assessed for infection by staining for β-galactosidase.  These micrographs were taken at x20 
objective.  
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Figure 6.18: Adenoviral infection of HEK.hCCR7 and HEK.hCCX-CKR cells. HEK293, 
HEK.hCCR7 and HEK.hCCX-CKR cells were incubated with CCL19 shrouded Ad5.CMV.LacZ or 
PBS alone for 48 hours. Following incubation the cells were washed and then incubated with anti-
hexon antibody followed by incubation with a PE-conjugated secondary antibody. Cells were then 
assessed for Ad5 infection using single-colour flow cytometry. The histogram plots demonstrate 
increased detection of Ad5 hexons in HEK.hCCR7 and HEK.hCCX-CKR cells compared to 
HEK293 cells indicating higher rates of infection. 
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Figure 6.19: Adenoviral infection of CHO.hCCR7 and CHO.hCCX-CKR cells. CHO, 
CHO.hCCR7 and CHO.hCCX-CKR cells were infected with CCL19 shrouded Ad5.CMV.LacZ and 
incubated for 48 hours. Following incubation cells were washed and incubated with anti-hexon 
antibody followed by incubation with a PE-conjugated secondary antibody. Cells were assessed for 
Ad5 infection using single-colour flow cytometry. The histogram plots demonstrate detection of Ad5 
hexons in CHO.hCCR7 and CHO.hCCX-CKR but not in CHO cells indicating Ad5 infection 
occurred in both hCCR7+ and hCCX-CKR+ cells.  
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6.7 Optimising the Infection of EL4 Cells Further 
At this point, there was concern that it would not be possible to use the EL4 cells as an 
adenoviral transducable lymphoma mouse model.  However, before searching for an 
alternative cell line a literature search was performed to investigate whether or not these 
cells had been successfully infected with adenovirus in the past.  Leon et al had used EL4 
cells as a CAR negative cell line to assess the efficiency of transfection with the CAR 
receptor, and analysed the ability of the adenovirus to infect the EL4 cells through this 
transfected receptor [127].  The vector used for transfection of EL4 cells with the CAR 
receptor also contained the reporter gene for GFP. A variety of different promoters 
including CMV were used as well as different MOIs.  They demonstrated that EL4 cells 
were able to be successfully infected with the adenovirus and express GFP once CAR 
expression had been successfully introduced to the cell.  However significant results were 
only obtained once the MOI reached 200 ifu/cell. Up until this point, the infection 
experiments in this project had been using a MOI of 2 ifu per cell.  It was therefore felt 
worthwhile to repeat the experiments using the higher MOI. 
 
6.7.1 Infection of EL4 cells with a higher MOI 
EL4 cells were infected with adenovirus shrouded in CCL19 as previously described, but 
this time a MOI of 200 ifu per cell was used compared to an MOI of 0.132 or 2 ifu/ml in 
previous experiments described in this thesis.  As a higher MOI was used in these 
experiments it was decided to attempt infection of untransfected EL4 cells first. The 
adenovirus infection was again assessed using single colour flow cytometry following 
incubation with the anti-hexon antibody.  Remarkably, increasing the MOI lead to 
detectable infection in 14.84% of the EL4 cells exposed to adenovirus shrouded with 
CCL19 and these results are shown in figure 6.20.  Although there was a trend towards 
increased detection of anti-hexon antibodies in the EL4 cells exposed to CCL19 shrouded 
adenovirus, this did not reach statistical significance, yet showed promise for future work. 
Work with EL4 cells would therefore continue as they maintained their potential for use in 
a lymphoma mouse model. 
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Figure 6.20: Infection of EL4 cells with CCL19 shrouded Ad5.CMV.LacZ at MOI of 200. EL4 
cells were incubated with Ad5.CMV.LacZ with or without CCL19 shrouding for 48 hours. The cells 
were then washed and incubated with anti-hexon antibody followed by incubation with a PE-
conjugated secondary antibody. Infection of EL4 cells was then assessed using single-colour flow 
cytometry. Each sample was run in triplicate and the error bars represent the SEM.  
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6.7.2 Development of an Adenoviral Vector using EF1-α  as a Promoter 
As previously discussed, one other potential reason for the inability to detect Lac Z in EL4 
cells is the low efficiency of the CMV promoter to induce gene expression in 
haematopoietic cells.  The EF1-α promoter is reported to increase the efficiency of 
transcription of reporter genes in haematopoietic cells [358], and as such the use of this 
promoter in subsequent infection experiments may improve results.  In addition, it has 
been shown that infection of EL4 cells with adenoviral vectors containing the GFP reporter 
gene can be successfully detected by examination for expression of GFP by flow 
cytometry.  
 
Therefore the next aim was to develop an adenoviral vector containing EF1-α as the 
promoter and GFP as the reporter gene.  In order to do this, the AdEasy adenoviral vector 
system was employed again.  The first step in this was to develop a pShuttle vector 
containing EF1-α instead of the CMV promoter.  A pShuttle vector was obtained from 
Stratagene, which contained IRES.GFP and the CMV promoter.  No vector was 
commercially available containing the EF-1α promoter, and therefore it was necessary to 
replace the CMV promoter with the EF-1α promoter using subcloning techniques. Suitable 
restriction enzyme sites were searched for but subsequently it was necessary to introduce a 
novel restriction enzyme site into the pShuttle vector in order to facilitate the subcloning 
strategy. Two restriction enzyme sites, Kpn1 and Nru1, were identified in the pEF6/V5-His 
TOPO®TA, obtained from Invitrogen, enabling a DNA fragment incorporating the gene 
sequence for EF1α to obtained following digestion with these two enzymes. A Kpn1 
restriction enzyme site was identified in the pShuttle vector at an appropriate site after the 
CMV promoter sequence however an Nru1 sequence was not identified at any point in the 
pShuttle vector.  For this reason, site directed mutagenesis was used to introduce an Nru1 
site upstream of the CMV promoter.  The method for this is described in section 2.2.4.11 
and an Nru1 site was successfully introduced into the correct position.  Following 
restriction enzyme digestion with Nru1 and Kpn1 of the pEF6/V5-His TOPO®TA, a 
product of 4.1KB was obtained containing the EF1α sequence.  This was then ligated into 
with the modified pShuttle vector now containing the Nru1 restriction enzyme site that had 
been digested with Nru1 and Kpn1 thereby removing the DNA containing the sequence for 
the CMV promoter.  This produced the pShuttle vector shown in figure 6.21. The pShuttle 
vector was then utilised for homologous recombination using BJ5187 cells as previously 
described.  Homologous recombination was successful and the vector 
pAdeasy.EF6.IRES.GFP, was created.  The next step would have been to transfect this 
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vector into HEK.293 cells in order to produce viral particles, however time restrictions 
prevented this. 
 
A B  
Figure 6.21: Vector maps of pShuttle.CMV.IRES.GFP and pShuttle.EF6.IRES.GFP. The first 
vector was obtained from Stratagene and an Nru1 site was introduced as indicated, using site 
directed mutagenesis. This allowed for replacement of the CMV promotor with the EF6 (EF-1α) 
promotor from the pEF6/V5-His TOPO®TA vector using subcloning techniques and the Nru1 and 
Kpn1 restriction sites as indicated above, to create pShuttle.EF6.IRES.GFP.  
 
6.8 Expression of CAR, αv-integrin and CCX-CKR in Murine Tissues 
and Cells 
Now that early experiments had demonstrated the possibility of redirecting adenoviral 
tropism through the chemokine receptors in EL4 cells, the next step was to assess the 
expression of the CAR receptor, αv-integrin and CCX-CKR in a variety of murine tissues 
and leukocytes. Examination of CAR and αv-integrins expression would provide 
information regarding the natural tropism of the adenovirus in tissues and cell populations 
within the mouse, therefore predicting where non-shrouded adenoviral particles were likely 
to be detected after infection and thus provide a comparison for those mice infected 
adenovirus shrouded with CCL19. Successful redirection of adenoviral tropism through 
CCX-CKR has been clearly demonstrated with resulting expression of the transfected 
reporter gene, LacZ. Thus knowing the distribution of CCX-CKR in mouse leukocytes and 
tissues, would enable prediction of the likely distribution of redirected adenovirus 
following infection with CCL19 shrouded virus and predict for potential toxicities using 
this virus to deliver cytolytic therapy.  
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It is already known that CCX-CKR is present in most tissues, although it is particularly 
strongly expressed in the heart, lung and brain [357], and this work was not repeated. 
CCR7 is expressed predominantly on naïve B and T cells, subsets of memory T cells and 
dendritic cells, however further analysis of CCX-CKR expression across a range of 
haematopoietic cells was required and the results of RT-PCR for CCX-CKR (using primers 
already developed in the laboratory) on haematopoietic cells is shown in figure 6.23. 
Analysis of CAR and αv-integrin expression was performed using RT-PCR and the 
primers used in earlier in this chapter.  The results of these studies are shown in figures 
6.22. A summary of these findings is shown in table 6.1.  Essentially they show that 
transcripts for CAR can be detected in RNA from the brain, heart, kidney, liver and lung 
and at a lower level in the spleen and thymus confirming the previously published findings 
as discussed in section 1.5. Alpha-integrin transcripts are present in all of these tissues too, 
with highest levels seen in the brain and kidney. With regards to expression in 
haematopoietic cells, CAR transcripts were detected in the bone marrow as a whole, but 
the only haematopoietic cells that were positive were Lin-Sca+ precursors. For α-integrin 
expression, again the bone marrow and Lin-Sca+ RNA contained transcripts for this, but in 
addition macrophages were also positive for α-integrin expression at the transcription 
level. The results of RT-PCR for CAR and α-integrin expression in these cells, again 
confirms the published findings demonstrating low or absent expression in haematopoietic 
cells. 
 
There was limited expression of CCX-CKR in haematopoietic cells, with only 
lymphocytes from lymph nodes and mast cells expressing this receptor at the transcript 
level. These results, in addition to those published by Townsen et al (348), indicate that it 
may be difficult to determine successful redirection of adenoviral tropism following 
shrouding with CCL19.  However subtle differences may be observed particularly on 
examination of lymph node tissue, which should not be infected by the un-shrouded virus. 
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Figure 6.22: Expression of CAR and αv-integrin in murine tissues and leukocytes. RNA was 
extracted from a range of murine tissues and leukocytes as detailed above, followed by DNAase 
treatment. cDNA was synthesised using +/- reverse transcriptase. Primers for actin, CAR and αv-
integrin were then used as in 2.2.4.3. PCR products were run on a 1% agarose gel containing 
ethidium bromide. In each case the first PCR product is actin (as positive control and 400bp in 
size), the second product is α-integrin and the third CAR. 
 
 
 
 
 
400bp 
400bp 
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Figure 6.23: Expression of CCX-CKR in mouse tissues and leukocytes. RNA was extracted 
from a range of murine tissues and leukocytes as follows: A- bone marrow, B- lymph node, C- 
dendritic cells, D- Lymph node B-cells, E- Lymph node T-cells, F- Splenic B-cells, G- Splenic T-
cells, H – mast cells, I- macrophages, J- polymorphonuclear cells, K-Lin-Sca+ precursors, L- Lin-
Sca- precursors. The RNA was DNAase treated and cDNA synthesised using +/- reverse 
transcriptase. Primers for mCCX-CKR were then used as in 2.2.4.3. PCR products were run on a 
1% agarose gel containing ethidium bromide. There is no actin control shown in this figure as this 
analysis was performed at the same time as the RT-PCR shown in figure 6.22. The red arrow 
indicates the CCX-CKR transcript that is 500bp in size. The RNA samples and primers for murine 
CCX-CKR were obtained from Clive McKimmie. 
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 α-integrin CAR CCX-CKR 
Tissue    
Bone Marrow - + + 
Brain + + ++ 
Heart  - + ++ 
Kidney + + + 
Liver wk + + + 
Lung wk + + ++ 
Lymph Node - - - 
Spleen  wk + wk+  
Thymus wk+ +  
Haematopoietic cell    
Dendritic cells - - - 
Lymph Node B-cells - - + 
Lymph Node T-cells - - + 
Splenic B-cells - - - 
Splenic T-cells - - - 
Mast cells - - + 
Macrophages + - - 
Polymorphonuclear Cells - - - 
Lin-Sca+ - + - 
Lin-Sca- - - - 
Table 6.10: Expression of CAR, αv-integrins and CCX-CKR in mouse tissues and leukocytes. 
RNA was extracted from a range of murine tissues and leukocytes as detailed above, followed by 
DNAase treatment. cDNA was synthesised using +/- reverse transcriptase. Primers for CAR, αv-
integrin and CCX-CKR were then used as in 2.2.4.3. PCR products were run on a 1% agarose gel 
containing ethidium bromide. Information on CCX-CKR expression in brain, heart, kidney, liver, 
lung, spleen and thymus was obtained from the paper by Townsen et al [349]. 
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6.9 Infection of C57/BL6 Mice with Adenovirus Shrouded in CCL19 
In order to assess whether the adenoviral tropism could be redirected through chemokine 
receptors in-vivo, infection of two groups of C57/BL6 mice were infected with 
Ad5.CMV.LacZ with or without shrouding with CCL19.  Twelve female mice were 
selected at six weeks old and each mouse was injected with 6.6 x108 viral particles in 100 
in 100 µL of PBS using via the tail vein.  Six mice were injected with adenovirus that had 
undergone shrouding with CCL19 and the remaining six were injected with adenovirus that 
had not been ‘shrouded’ with CCL19.  After 48 hours, three mice from each group were 
culled according to schedule 1 techniques.  The remaining mice were culled at 96 hours.  
From each mouse the inguinal lymph nodes, spleen, liver, gut, lungs, kidney and heart 
were harvested.  These were then placed in a cryopreservative and stored at -70oC.  In 
order to assess the degree of infection in each of the mouse tissues a cryostat was used to 
create sections suitable for microscopy.  This is described in methods section 2.2.7.4.1.  
Each sample was then assessed for infection using as indicated by expression of LacZ by 
staining for β−galactosidase.  
 
Initial analysis showed that there was possibly increased infection in the inguinal lymph 
nodes in those mice, which, had been exposed to the shrouded virus as opposed to those 
that had been exposed to the un-shrouded virus, suggesting in-vivo redirection of 
adenoviral tropism. However this did not appear to be consistent in all mice examined and 
differences in β-galactosidase staining were subtle.  Yet, there did appear to be a reduced 
rate of infection in the liver of those mice exposed to the shrouded virus when compared to 
the mice exposed to the un-shrouded virus. No significant differences in infection were 
shown seen upon with analysis of the lungs, kidney, spleen, heart or gut.  Figures 6.24a-f, 
demonstrate these findings. This early experiment shows that it may be possible to redirect 
adenoviral tropism in vivo as well as in vitro although further work is required.   
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a) Heart - CCL19 (x10 magnification)   b) Heart + CCL19 (x10) 
  
c) Liver – CCL19 (x10)                           d) Liver + CCL19 (x10) 
  
e) Lymph Node – CCL19 (x10)              f) Lymph Node + CCL19 (x10) 
Figure 6.24: Infection of C57/Bl6 Mice with CCL19 shrouded Ad5.CMV.LacZ. Mice were 
injected in the tail vein with equal quantities of Ad5.CMV.LacZ with or without CCL19 shrouding (6 
in each group).  After 48 or 96 hours mice were culled. Slides were prepared from lymph node, 
spleen, lung, gut, heart, kidney and liver. The slides were then assessed for infection using β-
galactosidase staining. The differences between the two groups were subtle. These images 
demonstrate the lack of LacZ expression in heart tissues, increased LacZ expression in hepatic 
tissue in mice infection with non-shrouded virus compared to those infected with CCL19 shrouded 
virus and increased β-galactosidase staining in the lymph nodes of mice infected with the CCL19 
shrouded virus compared to those infected with non-shrouded virus. The red arrows indicate 
positive cells. 
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6.10 Summary 
The results in this chapter demonstrate the following points.  
 
1. EL4 cells express mCCR7 at both the RNA and protein level as demonstrated by 
RT-PCR and single colour flow cytometry.   
 
2. mCCR7 expression in EL4 correlates with function as demonstrated by the ability 
of EL4 cells to migrate towards CCL19 and to bind  biotinylated CCL19. 
 
3. Infection of the EL4 cells with adenovirus shrouded with CCL19 was unsuccessful 
using a MOI of 2 ifu per cell, however increasing the MOI to 200 ifu per cell led to 
detectable infection in the EL4 cells, although the degree of infection did not reach 
statistical significance. 
 
4. Increasing mCCR7 expression in EL4 cells lead to enhanced chemotaxis and 
biotinylated CCL19 uptake.  Initial experiments also suggested that increased 
mCCR7 expression also correlated with improved infection with the shrouded 
adenovirus, even at a MOI of 2 ifu per cell. 
 
5. CAR receptor, αv-integrin and CCX-CKR expression in a range of murine tissues 
and cells was characterised enabling some prediction as to which cell types and 
tissues were likely to be in infected with the adenovirus with or without CCL19 
shrouding. 
 
6. Initial in-vivo experiments exploring the possibility of redirecting viral tropism 
through chemokine receptors suggested that there were possible differences in the 
rates of infections in different tissues, with those tissues expressing CCR7, with 
lymph nodes, showing higher degrees of infection when exposed to the adenovirus 
shrouded in CCL19.  In addition, the liver that does not express CCR7, showed a 
lower degree of infection in those mice exposed to the shrouded virus as opposed to 
those exposed to the non-shrouded virus. 
 
 
 
 
 
   
 
CHAPTER SEVEN 
DISCUSSION 
7.1 Non-Hodgkin’s Lymphoma and Chemokine Receptor Expression 
The results obtained from the analysis of clinical samples, outlined in chapter 3, 
demonstrated differences between non-Hodgkin’s lymphoma (NHL) subtypes and 
chemokine receptor expression. With the exception of CCR4 expression, which is 
discussed further below, the results were consistent, on the whole, with published data.  
 
As discussed in sections 1.3 and 1.4 of the introduction, the malignant lymphocytes in the 
various types of NHL appear to correlate with B-cells at a particular stage of B-cell 
development, as such, chemokine receptor expression on these lymphocytes reflect this. 
For example, the postulated normal B-cell counterpart for mantle cell lymphoma (MCL) is 
a CD5+ pre-germinal centre (GC) B-cell. Comparison of gene expression of CCR7, 
CXCR4 and CXCR5 between mantle cell lymphoma cells and CD5+ pre-GC B-cells has 
shown no obvious differences [349]. Therefore, it has been suggested that lymphoma 
dissemination reflects the physiological rather than pathological properties of the 
malignant lymphocytes.  
 
In discussion of the receptors more specifically, CXCR4 and CXCR5 were expressed at 
consistently high levels across the samples. This is unsurprising as CXCR5 has been noted 
to be a marker of mature B-cells and has been detected regularly in B-cell lymphomas 
[359], whilst CXCR4 is expressed at varying stages of B-cell differentiation including in 
mature B-cells [360].  Despite this there were some results observed on testing of the 
clinical samples, which, appeared contrary to these earlier published data.  
 
For example, in this thesis it has been noted that the average percentage of B cells 
expressing chemokine receptors in follicular lymphoma cases was lower in general than 
with all of the other subtypes studied. Initially, this appeared difficult to explain, however 
germinal centre cells have been noted to show a low level of migration in response to 
chemokines [361] and furthermore down regulation of CXCR4 , CXCR5 and CCR7 has 
been observed in germinal centre cells on comparison with other B-cells subsets [362].  
More recently, further analysis of GC B-cells has added to these data.  
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Within lymph node follicles the dark zone is a CXCL12 rich area predominantly 
comprised of centroblasts, whilst the light zone is a CXCL13 rich area comprised of 
centrocytes, the latter cell type being the normal B-cell counterpart of follicular lymphoma 
[359]. Analysis of CXCR4 expression on these two B-cell subsets has revealed that 
CXCR4 expression is detectable on centroblasts whilst down regulated or absent on 
centrocytes [176]. These observations would certainly help to explain the lower levels of 
chemokine receptor expression noted in the follicular lymphoma samples, discussed in 
chapter 3.  
 
With regards to expression of CCR6, the highest level of expression was seen in MALT 
lymphoma cases. MALT lymphomas represent post-GC marginal zone B-cells [363]. 
CCR6 expression is gained in B lymphocytes following migration out of the bone marrow 
[176] and  regulates mucosal and humoral immunity particularly in the small intestine 
[364] Therefore the higher, although not significantly so, level of expression in the MALT 
lymphoma cases was to be expected. Certainly, this is in accordance with published 
findings, with 20-28% of normal B-cells from this subset noted to express CCR6 in one 
study [365] with up to 90% of these B-cells expressing CCR6 in another [362]. What is 
perhaps a little unusual on first inspection is the lower level of CCR6 expression detected 
in the MCL cases. As has already been discussed MCL has a strong association with gut 
involvement and so a higher level of expression would be expected. Certainly CCR6 has 
been reported as being able to distinguish MCL, MALT and marginal zone lymphomas 
from others [366]. However, this has not been a consistent finding with lymphocytes from 
cases of MCL in another study being observed to show down regulation of CCR6 on 
comparison with their normal B-cell counterpart [342]. Furthermore, loss of CCR6 
expression has been reported in other B-cell lymphomas such as CLL/SLL and follicular 
lymphoma [367].  
 
A discussion regarding CCR9 expression in the subtypes of lymphoma is presented in 
section 3.5.2.4, with lower than expected expression noted in MCL and, although not 
significant, the highest level of expression being seen in MALT lymphomas. As already 
noted both MALT lymphoma and MCL have a high propensity to gut involvement, with 
CCR9 known to regulate homing towards the gut higher expression of this receptor in 
these NHL types would be expected. There is little remaining in the literature to expand 
this discussion further. 
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In all NHL subtypes analysed less than 1% of B-cells expressed CCR10. CCR10 is 
implicated in the homing of T-cells to the skin and mucosal surfaces [364]. However, the 
lack of CCR10 expressed observed in Burkitt’s lymphoma primary cells and cell line 
samples was contrary to the previously published data [366]. Moreover, whilst CCR10 is 
implicated in the recruitment of cells to mucosal surfaces, it has been shown that memory 
B-cells do not express this receptor, although plasmablasts have been shown to express it 
[336]. Unfortunately there are little data available relating to CCR10 expression in less 
mature B-cells, but it is possible that CCR10 expression only occurs following 
differentiation to plasmablasts, if this is the case the lack of CCR10 expression in the 
clinical samples analysed would be expected.  
 
Further discussion relating to CCR4 and CCR7 expression can be found later in this 
chapter. 
7.2 Chemokine Receptor Expression and Function: Differences 
Between Normal B-cells and Malignant B-cells 
Whilst expression of chemokine receptors may not enable easy differentiation between 
malignant lymphocytes or even their normal B-cell counterparts, other subtle aspects of 
chemokines and their receptors do distinguish them. 
 
Differences in the degree of expression of various chemokine receptors between malignant 
and normal lymphocytes have been observed. For example expression of CXCR4, CXCR5 
and CCR7 in patients with CLL/SLL appears to be increased when compared to 
comparable normal B-cell populations. Moreover the higher the expression of these 
receptors was associated with more advanced lymph node involvement [368, 369]. Higher 
expression of CXCR4 and CXCR5 has also been noted in other B-cell lymphoproliferative 
diseases such as nodal follicular lymphoma (although again lower expression than MCL 
and CLL/SLL) and mantle cell lymphoma [359]. However, in one study no such 
differences were detected between CXCR4 and CXCR5 expression in normal B cells and 
B cell lymphoproliferative disorders. However, in this instance unlike the other reports, the 
only normal control used was peripheral blood B-lymphocytes, whilst the test samples 
were obtained from a range of sources including lymph node, bone marrow and peripheral 
blood, and as such this may have affected the results obtained [359].  
 
Similar differences have been noted with CCR7 expression, and these will be explored 
later in this discussion. 
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With the differences in the intensity of expression noted, it would be logical to explore 
whether these differences equate to differences in responses to chemokines. Again, this has 
been examined. As discussed in section 1.4.3, MCL cells have been observed to migrate in 
response to CCL19, whilst their normal counterpart B-cells do not, despite also expressing 
CCR7 [364]. This is not an isolated finding with migration in response to CXCL12 in 
CLL/SLL cells enhanced in comparison to normal B-cells [286]. Although it has also been 
shown that both normal and malignant CXCR4+ B-cells of germinal centre origin have a 
lower migratory response to CXCL12 than those of non-germinal centre cells origin, 
despite similar expression of the receptor due to differences in the intracellular pathways 
triggered [359]. These studies indicate that receptor expression does not always equate to 
migratory function with a host of factors influencing chemotaxis. This is supported by 
earlier data on normal B-cells, which, showed that despite high levels of CXCR4 
expression a diminishing response of normal B-cells to CXCL12 was observed as they 
matured [370].  
 
Finally, other functions may be gained in malignant B-cells with respect to chemokines. 
Interestingly, CXCL13 and CCL19 have been shown to act synergistically to induce 
resistance to TNFα medicated apoptosis in B-cell CLL cells but not in normal CD5+ B-
cells [361]. This shows that chemokines do not only play a role in the trafficking of 
malignant cells. 
7.3 CCR4 and Non-Hodgkin’s Lymphoma 
7.3.1 CCR4 Expression 
CCR4 binds to two ligands CCL17 and CCL22 [371] and is present on Th2 cells, 
regulatory T (Treg) cells, skin-homing T cells and subsets of B-cells, as well as on 
platelets, monocytes and macrophages [340].  The ligands for CCR4 are not monogamous, 
and both CCL17 and CCL22 will bind the atypical receptor D6 [372]. 
 
In chapter 3, the results of CCR4 expression in the NHL samples tested revealed a higher 
than expected expression in certain sub-types, namely DLBCL, MCL, Burkitt’s lymphoma 
and MALT lymphoma. At that point is was observed that the higher expression appeared 
to correlate with more aggressive disease subtype, with less expression noted in the more 
indolent follicular lymphoma and CLL/SLL. The higher expression of CCR4 in the higher-
grade lymphomas may provide a reason in part, why the cytokine driven B-symptoms are 
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more often seen at presentation in these diseases. Studies comparing CCR4+/+ with CCR4-
/- mice following lipopolysaccharide exposure revealed a higher mortality rate in the 
CCR4+/+ mice with higher levels of cytokines such as TNFα detected [373]. Whilst CCR4 
expression may help to explain some of the clinical features noted with these NHL 
subtypes, it does not explain the reason for the differences in receptor expression. 
 
The implications of CCR4 expression in T-cell lymphomas has been reported, with a clear 
correlation between CCR4 expression and an adverse outcome [372] which has lead to the 
development of anti-CCR4 antibody therapy by the same group. Yet, with regards to B-cell 
lymphomas, little can be found. Ishida et al reported a case of DLBCL, in which CCR4 
expression could be detected. However, in this instance it was postulated that the CCR4 
expression was due to the fact that this patient was unusual due to extensive and localised 
cutaneous involvement. Thus the CCR4 expression related to skin-homing lymphocytes 
[291] with the implicit assumption that DLBCL is not associated with expression of this 
receptor. This is likely to have been an erroneous assumption, and it can be argued that 
CCR4 expression was actually related to the DLBCL subtype, or more specifically to the 
normal B-cell counterpart of DLBCL lymphocytes. 
 
A number of studies have been reported looking at the role of CCR4 in the various T cell 
subsets, however very little has been published relating to CCR4 expression in B-cells. 
One of the first studies assessed the response of normal non-germinal centre (GC) and GC 
B-cells, from tonsils, to CCL22.  CD38 was used to characterize the B-cells as being of GC 
(CD38+) or non-GC (CD38-) origin. It was noted that non-GC cells, consisting of both 
naïve and memory B-cells, migrated in response to CCL22, whereas the GC cells did not. 
Subsequently, analysis of CCR4 expression supported these results with 56-70% of CD38-, 
naïve B-cells expressing CCR4 and 40-73% of memory B-cells expressing CCR4, whilst 
there was no expression detected in GC cells [341]. It is possible that CCR4 may aid in the 
migration of the naïve and antigen activated/memory B-cells along with other chemokine 
receptors as these cells home to specific anatomical sites or re-circulate, whilst GC cells 
demonstrate very little motility remaining within germinal centres.  
 
Later, CCR4 expression at the transcriptional level was noted in a number of different 
subtypes of B-cell lymphoma (DLBCL, follicular lymphoma, mantle cell lymphoma, 
lymphocytic lymphoma and marginal lymphoma) as part of a paper on the use of CXCR4 
neutralizing antibodies in the control of Raji cell induced tumours in mice [362]. However, 
other than a single figure in the paper, no further investigation of this expression was 
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undertaken, but it does confirm that CCR4 expression is not restricted to the T-cell 
lymphomas.  
 
Finally, analysis of chemokine receptor expression on normal IgA+ and IgG+ cells has 
again revealed a population of CCR4+ cells. IgA+ B-cells are involved in mucosal and 
intestinal immunity, whereas IgG+ B cells preferentially migrate to the bone marrow and 
secondary lymphoid organs [295]. On reporting CCR4 expression in these two B-cell 
groups it was noted that both IgA+ and IgG+ B-cell populations contained subpopulations 
of CCR4+ cells. Furthermore, IgG+ cells had higher expression than the IgA+ cells, which 
was even more evident when the B-cells were classified as small (resting) or large 
(activated), with CCR4 expression noted on 5% of small IgA+ vs. 13.8% of small IgG+ B-
cells, and 11.6% of large IgA+ vs. 25.9% of large IgG+ B-cells [366].   
 
Therefore, if the results discussed in chapter 3 are related to the findings in these papers it 
can be argued that as with expression of the other constitutive chemokine receptors 
studied, CCR4 expression relates to the normal B-cell counterpart of the NHL subtype.  
For DLBCL the normal B-cell counterpart falls predominantly into three groups, the 
germinal centre B-cell (GCB) or the activated B-cell (ABC) and the primary mediastinal 
B-cell lymphoma (PMBCL) [366]. Unfortunately, due to the time span over which the 
samples were collected, information on the category of DLBCL was not available as, 
further classification into GCB or ABC did not become part of routine diagnostic practice 
until after these samples were collected. Furthermore PMBCL would not have been 
represented, as by definition, it only involves the mediastinum, and the samples consisted 
of peripheral lymph nodes. However if, as suggested by Corcione et al, CCR4 expression 
identifies non-GC B-cells then it is not unreasonable to postulate that the higher CCR4 
expressing samples represented the ABC type of DLBCL. Yet, if this was the case, then 
the better outcome in the high CCR4 expressing group is unusual as ABC DLBCLs have 
been noted to have a poorer outcome that the GCB DLBCLs [374].   
 
With regards to the remaining NHL subtype expressing higher levels of CCR4, MALT 
lymphoma and mantle cell lymphomas have post germinal-centre and naïve B-cells as their 
normal B-cell counterparts respectively [375]. Therefore the chemokine receptor 
expression is consistent with the findings of Corcione et al. Although, intriguingly, CCR4 
expression was only detected in a small subset of MALT lymphomas examined in one 
study analysing chemokine receptor expression in this disease. Further examination of the 
CCR4 positive MALT lymphomas revealed that they all demonstrated adverse 
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cytogenetics with trisomy 3 [176], an abnormality exclusively associated with nodal 
MALT lymphomas [376]. Cytogenetics is not routinely performed in many centres as part 
of the diagnostic work up of MALT lymphomas, but it is an interesting hypothesis that the 
samples examined in this study may have demonstrated this cytogenetic abnormality 
considering that they were all lymph node samples. 
 
However, the postulated normal B-cell counterpart in Burkitt’s lymphoma has not yet been 
confirmed with it thought to be either of GC or post-GC origin [176]. The results in this 
study, may add support to the theory that the cell of origin is actually post-GC in view of 
the high CCR4 expression.  
 
Finally, the lower expression of CCR4 in the follicular lymphoma samples is again 
consistent, with this being a lymphoma of GC B-cell origin, yet the lower expression in 
CLL/SLL is interesting. The expression of the GC marker, CD38, is variable in CLL/SLL 
and has been noted to be of adverse prognostic significance [176], it would therefore been 
of interest to know the CD38 status of the CLL/SLL samples. The reason for the lack of 
this information is the same as with the lack of information on the DLBCL samples. It is 
unfortunate that correlative clinical data was not available for these samples, as it could be 
postulated that CCR4 expression would correlate with a good outcome in keeping with 
CD38- status.   
7.3.2 CCR4 Targeted Therapy  
Having shown that CCR4 is expressed in certain lymphoma subtypes, the question arises 
as to whether or not this is a good target for therapy. A phase I clinical study using a 
monoclonal anti-CCR4 antibody has certainly demonstrated some efficacy in patients with 
relapsed adult T-cell leukaemia/ lymphoma (ATLL) and peripheral T cell lymphomas 
(PTCL) [251]. The identification of CCR4 as a target in ATLL was identified by the same 
group, although the patient’s sample were considered to be CCR4+ if greater than 10% of 
T-cells expressed the receptor, with no details given on which cells were used to calculate 
the proportion identified [297]. With the proportion of CCR4+ cells in the samples 
analysed in this thesis ranging from 11.84 (± 3.98)% in follicular lymphoma cases to 
61.59(±6.52)% in DLBCL cases, then the simple answer is that CCR4 is a valid target, 
particularly in the non-GC NHL subtypes. 
 
Although it would appear that CCR4 would be a reasonable therapeutic target for B-cell 
lymphomas, it is also worth considering which other CCR4 positive cells may be depleted 
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as a consequence. As mentioned earlier, CCR4 is also expressed on T regulatory cells, Th2 
cells, monocytes, macrophages and platelets.   
 
In recent years, there has been a lot of interest in the role of T regulatory cells in the 
microenvironment of lymphomas and other malignant diseases. T regulatory cells are 
CD4+ cells that regulate the immune response by a number of mechanisms leading to self-
tolerance and suppression of cellular immunosurveillance [291]. They are further identified 
by the expression of CD25+ (in a subgroup) and more specifically by expression of the 
transcription factor FOXP3 [377]. Additionally, Treg cells have been shown to express 
CCR4 and to migrate in response to both CCL17 and CCL22 [378]. The impact of 
increased numbers of Treg cells in solid tumours such as non-small cell lung cancer, 
ovarian cancer and gastrointestinal cancers, either within the tumour itself or in the 
peripheral blood, has been associated with poorer outcomes (379, 380). This is postulated 
to be related, to escape from immunosurveillance therefore providing a more hospitable 
environment for the malignant cells. Thus targeting of CCR4 in solid tumours may also be 
advantageous by depleting Treg cells and thus assisting malignant cell destruction through 
the recognition of tumour antigens. 
 
However, this association has not held true for lymphoid malignancies. On the whole, 
higher numbers of Treg cells have been associated with improved outcomes in a range of 
lymphomas. The first suggestion of this associated came in 2001 when higher numbers of 
CD4+ cells correlated with a longer overall survival in patients with DLBCL [379] It was 
subsequently demonstrated that these represented Treg cells. Increased numbers of 
CD4+CD25+CTLA+FOXP3+ Treg cells were demonstrated in a variety of lymphomas by 
Yang et al. In this study it was noted that these cells suppressed the migration of 
CD4+CD25- cells into the tumor microenvironment by the suppressing the release of IFN-
γ and IL-4, thus also suppressing cellular proliferation [380]. Two other interesting 
observations were made. Firstly, the lymphoma cells actually released CCL22 thereby 
attracting T regulatory cells into the microenvironment. Secondly, cell-cell interaction 
between CD4+CD25- T cells and the lymphoma cells lead to the induction of CD25 on the 
T cells, showing that the lymphoma cells have the ability to induce Treg cells [381]. This 
latter observation has been confirmed in subsequent studies [381]. 
 
The majority of studies exploring Treg numbers and lymphoma have confirmed the 
association between higher Treg numbers and improved survival in DLBCL and follicular 
lymphoma [382, 383]. Although, one study has suggested the opposite, with higher 
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numbers of Tregs detected in both the tumour bulk and in the peripheral blood being 
associated with more advanced disease in a range of lymphoma subtypes [384].  
The more common correlation between higher numbers of Tregs and improved survival in 
lymphomas appears counter-intuitive if these cells help the malignant cells to escape 
immune-mediated cytotoxicity, which leads to the question, why would higher numbers 
lead to improved outcomes in lymphomas? There are a number of potential explanations. It 
has been shown that they suppress T helper dependent B-cell immunoglobulin production 
and class switching [382] and Treg cells have also been shown to selectively induce 
apoptosis in activated B-lymphocytes following stimulation by CD3 or exposure to antigen 
[385]. Thus targeting CCR4 in lymphomas may have a detrimental affect, and finding a 
way to harness these suppressive and apoptotic properties of Treg cells may be a more 
useful therapeutic approach. However, until the studies have been performed with anti-
CCR4 approaches, firm conclusions cannot be drawn.  
 
Finally, CCR4 could be used therapeutically in a different way. The fact that Reed-
Sternberg cells in Hodgkin’s lymphoma express CCL17 and CCL22 has been employed to 
provide an elegant treatment option. Cytotoxic T-lymphocytes (CTLs) are rare in the 
cellular milieu surrounding Reed-Sternberg cells. CTLs were engineered to express CCR4 
as well as a CD30-specific antigen receptor (CD30 is expressed by Reed-Sternberg cells). 
These were then adoptively transferred into SCID mice manipulated to develop tumours 
from a Hodgkin’s lymphoma cell line. The CCR4+ CTLs successfully migrated towards 
the CCL17 and CCL22 expressing lymphoma cells with early tumour control noted and 
tumour regression observed by day 30 due to the cytotoxic effects of the engineered cells 
[386]. 
7.4 CCR7 and NHL 
7.4.1 CCR7 Expression 
As CCR7 was chosen as the chemokine receptor for testing the feasibility of targeting the 
chemokine system in this thesis, further exploration of this receptor in lymphoma and other 
malignant diseases is worthwhile. Under normal circumstances, CCR7 is expressed on 
dendritic cells, thymocytes, naïve and memory T-cells subsets and subsets of B-cells [387]. 
CCR7 and its ligands, CCL19 and CCL21, are involved in the homing of lymphocytes to, 
and the development of, secondary lymphoid organs thus making CCR7 an ideal receptor 
to study in relation to lymphomas. 
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In chapter 3, it was shown that, although all 6 lymphoma subtypes studied expressed CCR7 
to some degree, there were significant differences in the level of expression. In particular 
samples from patients with mantle cell lymphoma or CLL/SLL showed significantly 
higher expression when compared to the remaining four subtypes with 91.03 (± 4.97)% of 
B-cells expressing this in MCL cases and 95.83 (± 2.1.)% of B-cells expressing the 
receptor in CLL/SLL cases. These findings are consistent with the published data. Higher 
expression of CCR7 in CLL when compared to both normal B-cell counterparts and other 
lymphoma subtypes has been consistently demonstrated [296, 347, 359, 364]. The data for 
mantle cell lymphoma are less robust with comparatively higher expression of CCR7 
reported more often than not [359, 369]. However, in the one publication CCR7 expression 
in mantle cell lymphoma was reported as equal to that of its normal B-cell counterpart, this 
conclusion was based on gene expression rather than protein expression analysis [286] 
whereas the other papers reported on protein expression of CCR7 as with this thesis. 
 
It is also worth pointing out that CCR7 expression is detected in other B-cell 
lymphoproliferative disorders such as follicular lymphoma, marginal zone lymphomas 
[367] [364] and Burkitt’s lymphoma (cells from which the receptor was first characterised) 
[359]. Interestingly, aberrant or reduced expression of CCR7 has been observed in primary 
CNS lymphomas (PCNSL). However, on closer examination the receptor is located 
intracellularly rather on the cell surface [388]. Where as on cells from primary mediastinal 
B-cell lymphoma CCR7 expression is reduced in comparison with thymocytes (PMBCL 
arises from thymic tissues) [288]. In PCNSL and PMBCL nodal involvement is absent, by 
definition, which may be explained by the altered expression of CCR7. However the work 
by Rehm et al, also demonstrated a low level of CCR7 expression in primary DLBCL 
samples by immunohistochemistry. This is less easy to explain, but, as with the samples 
studied in this thesis, further categorisation into GB B-cell or activated B-cell type was not 
possible, and so these results could potentially be explained by an incidentally larger 
number of GC B-cell type DLBCL cases. 
 
Functional differences between CCR7+ lymphoma and CCR7+ normal B-cells have also 
been described, with responses to CCL19 demonstrated in mantle cell lymphoma cells but 
not their normal counterparts [389]. CCR7 has also been shown to be functional in CLL, 
with transendothelial migration demonstrable, and higher levels of migration noted with 
cells from those individuals with lymph node involvement [286]. 
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What is clear from published results and those discussed in chapter 3 is that CCR7 is a 
suitable target for the development of anti-lymphoma treatments. However the value of 
CCR7 as a target does not end with lymphoma.  
 
Nodal metastases in solid tumours are a common occurrence; furthermore, CCR7 has been 
implicated in the pathogenesis of the nodal spread of numerous tumour types. It has been 
proposed that up regulation of CCR7 precedes nodal metastasis in a number of tumour 
types as evidenced by detectable CCR7 expression in cells that would normally be 
negative for this receptor. Such examples include oesophageal squamous cell carcinoma 
[390], prostate carcinoma [391], breast carcinoma [392] and melanoma [393]. In all of 
these instances, CCR7 expression was associated with lymph node metastasis and an 
adverse prognosis. 
7.4.2 CCR7 Targeted Therapy 
Therefore it is clear that targeting CCR7 to induce cytotoxicity is a valid approach to the 
treatment of not only lymphomas, but also a range of solid tumours. In particular mantle 
cell lymphoma and CLL/SLL would be ideal targets for such treatment. However, whilst 
many papers on CCR7 expression in a range of diseases conclude with the comment that 
inhibition of CCR7 would provide a potentially useful therapeutic approach, to date there 
is remarkably very little literature describing strategies to specifically target this receptor.  
 
Neutralizing antibodies have been used in murine in-vivo studies. A melanoma cell line 
B16, was engineered to express either CCR7 (CCR7-B16) or CXCR5 (CXCR5-B16) and, 
along with untransfected B16 cells, were injected into the footpads of mice. In all cases 
tumours became detectable. However there was a faster and a higher rate of metastasis in 
the mice injected with the CCR7-B16 cells [394]. Following this, a neutralizing anti-
CCL21 antibody was administered to those mice that had been injected with CCR7-B16 
cells. This led to the regression of nodal metastasis although no mention was made of the 
effect on the initial tumour [395]. This study shows that CCR7 mediated migration to 
lymph nodes can be inhibited and may offer a therapeutic approach. However, in the case 
of solid tumours, anti-CCR7 therapy alone is unlikely to suffice, as the primary tumour is 
unlikely to be affected and a combined approach with chemotherapy will probably be 
required. 
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An anti-CCR7 monoclonal antibody has been developed, which has demonstrated the 
ability to induce apoptosis of CLL cells in-vitro. As the intensity of CCR7 expression on 
CLL cells is much higher than normal cells, the ability of this anti-CCR7 antibody to 
induce apoptosis in normal B-cells was also examined. Normal T and B-cells were 
relatively spared due to their lower expression of CCR7 [395]. This suggests that targeting 
CCR7 may not be as immunosuppressive as its normal expression profile may suggest. 
This is analogous to the situation seen with rituximab in which there is relative sparing of 
CLL cells at standard treatment doses due to relatively lower expression of CD20. The 
majority of CLL and mantle cell lymphoma cells express CCR7, as shown by the results in 
this thesis, and so it is proposed that anti-CCR7 antibody therapy could be applicable as a 
single agent in these diseases. 
 
Whilst, the bias of this thesis was towards targeted cytotoxic therapy, as with CCR4, 
engineering cells to express CCR7 may also offer a therapeutic approach. There has been a 
lot of interest in the development of anti-cancer vaccines utilising dendritic cells (DC). One 
issue with immunotherapy has been the poor migratory properties of the DCs expressing 
the cancer antigen of interest. By engineering DCs to express higher levels of CCR7, 
migration to lymph nodes was enhanced allowing for a more robust immune response to 
the endogenous cancer antigen. In addition, potentially a lower number of DCs would be 
required [296], which is currently a problem with anti-cancer vaccinations. 
 
Finally, although not developed specifically to target CCR7 a few agents have been 
observed to down-regulate CCR7. Triptolide has been used as an anti-inflammatory agent 
in China for many years and has been shown to reduce transplant rejection in both solid 
organ and bone marrow transplantation [396]. Its immunosuppressive effects have bee 
further studied and it has been shown that one mechanism of suppression is through down-
regulation of CCR7 expression on DCs [397]. Certain retinoids have also demonstrated 
similar effects. Two retinoids, 9-cis retinoic acid (9cRA) and retinoid fenretinide (4-HPR) 
also downregulate CCR7, as well as CXCR4 [397] and so may also have anti-
inflammatory properties. Of interest, in the same study all-trans retinoic acid (ATRA), a 
drug used very effectively in the treatment of acute promyelocytic leukaemia [398], was 
also tested and did not show any down-regulation of either CCR7 or CXCR4 [399], 
demonstrating that not all members of this class of agents will have the same effects. It is 
likely that other agents have inhibitory effects on CCR7. However as with the three agents 
discussed above, these are not specific. Never the less, they may offer some therapeutic 
potential in lymphomas and solid tumours. 
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7.5 Using the Chemokine System to Target Specific Cell Populations 
with Cytotoxins  
There has been a lot of interest and research in recent decades looking at the development 
of monoclonal antibodies to deliver targeted therapy. There is no doubt that this approach 
has been successful as evidenced by the impact that rituximab has had on the management 
of B-cell lymphomas. However, monoclonal antibody relies on other functioning elements 
of the immune system to induce cell death such antibody dependent cell-mediated toxicity 
or complement dependent cytotoxicity. Additionally, at relapse, expression of the targeted 
antigen may be lost, meaning that repeated use of the agent may be ineffectual. Loss of 
CD20 expression has been noted in up to 60% of cases of diffuse large B-cell lymphoma 
and follicular lymphomas at relapse, and is associated with poorer outcomes [398, 400]. 
Therefore, theoretically at least, agents causing direct, targeted cytotoxicty could overcome 
some of these issues. Having established that the chemokine system, more specifically 
chemokine receptors, are a suitable therapeutic target for B-cell non-Hodgkin’s lymphoma, 
the next sections of this thesis detailed ways in which the system could be targeted to 
directly deliver a cytotoxic agent.  
7.5.1 Chemotoxins and Chemokine-toxin Conjugates 
In this thesis, targeting of the chemokine system used the radioisotope 125I conjugated to 
either CCL19 or PM2 (a mutated form of CCL3) was attempted. Unfortunately, no 
significant differences in cell kill were detected between the CCR7+ and D6+ cells 
compared to CCR7- and D6- cells exposed to the radioisotope-chemokine conjugates.  There 
are many potential reasons for this, the main one being that the dose of 125I could have 
been too high therefore negating any specific targeting. Repeating this work using lower 
concentrations of the radioisotope and using a different control cell population may be 
worthwhile. However, developing an alternative approach utilizing chemotoxins, may be 
more viable and would certainly be easier to use in the clinical setting. 
 
As previously described, chemotoxins are defined as chemokines fused with a toxic 
moiety. A toxin, which will only cause cell death intracellularly would be ideal, and 
therefore would overcome the problems encountered with the radioisotope-chemokine 
conjugation. As discussed in section 1.4.5.4, this approach has been tried in-vivo in murine 
studies using CCR4 as the target in cutaneous T-cell lymphomas/leukaemias. CCL17 was 
fused with one of two toxins and administered to mice. Whilst initial responses were 
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promising, relapse occurred with reduced expression of CCR4 observed on the tumour 
cells [401], therefore preventing effective re-use of the agent, analogous to the situation 
seen with rituximab. However, as proof-of-principle, this study demonstrated that this was 
a valid approach. Certainly, fusing chemokines with a cytotoxic agent already in clinical 
use for haematopoietic malignancies such as cytosine is an interesting concept and worth 
exploring further. Although results from studies performed by Clare McCulloch in our 
laboratory with chemokine-doxorubicin conjugates were disappointing. 
 
7.5.2 Adenoviral Vectors Gene Therapy – Oncolytic Vectors 
The use of adenoviral vectors in oncology is expanding as discussed in section 1.5. 
However, there are a number of issues limiting their use including immunogenicity, robust 
and consistent gene expression and of course specificity. In chapter 5 and 6, it was 
demonstrated that adenoviral tropism could be successfully redirected through chemokine 
receptors, although a number of issues did arise meaning that final proof-of-principle 
studies could not be conducted.  
 
One issue was the persistence of background infection due largely to incomplete shrouding 
of the virus with chemokine. As a consequence a vector had been designed incorporating 
an acceptor peptide (AP) into the fibre knob protein sequence of the adenovirus. The AP is 
able to be biotinylated by biotin ligase [298]. The theory is that the virus can then be more 
efficiently biotinylated and subsequently shrouded following the use of biotin ligase, thus 
eliminating the background infection rate whilst more efficiently redirecting the adenovirus 
away from its CAR receptor to the chemokine receptor. Unfortunately, time did not allow 
for the transfection of this vector into HEK293 cells and the subsequent creation of viral 
particles to test this theory. However, it is likely that background infection may not be 
entirely eliminated due to the residual non CAR-dependant mechanisms of viral entry such 
as the utilization of α-integrins [354] and additional mechanisms to block α-integrin 
mediated cellular entry may also be required. 
 
Another potential problem with this approach is the promiscuity of chemokines. In this 
study CCR7 was the receptor predominantly under investigation, yet for a variety of 
reasons adenoviral experiments were performed with cell lines expressing alternative 
receptors such as CCR5 and the atypical chemokine receptors D6 and CCX-CKR. This led 
to the observation that not only could adenoviral tropism be redirected through the atypical 
chemokine receptors, but also led to transduction of the cell with the reporter gene LacZ.  
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Therefore, any adenoviral vector shrouded with CCL19 has the potential to enter a broader 
range of tissues and cells than initially surmised. This is because in comparison to CCR7, 
CCX-CKR has a broader range of expression being detectable in bone marrow, brain, 
heart, kidney, liver and lung tissues [319] as well as in mast cells, and both B and T cells 
from the lymph nodes (outlined in chapter 6). This has the obvious disadvantage that if a 
cytolytic adenoviral vectors is redirected by shrouding with CCL19, then all of these 
tissues could be affected, potentially resulting in a widely toxic therapy. The widespread 
expression of CCX-CKR may also explain why there were no major differences in the 
distribution of LacZ expression in the in-vivo study outlined in chapter 6 in which 
C57/BL6 mice were injected with the Ad5.CMV.LacZ vector with, or without, CCL19 
shrouding. 
 
However, this does not preclude this approach, as the degree of cytotoxicity may be 
influenced by a range of factors, not least, the intensity of surface expression of CCR7 and 
CCX-CKR. It has already been noted that CCR7 expression on CCR7+ B-cell lymphomas 
is often of a higher level than normal cells, and this may also be true for solid tumours, 
therefore there maybe increased uptake in these cells, although of course an examination 
into the expression of CCX-CKR in lymphomas is currently lacking. It is also interesting 
to note that NOD/SCID mice, in which a CCR4+ human acute T-lymphoblastic leukaemia 
cell line (CEM) had been injected to induce tumours survived without any obvious 
(although not specifically reported) tissue toxicity following administration of a 
chemotoxin derived from CCL17 [349]. This is worth noting as another atypical 
chemokine receptor, D6, that internalizes and subsequently degrades a number of 
chemokines including the ligands for CCR4 namely CCL17 and CCL22 [126, 298] has 
wide expression including lung, heart, brain, thymus, ovary, liver and skeletal muscle 
[402]. 
 
Finally, as discussed in section 1.5, further levels of specificity can be introduced into 
adenoviral vectors using either conditionally replicative vectors or those requiring tumour 
specific promotors such as telomerase.  
7.6 Development of a Murine Lymphoma Model 
In chapter 6 the murine T-lymphoblastic lymphoma cell line EL4 was characterised to 
assess its suitability as a murine lymphoma model. The cell line fulfilled the first 
requirement in that it expressed functional CCR7, although it was subsequently shown that 
it also expressed CCX-CKR. Interestingly EL4 cells express neither the CAR receptor nor 
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α-integrins meaning that any infection detected in these cells would have to have occurred 
via altered tropism of the adenoviral vector. 
 
Following this attempts at infecting the cell line with shrouded adenovirus proved 
challenging, although eventually, a small but not significant degree of infection was 
detected in the cells after increasing the multiplicity of infection (MOI) 100 fold. 
 
Having finally successfully infected the EL4 cells, improved detection of infection was 
optimized by using an adenoviral vector engineered to use the EF-1α promotor, which may 
improve the efficiency of transgene expression [122]. The development of the adenoviral 
vector containing this sequence was successful, but obtaining viral particles following 
transfection of HEK293 cells was not achieved due to time constraints. It would be 
interesting to repeat the infection experiments, not only on EL4 cells, but also other 
haematopoietic cell lines, using this vector to see if improvements in transgene expression 
can be obtained.  
 
Prior to testing any directed therapy in-vivo using adenoviral vectors, it would be useful to 
study the induced tumors further. Using EL4 cells engineered to up regulate CCR7 or 
CCX-CKR, may affect the pattern of distribution and speed at which the tumor cells grow 
or metastasize. Conversely, using techniques such as siRNA technology to block 
expression of each of these receptors may also alter tumour behaviour and provide clues 
with regards to the likely effects of targeted therapy. Additionally, techniques such as 
CFSE CelltrackTM, could be employed to assess the migration of the altered cells, to add 
further to the characterization of this cell line. 
 
Furthermore, experiments using neutralizing antibodies to either the receptor or its ligands, 
as described by Wiley et al in targeting CCR7+ tumours formed by the melanoma cell line 
B16 in mice [357], would be of interest too. 
 
Finally, using EL4 induced tumours to provide the ‘proof-of-principle’ for targeted therapy 
with chemokine shrouded adenoviral vectors, or even chemotoxins, at least at this point, 
appears to be a valid approach, although further work is required. Later, an alternative 
model using a murine B-cell malignancy such as CLL would be desirable, as this is one of 
the lymphomas in which CCR7 directed therapy would appear to be most efficacious. 
Certainly, murine B-cell CLL models have been described [395, 403]. 
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7.7 Summary and Future Directions 
This thesis has addressed and answered a number of questions. Firstly, there are variations 
between lymphoma subtypes and constitutive chemokine receptor expression, and with the 
exception of CCR4, the expression profiles of each of the lymphoma subtypes was 
consistent with published data. With regards to CCR4 expression in B-cell non-Hodgkin’s 
lymphoma, this is the first systematic analysis of this receptor, but as discussed, may well 
correspond with expression on the normal B-cell counterpart of the lymphoma subtypes.  
 
The correlation between higher CCR4 expression and improved survival in diffuse large B-
cell lymphoma was unexpected and not easily explained. An analysis (preferably 
prospective) of CCR4 expression and Treg numbers in DLBCL would be valuable, and 
that along with a study of CCL17 and CCL21 expression and may help to explain this 
phenomenon. In addition collection of clinical data including the stage of disease at 
presentation, response to treatment, time of relapse and survival data should be collected 
for further correlation with CCR4 expression. Of course, although the differences in 
survival were significant, the overall numbers were small, and further studies would 
require a larger patient population. In addition, further testing of the DLBCL samples 
would enable differentiation between activated-B-cell type and germinal centre cell type, 
allowing for correlation between CCR4 status and DLBCL subtype. 
 
Functional studies on the lymphoma samples may also be of value. In chapters 4 and 5, the 
QCMTM Chemotaxis assay was used successfully albeit with less convincing results than 
with the Transwell® assay, this has the advantage of requiring fewer cells for analysis, 
therefore enabling more efficient use of clinical samples. Of course the absence of 
migration towards a ligand does not always equate with lack of signal induction and 
initiation of an alternative function. Calcium flux assays could be of use too. However, 
they can be difficult to optimize and a much larger number of cells are required, which are 
not always available with primary samples. Alternatively, biotin-chemokine uptake studies 
could be performed, requiring the same number of cells as for flow cytometry analysis.  
The number and range of studies that could potentially be performed on primary 
lymphoma cells obviously stretches beyond those detailed above.  
 
The second aim was with regards to utilising the chemokine system to provide targeted 
therapy. Initial experiments with radiolabelled chemokines were disappointing and 
ultimately not very informative. This has been discussed earlier. However, using oncolytic 
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or cytolytic adenoviral vectors holds some promise although a lot more work is required. 
Which leads on the third aim of this study. 
 
Can adenoviral vectors be redirected to chemokine receptors? The simple answer is yes, 
however, work to increase the specificity of the tropism was not completed. With time and 
resources, the aim would be to use the vectors created containing the acceptor peptide to 
attempt comprehensive adenoviral biotinylation and to subsequently assess the efficiency 
of chemokine shrouding by repeating the electron microscopy and infection experiments. 
Following this, engineering the virus to contain ‘suicide’ genes and potentially tissue 
specific promoters would need to be undertaken before progressing on to therapeutic in-
vivo murine studies. Furthermore in-vivo infection experiments would need to be repeated 
following confirmation of more efficient chemokine shrouding. 
 
The final aim of this study was to develop a suitable in-vivo mouse model for testing 
targeted therapy. So far, EL4 cells remain the most viable option due to the ease of 
obtaining them and the ability to use a standard laboratory strain of mouse for any 
experiments. Of course, the proposed experiments outlined previously will need to be 
performed first. 
 
In summary, although a lot more work is needed, it has been established that there is an 
association between B-cell lymphoma subtype and constitutive chemokine receptor 
expression, chemokine directed targeted therapy remains a viable approach to the treatment 
of B-cell lymphomas, adenoviral tropism can be redirected through chemokine receptors 
and the identification of EL4 cells for used as an in-vivo mouse lymphoma model remains 
valid. 
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APPENDICES 
 
8.1    WHO Classification of Tumours of the Lymphoid Tissues 
 
B-CELL NEOPLASMS ICD-O 
  
PRECURSOR LYMPHOID NEOPLASMS  
B lymphoblastic leukaemia/lymphoma  
B lymphoblastic leukaemia/lymphoma, NOS 9811/3 
B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities  
B lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR-
ABL1 
9812/3 
B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged 9813/3 
B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-
AML1 (ETV6-RUNX1) 
9814/3 
B lymphoblastic leukaemia/lymphoma with hyperdiploidy 9815/3 
B lymphoblastic leukaemia/lymphoma with hypodiploidy (hypodiploid 
ALL) 
9816/3 
B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 9817/3 
B lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); E2A-
PBX1 (TCF3-PBX1) 
9818/3 
  
T lymphoblastic leukaemia/lymphoma 9837/3 
  
MATURE B-CELL NEOPLASMS  
Chronic lymphocytic leukaemia/ small lymphocytic lymphoma 9823/3 
B-cell prolymphocytic leukaemia 9833/3 
Splenic marginal zone lymphoma 9689/3 
Hairy cell leukaemia 9940/3 
Splenic B-cell lymphoma/leukaemia, unclassifiable 9591/3 
Splenic diffuse red pulp small B-cell lymphoma 9591/3 
Hairy cell leukaemia-variant 9591/3 
Lymphoplasmacytic lymphoma  9671/3 
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Waldenström macroglobulinaemia 9761/3 
Heavy chain diseases 9762/3 
Alpha heavy chain disease 9762/3 
Gamma heavy chain disease 9762/3 
Mu heavy chain disease 9762/3 
Plasma cell myeloma  9732/3 
Solitary plasmacytoma of bone 9731/3 
Extraosseous plasmacytoma 9734/3 
Extranodal marginal zone B-cell lymphoma of mucosa-associated 
lymphoid tissue (MALT-lymphoma)  
9699/3 
Nodal marginal B-cell lymphoma 9699/3 
Paediatric nodal marginal zone lymphoma 9699/3 
Follicular lymphoma 9690/3 
Paediatric follicular lymphoma 9690/3 
Primary cutaneous follicle centre lymphoma 9597/3 
Mantle cell lymphoma 9673/3 
Diffuse large B-cell lymphoma (DLBCL), NOS 9680/3 
T-cell/histiocyte rich large B-cell lymphoma 9688/3 
Primary DLBCL of the CNS 9680/3 
Primary cutaneous DLBCL, leg type 9680/3 
EBV positive DLBCL of the elderly 9680/3 
DLBCL associated with chronic inflammation 9680/3 
Lymphomatoid granulomatosis 9766/1 
Primary mediastinal (thymic) large B-cell lymphoma 9679/3 
Intravascular large B-cell lymphoma 9712/3 
ALK positive large B-cell lymphoma 9737/3 
Plasmablastic lymphoma 9735/3 
Large B-cell lymphoma arising in HHV8-associated multicentric 
Castleman disease 
9738/3 
Primary effusion lymphoma 9678/3 
Burkitt lymphoma 9687/3 
B-cell lymphoma, unclassifiable, with features intermediate between 
diffuse large B-cell lymphoma and Burkitt lymphoma 
9680/3 
B-cell lymphoma, unclassifiable, with features intermediate between 
diffuse large B-cell lymphoma and Hodgkin lymphoma 
9596/3 
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MATURE T-CELL AND NK CELL NEOPLASMS  ICD-O 
  
T-cell prolymphocytic leukaemia 9834/3 
T-cell large granular lymphocytic leukaemia 9831/3 
Chronic lymphoproliferative disorder of NK-cells 9831/3 
Aggressive NK cell leukaemia 9948/3 
Systemic EBV positive T-cell lymphoproliferative disease of childhood 9724/3 
Hydroa vacciniforme-like syndrome 9725/3 
Adult T-cell leukaemia/lymphoma 9827/3 
Extranodal NK/T cell lymphoma, nasal type 9719/3 
Enteropathy-associated T-cell lymphoma 9717/3 
Hepatosplenic T-cell lymphoma 9716/3 
Subcutaneous panniculitis-like T-cell lymphoma 9708/3 
Mycosis fungoides 9700/3 
Sézary syndrome 9701/3 
Primary cutaneous CD30 positive T-cell lymphoproliferative disorders  
Lymphomatoid papulosis 9718/1 
Primary cutaneous anaplastic large cell lymphoma 9718/3 
Primary cutaneous gamma-delta T-cell lymphoma 9726/3 
Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-
cell lymphoma 
9709/3 
Primary cutaneous VD4 positive small/medium T-cell lymphoma 9709/3 
Peripheral T-cell lymphoma, unspecified 9702/3 
Angioimmunoblastic T-cell lymphoma 9705/3 
Anaplastic large cell lymphoma, ALK positive 9714/3 
Anaplastic large cell lymphoma, ALK negative 9702/3 
  
HODGKIN LYMPHOMA  
Nodular lymphocyte predominant Hodgkin lymphoma 9659/3 
Classical Hodgkin lymphoma 9650/3 
Nodular sclerosis classical Hodgkin lymphoma 9663/3 
Lymphocyte-rich classical Hodgkin lymphoma 9651/3 
Mixed cellularity classical Hodgkin lymphoma 9652/3 
Lymphocyte-depleted classical Hodgkin lymphoma 9653/3 
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POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS 
(PTLD) 
 
Early lesions  
Plasmacytic hyperplasia 9971/1 
Infectious mononucleosis-like PTLD 9971/1 
Polymorphic PTLD 9971/3 
Monomorphic PTLD (B- and T/NK-cell types)* 
Classical Hodgkin lymphoma type PTLD* 
 
* These are classified according to the lymphoma or leukaemia to which 
they correspond, and assigned the respective ICD-O Code 
 
 
NOS – not otherwise specified  
Morphology code of the International Classification of Diseases (ICD-O), fourth edition. 
Behaviour is coded /3 for malignant tumours and /1 for lesions of low or uncertain 
malignant potential. 
The italics indicate provisional entities for the WHO working group felt that there was 
insufficient evidence to recognise them as distinct diseases at the time of compilation 
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8.2    Eastern Cooperative Oncology Group Performance Status [404] 
 
Score Definition 
0 Asymptomatic (Fully active, able to carry on all pre-disease activities without 
restriction) 
1 Symptomatic but completely ambulatory (Restricted in physically strenuous 
activity but ambulatory and able to carry out work of a light or sedentary 
nature. For example, light housework, office work) 
2 Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-
care, confined to bed or chair 50% or more of waking hours) 
3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-
care, confined to bed or chair 50% or more of waking hours) 
4 Bedbound (Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair) 
5 Death 
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